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John Laroche: ...the point is, what's so wonderful is that every 
one of these flowers has a specific relationship with the insect 
that pollinates it. There's a certain orchid look exactly like a 
certain insect so the insect is drawn to this flower, its double, 
its soul mate, and wants nothing more than to make love to it. 
And after the insect flies off, spots another soul-mate flower and 
makes love to it, thus pollinating it. And neither the flower nor 
the insect will ever understand the significance of their 
lovemaking. I mean, how could they know that because of their 
little dance the world lives? But it does. By simply doing what 
they're designed to do, something large and magnificent 
happens. In this sense they show us how to live, how the only 
barometer you have is your heart. How, when you spot your 
flower, you can't let anything get in your way. 
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1. Summary 
The human genome harbors numerous sequences derived from ancient retroviral infections, so-called 
human endogenous retroviruses (HERVs). The HERVs of the HERV-K(HML-2) group, in short HML-
2, encode various retroviral proteins that, if expressed, may affect cell biology. HML-2 transcription 
is upregulated in different disease contexts including presence of HML-2 encoded proteins. Some 
HML-2 proteins have been implicated in disease development, although definitive associations with 
diseases were not reported yet. 
 
This work focused on HML-2 protease (Pro) and HML-2 integrase (IN), two HML-2 encoded proteins 
that received little attention so far, although their enzymatic activities can, in principle, have 
detrimental effects in the cell. 
 
In the first part of this work we investigated HML-2 Pro. Besides the retroviral proteins that constitute 
the virion, some retroviral aspartyl proteases, among them HIV-1 protease, are known to process 
cellular proteins. We wondered whether HML-2 Pro proteolytic activity can process cellular proteins 
as well. By cleaving cellular proteins, HML-2 Pro may impair cellular processes, thus have a role in 
disease development. The major aim for this part was to identify cellular proteins processed by HML-
2 Pro. We also performed initial experiments documenting HML-2 Pro activity against cellular proteins 
in a cellular environment and provided insights into cellular processes that could be potentially 
influenced by HML-2 Pro activity. 
 
HML-2 Pro was successfully purified and reaction conditions for assaying its activity in vitro were 
optimized. Purified HML-2 Pro was incubated with cellular proteins derived from HeLa cells. 
Employing terminal amine isotope labeling of substrates (TAILS) we then identified cellular proteins 
cleaved by HML-2 Pro. TAILS experiment and subsequent analyses of raw data produced a list of 872 
human proteins as putative cellular substrates of HML-2 Pro. Identified proteins were profiled using 
suited bioinformatic tools. Processed proteins could be assigned to different cellular compartments and 
various, often disease-relevant cellular processes. We verified through additional experiments 
processing of selected candidate proteins by HML-2 Pro in vitro and in vivo. Cleavage by HML-2 Pro 
was confirmed for 9 out of 14 selected candidate proteins in vitro. Further verification experiments 
demonstrated in vivo cleavage of cellular proteins by HML-2 Pro in a cellular environment. Sizes of 
processing products observed for some of the tested proteins coincided with product sizes predicted by 
TAILS, thus corroborating TAILS results. We documented cell death and activation of apoptotic 
processes during HML-2 Pro overexpression, hence providing initial experimental evidence of cellular 
processes being influenced by HML-2 Pro activity. Finally, we obtained preliminary evidence of 
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functional, enzymatically active endogenous HML-2 Pro being present in some tumor cell lines known 
to express HML-2 proteins. 
 
Our results suggest that hundreds of cellular proteins are potential substrates of HML-2 Pro. It is 
therefore conceivable that upregulated HML-2 transcription might lead to increased expression of 
active HML-2 Pro that might subsequently affect various cellular processes by degrading cellular 
proteins. HML-2 Pro is present in cells of some tumor types where its proteolytic activity could play a 
role. HML-2 Pro thus deserves further attention because cellular processes impaired by its activity 
potentially contribute to human diseases. 
 
In the second part of this work we investigated HML-2 IN, an enzyme that, if expressed, might locate 
to the cell nucleus and exhibit catalytic activities inducing DNA damage and formation of DNA 
double-strand breaks (DSBs). DSBs are a severe type of DNA damage that may contribute to genome 
instability and tumor development. We aimed at evaluating whether HML-2 IN causes DNA damage 
resulting in formation of DSBs. 
 
Following transient expression of HA-tagged wild-type and mutant HML-2 IN in HeLa cells, we 
performed immunofluorescence assays for monitoring HML-2 IN cellular localization through HA-
tag detection as well as formation of DSBs through analysis of 53BP1 foci.  
Transiently expressed HML-2 IN localized to nuclei but we did not observe significant differences 
regarding 53BP1 foci when comparing cells expressing wild-type HML-2 IN and controls. Although 
our results point towards HML-2 IN not causing DSBs when expressed in HeLa cells the experimental 







Analysen Humaner Endogener Retrovirus-kodierter Proteine hinsichtlich deren 
Relevanz für die menschliche Biologie und Erkrankungen 
 
Das menschliche Genom enthält zahlreiche Sequenzen, die von ehemaligen retroviralen Infektionen 
stammen, sogenannte humane endogene Retroviren (HERVs). Die HERVs der HERV-K (HML-2) 
Gruppe, kurz HML-2, kodieren verschiedene retrovirale Proteine, die, wenn sie exprimiert werden, die 
Zellbiologie beeinflussen können. Die HML-2 Transkription wird in verschiedenen 
Krankheitskontexten hochreguliert, einschließlich der Expression HML-2-kodierter Proteinen. Einige 
HML-2 Proteine sind eventuell an der Entwicklung bestimmter Krankheiten beteiligt, obwohl 
definitive Assoziationen mit solchen Krankheiten noch nicht beschrieben sind. 
 
Diese Arbeit konzentrierte sich auf HML-2 Protease (Pro) und HML-2 Integrase (IN), zwei HML-2 
kodierte Proteine, die bisher wenig Beachtung fanden, obwohl ihre enzymatischen Aktivitäten im 
Prinzip schädliche Auswirkungen auf die Zelle haben können. 
 
Im ersten Teil dieser Arbeit haben wir HML-2 Pro untersucht. Es ist bekannt, dass neben den 
retroviralen Virion-bildenden Proteinen einige retrovirale Aspartylproteasen, darunter die HIV-1-
Protease, auch noch zelluläre Proteine spalten können. Es bestand die Frage, ob die proteolytische 
Aktivität von HML-2 Pro auch zelluläre Proteine spalten kann. Durch die Spaltung von zellulären 
Proteinen kann HML-2 Pro zelluläre Prozesse beeinträchtigen und somit eine Rolle bei der 
Krankheitsentwicklung spielen. Das Hauptziel dieses Teils der Arbeit war die Identifizierung von 
zellulären Proteinen, die von HML-2 Pro prozessiert wurden. Wir führten auch erste Experimente 
durch, die die HML-2 Pro Aktivität gegen zelluläre Proteine in einer zellulären Umgebung 
dokumentierten, und lieferten Einblicke in zelluläre Prozesse, die möglicherweise durch die HML-2 
Pro Aktivität beeinflusst werden könnten. 
 
HML-2 Pro wurde erfolgreich gereinigt und die Reaktionsbedingungen zum Testen seiner Aktivität in 
vitro wurden optimiert. Gereinigtes HML-2 Pro wurde mit zellulären nativen Proteinen aus HeLa-
Zellen inkubiert. Unter Verwendung der terminalen Aminisotopenmarkierung von Substraten (TAILS) 
identifizierten wir zelluläre Proteine, die durch HML-2 Pro prozessiert wurden. Das TAILS-
Experiment und die anschließende Analyse der Rohdaten ergaben eine Liste von 872 humanen 
Proteinen als mutmaßliche zelluläre Substrate von HML-2 Pro. Die dentifizierten Proteine wurden 
unter Verwendung geeigneter bioinformatischer Werkzeuge charakterisiert. Die identifizierten 
Proteine konnten verschiedenen Zellkompartimenten und verschiedenen, oft krankheitsrelevanten 
Zellprozessen zugeordnet werden. Wir verifizierten ferner durch zusätzliche Experimente die 
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Prozessierung ausgewählter Kandidatenproteine durch HML-2 Pro in vitro und in vivo. Eine solche 
Prozessierung durch HML-2 Pro wurde für 9 von 14 ausgewählten Kandidatenproteinen in vitro 
bestätigt. Weitere Verifikationsexperimente zeigten in vivo die Prozessierung von zellulären Proteinen 
durch HML-2 Pro in einer zellulären Umgebung. Die Größen der für einige der getesteten Proteine 
beobachteten Prozessierungsprodukte stimmten hierbei mit den von TAILS vorhergesagten 
Produktgrößen überein, was die TAILS-Ergebnisse bestätigte. Wir dokumentierten weiter den Zelltod 
und die Aktivierung apoptotischer Prozesse während der Überexpression von HML-2 Pro und lieferten 
damit erste experimentelle Beweise, dass zelluläre Prozesse durch die HML-2 Pro-Aktivität beeinflusst 
werden. Schließlich erhielten wir vorläufige Beweise dafür, dass funktionelles, enzymatisch aktives 
endogenes HML-2 Pro in einigen Tumorzelllinien, von denen HML-2 Proteinexpression bekannt ist, 
ebenso exprimiert wird. 
 
Unsere Ergebnisse legen nahe, dass Hunderte von zellulären Proteinen potenzielle Substrate von HML-
2 Pro sind. Es ist daher denkbar, dass hochregulierte HML-2 Transkription zu einer erhöhten 
Expression von aktivem HML-2 Pro führt, die anschließend verschiedene zelluläre Prozesse durch 
Abbau zellulärer Proteine beeinflussen könnte. HML-2 Pro ist in Zellen einiger Tumortypen 
vorhanden, in denen seine proteolytische Aktivität eine Rolle spielen könnte. HML-2 Pro verdient 
daher weitere Aufmerksamkeit, da zelluläre Prozesse, die durch seine Aktivität beeinträchtigt werden, 
möglicherweise zu menschlichen Krankheiten beitragen. 
 
Im zweiten Teil dieser Arbeit untersuchten wir HML-2 IN, ein Enzym, das bei Expression im Zellkern 
lokalisieren und katalytische Aktivitäten aufweisen könnte, die eine DNA-Schädigung und die Bildung 
von DNA-Doppelstrangbrüchen (DSBs) induzieren. DSBs sind eine schwerwiegende Art von DNA-
Schäden, die zur Instabilität des Genoms und zur Tumorentwicklung beitragen können. Wir wollten 
untersuchen, ob HML-2 IN DNA-Schäden verursacht, die zur Bildung von DSBs führen. 
 
Nach der Expression von HA-markiertem Wildtyp- und mutiertem HML-2 IN in HeLa-Zellen führten 
wir Immunfluoreszenzexperimente zur Untersuchung der HML-2 IN-Zelllokalisation durch HA-Tag-
Detektion sowie zur Analyse der Bildung von DSBs durch Analyse von 53BP1-Foci durch. 
Transient exprimiertes HML-2 IN lokalisiert im Zellkern, jedoch beobachteten wir keine signifikanten 
Unterschiede in Bezug auf 53BP1-Foci im Vergleich von Zellen, die Wildtyp-HML-2 IN oder 
Kontrollen exprimierten. Obwohl unsere Ergebnisse darauf hindeuten, dass HML-2 IN bei Expression 
in HeLa-Zellen keine DSBs verursacht, kann der von uns etablierte experimentelle Ansatz als 





2.1. Retroviruses and endogenous retroviruses 
Retroviruses, classified in the family Retroviridae, represent a vast group of enveloped RNA viruses 
with the ability to reverse transcribe their genome into a linear double-stranded DNA (dsDNA) that is 
subsequently integrated into the genome of their host cell. Because of such replication strategy, 
retroviruses can exist as exogenous virus particles or as endogenous DNA sequences permanently 
integrated in the host genome, the latter called proviruses [211]. Retroviruses that target somatic cells 
can be transmitted to new individuals through typical horizontal transmission of virus particles. 
Vertical transmission of virus particles can happen from mother to fetus, but if germ cells or gametes 
are infected, another way of vertical transmission is possible: if a provirus is integrated in a 
reproductive cell that subsequently forms a zygote, thus originating a new organism, a copy of that 
provirus will be carried by each cell of the newborn. Starting from that individual, the provirus will be 
transmitted in a mendelian fashion as a host allele, having a chance to be fixed in the entire progeny. 
Through this mechanism of vertical transmission, during the evolution of vertebrates, in the course of 
many million years, thousands of retrovirus elements have been integrated and fixed in the genome of 
species. Such retroviral elements are called endogenous retroviruses (ERVs) [137]. 
 
2.2 Human endogenous retroviruses (HERVs) 
Originally identified in mice and chickens, ERVs were found in the genome of all vertebrates studied 
so far, including humans [102]. The first human endogenous retrovirus (HERV) was discovered in 
1981 [133]. Since then, more than 700.000 retroviral elements have been identified in the human 
genome, corresponding to almost the 8% of the entire human genome [75,137]. Surprisingly, this is 
more than the percentage of human genome that encodes proteins, which corresponds to approximately 
1.5% [84]. In some species, for example, in koala or mice, an active process of germ line colonization 
by novel ERV is still ongoing. In humans, it seems that the process of HERV endogenization has 
virtually ceased [128]. However, as will be described later, this does not mean that HERVs no longer 
influence human biology. 
 
2.2.1 Proviral structure  
HERVs share with exogenous retroviruses the typical proviral structure [128] (Figure 1). Their 
sequence consists of ~10 kb in full-length proviruses, although it can be shorter in defective proviruses 
(see later). The proviral genome is enclosed at the 5' and 3' ends by sequence regions called long 
terminal repeats (LTRs). LTRs are composed of regions U3, U5 and R. Such regions contain sequence 
elements that have a regulatory function in the retroviral replication cycle, in particular during reverse 
transcription, integration and transcription. In proximity of the 5' LTR is located the primer binding 
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site (PBS), which is the binding site for a tRNA that serves as primer during initiation of reverse 
transcription. In the portion of the proviral genome flanking the PBS, there is a coding-region 
containing the viral genes: gag, pro, pol and env. gag encodes the Gag (group-specific antigen) 
polyprotein that generates three structural proteins that compose the virion: matrix (MA), capsid (CA) 
and nucleocapsid (NC). pro encodes the viral protease (Pro). pol encodes the reverse transcriptase 
(RT), RNaseH and integrase (IN). env encodes the surface glycoprotein (SU) and transmembrane 
protein (TM), which are included in the lipidic envelope that surround the virion. Apart from these 
canonical proteins, some HERVs are characterized by a more complex genome that in some cases 
encode additional proteins. For instance, some HERV groups contain motifs for a deoxyuridine 
triphosphatase (dUTPase) [135]. Such dUTPase motifs has been found in variable genome positions 
among different groups, in particular in an N-terminal region of pro or in a C-terminal region of pol 
[135]. Other accessory proteins can derive from alternative splicing of the env gene (see chapter 2.3.1). 
 
Looking at the genomic structure of the multitude of retrovirus-derived elements dispersed in the 
human genome, it became clear that, after integration, the majority of HERVs have been subjected to 
mutations and recombination processes. Such processes have reduced most of HERVs to defective 
proviruses with lower or totally missing coding capacity [206]. One representative case of defective 
HERVs are the so-called “solo LTRs”, which consist of just an LTR generated by homologous 
recombination between the two proviral LTRs. Of note, solo LTRs are present at approximately 10-fold 
higher numbers in the human genome compared to HERV proviral sequences [128]. It is conceivable 
that evolutionary processes favored the proliferation of defective proviruses as a consequence of their 
reduced impact on genome stability. Although, several HERVs still retain intact genes and ability to 
encode functional proteins. 
 
 
Figure 1: Representative structure of a HERV provirus. A full-length provirus consist of nearly 10 kb 
composed of two long terminal repeats (LTRs) that flank the internal portion of the viral genes gag, pro, pol and 
env. LTRs can be divided into the domains U3, R and U5. Reverse transcription starts from the primer binding 
site (PBS), located between the 5' LTR and gag. Viral genes encode proteins composed of different domains: 
MA = matrix, CA = capsid, NC = nucleocapsid, RT = reverse transcriptase, IN = integrase, SU = surface protein, 
TM = transmembrane protein. Several proviruses encode a protein domain for dUTPase, in some cases located 
in an N-terminal region of pro. 
 
2.2.2 Classification and nomenclature of HERVs 
Various criteria have been employed for classification and nomenclature of HERVs. For example, 
according to sequence similarities in the pol gene, HERVs have been broadly grouped in three main 
classes that basically reflect their similarities with exogenous retroviruses [70,88,206]: Class I elements 
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are more closely related to exogenous gamma- and epsilonretroviruses, Class II to alpha- and 
betaretroviruses, and Class III to spumaviruses. Another HERV classification was based on the tRNA 
that binds to the PBS to initiate reverse transcription [38]. For instance, HERV-K indicates a human 
ERV (or ERV lineage) that uses a lysin (K) tRNA, whereas HERV-W indicates an ERV that uses a 
tryptophan (W) tRNA. Some specific HERV loci were named using arbitrary designations that have 
evolved according to internal laboratory criteria based on, for instance, HERVs neighboring genes (e.g. 
HERV-ADP [126]), clone number (e.g. HERV-S71 [218]) or place of identification (e.g. HERV-
K(HML-2.HOM) [134]). Very often in the literature a specific HERV locus was reported in different 
studies with different names, increasing confusion. Only recently a system has been proposed that 
would unify the nomenclature of ERVs to the level of individual proviral loci [71]. 
 
2.2.3 Impact of HERVs on human biology 
After their discovery, retrovirus-related elements have been considered for a relatively long time as 
“useless” junk sequences, without a functional role in the cell. Nowadays, it is known that through 
different mechanisms HERVs can influence cellular processes, inducing both positive or negative 
effects [113]. 
Beneficial roles of HERVs are the consequence of adaptation processes, which provided novel 
functions to specific HERVs that became advantageous for the host. Several HERVs, including those 
that are relatively degraded in terms of coding capacity, can have important functions as cellular gene 
regulators. HERV LTRs harbor promoter and enhancer elements, binding sites for transcription factors, 
and a polyadenylation signal. These transcription-related elements provided fundamental functions for 
the integrated provirus, but it was demonstrated that they can contribute as functional elements to 
cellular genes [37]. For instance, LTRs can serve as alternative gene promoter, bringing to variable 
expression of cellular genes in different tissues or conditions [13]. There are also rarer examples of 
LTRs that replaced the original promoter of a gene, serving as unique promoter [167]. One 
representative case is the transcription of the amylase gene in the human salivary gland, which depends 
on the activity of a HERV-E LTR [177]. 
Another way HERVs can influence the cellular processes is through the production of retroviral 
proteins. The most remarkable example of HERV-derived proteins with a known cellular function is 
represented by syncytins, that are proteins encoded by cellular genes originated from the env gene of 
HERVs [115]. These proteins have been exapted on multiple occasions and independently in diverse 
mammalian species to play a role in placentation [115]. Syncytin-1, encoded by a proviral locus of the 
HERV-W group, has fusogenic properties that appear to be fundamental during the formation of the 
syncytial trophoblast layer during placenta development [131]. Curiously, it has been speculated also 
an involvement of syncytin-1 in multiple sclerosis [173], suggesting potential deleterious effects of 
this HERV-derived protein. Although nothing has been concretely established so far concerning the 
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relationship between syncytin-1 and multiple sclerosis, this example can be used to remark that, 
domesticated or not, HERVs could also have detrimental roles [113]. In fact, negative effects of 
apparently harmless HERVs could be suddenly triggered by various mechanisms. For instance, it is 
known that most HERVs are typically silenced in somatic cells by epigenetic mechanisms including, 
but not limited to, DNA methylation [128]. CpG methylation was demonstrated to have a role on the 
transcriptional activity of many HERVs [116]. As a consequence, it is conceivable that conditions of 
epigenetic reprogramming or altered epigenetic controls, with associated loss of DNA methylation, 
could reactivate suppressed HERVs. In support of this notion is the observation of increased levels of 
HERV expression after treatment of cells with demethylating agents [197]. HERV overexpression or 
HERV expression in situations when they should not be expressed could have detrimental 
consequences for the cell. As insertional elements, HERVs could have the potential to cause deleterious 
mutations, for example, disrupting the integrity of a gene or inducing activation of oncogenes, when 
integrated in their proximity. Also, HERV-derived proteins could potentially interact with cellular 
components and impair cellular processes, leading to alteration of cell functions. These phenomena 
could, for example, take place during tumorigenesis, when the genome methylation level is remarkably 
altered. 
 
Some HERV groups could be more relevant than other in the disease context. In the following, 
attention will be focused on HERV-K(HML-2), a group of HERVs that has been investigated for its 
potential roles in tumor and other diseases. The remaining part of this introduction will describe general 
characteristics of HERV-K(HML-2), then consider specific aspects related to the two proteins studied 
here. 
 
2.3 HERV-K(HML-2) proviruses 
HERV-K is the only group of HERVs having human-specific members [54]. HERV-K group is 
currently divided into 11 subgroups, created on the base of similarities in the RT sequence [4,199]. 
The HERV-K subgrups are indicated with the acronim HML, for human MMTV-like, because they 
are closely related to the betaretrovirus mouse mammary mumor virus (MMTV). The most recently 
integrated and best preserved HERV-K proviruses belong to the HERV-K(HML-2) subgroup [139], 
hereafter referred to as HML-2. Because of several peculiar features, HML-2 has attracted a 
considerable interest in the scientific community. In 1986, the complete nucleotide sequence of HERV-
K10 was published [148] (later classified as member of the HML-2 group), describing for the first time 
a HERV with intact ORFs for retroviral proteins. Because of its peculiar integrity, HERV-K10 has 
been used as a reference in the study of HML-2 proviruses. Various research groups started to 
investigate HERV-K10 and other HML-2 elements to elucidate properties, activities and eventually 
define potential functions in the cell. In a recent analysis, 944 HML-2 solo LTR elements and 91 full-
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length HML-2 proviruses have been catalogued, reporting a number of exceptionally well-preserved 
proviruses [199]. As a consequence of relatively recent integrations, the HML-2 group also includes 
human-specific proviruses, some of which are polymorphic in the human population [11,81,208], i.e., 
specific proviral loci that are not fixed in the population and can be found in various allelic forms, 
including cases of full-length proviruses, solo LTRs, ERVs tandem repeats, or no viral sequence in the 
concerned genome position at all. One study that analyzed more than 2500 sequenced human genomes 
identified 36 polymorphic HML-2 proviruses, with insertion frequencies ranging from <0.0005 to 
>0.75 [219]. Taking into account that many unidentified HML-2 proviral loci may be polymorphic, it 
is conceivable that the number of HML-2 loci known at the moment could be an underestimation of 
the actual number in the entire human population [199]. 
 
2.3.1 Genomic organization  
The genomic organization of HML-2 proviruses resemble that of betaretroviruses, with the four major 
genes (gag, pro, pol, env) having different, overlapping ORFs (Figure 2 A) [78]. Based on sequence 
properties, HML-2 proviruses can be clustered in different groups. Depending on the absence or 
presence of a 292-bp deletion in the junction between pol and env genes HML-2 proviruses can be 
classified as type 1 or type 2 [123], respectively. Another HML-2 variant, harboring a 96-bp insertion 
in a central region of the gag gene has been categorized in a group named HERV-K(OLD), with 
additional sequence features of HERV-K(OLD) proviruses suggesting a longer-time presence in the 
human genome [160]. Based on phylogenetic analysis of the LTR sequences, HML-2 can be also 
classified in three subgroups: LTR5Hs, LTR5A or LTR5B [64], with the former group including the 
most recently acquired proviruses, whereas the last two groups including evolutionarily older 
proviruses [30]. 
 
2.3.2 Proviral transcripts and proteins 
For transcription of HML-2 proviruses, the 5' LTR provides the promoter recognized by the cellular 
RNA polymerase II. Transcription starts in the U5 region and results in full-length viral RNA 
molecules and subgenomic-sized RNA molecules that are spliced by the host cell spliceosome. Two 
donor sites (SD) and two acceptor site (SA) are present for splicing of the HML-2 transcripts (see 
Figure 2 A). All mRNA species (see Figure 2 B) are modified with a 5´CAP and a 3´poly-A tail, and 
exported to the cytoplasm, where they serve as mRNAs for translation of viral proteins. Full-length 
viral RNA transcripts are also packaged into newly generated virions as genomic RNA [78]. Typical 
for retroviruses, some HML-2 proteins are produced as polyproteins that need to be processed in order 
to release the single proteins. Gag, Pro and Pol are translated from a full-length, unspliced viral mRNA. 
Their translation is initiated at the starting AUG codon of the Gag ORF. Pro and Pol (the second and 
third ORFs) are produced as a Gag-Pro and Gag-Pro-Pol polyprotein. Since ORFs are arranged in 
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different reading frames, a mechanism of ribosomal frameshift is necessary to produce the different 
products. Gag is translated when the termination codon at the end of Gag ORF is recognized. 
Occasionally, the Gag termination codon is not reached due to slippage of the ribosome upstream of 
the Gag ORF stop codon. In this case, translation continues in a different reading frame that produces 
Gag-Pro fusion protein, instead of Gag alone. A similar frameshift mechanism can occasionally happen 
upstream of the Pro stop codon, generating Gag-Pro-Pol [174]. All protein domains embedded in the 
polyproteins mentioned above, are released by the proteolytic activity of Pro, which releases itself from 
the Gag-Pro polyprotein. The canonical proteins MA, CA and NC are released through cleavage of 
Gag polyprotein by Pro [185]. Similar to MMTV, at least one additional protein, designated p15, is 
encoded between the MA and CA subdomains of HML-2 Gag. The precise functions of this protein 
are still poorly understood [66]. Almost all HML-2 loci contain dUTPase motifs within the N-terminal 
region of pro [135]. dUTPase and Pro are released through cleavage of Gag-Pro polyprotein by Pro. 
Mature RT, RnaseH and IN are released through cleavage of Gag-Pro-Pol polyprotein by Pro. A spliced 
form of the full-length mRNA encodes the Env protein, whose typical domains SP, SU and TM are 
released by cellular proteases [78]. 
In addition to transcripts for translation of Gag-Pro-Pol and Env, HML-2 type 2 proviruses can generate 
an additional mRNA via alternative splicing of the env gene. This transcript encodes an accessory 
protein, named Rec, that appears to be a peculiarity of the HML-2 group [136]. Rec displays similarities 
to proteins encoded by complex exogenous retroviruses, in particular Rev/Rex proteins of HIV-1 and 
human T-lymphotropic virus (HTLV) [130], as well as Rem protein of MMTV [83]. In the life cycle 
of those exogenous retroviruses, that accessory protein facilitates shuttling of unspliced viral 
transcripts from the nucleus to the cytoplasm. Rec likely was a functional equivalent of those proteins 
in the exogenous precursor of HML-2 [129]. Due to the 292-bp deletion, type 1 proviruses have lost a 
SD and are incapable of encoding Env or Rec. Of note, an alternative SD site located upstream of the 
292-bp deletion is instead used to splice an mRNA that encodes a 9-kDa protein named Np9 [7,77]. 
The role of Np9 in HML-2 biology is not known, but both Np9 and Rec may be involved in cell 
tumorigenesis, as will be described later. 
 11 
 
Figure 2: Proviral structure and transcripts of HERV-K(HML-2). A) General structure of an HML-2 full-
length provirus with ORFs of the retroviral genes gag, pro, pol, env and flanking LTRs. The 96-bp deletion (Δ96 
bp) in the gag ORF, which differentiates HML-2 from the older HERV-K (OLD) proviruses and the 292-bp 
deletion (Δ292 bp) at the pol-env junction (dotted line), which differentiate type 1 and 2 proviruses (see text), are 
shown. The position of splice donor (SD) and splice acceptor (SA) sites are shown. B) Splice variants of mRNA 
of the HML-2 proviruses of types 1 and 2. HML-2 transcription starts from the R region. All transcripts are 
modified with a 5' CAP and a poly-A tail (pA). Introns are represented with dotted lines. A full-length transcript 
includes three ORFs encoding proteins Gag, Pro and Pol. In this transcript there is only a starting codon at the 5' 
end of Gag, thus Pro and Pol are translated through ribosomal frameshifts (fs). A second mRNA, where a region 
is spliced between SD1 and SA1 encodes the protein Env. A third mRNA encodes the Rec protein. That mRNA 
is the product of an alternative splicing of the env mRNA, between SD2 and SA2, and is produced only in 
proviruses of type 2, which do not have the 292-bp deletion. In type 1 proviruses, SD2 is missing due to the 292-
bp deletion but an alternative splice donor site (SDNP9) is used immediately upstream of the 292-bp deletion. As 
a result, the alternative splicing of the env mRNA in type 1 proviruses generates a transcript that encodes for Np9 
protein. 
 
2.3.3 Transcription of HML-2 in healthy and disease-derived tissues 
Although HML-2 transcription can be suppressed by epigenetic mechanisms [116], several studies 
identified HML-2 transcripts in human tissues. An analysis conducted more than 10 years ago in our 
laboratory detected 23 transcriptionally active HML-2 proviruses [58]. Additional transcribed 
proviruses were identified subsequently [15,142]. Of note, HML-2 transcription in healthy tissues was 
reported by various research groups. In the placenta, an organ where decreased epigenetic regulation 
has been observed, HML-2 expression appears particularly active [152]. Also, testes and other steroid 
hormone-regulated tissues appear to be privileged for HML-2 expression [3]. Expression profiles of 
other healthy tissues, including brain, heart, peripheral blood mononuclear cells, lung, liver and breast, 
indicate low-level transcription of several HML-2 proviruses [58]. Detection of HERV transcripts in 
healthy tissues sparks speculation about beneficial roles of HML-2 products [113], although, the few 
HERVs that seem to be under strong positive selective pressure, do not belong to the HML-2 group 
[21]. On the contrary, upregulation of HML-2 proviruses has been strongly associated with several 
disease conditions, notably tumors. Elevated HML-2 transcription was reported for certain types of 
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germ cell tumor (GCT) including seminoma [76,179], teratocarcinoma [15] and ovarian cancer [215]. 
HML-2 transcripts have been detected in prostate cancer [72]. HML-2 is upregulated also in melanoma 
[183]. Concerning melanoma, one specific HML-2 locus that has been found to be transcribed only in 
melanoma-derived samples but not in melanocytes, might represent a marker for melanoma [183]. 
HML-2 env transcripts are also present in human breast cancer, with significantly higher amounts of 
transcripts than in normal breast tissue [214]. Expression of HML-2 env transcripts was 5–10-fold 
higher in breast cancer cell lines treated with estradiol and progesterone than in cells without treatment 
[214]. Moreover, HML-2 RNA was found at very high titers in plasma of patients with lymphomas 
[42]. 
 
Apart from tumor diseases, HML-2 proviruses may play a role in other pathological conditions for 
which HML-2 upregulation was observed. For example, HML-2 transcripts are increased in brain 
samples from patients with bipolar-disorder and schizophrenia in comparison with control samples 
[61]. HML-2 was reported to be upregulated also in neurons of patients with amyotrophic lateral 
sclerosis (ALS) [51], although such evidence could not be corroborated in subsequent analyses 
[65,138]. Significant upregulation of HML-2 mRNA levels was observed for rheumatoid arthritis 
compared to inflammatory and healthy controls [62]. Moreover, HML-2 RNA sequences were found 
in plasma samples from HIV-1 positive patients but rarely detected in plasma of patients with hepatitis 
C or control subjects [41]. 
 
2.3.4 Expression of HML-2 proteins in disease-derived tissues  
In human cancers and cell lines, not only HML-2 transcripts but also HML-2 proteins have been 
identified. Representative examples will be described in the following. HML-2 Env, Rec and Np9 
proteins were detected in primary melanoma and melanoma derived cell lines [29]. Several studies 
demonstrated the oncogenic potential of such HML-2 proteins. Stable expression of HML-2 Env in 
non-transformed breast epithelial MCF10A cell line induced tumorigenic processes, resulting in altered 
cell morphology and increased motility [119]. In HEK293T cells, 24 h post-transfection (hpt) with 
expression vector encoding HML-2 Env, many cellular genes showed modified expression levels. 
Among the identified upregulated genes, there was a strong enrichment of transcription factors 
associated with oncogenesis [119]. Similar conclusions come from investigations of HML-2 Rec and 
Np9. Both proteins have been reported to interact physically and functionally with nuclear 
promyelocytic zinc finger (PLZF) protein, a tumor suppressor that has been implicated in 
leukemogenesis in humans and spermatogenesis in mice [48]. Also, Rat-1 fibroblasts stably expressing 
HML-2 Rec have undergone cell transformation when injected in immunodeficient mice [19]. 
Analogous experiments, with injection of cells overexpressing Np9 into mice, showed much faster 
tumor growth than controls without Np9 [33]. Np9 protein is highly expressed also in leukemia patients 
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where it may be essential for growth of myeloid and lymphoblastic leukemia cells [33]. When Np9 
was expressed in vitro or in vivo proliferation of leukemia cells was significantly promoted [33]. 
Moreover, crucial cellular pathways like ERK, AKT, Notch1 and β-catenin, involved in the survival 
of leukemia stem cells, were activated by Np9 [33]. 
 
HML-2 Env protein was found also in brain tissue from patients with ALS, where it could have a role 
in ALS pathophysiology [138,224]. Expression of Env protein in human neuronal cell cultures caused 
neurotoxicity and neuronal death [121]. Expression of Env protein in transgenic mouse neurons led to 
motor dysfunction, DNA damage, morphological and functional changes [121]. Thus, HML-2 could 
be involved in some neurologic diseases [35], although the contribution of HML-2 elements in 
neurodegeneration is speculative at the moment and requires further investigations [138]. 
 
A novel HML-2 protein derived from Env, called Env-SP, was identified in our laboratory [168]. Env-
SP is the signal peptide of HML-2 type 2 Env that, instead of being degraded, is relatively stable and 
localizes to various cell compartments [168]. It has been hypothesized that, in case of expression, Env-
SP may interfere with important cellular processes, potentially being involved in immune evasion of 
GCT cells or tumorigenesis [168]. 
 
As Env-SP, HML-2 dUTPase is another protein that it could be associated with detrimental effects if 
expressed, although its expression in human cells has not been investigated in detail yet. For example, 
it was demonstrated that dUTPase has a pro-inflammatory potential, triggering secretion of cytokines 
and activation of NF-κB and other immune response factors [5]. In this context, HML-2 dUTPase has 
been proposed as potential contributor to psoriasis, a chronic inflammatory immune disease of the skin 
[5]. 
 
Concerning HML-2 Gag, antibodies against that protein were detected in patients with GCTs, 
especially seminoma [179]. A larger amount of HML-2 Gag protein is produced in GCT tissues, where 
HML-2 protease-cleaved Gag was also detected, indicating presence of active HML-2 Pro in GCT 
tissue [179]. Immature and properly processed HML-2 Gag and Env proteins were observed also in 
plasma of patients with lymphoma [42]. 
Moreover, retrovirus-like particles derived from expression of HML-2 were observed in human 
teratocarcinoma many years ago [20,170]. Such viral particles were identified more recently also in 
melanoma [28,144], in the plasma of lymphoma patients [42] and in the context of multiple sclerosis 
[109]. It is known that Gag has the ability to induce the budding of virus-like particles from the cell, 
even when expressed in the absence of the other virus-encoded proteins. However, isolated retroviral 
particles harbor reverse transcriptase activity and were shown to contain mature forms of Gag and Env 
proteins [144], suggesting that apart from Gag, also other functional HML-2 components were 
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expressed and packaged into viral particles. Up to date, there is no study that demonstrated infectivity 
of HML-2 encoded particles budding from cells. However, taking into account that some HML-2 
elements are polymorphic, it is conceivable that in some individuals HML-2 proviral loci capable of 
producing infectious particles could exist [10]. It is also known that reversion of a few nucleotide 
mutations could render a defective provirus replication-competent, as demonstrated by two 
independent studies [50,118]. 
 
In summary, expression of HML-2 proviruses is known to be up-regulated in several disease-derived 
tissues. In those tissues, not only transcripts but also proteins, and retrovirus-like particles originating 
from HML-2 proviruses have been observed. HML-2 products may represent initiating factors and/or 
promoters of pathological conditions. Most evidence associates HML-2 products with tumorigenesis. 
Actual functional relevance of HML-2 products in disease contexts has not been confirmed with 
certainty so far. Further specific analyses are required. 
 
2.4 HERV-K(HML-2) encoded protease and integrase  
Some HML-2 proteins were not studied in greater detail so far, although they may have crucial roles 
in human health and disease as well. HML-2 encoded protease (Pro) and integrase (IN) were 
investigated in the work presented for their potential impact on cellular biology. In the following, 
typical features of retroviral Pro and IN will be summarized, followed by a description of current 
knowledge on HML-2 Pro and IN. As will be noted, currently available evidence regarding the impact 
of retroviral Pro and IN on cell biology derives from studies of exogenous retroviruses, in particular 
HIV-1. 
 
2.4.1 Retroviral proteases 
Retroviral proteases belong to a specific class within the family of aspartic proteases [220] and are 
functional as homodimers. A monomer is formed by the duplication of four core structural elements: 
a β-hairpin; a wide loop containing a highly conserved DTG (Asp-Thr-Gly) catalytic triad; a C-terminal 
α-helix; a second β-hairpin, also called “flap”, that is fundamental for the binding and release of 
substrates [220]. Dimerization of two Pro monomers in retroviral proteases creates a cleft between the 
two subunits, where substrate is bound and where the catalytic site is located [52]. The two aspartic 
acids from the DTG triad of each Pro monomer cooperate in presence of a water molecule to perform 
substrate lysis. Cleavage of substrates does not happen at random amino acid positions. Cleavage sites 
are recognized with a certain specificity that varies between retroviral proteases. For example, each 
retroviral protease can cleave with higher specificity cleavage sites in the polyproteins of its own virus 
[220]. When the substrate is accommodated in the Pro catalytic site, the efficiency of the cleavage 
derives from more or less favorable interactions between side chains of substrate and corresponding 
 15 
subsites located in the cleft of Pro. By convention, the peptide bond that is cleaved is referred to as the 
scissile bond, with flanking amino acids in N-terminal direction referred to as P1, P2, P3, etc. Amino 
acids flanking in C-terminal direction are referred to as P1′, P2′, P3′, etc. Accordingly, the scissile bond 
is located between P1 and P1′ [200]. The properties of amino acids in P1 and P1′ positions appear to 
be major determinants of Pro specificity. A study involving proteases from 10 different retroviruses 
reported that approximately 80% of all known Pro cleavage sites can be classified into two groups: 
type 1 sites have an aromatic residue in P1 (favouring phenylalanine or tyrosine) and prolin in the P1′ 
position; while type 2 sites favor leucine over phenylalanine or tyrosine in P1 and have a preference 
for valin, leucin or alanin in P1′ [154]. Amino acids with side chains branched at the β-carbon are 
excluded from the P1 position of both types. 
 
In several retroviruses, Pro is translated as part of a Gag-Pro polyprotein from which Pro is released 
by self-processing. The precise mechanism of the initial steps that release the Pro domain from the 
Gag-Pro precursor was studied for HIV-1 Pro [154]. It appears that through dimerization of two Gag-
Pro precursors the Pro domain embedded in the precursor can cause intra- or intermolecular release of 
free Pro [154]. The binding properties of the Gag domain enable interactions of precursor proteins and 
formation of viral particles through a process called particle assembly. Independent of the cellular 
compartment in which the assembly takes place (in the cell membrane for some retroviruses and in the 
cytoplasm for others) activation of Pro is known to typically occur during or after the budding of new 
retroviral particles from the host cellular membrane. During this phase, Pro activity induces a 
characteristic change of morphology in the virion that is called maturation [200]. However, several 
studies of retroviruses from different genera documented Pro activity also in the cytoplasm, thus not 
just during maturation of retroviral particles. For example, premature activation of Pro has been 
observed during acute HIV-1 infection, resulting in accumulation of processed HIV-1 Gag that was 
excluded from the assembly pathway [96]. In some HIV strains, up to 50% of HIV-1 Pro activity is 
not associated with virions due to low packaging efficiency [96]. Intracellular activation of HIV-Pro 
and intracellular processing of the HIV-1 Gag-Pol polyprotein was also observed when overexpressing 
Gag-Pol in cells [97]. For MMTV, that is phylogenetically closely related to HERV-K(HML-2), 
intracellular processing of MMTV Gag was also confirmed, with evident accumulation of unprocessed 
Gag polyprotein in presence of inactive Pro [223]. 
  
 16 
2.4.2 Cellular proteins as substrates of retroviral proteases 
In addition to catalyzing maturation of viral proteins, retroviral proteases may also process functionally 
relevant cellular proteins. Cleavage of such proteins may have severe consequences for cell biology, 
as demonstrated by several pubblications. A number of proteins associated with the cytoskeleton can 
be cleaved by HIV-1 Pro. Among those, cleavage of actin, vimentin, spectrin, desmin, myosin, 
tropomyosin, glial fibrillary acidic protein [187–189] and microtubule associated protein-2 [213] was 
demonstrated more than 20 years ago in vitro. Cleavage of actin and vimentin was also observed in 
vivo [79,204]. In the case of vimentin, the protein cleavage was accompanied by altered cytoskeletal 
architecture and nuclear morphology [79]. Also, it was observed that fibroblasts microinjected with 
HIV-1 Pro assume a rounded form, detached from the surface of the cell culture flask, or were dying 
[79]. Using the same approach, it was reported cleavage of various proteins comprising the focal 
adhesion plaque [190], a multi-protein structure necessary for interaction between cell and extracellular 
matrix, but also involved in signal transduction, cell proliferation and regulation of gene expression. 
Processing of vimentin was also reported for proteases of bovine leukemia virus, Mason–Pfizer 
monkey virus, and myeloblastosis-associated virus [194]. 
Wagner et al. (2015) [212] reported cleavage of serine-threonine kinases RIPK1 and RIPK2, both 
involved in innate immune response, by HIV-1 Pro, followed by reduced NF-kB activation [212]. NF-
kb is a protein complex that controls transcription, cytokine production and cell survival, whose 
regulation is critical during cellular stress. Interestingly, Rivière et al. (1991) [165] observed processing 
of the precursor of NF-kB during HIV-1 acute infection, with an increased level of active NF-kB in 
the nucleus [165]. Other important cellular factors processed by HIV-1 Pro are pro-interleukin 1β [204] 
and serine-threonine kinases NDR1 and NDR2 [49]. 
Among the restriction factors that are part of the cellular antiviral defense, cleavage of APOBEC3 by 
the proteases of murine retrovirus and feline immunodeficiency virus was observed [222]. Proteases 
from several members of the family Retroviridae, including MMTV, are able to cleave translation 
initiation factor eIF4GI, severely inhibiting cap-dependent translation [1]. Translation initiation factor 
eIF3d is also known to be targeted by HIV-1 Pro [87]. 
Of further note, a recent investigation reported more than 120 cellular substrates processed by HIV-1 
Pro in vitro, including proteins having functions with biological relevance [82]. In addition, several 
lines of evidence suggest that retroviral proteases may process cellular factors that can induce cell 
death. Nie et al. (2002) [146] demonstrated that HIV-1 Pro directly cleaves and activates procaspase 8 
in T-cells, followed by induction of the molecular events leading to apoptosis. Rumlová et al. (2014) 
[169] observed HIV-1 Pro localizing to mitochondria and demonstrated that HIV-1 Pro mediates 
cleavage of mitochondrial proteins Tom22, VDAC and ANT, leading to release of apoptosis-inducing 
factors. Blanco et al. (2003) [18] expressed HIV-1 Pro in yeast, observing drastic alteration of 
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membrane integrity followed by cell lysis. Similarly, HIV-1 Pro expression in mammalian COS7 cells 
increased plasma membrane permeability and cell lysis by necrotic processes [18]. 
 
Altogether, quite a number of host cellular proteins are susceptible to proteolysis by retroviral 
proteases. Proteins identified are diverse, locate to various cellular compartments and participate in 
various, often important cellular processes. Among those processes are, for instance, fundamental 
processes performed by the cytoskeleton (intracellular transport, chromosome segregation, cell 
signaling etc.), but also cell adhesion, innate immune response, cell signaling, translation initiation, 
apoptosis. For several proteins, e.g. actin, vimentin, RIPK1, RIPK2, NF-kB, NDR1, NDR2, eIF4GI, 
processing by retroviral protease was documented through experiments conducted in vivo, 
demonstrating that observed proteolytic events can take place in the cellular environment. There is 
evidence of detrimental effects on cell biology as a consequence of proteolytic activity of retroviral 
proteases, e.g, perturbation of the cytoskeletal organization along with alteration of cell morphology, 
altered levels of cellular regulatory factors, translation inhibition, induction of apoptosis, and cell lysis. 
 
2.4.3 HML-2 protease 
Sequence analysis and biochemical characterization of HML-2 Pro confirmed pronounced similarities 
with retroviral aspartic proteases [205]. Typical retroviral protease motifs are present in the HML-2 
Pro ORF, including the DTG motif, the flap motif and the GRDLL motif (corresponding to the C-
terminal α-helix) [207]. As in Betaretroviruses, the HML-2 Pro gene is located in a separate ORF [148]. 
Expression of the full-length HML-2 Pro ORF in bacteria resulted in self-processing of the translation 
product with accumulation of a ~18 kDa mature enzyme composed of 156 amino acids. The HML-2 
Pro core domain, corresponding to the 106 N-terminal amino acids of the mature enzyme, was defined 
on the basis of sequence similarity with HIV-1 Pro. That region is 28% identical with HIV-1 Pro on 
the amino acid level [205]. No similarity with HIV-1 Pro was observed for the C-terminal 50 amino 
acids, although such a C-terminal extension is characteristic for proteases of betaretroviruses. HML-2 
Pro is translated as a Gag-Pro polyprotein that self-processes and further processes Gag subdomains 
[143]. The cleavage sites of HML-2 Pro within HML-2 Gag were recently mapped by two different 
research groups [66,111]. For all cleavage sites identified, but one site, the amino acid in P1 was 
hydrophobic and unbranched at the β-carbon, whereas proline, tyrosine and valine were found in P1′. 
The HML-2 Pro N-terminal self-processing site was also identified [205]. Self-processing was 
demonstrated to occur at the aa sequence KAAY-WASQ, thus with a tyrosine in P1 and a Tryptophan 
in P1′. The C-terminal cleavage site has not been precisely mapped as yet, although initial studies 
subjecting a purified HML-2 Pro to prolonged incubation observed some limited cleavage in the region 
corresponding to the C-terminus of the Pro ORF [149,205]. In a recent publication, a profile of HML-
2 Pro cleavage site specificity was obtained from analysis of 95 cleavage sites identified through 
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incubation of a tryptic peptide library with purified HML-2 Pro. That study revealed for HML-2 Pro a 
preference for aromatic amino acids in P1 (thus suggesting a preference for retroviral Pro cleavage 
sites of type 1, see above), although a considerable proportion (21%) of cleavage sites had glycine in 
P1. Aromatic and aliphatic amino acid residues were found for P1′, and acidic residues (aspartic acid 
or glutamic acid) were found in 32% of cleavage sites for P2 [17]. 
Concerning cleavage specificity, it was also demonstrated that HML-2 Pro is able to process HIV-1 
Gag at the authentic MA/CA cleavage site of HIV-1 Pro [205]. That finding led to the hypothesis that 
HML-2 Pro may complement processing of HIV-1 poplyprotein during HIV-1 infection [205], a 
finding of potential relevance in view of the fact that HML-2 Pro was found insensitive to various 
HIV-1 Pro inhibitors used in treatment of HIV-infected patients [149]. 
 
Several HML-2 proviruses harboring an intact Pro ORF were identified in the human genome. Apart 
from the abovementioned HERV-K10, another example relevant for experiments performed in the 
present studies is a provirus discovered by our research group and originally termed HERV-K(HML-
2.HOM) [134], subsequently reported by other studies with alternative designations HERV-K108, 
HERV-K(C7) or ERVK-6, the latter being the official locus name [64]. Located in human chromosome 
7p22.1, HERV-K(HML-2.HOM) harbors full-length ORFs for all retroviral proteins, with an 
inactivating mutation only within the reverse transcriptase coding region. The proviral allele originally 
investigated was present as a tandem arrangement consisting of two proviruses and three LTRs, with 
the central LTR shared by both proviruses [161]. Extensive analysis identified allelic variants of 
HERV-K(HML-2.HOM), for example, alleles consisting of only a single provirus or a solo LTR, 
alleles with mutations within Gag or Pro domains and alleles with an intact reverse transcriptase 
[161,199]. Other HML-2 loci able to encode an intact Pro are known [118], and the majority of those 
loci also retain an intact gag gene, that is necessary for translation of Pro (see chapter 2.4.1). Potentially 
relevant variations in the Pro sequence have been found for different HML-2 proviruses that may affect 
interactions with substrates [207]. 
There is evidence of transcription of Pro-encoding HML-2 loci in various human tissues (for instance, 
see [58,183]). Moreover, considerable levels of HML-2 Gag protein are detectable in GCT tissues, 
where products of Gag processing, expected if processed by active HML-2 Pro, were identified [179]. 
In GCT cell lines, HML-2-encoded retroviral particles budding from the cellular membrane can also 
be identified [20,170]. Of note, HML-2-encoded retroviral particles with a morphology that suggested 
a maturation process due to Pro activity have been observed [16]. Thus, in those tissues and derived 
cell lines there is strong evidence of presence of enzymatically active HML-2 Pro. Moreover, bacterial 
expression of constructs harboring HML-2 Gag-Pro ORFs showed self-processing of Pro from the 
Gag-Pro precursor and processing of Gag subdomains [134,143], confirming functionality of HML-2 
Pro. 
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2.4.4 Retroviral integrases 
As their name suggests, retroviral integrases (INs) are enzymes that catalyze the integration of the 
retroviral dsDNA genome into the genome of the host cell. INs are commonly composed of three 
conserved domains: The N-terminal domain (NTD), the catalytic core domain (CCD), and the C-
terminal domain (CTD). The NTD contains a highly conserved HHCC motif, composed of two 
histidine (H) and cysteine (C) residues that, via binding of Zn2+, fold the NTD in a compact three-
helical bundle [120]. The CCD domain contains a DDE motif, composed of two highly conserved 
aspartic acid (D) residues and a glutamic acid (E) residue that together constitute a catalytic triad. The 
two aspartic acids coordinate a cationic cofactor, usually Mg2+, necessary for IN catalytic activity. The 
CTD domain contains conserved tryptophan residues and is involved functionally in the interaction 
with DNA, stabilizing the protein-DNA complex [120].  
IN is usually produced as part of the Gag-Pro-Pol polypeptide precursor, then released by Pro activity. 
In the cytoplasm, IN proteins assemble on viral dsDNA ends forming a stable nucleoprotein complex 
referred to as the intasome [120]. IN is catalytically active as a multimeric protein. The number of 
integrase molecules required to form the intasome differs between viral genera, for example, four 
subunits are typical for spumaviruses, whereas lentiviral IN comprises up to sixteen subunits [53]. 
Betaretroviruses employ eight IN subunits that create an octameric architecture, specifically a tetramer-
of-dimers [53]. Apart from IN and viral DNA, the intasome also includes host cellular proteins that 
have various functions, for example, identification of a suitable integration site or protection from 
proteolysis [67].Two of the IN molecules enclosed in the intasome carry out the integration process by 
virtue of two distinct reactions: 3´ processing and strand transfer [46]. The first reaction occurs in the 
cytoplasm during migration of the intasome toward the cellular nucleus. 3´ processing results in the 
removal of two (or three) nucleotides from each 3´ end of the retroviral dsDNA. Such cleavage is 
specific and occurs downstream of a conserved CA dinucleotide present in retroviral LTRs. A 
nucleophilic attack by the OH group of a water molecule is involved, although other molecules may 
also provide the nucleophile necessary for this process [193]. After 3´ processing, the retroviral dsDNA 
presents recessed 3´-OH ends exposing highly reactive hydroxyl groups. The strand transfer takes place 
when the intasome, having entered the cell nucleus, approaches and interacts with the host DNA. At 
that stage, IN coordinates a nucleophilic attack by the retroviral free 3´ hydroxyl groups to a 
phosphodiester bond of the host DNA. This reaction occurs at both ends of the viral DNA molecule 
with an offset of some base pairs between the two points of insertion. As a consequence of integrase-
mediated joining, the two ends of viral DNA are ligated to the target DNA, however portions of single-
stranded DNA (ssDNA) remain between host DNA and provirus. After the strand transfer, the cellular 
DNA repair machinery is necessary to restore genome integrity, thus complete the integration [120]. 
3´ processing and strand transfer have been modelled in vitro using short oligonucleotide substrates 
designed to mimic the retroviral DNA LTRs [100]. Experiments in vitro demonstrated that IN can also 
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exhibit two other activities: 1) disintegration, which may be considered as the strand transfer reaction 
in reverse [34]; 2) nonspecific alcoholysis, that takes place through nucleophilic attack of the DNA 
phosphodiester bonds by the OH group from a variety of molecules, including small alcohol molecules 
[99–101,193]. Through the latter activity, IN can potentially induce nicking of any DNA target 
sequence at almost any internal site. 
 
2.4.5 Retroviral integrases as cause of DNA damage 
Disruption of genome integrity by new provirus integrations, temporary formation of ssDNA gaps 
during the integration process and DNA lesions (potentially) induced by nonspecific alcoholysis are 
processes by which an IN could potentially induce genomic instability of the host cell. Each time that 
the stable structure of a dsDNA is altered and an ssDNA region becomes exposed, there is a hotspot 
for the formation of a DNA double-strand break (DSB), a serious damage in a cell genome [176]. DSBs 
impact cellular processes drastically, for instance, inducing transcriptional activation of genes, post-
transcriptional modifications, genetic recombination, cell-cycle arrest, and in some cases, programmed 
cell death [44,103]. DSBs are typically repaired by the cellular repair system in order to prevent cell 
health, but gene translocations, rearrangements, amplifications, and deletions arising during repair and 
misrepair of DSBs may contribute to cell transformation and tumor development [210]. 
There is evidence to believe that retroviral IN can induce DNA damage in the cell genome, potentially 
resulting in formation of DSBs. It was observed that cells respond to retroviral DNA integration by 
activating the repair machinery in a manner similar to the DSB response [176], thus suggesting 
formation of DSBs due to presence of IN activity. A decrease in retroviral infectivity has been observed 
in cells lacking DSB repair enzymes [44], suggesting that during retroviral integration there is 
formation of DSBs that need to be repaired for efficient completion of the retroviral DNA integration. 
Although the biological role of IN nonspecific alcoholysis (see above) is unknown, it is conceivable 
that, if occurring in cells, such uncontrolled activity may cause DNA damage in the cell genome. For 
instance, in a previous study, expression of HIV-1 IN in yeast cells led to a lethal phenotype that was 
not induced in presence of inactive HIV-1 IN mutated in the DDE motif [151]. Considering that there 
were no HIV-1 LTRs present in yeast, it has been hypothesized that cell death in that case was due to 
nonspecific alcoholysis, causing cleavage of genomic DNA and cell death. It appears that IN activity 
can also interfere with DNA recombination both in vitro and in vivo [151], thus providing further 
support to the notion that retroviral IN may be a source of genomic instability. 
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2.4.6 HML-2 integrase 
An HML-2 IN domain was originally identified in the HERV-K10 provirus by sequence similarity 
with Rous sarcoma virus (RSV) IN [105]. Specifically, HML-2 IN is encoded by the 3´ region of the 
pol gene, where a sequence corresponding to a 288 aa protein, was demonstrated to suffice for IN 
functionality [105]. Protein modelling indicated for HML-2 IN the typical domain architecture of 
betaretroviral IN [25]. Several HML-2 loci potentially able to encode a full-length IN have been 
identified in the human genome. Apart from proviruses HERV-K10 and HERV-K(HML-2.HOM) 
mentioned above, at least another 20 HERV-K(HML-2) proviruses containing a full-length IN were 
identified [25]. Among HML-2 proviruses with full-length IN, 9 displayed intact active sites motifs 
and no known inactivating mutations [25]. Those 9 loci have been shown to be transcriptionally active 
[15,58]. Functionality of HML-2 IN was demonstrated through a series of experiments conducted in 
vitro, using short substrates mimicking retroviral LTR ends. In those experiments, HML-2 IN could 
efficiently perform 3’ processing and strand transfer on HML-2 LTR substrates, but it was also active 
on LTR substrates derived from HIV-1 and RSV [105]. The relaxed substrate specificity of HML-2 IN 
appeared to be a peculiar characteristic of this enzyme not typical for other retroviral INs. For example, 
HIV-1 IN and RSV IN could act only on their own viral LTRs [105]. It is conceivable that HML-2 IN 
can also perform nonspecific alcoholysis, although never investigated so far. In view of the numerous 
human loci containing an intact HML-2 IN, and in view of the HML-2 IN activities confirmed in vitro, 




2.5 Aims of the study 
Although most of HERVs have been severely mutated during evolution, the HML-2 group includes 
proviruses that still encode intact proteins. Some HML-2 proteins exhibit activities that could 
potentially damage the cell, with consequential activation of pathological processes. HML-2 
upregulation and HML-2 proteins have been documented in various human diseases whose causes are 
not fully understood. HML-2 proteins may play a role in the development of those diseases. Thus, 
investigation into HML-2 proteins could be the key to clarify the biological mechanisms behind some 
human conditions. 
 
In the present study, we focused on HML-2 protease (Pro) and HML-2 integrase (IN), two enzymes 
that have not been extensively investigated concerning biological and clinical significance. 
 
Regarding HML-2 Pro, it was previously confirmed through experiments in vitro and in vivo that the 
enzyme is functional against HML-2 Gag, a protein specifically processed by HML-2 Pro in the context 
of the retroviral replication cycle. Processing products of HML-2 Gag protein were observed in germ 
cell tumors and derived cell lines, indicating presence of an endogenous active HML-2 Pro in those 
cells. Considering evidence of active HML-2 Pro in human cells, it was interesting to know whether, 
apart from targeting its specific retroviral substrates, HML-2 Pro activity could also target cellular 
proteins. As for the latter point, there is well documented evidence for some other retroviral proteases, 
among them HIV-1 Pro. Through cleavage of cellular proteins, HML-2 Pro could potentially affect 
cellular processes leading to pathological cell states. The ability of HML-2 Pro to process cellular 
proteins was not investigated so far. 
 
Particular investigations of HML-2 Pro comprised the main part of the study. The major aims were to 
establish whether HML-2 Pro is able to process cellular proteins and to identify cellular proteins 
specifically cleaved by this enzyme. We also aimed at producing initial indications of how cells 
respond to HML-2 Pro expression, thus providing initial insights into a functional impact of HML-2 
Pro on cell biology and possible relevance for human diseases. To achieve major aims, we 
accomplished various sub-aims. We aimed at purifying HML-2 Pro by applying a procedure suited to 
preserve enzymatic functionality. We also aimed at purifying a mutated, enzymatically inactive HML-
2 Pro. Employing a specifically designed fluorescence in vitro assay, we aimed at characterizing the 
enzymatic activity of HML-2 Pro biochemically and optimizing reaction conditions for subsequent 
experiments. Incubating purified HML-2 Pro with native human proteins in vitro and subsequently 
subjecting reactions to a sophisticated proteomics technique called terminal amine isotope labeling of 
substrates (TAILS), we aimed at identifying cellular proteins cleaved by HML-2 Pro in vitro and 
producing a list of human proteins that could be considered as substrates of HML-2 Pro. We also aimed 
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at validating selected cellular substrates of HML-2 Pro in more specific experiments suited to verify 
processing of cellular proteins in vitro and in vivo. We aimed at gathering indications of cellular 
processes and molecular pathways that might become affected by HML-2 Pro activity. We therefore 
compiled for cellular substrates of HML-2 Pro information on cellular localization, cellular processes, 
and involvement in diseases, employing suited bioinformatics tools.  
 
Regarding HML-2 IN, it was previously demonstrated through experiments in vitro that HML-2 IN 
can interact with DNA and perform catalytic reactions that disrupt DNA integrity. If expressed in cells, 
HML-2 IN might interact with the host genomic DNA and induce DNA damage leading to DNA 
double-strand breaks (DSBs). As an endogenous potential genotoxic agent, HML-2 IN could represent 
a contributor to genomic instability, a hallmark of various human diseases including cancer. The notion 
that HML-2 IN might be a cause of genomic instability is intriguing, but there is no experimental 
evidence in support of this hypothesis. There is even lack of knowledge as to whether HML-2 IN 
localizes in the cell nucleus, which is prerequisite for speculations on an impact of HML-2 IN at level 
of the cell genome. 
 
The second part of our study therefore concerned HML-2 IN. We aimed at assessing experimentally 
whether HLM-2 IN causes DNA damage. In particular, we performed immunofluorescence 
experiments targeting transiently expressed HA-tagged HML-2 IN and a biomarker for DSBs thereby 
evaluating whether HML-2 IN could localize to the cell nucleus and induce DSBs in the cell genome. 
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1,4-Dithiothreitol (DTT) Carl Roth (Karlsruhe, Germany) 
5-Brom-4-chlor-3-indoxyl-β-Dgalactopyranosid (X-Gal) AppliChem (Darmstadt, Germany) 
Acetic Acid Glacial ≥ 99.7% VWR (Radnor, USA) 
Acrylamid/Bisacrylamid (30%) (37,5:1) Bio-Rad (Hercules, USA) 
Agar, Bacto BD (Franklin Lakes, USA) 
Agarose, Ultra Pure Invitrogen/Life Technologies (Carlsbad, USA) 
Ammonium Peroxodisulfate (APS) Carl Roth (Karlsruhe, Germany) 
Ampicillin-Natriumsalt Carl Roth (Karlsruhe, Germany) 
Anthranilyl-HIV Protease Substrate Trifluoroacetate salt Bachem (Bubendorf, Switzerland) 
Bis(2-hydroxyethyl)amino-tris(hydroxymethyl) methan 
(Bis-Tris) 
Carl Roth (Karlsruhe, Germany) 
Bovine Serum Albumin (BSA)  Sigma-Aldrich (St. Louis, USA) 
Brilliant Blue R250 Carl Roth (Karlsruhe, Germany) 
Bromophenol Blue Carl Roth (Karlsruhe, Germany) 
cOmplete EDTA-free protease inhibitor cocktail Sigma-Aldrich (St. Louis, USA) 
Deoxynucleoside Triphosphate Set (dNTPs) Roche (Basel, Schweiz) 
Dimethyl sulfoxide (DMSO) Carl Roth (Karlsruhe, Germany) 
Dulbecco’s Phosphate Buffered Saline (DPBS) Gibco/Life Technologies (Carlsbad, USA) 
Ethidium Bromide Carl Roth (Karlsruhe, Germany) 
Ethylene Glycol Carl Roth (Karlsruhe, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth (Karlsruhe, Germany) 
Formaldehyde Solution 37% Carl Roth (Karlsruhe, Germany) 
Glycerin Zentrales Chemikalienlager, UdS, Saarbrücken 
Indinavir Sulfate (orb321983) Biozol (Eching, Germany) 
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) Carbolution Chemicals GmbH (St. Ingbert, 
Germany) 
L-35S-methionine (370 MBq, 10mCi/ml) Hartmann Analytic (Braunschweig, Germany) 
Kanamycin Sigma-Aldrich (St. Louis, USA) 
Methanol Zentrales Chemikalienlager, UdS, Saarbrücken 
N,N,N’,N’-Tetramethylethylendiamin (TEMED) Sigma-Aldrich (St. Louis, USA) 
NuPAGEÔ 4x LDS Sample Buffer Thermo Fisher (Waltham, USA) 
NuPAGEÔ Antioxidant Thermo Fisher (Waltham, USA) 
NuPAGEÔ MES SDS Running Buffer Thermo Fisher (Waltham, USA) 
NuPAGEÔ MOPS SDS Running Buffer Thermo Fisher (Waltham, USA) 
NuPAGEÔ Transfer Buffer Thermo Fisher (Waltham, USA) 
Opti-MEMÔ Reduced Serum Medium (31985062) Gibco/Life Technologies (Carlsbad, USA) 
Pancaspase Inhibitor Q-VD-Oph hydrate Sigma-Aldrich (St. Louis, USA) 
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Pepstatin A Calbiochem Merck/Millipore (Burlington, 
USA) 
Pepstatin A−Agarose Sigma-Aldrich (St. Louis, USA) 
Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) Carl Roth (Karlsruhe, Germany) 
Poly-L-Lysine Hydrobromide Sigma-Aldrich (St. Louis, USA) 
Ponceau S P3504 Sigma-Aldrich (St. Louis, USA) 
Potassium Sodium Tartrate Tetrahydrate Carl Roth (Karlsruhe, Germany) 
Powdered Milk Blotting Grade  Carl Roth (Karlsruhe, Germany) 
Rotiphorese NF-Urea Carl Roth (Karlsruhe, Germany) 
Sodium Chloride (NaCl) VWR (Radnor, USA) 
Sodium Deoxycholate Sigma-Aldrich (St. Louis, USA) 
Sodium Dodecyl Sulfate (SDS) Carl Roth (Karlsruhe, Germany) 
Sodium Hydroxide (NaOH) Zentrales Chemikalienlager, UdS, Saarbrücken 
Tris(hydroxymethyl)-Aminomethan (Tris) Carl Roth (Karlsruhe, Germany) 
Triton X-100 Carl Roth (Karlsruhe, Germany) 
Trypan Blue Solution Sigma-Aldrich (St. Louis, USA) 
Trypton, Bacto BD (Franklin Lakes, USA) 
TweenÒ-20 Carl Roth (Karlsruhe, Germany) 
VectashieldÒ Mounting Medium with DAPI  Vector Laboratories (Burlingame, USA) 
Yeast Extract, Bacto BD (Franklin Lakes, USA) 
 
3.1.2 Buffers 
Buffers for agarose gel electrophoresis 
1x TAE Running Buffer  10x DNA Loading Buffer 
40 mM Tris-HCl, pH 8.0  10% [v/v] 10x TAE Running Buffer 
1 mM EDTA  70% [v/v] Glycerol 
20 mM Glacial acetic acid  20% [v/v] 20 mM EDTA, pH 8.0 
   0.2 g Bromophenol blue 
Buffers for protein recovery from inclusion bodies 
5x TE Buffer  Solving Buffer 
0,1M Tris-HCl pH 7.5  0,1M Tris-HCl pH 7.5 
5 mM  EDTA  8 M Urea 
   1 mM  DTT 
Dialysis Buffer    
20 mM  PIPES, pH 6.5    
1 M  NaCl    
1 mM  DTT    
Buffers for protease purification by affinity chromatography 
Buffer A  Buffer B  
50 mM PIPES, pH 6.5  0.1 M  Tris-HCl, pH 8.0 
1 M  NaCl  1 mM NaK tartrate 
1 mM  EDTA  10% [v/v] Glycerol 
1 mM NaK tartrate  5% [v/v] Ethylene glycol 
10% [v/v] Glycerol    
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Buffers for Western blot    
10x TBS (Tris-Buffered Saline)  TBS-T  
500 mM Tris-HCl, pH 7.5  1x  TBS 
1.5 M NaCl  0.05% [v/v] Tween 20 
Blocking Buffer 
   
1x  TBS    
5% [w/v] Nonfat dry milk    
     
Buffers for protein staining    
Coomassie Staining Solution  Coomassie Destaining Solution 
0.2% [w/v] Coomassie Brilliant Blue R250  50% [v/v] Methanol 
50% [v/v] Methanol  10% [v/v] Acetic acid 
10% [v/v] Acetic acid    
Ponceau S Solution 
   
0.1% [w/v]  Ponceau S     
10% [v/v] Acetic acid    
     
Buffer for lysis of mammalian cells under denaturing conditions  
RIPA Buffer 
50 mM Tris-HCl, pH 8.0    
150mM NaCl    
1% [v/v] NP-40    
0.5% [w/v] Sodium deoxycholate    
0.1% [w/v] SDS    
 
3.1.3 Enzymes 
Enzyme Buffer Manufacturer 
BamHI-HF® (20000 U/ml) CutSmart® Buffer NEB (Ipswich, USA) 
BglII (10000 U/ml) NEBufferä 3.1 NEB (Ipswich, USA) 
EcoRI-HF® (20000 U/ml) CutSmart® Buffer NEB (Ipswich, USA) 
HindIII (10000 U/ml) NEBufferä 2.1 NEB (Ipswich, USA) 
MscI (10000 U/ml) CutSmart® Buffer NEB (Ipswich, USA) 
NheI-HF® (20000 U/ml) CutSmart® Buffer NEB (Ipswich, USA) 
NotI-HF® (20000 U/ml) CutSmart® Buffer NEB (Ipswich, USA) 
Phusion® High-Fidelity DNA 
Polymerase (2000 U/ml) 
5x Phusion® HF Buffer NEB (Ipswich, USA) 
PstI (10000 U/ml) NEBufferä 3.1 NEB (Ipswich, USA) 
rAPid Alkaline Phosphatase (1000 
U/ml) 




T4 DNA Ligase (400000 U/ml) T4 DNA Ligase Buffer (10x) NEB (Ipswich, USA) 
T4 Polynucleotide Kinase (10000 
U/ml) 
T4 DNA Ligase Buffer (10x) NEB (Ipswich, USA) 
Taq DNA Polymerase (5000 U/ml) 10x PCR Buffer with MgCl2 Merck/Sigma-Aldrich (St. 
Louis, USA) 
Trypsin-EDTA  Gibco/Life Technologies 
(Carlsbad, USA) 
XhoI (10000 U/ml) NEBufferä 3.1 NEB (Ipswich, USA) 
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3.1.4 Molecular biology kits 
Kit name Manufacturer 
FuGENE® HD Transfection Reagent Promega (Madison, USA) 
NucleoBondÒ PC 100 Macherey-Nagel (Düren, Germany) 
NucleoSpinÒ Gel and PCR Clean-up Macherey-Nagel (Düren, Germany) 
peqGOLD Plasmid Miniprep Kit I Peqlab (Erlangen, Germany) 
pGEM®-T Easy Vector System Promega (Madison, USA) 
SignalFire™ Elite ECL Reagent Cell Signaling Technology (Zweigniederlassung, Germany) 
TNT® T7 Quick for PCR DNA Promega (Madison, USA) 
 
3.1.5 Antibodies 
Primary antibodies * 
Antibody Host / Clonality Dilution Manufacturer 
α-53BP1 Alexa Fluor 488 
(NB100-304AF488) 
Rabbit / Polyclonal IF 1:800 Novus Biologicals USA (Littleton, 
USA) 
α-53BP1 (NB100-304) Rabbit / Polyclonal IF 1:5000 Dr. Nadine Schuler (Klinik für 
Strahlentherapie und Radioonkologie. 
Homburg, Germany) 
α-HML-2 Gag n. 2548  Rabbit / Polyclonal WB 1:800 Mueller-Lantzsch et al. 1993 [143] 
α-GFP Rabbit / Polyclonal WB 1:1000 Prof. Dr. Schlenstedt Gabriel 
(Homburg, Germany) 
α-HA (clone 3F10) Rat / Monoclonal WB 1:5000 
IF 1:800 
Prof. Dr. Friedrich Grässer (Institute of 
Virology, University of Saarland. 
Homburg, Germany) 
α-Histone H3 (D1H2) Rabbit / Monoclonal WB 1:2000 Cell Signaling Technology 
(Zweigniederlassung, Germany) 
α-HML-2 Pro n. 9367  Rabbit / Polyclonal WB 1:1000 
IF 1:1000 
Schommer et al. (1996) [185] 
α-Ki67/MKI67 Mouse / Monoclonal IF 1:1000 Novus Biologicals USA (Littleton, 
USA) 
    
Apoptosis Western Blot Cocktail  Abcam (Cambridge, UK) 
250x primary antibodies 
cocktail containing: 
 WB 1:250  
α-Actin Rabbit / Monoclonal 
α-Pro/p17-caspase-3 Rabbit / Monoclonal 
α-Cleaved PARP1 Mouse / Monoclonal 
* Antibody dilutions employed are reported for Western blot (WB) and/or immunofluorescence (IF) 
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Secondary antibodies * 
Antibody Host / Clonality Dilution Manufacturer 
α-Mouse IgG (A9044)  Rabbit/Polyclonal WB 1:5000 Merck/Sigma-Aldrich (St. 
Louis, USA) 
α-Rat IgG (A5795)  Rabbit / Polyclonal WB 1:5000 Prof. Friedrich Grässer 
(Institute of Virology, 
University of Saarland) 
α-Rabbit IgG Alexa Fluor 488  Goat / Polyclonal IF 1:1000 Invitrogen/Fisher Scientific 
(Waltham, USA) 
α-Rat IgG Alexa Fluor 594  Goat / Polyclonal IF 1:1000 Invitrogen/Fisher Scientific 
(Waltham, USA) 
α-Mouse IgG Alexa Fluor 647  Goat / Polyclonal IF 1:1000 Invitrogen/Fisher Scientific 
(Waltham, USA) 
 
Apoptosis Western Blot Cocktail  Abcam (Cambridge, UK) 
100x secondary antibodies 
cocktail containing: 
 WB 1:100  
α-Mouse IgG Goat/Polyclonal   
α-Rabbit IgG Rabbit/Monoclonal   
* Antibody dilutions employed are reported for Western blot (WB) or immunofluorescence (IF) 
 
3.1.6 Molecular standards for agarose and polyacrylamide gels 
Lengths of DNA fragments in agarose gel were estimated employing the 2-Log DNA Ladder (0.1-10.0 
kb) (N3200S, New England Biolabs, Ipswich, USA). 5-10 µl per lane of 2-Log DNA Ladder were 
loaded onto at least one lane per agarose gel. Molecular weight of proteins in SDS-PAGE and Western 
Blot was estimated employing the Precision Plus Protein Dual Color Standards (1610374, Bio-rad, 




Figure 3: Molecular weight standards for agarose and polyacrylamide gel electrophoresis. A) 2-Log DNA 
Ladder (0.1-10.0 kb) (N3200S, New England Biolabs, Ipswich, USA). B) Precision Plus Protein Dual Color 
Standards (1610374, Bio-rad, Hercules, USA). 
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3.1.7 Culture media and cell lines 
Prokaryotic cell culture media 
LB-Medium   LB-Agar for plates 
1% [w/v] Trypton  1.5% [w/v] Agar 
0.5% [w/v] Yeast extract  in LB-Medium 
170 mM NaCl   
pH 7.0    
 
Prokaryotic cell culture media were subjected to autoclave sterilization. LB-Agar was cooled down to 
approximately 50°C and poured in sterile Petri dishes immediately after sterilization of the LB-Agar 
solution. LB-Medium and LB-Agar plates were stored at 4°C. 
 
Antibiotic standard concentrations 
Ampicillin Kanamycin 
100 µg/ml 50 µg/ml 
 
LB-Medium and LB-Agar plates supplemented with ampicillin at standard concentration are referred 
to in the text as LBamp and LB-Agaramp plate, respectively. 
 
Mammalian cell culture media 
Medium Manufacturer 
Dulbecco's Modified Eagle's Medium (DMEM) (41966029) Gibco/Life Technologies (Carlsbad, 
USA) 
RPMI-1640 (21875034) Gibco/Life Technologies (Carlsbad, 
USA) 
Opti-MEMÔ Reduced Serum Medium (31985062) Gibco/Life Technologies (Carlsbad, 
USA) 
 
DMEM and RPMI media were supplemented with: 
 
10% [v/v] Heat-Inactivated Fetal Bovine Serum (FBS) (S0615 
0114G) 
Merck/Millipore (Burlington, USA) 




Cell line Source 
NEBÒ 5-alpha Competent E. coli (High Efficiency) (C2987H) NEB (Ipswich, USA) 





Cell line Tissue (human) Tumor type Medium Usual split ratio for 
culturing 
HEK293T Embryonic kidney  DMEM 1:30 
HeLa (DSMZ) Cervix Cervical cancer DMEM 1:10 
MeWo Skin, derived from lymph 
node-metastasis 
Melanoma RPMI 1:10 
SK-MEL-28 Skin, derived from axillary 
lymph node-metastasis 
Melanoma RPMI 1:5 













General purpose Manufacturer 
pET11d Low  Ampicillin Protein expression in 
prokaryotic cells 
Agilent (Santa Clara, USA) 
phCMV High  Ampicillin Protein expression in 
eukaryotic cells  
In-house, originally 
contributed by Dr. Alessia 
Ruggieri 
pEGFP-C1 High Kanamycin, 
Neomycin 
Expression of EGFP protein 
or EGFP-fused proteins in 
eukaryotic cells 
Clontech Laboratories 
(Otsu, Japan)  
pcDNA3.1  High Ampicillin, 
Neomycin 




pSG5 High Ampicillin Protein expression in 
eukaryotic cells 




High  Ampicillin Sub-cloning of DNA 
constructs 





Oligonucleotides were synthesized by Eurofins MWG Genomics GmbH (Ebersberg, Germany). 
Purification method was High Purity Salt Free (HPSF), a cartridge purification technology based on 
liquid chromatography. The usual synthesis scale was 0.01 µmol or 0.05 µmol for oligonucleotides 
with lengths less or greater than 50 bases, respectively. 
Upon reception, primers were resuspended in H2Odd to produce a 100 µM stock solution, based on 
information provided by the manufacturer. For each primer, a working solution of 25 µM was prepared 
for setting up PCR reactions. 
 
Table 1: Primers used for generation of DNA constructs for protease and integrase expression * 
Primers for protease studies  
Primer name Orientation Sequence (5´-3´direction) Remarks 
HOMProFOR  forward AGCTAGCGACTATAAAGGCGAAATTCAA NheI restriction site 
HOMProREV reverse AGGATCCTTAGGGCATGGTGATTTCCGCACC BamHI restriction site 
Pro3415F forward AGGATCCGCCGCCACCATGGGAAGCACTGATCCA
ACAGG 
BamHI restriction site; 
Kozak sequence 
Pro3946R reverse AGGATCCGGTTTAGGAGGCTCTACAGTGG BamHI restriction site 
phCMV-GFPpro 
FOR 
forward CGCGGATCCGGAAGCACTGATCCAACAGG BamHI restriction site 
phCMV-GFPpro 
REV 
reverse CGCGGATCCGGTTTAGGAGGCTCTACAGTGG BamHI restriction site 
Pro-mutDTG-FOR forward GGTAAACACTGGAGCAGATGT Introduction of a  
G->A substitution 
Pro-mutDTG-REV reverse AACCCTTCAAACTGTTTTCCTTGA  
Pro-mutCGA-FOR forward TCTGTGGGGTAAAGATTTATTAC Introduction of a  
CG->AA substitution 
Pro-mutCGA-REV reverse TTAAGAGGAATTGAAGTAATCATTG  
 
Primers for integrase studies  
Primer name Orientation Sequence (5´-3´direction) Remarks 
HOM-HA-IN-FOR  forward GGATCCACCATGGCATATCCTTATGATGTTCCTG
ATTATGCTGCAGGGCCTTTGACTAAAGC 
BamHI restriction site; 
Kozak sequence, HA-
tag 
HOM-HA-IN-REV reverse GGATCCTAGGTGCTTTTCTTTGCATCTC BamHI restriction site 
HOM-INdelDNGfor forward CCAGGATATTGTAGTAAAGCTTTC  
HOM-INdelDNGrev reverse AGTTTTGATTTTTTCTGGAACTCC  
* Names and sequences of primers employed for generation of plasmid constructs for prokaryotic expression, 
eukaryotic expression and site-directed mutagenesis of HML-2 protease and HML-2 integrase. Restriction sites 
in oligonucleotide sequences are underlined, Kozak sequence is in italics and HA-tag is in bold. Nucleotide 
substitutions are double underlined. 
 
Table 2: Primers for amplification of DNA templates employed for generation of proteins through in vitro 
transcription/translation system * 
Primer Name Orientation Sequence (5´-3´direction) 
T7gesgag-2 forward GGATCCTAATACGACTCACTATAGGAACAGACCACCATGGGGCAAACTAAAAGT 
gesgagREV reverse TAGGCAGGGGTCCATATAC 
MAP2K2-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCTGGCCCGGAGGAAG 
MAP2K2-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTACACGGCGGTGCGCG 
C15ORF57-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGAAAATGTTTGAGAGCG
CTG 
C15orf57-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTACTGTTCTGCTGCTGCTGG 
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HSP90AB1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCCTGAGGAAGTGCACC 
HSP90AB1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAATCGACTTCTTCCATGCGAG 
FSCN1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGACCGCCAACGGCACA 
FSCN1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGTACTCCCAGAGCGAGGC 
CALR-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCTGCTATCCGTGCCG 
CALR-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTACAGCTCGTCCTTGGCCT 
PSMC4-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGGAGGAGATAGGCATCT
TGG 
PSMC4-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTACTTGTAAAACTCATGCTCCTGC 
DDX3X-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGAGTCATGTGGCAGTGG
A 
DDX3X-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGTTACCCCACCAGTCAACC 
S100A4-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGGCGTGCCCTCTGG 
S100A4-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTATTTCTTCCTGGGCTGCTTATC 
ENO1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGTCTATTCTCAAGATCC
ATGCC 
ENO1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTACTTGGCCAAGGGGTTTCTG 
PDIA3-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCGCCTCCGCCG 
PDIA3-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGAGATCCTCCTGTGCCTTCT 
RNASEH2B-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGGCCGCTGGCGTG 
RNASEH2B-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGGAAGGACAAACTGAAACATGTAAA 
TUBA1A-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCGTGAGTGCATCTCCA 
TUBA1A-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGTATTCCTCTCCTTCTTCCTCAC 
CIAPIN1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGGCAGATTTTGGGATCT
CTG 
CIAPIN1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGGCATCATGAAGATTGCTATCAC 
RANBP1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGAGGACCATGATTTCCA
CTG 
RANBP1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTATTGCTTCTCCTCAGCATCCT 
HSP90AA1-FOR forward GGATCCTAATACGACTCACTATAGGGAACAGCCACCATGCCTGAGGAAACCCAGA 
HSP90AA1-REV reverse TTAAGCGTAATCTGGAACATCGTATGGGTAGTCTACTTCTTCCATGCGTGAT 
* Target sequence-specific sequence portions are underlined, Kozak sequence is in italics, T7 primer is underlined 
with a dashed line, HA-tag is in bolb. All reverse primers include a stop codon (TTA or TAG) at the 5´end (thus 
at the 3' end of the final PCR-product). 
 
Table 3: Primers used for sequencing of plasmids generated in this study 
Primer name Orientation Sequence (5´-3´direction) 
CMV fwd forward CGCAAATGGGCGGTAGGCGTG 
EGFP-C F forward CATGGTCCTGCTGGAGTTCGTG 
pEGFP-C.rev reverse TGCATTCATTTTATGTTTCAGG 
SP6 reverse GATTTAGGTGACACTATAG 






Agarose gel electrophoresis chamber Renner GmbH (Dannstadt, Germany) 
Analytical balance (Basic) Sartorius (Göttingen, Deutschland) 
Analytical precision balance (Europe 60) Gibertini Elettronica (Novate Milanese, Italy) 
Autoclave (VE-150) Systec (Wettenberg, Germany) 
Automatic cell counter (Luna) Logos Biosystems (Annandale, USA) 
Biophotometer (6131) Eppendorf (Hamburg, Germany) 
Blotting system (XCell II™ Blot module) Invitrogen/Life Technologies (Carlsbad, USA) 
Blue light transilluminator (Flu-0-Blu) Biozym Scientific (Hessisch Oldendorf, 
Germany) 
CCD-camera (DP71) Olympus (Tokyo, Japan) 
CCD-camera (LU105M) Lumenera (Ottawa, Kanada) 
Centrifuge (Rotofix 32) Hettich (Tuttlingen, Germany) 
Centrifuge (Universal 1200-01 D-7200) Hettich (Tuttlingen, Germany) 
Dounce homogenizer  Fortuna (Germany) 
Electrophoresis system (PerfectBlueTM Mini ExW) Peqlab/Avantor (Erlangen, Germany) 
Electrophoresis system (XCell SureLock™ Mini-Cells) Invitrogen/Life Technologies (Carlsbad, USA) 
Flow cytometer (BD FACSCanto™ II) BD Biosciences (San Jose, USA) 
Freezing container (CoolCell) BioCision (Mill Valley, USA) 
Gel documentation system (DeVision Dbox) DC Science Tec (Hohengandern, Germany) 
Horizontal mixer (RM-5) CAT (Ballrechten-Dottingen, Germany) 
Ice machine (F75L) Migel (Milano, Italy) 
Imaging system (Chemidoc Touch) Bio-Rad (Hercules, USA) 
Incubation shaker (Multitron II) Infors (Basel, Switzerland) 
Incubator (Galaxy 170S CO2) Eppendorf (Hamburg, Germany) 
Incubator (Jouan) Thermo Fisher Scientific (Waltham, USA) 
Inverted light microscope (Axiovert 25) Carl Zeiss (Jena, Germany) 
Liquid nitrogen tank (Biosafe-MDβ) Cryotherm (Denver, USA) 
Magnetic stirrer (IKAMAG RCT) IKA (Staufen, Germany) 
Microcentrifuge (MIKRO 120) Hettich (Tuttlingen, Germany) 
Micropipettes (Pipetman) (10-20-200-1000 µl) Gilson (Middleton, USA) 
Microplate reader (Spark 10M) Tecan (Männedorf, Switzerland) 
Microscope (AX70 system) Olympus (Tokyo, Japan) 
Mixing block (MB-102) Bioer (Hangzhou, China) 
Molecular imager (Typhoon 9410) GE Healthcare (Uppsala, Sweden) 
pH meter (Seven Easy) Mettler-Toledo (Gießen, Germany) 
Pipette controller (accu-jet pro) Brand (Wertheim, Deutschland) 
Power supply (Standard Power Pack p25) Biometra/Analytikjena (Göttingen, Germany) 
Refrigerated centrifuge (2-16K) Sigma (Osterode am Harz, Germany) 
Refrigerated microcentrifuge (5417R) Eppendorf (Hamburg, Germany) 
Shaker (KS 125 Basic) IKA (Staufen, Germany) 
Shaker (VORTEX 3) IKA (Staufen, Germany) 
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Sonicator (Ultrasonics Sonifier S-250A) Branson (Danbury, USA) 
Spectrophotometer (Infinite® m200) Tecan (Männedorf, Switzerland) 
Spectrophotometer (NanoDrop™ 2000) Thermo Fisher Scientific (Waltham, USA) 
Thermoblock (TCR 100) Carl Roth (Karlsruhe, Germany) 
Thermocycler (TGradient) Biometra/Analytikjena (Göttingen, Germany) 
Ultracentrifuge (Avanti J-26 XP)  Beckman Coulter (Brea, USA) 
Ultracentrifuge rotor (JLA-8.100) Beckman Coulter (Brea, USA) 
UV light transilluminator Wealtec (Sparks, USA) 
Water heater bath (Thermomix 5 BU) B. Braun (Melsungen, Germany) 




12-well cell culture plates (665180) Greiner BioOne (Frickenhausen, Germany) 
8-well cell culture chambers (94.6140.802) Sarstedt (Nümbrecht, Germany) 
96-well microplates (655087) Greiner BioOne (Frickenhausen, Germany) 
Amicon® Ultra-15 centrifugal filter unit (UFC9003) Merck/Millipore (Burlington, USA) 
Cell culture flasks 175 cm² (661175) Greiner BioOne (Frickenhausen, Germany) 
Cell culture flasks 75 cm² (658175) Greiner BioOne (Frickenhausen, Germany) 
Dialysis tubing (68100) Thermo Fisher Scientific (Waltham, USA) 
FACS tubes (5 ml, 75x12 mm, PS) (55.1579) Sarstedt (Nümbrecht, Germany) 
Falcon tubes (15 ml - 50 ml) Greiner BioOne (Frickenhausen, Germany) 
Gel casting cassettes (NC2010) Novex/Invitrogen (Winston-Salem, USA) 
Parafilm M Bemis VWR (Radnor, USA) 
PCR tubes (0.2 ml) VWR (Radnor, USA) 
Pipette tips (10 µl) Sorenson Biosciences (Salt Lake City, USA) 
Pipette tips (20 µl - 200 µl - 1000 µl) VWR (Radnor, USA) 
Polypropylene disposal bags Carl Roth (Karlsruhe, Germany) 
PVDF membrane (Amersham Hybond-P) GE Healthcare (Uppsala, Sweden) 
Serological pipettes (5 ml - 10 ml - 25 ml) Greiner BioOne (Frickenhausen, Germany) 
Syringe filters (Minisart 0.4 µm - 0.2µm) Sartorius (Göttingen, Deutschland) 
Syringes (Injekt 20 ml) B. Braun (Melsungen, Germany) 
Tubes (301003) Glasgerätebau Ochs (Bovenden, Germany) 




3.1.12 Software, online-tools and databases 
• CellSens Imaging Software (Olympus, Tokyo, Japan): analysis and acquisition of images via 
Olympus AX70 system 
• DeVision G V2.0 (DC Science Tec, Hohengandern, Germany): documentation of agarose gels 
• Geneious Prime (Biomatters Ltd., Auckland, New Zealand): analysis and processing of DNA 
and protein data 
• Graphic Converter 10 (Lemke Software GmbH, Peine, Germany): image processing 
• Image Lab 5.2.1 (2014) (Bio-Rad, Hercules, USA): analysis and processing of images captured 
with Chemidoc; quantification of band volume intensities 
• Mendeley Desktop V1.19 (Mendeley Ltd., London, UK): reference manager 
• NCBI (National Center for Biotechnology Information) (Bethesda, Maryland, USA): database 
providing biomedical and genomic information 
• Office 2016 for Mac (Microsoft, Redmond, USA): texting, data analysis, slides 
• Venn diagrams tool (http://bioinformatics.psb.ugent.be/webtools/Venn/): intersection of data 
sets, Venn diagrams 
• PANTHER (Protein ANalysis THrough Evolutionary Relationships) classification system 
(http://pantherdb.org/about.jsp): classification of proteins and their genes; identification of 
cellular localization and function of gene products  
• Catalogue Of Somatic Mutations In Cancer (COSMIC) database 
(https://cancer.sanger.ac.uk/cosmic): identification of cancer diseases related to a certain 
gene/protein 
• Online Mendelian Inheritance in Man (OMIM) database (https://www.omim.org): 
identification of disease phenotypes related to a certain gene/protein  






3.2.1 Manipulation of nucleic acids 
3.2.1.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) [175] is an in vitro enzymatic assay that allows for amplification of 
specific DNA fragments. The key component of this methodology is a DNA polymerase that is 
resistant to heat inactivation. The DNA polymerase derived from the bacterium Thermus aquaticus 
(Taq) is commonly employed as a standard for applications that involve the PCR. Taq polymerase has 
a temperature optimum of 70-80°C and an activity half-life of 45-50 min at 95°C [117]. The PCR 
reaction takes place in a defined buffer that usually includes MgCl2, necessary as cofactor of the Taq 
DNA polymerase. General PCR buffers also include Tris-HCl, KCl, glycerol and additional variable 
components, with a final buffer pH of approximately 8.0. PCR buffers are usually provided by 
manufacturers as concentrated mixtures that include all components necessary for optimal polymerase 
reaction conditions. In addition to the DNA polymerase and its proper buffer, other elements to be 
included in a PCR reaction are as follows: 1) a DNA template; 2) primers, short oligonucleotides 
complementary to the target DNA region; 3) deoxynucleoside triphosphates (dNTPs), the molecular 
blocks for building new DNA strands. The thermal cycler is the device that, via programmed 
temperature shifts, permits cycling of the three main PCR steps: 1) denaturation of the dsDNA template 
generating ssDNA; 2) annealing of the primers to each of the ssDNA templates; 3) synthesis and 
extension of a nascent DNA strand (complementary to the DNA template) by addition of free dNTPs 
to the 3´-terminus of the primers and subsequently synthesized DNA-strand. Concentration of reaction 
components, duration and temperature of each step of the procedure, are usually recommended by 
manufacturers. Some parameters can be optimized towards best possible results. For instance, it may 
be necessary to evaluate the melting temperature of primers, purity of the DNA template and the 
duration of the extension step, the latter depending on the length of the amplified DNA fragment. 
Primers can vary in length and they can be designed so that specific sequence features, such as 
restriction sites, promoters or nucleotide substitutions necessary for downstream applications, are 
added in the final DNA product. A characteristic of certain thermostable polymerases, including Taq 
DNA polymerase, is the addition of a 3'-adenine overhang at the 3' ends of the amplified DNA 
fragment, that becomes useful in some cloning systems (see chapter 3.2.1.6). 
In our work, we performed PCRs employing Taq DNA Polymerase (Sigma-Aldrich) for amplification 
of specific DNA constructs to be cloned into expression vectors and for generation of PCR products to 
be used in an in vitro transcription/translation system. Taq DNA Polymerase was supplied with a 
standard 10x PCR buffer including MgCl2 at 15 mM. dNTPs were prepared as a stock solution (dNTP 
mix) containing dATP, dCTP, dGTP, and dTTP at a concentration of 2.5 mM each. Typical 
composition and cycling parameters of PCR reactions performed in our lab with Taq DNA Polymerase 
are given in Table 4 and Table 5, respectively. 
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Table 4: Composition of PCR reactions with Taq DNA polymerase 
Component Final concentration 
10x PCR Buffer 1x 
Template DNA ~ 0.1 ng/µl 
dNTP mix 100 µM (each dNTP) 
Forward primer 0.25 µM 
Reverse primer 0.25 µM 
Taq DNA Polymerase 0.05 unit/µl 
H2Odd to a final volume of 50 µl 
 
Table 5: PCR cycling parameters for PCR reactions with Taq DNA polymerase 
PCR step Temperature °C Duration 
Initial denaturation step 94°C 3 min 
Around 30 cycles of: 
Denaturation of DNA Template 94°C 1 min 
Primer annealing  56°C 1 min 
Primer extension  72°C 1 min per 1000 bp 
Final extension  72°C 10 min 
Hold 8°C ∞ 
 
As will be described in more detail in chapter 3.2.1.9, we also employed the PCR method for site-
directed mutagenesis. In such a procedure, pGEM-T Easy vector harboring the DNA fragment to be 
mutated was amplified and subsequently re-ligated. Considering that the Taq polymerase has a 
relatively high error rate during DNA synthesis and is usually not suited for amplification of longer 
PCR amplicons, we used PhusionÒ High-Fidelity DNA Polymerase (NEB), a highly accurate 
thermostable DNA polymerase that is suitable for amplification of long PCR-amplicons including a 
low error rate. The 10x PhusionÒ HF Buffer (supplied by the manufacturer) included MgCl2 at 7.5 
mM. The dNTP mix was the same as for PCRs with Taq DNA polymerase. Reaction conditions used 
for PCRs with PhusionÒ High-Fidelity DNA Polymerase and cycling parameters are given in Table 6 
and Table 7, respectively. 
 
Table 6: Composition of PCR reactions with Phusion DNA polymerase 
Component Final concentration 
5x PhusionÒ HF Buffer 1x 
Template DNA ~ 0.3 ng/µl 
dNTPs mix 100 µM (each dNTP) 
Forward primer 0.5 µM 
Reverse primer 0.5 µM 
PhusionÒ High-Fidelity DNA Polymerase 1 unit/50 µl 




Table 7: PCR cycling parameters used for PCR reactions with Phusion DNA polymerase 
PCR step Temperature °C Duration 
Initial denaturation step 98°C 30 sec 
Around 30 cycles of: 
Denaturation of DNA Template 98°C 10 sec 
Primers annealing 55°C 20 sec 
Primers extension 72°C 80 sec 
Final extension step 72°C 10 min 
Hold 8°C ∞ 
 
3.2.1.2 Agarose gel electrophoresis 
In agarose gel electrophoresis, application of an electric field causes migration of charged biomolecules 
through an agarose matrix, separating those biomolecules by size. This method is mostly employed for 
separation of nucleic acids, that migrate towards the positively charged anode because of negatively 
charged phosphates in the sugar phosphate backbone. Fluorescent agents intercalating with nucleic 
acids are commonly used to visualize nucleic acid fragments subsequent to gel electrophoresis. 
Composition of buffers employed for agarose gel electrophoresis is reported in chapter 3.1.2. In our 
experiments, DNA samples were mixed with 10x DNA Loading Buffer (1x final concentration) before 
loading them onto an agarose gel containing 1-2% [w/v] agarose in 1x TAE Running Buffer. DNA 
was separated by applying an electrical field in standard electrophoresis chambers filled with 1x TAE 
Running Buffer. DNA samples were usually separated at 80 V for 1.5 h. 2-Log DNA Ladder (NEB) 
was used as size standard for DNA fragments (see chapter 3.1.6). For documentation purposes, DNA 
fragments were detected by ethidium bromide present in the agarose gel at a final concentration of 
0.625 µg/ml, and visualized under UV light (365 nm) subsequent to electrophoresis. For experiments 
requiring preserved integrity of nucleic acids, agarose gels lacked ethidium bromide and were instead 
soaked, after electrophoresis, in 1x GelStar® Stain (Lonza) in 1x TAE for 30 min, and the DNA was 
then visualized and documented using a blue light (470 nm) transilluminator. 
 
3.2.1.3 PCR clean-up and DNA extraction from agarose gels 
NucleoSpinÒ Gel and PCR Clean-up Kit (Macherey Nagel) was employed for DNA purifications from 
enzymatic reactions as well as for purifications of DNA fragments from agarose gels. Buffers were 
supplied with the kit and the kit was used according to the manufacturer's recommendations. In this 
procedure the sample is mixed with a binding buffer and, in case of a cut-out gel band, is heated to 
dissolve the agarose. The DNA is bound to a silica membrane of a centrifugable column in presence 
of chaotropic salt. Contaminations are removed by washing steps in presence of ethanol. The purified 
DNA is then eluted under low salt conditions in a mildly alkaline elution buffer. 
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3.2.1.4 Nucleic acids concentration measurements 
Nucleic acids concentration was measured by spectrophotometric absorption at 260 nm (RNA/DNA 
absorption) using a NanoDropTM 2000 Spectrophotometer. Nucleic acids purity was determined by 
measuring absorption at 280 nm (proteins absorption) and calculating the ratio of absorption at 260 nm 
and absorption at 280 nm. A value greater than or equal to 1.8 indicated sufficient purity of DNA. 
 
3.2.1.5 Digestion of DNA by restriction enzymes 
Restriction enzymes (REs) are fundamental tools employed to cut dsDNAs into fragments. The 
cleavage of a dsDNA by a RE occurs at a so-called restriction site, a specific nucleotide sequence 
recognised by the RE. We involved REs in our cloning strategies to generate plasmids harboring 
desired sequence regions and as a screening tool to confirm presence and orientation of DNA inserts 
in plasmids generated. REs and buffers employed were from New England Biolabs (NEB). Each RE 
exhibits an optimal enzymatic activity at conditions that can differ between enzymes. RE reactions 
were usually performed as shown in Table 8. Buffers varied between REs as recommended by the 
manufacturer (see chapter 3.1.3). The volume of RE was typically 5% of the total reaction volume. 
The final concentration of RE varied depending on the enzyme's stock concentration, the latter being 
10000 U/ml for some REs and 20000 U/ml for others (see chapter 3.1.3). In reactions with two different 
REs (double digests), the volume of each RE was typically 2.5% of the total reaction volume. All the 
REs employed required incubation at 37°C, as recommended by the manufacturer. Incubation time 
was 2-3 h when REs were used for confirmation of presence and orientation of inserts in plasmids. For 
preparation of DNA inserts to be subsequently cloned into expression plasmids, RE reactions were 
incubated overnight for higher yield of restriction fragments and a reduced amount of undigested 
plasmid. When recommended by the manufacturer, REs were inactivated by incubation for 10 min at 
80°C. 
 
Table 8: Typical reaction composition for DNA digestion using restriction enzymes 
2 µl  10x NEB Buffer 
~1 µg DNA 
1 µl Restriction enzyme (10000 U/ml or 20000 U/ml) 




3.2.1.6 Ligation of DNA inserts into plasmids 
In combination with restriction enzymes, DNA ligation, mediated by DNA ligases, enables a workflow 
where a defined DNA fragment is cloned into a plasmid or transferred from one plasmid to another.  
 
pGEM-T Easy vector system 
PCR products generated for cloning purposes were cloned into pGEM-T Easy vector (Figure 4) using 
pGEM®-T Easy Vector Systems (Promega). pGEM-T Easy vector is a linearized vector with a single 
3´-terminal thymidine overhang at both 3´ends that greatly improves ligation efficiency of 3´ A-tailed 
fragments generated by Taq DNA polymerase. Standard ligation reactions with pGEM-T Easy vector 
were set up as given in Table 9. 
 
Table 9: Standard reaction for ligation of PCR product into pGEM-T Easy vector 
5 µl 2x Rapid Ligation Buffer 
1 µl pGEM-T Easy vector (50 ng/µl) 
~150 ng PCR product 
1 µl T4 DNA Ligase (3000 U/ml) 
H2Odd to a final volume of 10 µl. 
 
A reaction with a control insert DNA (supplied with the kit) and a reaction without PCR product were 
usually included as controls for further blue/white color screening of clones (see below). After 
overnight incubation at 4°C, 2 µl from each reaction were used for transformation of NEBÒ 5-alpha 
Competent E. coli (see 3.2.1.7). Transformed cells were plated onto LB-Agaramp plates containing 80 
µg/ml 5-Brom-4-chlor-3-indoxyl-β-Dgalactopyranosid (X-Gal). The pGEM T-Easy vector is 
engineered in a way that successful cloning of an insert interrupts a sequence coding for β-
galactosidase. X-Gal is a colorless compound that can be cleaved by β-galactosidase resulting in a 
reaction product of bright blue-color. Thus, bacteria transformed with vector harboring an insert grow 
into white colonies, whereas those transformed with only the vector lacking an insert result in blue 
colonies. Control ligations without PCR product generated blue colonies only, whereas controls with 




Figure 4: pGEM-T Easy vector map and selected sequence features. Figure retrieved from the pGEM®-T 
and pGEM®-T Easy Vector Systems Technical Manual (Rev. 6/15 TM042). 
 
Ligation of DNA inserts into linearized expression vector 
DNA inserts were excised from pGEM-T Easy plasmids by restriction enzyme digests, purified 
subsequent to agarose gel electrophoresis, and cloned into a linearized expression vector using T4 
DNA Ligase (NEB). In order to reduce self-ligation of linearized expression vector backbone, 
linearized plasmid was first treated with rAPid Alkaline Phosphatase (Merck/Sigma-Aldrich) to 
remove 5′-phosphoryl termini in plasmid DNA strands. By doing so, ligation of linearized vector DNA 
was possible only via the 5′-phosphoryl termini provided by the DNA strands to be inserted into the 
expression vector. Dephosphorylation reactions (Table 10) were incubated for 10 min at 37°C followed 
by 2 min at 75°C for heat inactivation of rAPid Alkaline Phosphatase. Dephosphorylated vector DNA 
was directly used in ligation reactions (Table 11) in presence of to be cloned DNA fragments. In some 
cases, control reactions with non-dephosphorylated vector or with dephosphorylated vector, in both 
cases without insert, were also performed in parallel in order to evaluate background ligation of 
plasmid backbone. Ligation reactions were incubated overnight at 16°C, followed by 10 min 
incubation at 65°C in order to heat-inactivate T4 DNA Ligase. 1-5 µl of ligation mixtures were used 
for transformations of E. coli cells each. 
 
Table 10: Reaction for dephosphorylation of linearized vector by alkaline phosphatase 
0.5 µg Linearized expression vector  
2 µl rAPid Alkaline Phosphatase Buffer (10X) 
1 µl  rAPid Alkaline Phosphatase (1000 units/ml) 
H2Odd to a final volume of 20 µl 
 
Table 11: Reaction for ligation of vector and insert DNA by DNA ligase 
2 µl 10x T4 DNA Ligase Buffer 
50 ng Dephosphorylated expression vector DNA 
~150 ng  Insert DNA 
1 µl T4 DNA Ligase (40000 units/ml) 
H2Odd to a final volume of 20 µl 
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3.2.1.7 Transformation of E. coli cells 
Transformation is the process by which an exogenous DNA is introduced into a bacterial cell. There 
are various bacterial strains that can be transformed very efficiently and are suitable for molecular 
biology applications. In our work, NEBÒ 5-alpha Competent E. coli (C2987H, NEB), a high efficiency 
strain derivative of E. coli DH5α cells, were employed for propagation of plasmids and screening of 
plasmid clones; while BL21 (DE3) Competent E. coli (C2527I, NEB) were employed for higher-level 
production of HML-2 Pro. 
Transformation of NEBÒ 5-alpha Competent E. coli was performed as follows. 20 µl of cells were 
pipetted into an Eppendorf tube and kept on ice. 1 µl containing approximately 1 ng of plasmid DNA 
was gently added to the cell mixture, followed by incubation on ice for 30 min. Cells were then 
subjected to heat shock for 30 sec at 42°C in a waterbath and incubated again on ice for 5 min. 80 µl 
of LB-Medium was then gently added to transformed cells and the mixture was incubated for 1 h at 
37°C. During this incubation step, E. coli cells could recover from the heat shock and establish 
antibiotic resistance gained by transformed plasmids. The 100 µl mixture was then plated onto an LB-
Agar plate for the purpose of subsequent screening of plasmid-harboring clones, whereas it was 
directly inoculated into LB-Medium for the purpose of subsequent isolation of larger amounts of 
plasmid DNA. In both cases, LB-Medium was supplemented with specific antibiotics at standard 
concentration (see chapter 3.1.7). E. coli cells were grown overnight in liquid culture flasks in a shaking 
incubator at 37° C and 200 rpm. The following day, liquid cultures were subjected to plasmid-DNA 
isolation, whereas E. coli colonies grown on LB-Agar plates (with antibiotics) were further screened 
for transformed clones. The protocol employed for transformation of E. coli BL21 (DE3) Competent 
cells is described in chapter 3.2.2.3. 
 
3.2.1.8 Isolation of plasmid DNA from E. coli cells 
The peqGOLD Plasmid Miniprep Kit I (PeqLab) was used for isolating relatively small amounts (15-
25 µg) of plasmid DNA from E. coli cells, with that amount of plasmid DNA being sufficient for 
screening of plasmid constructs. The principle of the purification is based on alkaline lysis of bacteria 
and subsequent binding of plasmid DNA to a silica membrane in a centrifugable column. DNA binding 
occurs in presence of high salt concentration, proteins and other contaminants are removed through a 
wash step, nucleic acids are eluted with a low salt buffer. In our procedure, a single E. coli colony, 
harboring transformed plasmid, was picked from an LB-Agar plate with a plastic tip. The tip of the tip, 
thus E. coli cells, were streaked (forming a line) in a particular cell of a numbered grid of an LB-Agar 
plate (Master-plate). The same tip, that is remaining E. coli cells, was then inoculated into 5 ml of 
LB-Medium, with that tube labeled with the same number as the grid cell. This was repeated for at 
least 10 plasmid clones per plasmid construct generated. The 5 ml cultures were incubated overnight 
in an orbital shaker at 37°C. Then, E. coli cells were centrifuged for 10 min at 5000 g and cell pellets 
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were further processed following the kit manufacturer's recommendations. Plasmid DNAs were eluted 
into 100 µl of elution buffer each (provided with the kit) and stored at -20°C after measuring DNA 
concentration. The Master-plate, incubated overnight at 37°C and then stored at 4°C, served as a source 
of positive E. coli cells for producing larger amounts of plasmid DNA, sparing another transformation 
by inoculating the desired E. coli clone from the Master-plate directly into a liquid culture.  
 
Isolation of larger amounts (20-100 µg) of plasmid DNA were carried out using the NucleoBondÒ PC 
100 plasmid DNA purification kit (Macherey Nagel). The method employs a modified alkaline/SDS 
lysis procedure to prepare the bacterial cell pellet for plasmid purification. Nucleic acids are denatured 
under alkaline conditions. Potassium acetate is added to the denatured lysate, causing formation of a 
precipitate containing chromosomal DNA and other cellular compounds. Plasmid DNA remains in 
solution. Plasmid DNA is then specifically bound to an anion exchange column under low salt 
concentration and appropriate pH conditions, washed and eluted under high salt concentration. Plasmid 
DNA is then concentrated by isopropanol precipitation, centrifugation, a wash step, and finally 
dissolved in H2Odd. For our procedure, an E. coli colony picked from a Master-plate, or a just a liquid 
culture of transformed E. coli cells (see above), were inoculated and cultured overnight at 37°C, in a 
flask containing LB-Medium supplemented with the appropriate antibiotic. Culture volumes were 30 
ml or 100 ml when E. coli cells harbored, respectively, high-copy or low-copy number plasmids. 
Plasmid DNA was eluted into 100 µl of H2Odd. Plasmid DNA concentration was determined by UV 
spectrophotometry and subsequently adjusted to 500 ng/µl with H2Odd. 
 
3.2.1.9 Generation of plasmids harboring mutated variants of HML-2 Pro and HML-2 
IN coding sequences 
Enzymatically inactive Pro and IN variants were generated by site-directed mutagenesis. Site-directed 
mutagenesis was performed via PCR, employing two strategies for generation of nucleotide 
substitution or deletion, respectively (Figure 5). The general procedure consists of PCR amplification 
of the complete sequence of a plasmid harboring the sequnce region to be mutated. PCR primers used 
for the amplification are designed in a way that the resulting PCR product (representing the linearized 
plasmid) contains the desired mutation. Re-ligation of the linear PCR product creates a circular plasmid 
harboring the mutation of interest. 
In our procedure we used PhusionÒ High-Fidelity DNA Polymerase with PCR conditions as indicated 
in chapter 3.2.1.1. Pro and IN constructs cloned into pGEM-T Easy vector served as DNA templates 
for PCR. We aimed at generating two Pro mutants (Pro-mutDTG and Pro-mutGRDL) and an IN mutant 
(IN-mut). The strategy employed for generating Pro mutants involved nucleotide substitution 
introduced by the forward PCR primers (Figure 5). More specifically, a single nucleotide exchange 
G→A was introduced in PromutDTG-FOR, the forward primer for generation of plasmids pGEM Pro 
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mut DTG (for pET11d) and pGEM Pro-mut DTG (for phCMV). A dinucleotide cexhange CG →AA 
was introduced by Pro-mutCGA-FOR, the forward primer for generation of plasmid pGEM Pro-
mutCGA (for pET11d) (see Table 1 for primer sequences). The strategy for generating IN-mut 
introduced a nucleotide deletion. Nucleotides 5'-GACAATGGA-3' were deleted employing PCR 
primers complementary to the template DNA yet spacing away from each other by a nucleotide 
distance that excludes the sequence region to be deleted. 
 
 
Figure 5: Schematic representation of the strategy employed for generation of plasmids harboring 
mutated variants of Pro and IN coding sequences. PCR site-directed mutagenesis was performed by two 
methods for generation of nucleotide substitution or deletion. Plasmids harboring the sequence region of interest 
to be mutated comprised the template DNA. PCR primers are depicted in yellow. Protein coding sequences are 
shown in blue. For nucleotide substitution, the forward primer contains the mutation (in green). For nucleotide 
deletions, primers are spaced away from each other to exclude the region to be deleted (in red). Following PCR, 
steps for generating circularized functional plasmids were the same for all constructs. 
 
Resulting PCR products represented linear pGEM plasmids, including the DNA insert, yet harboring 
the mutated variants of the protein coding sequences of interest. Circular plasmids could be recreated 
by re-ligation of such linear plasmids. For this purpose, PCR products were first purified following 
agarose gel electrophoresis in order to remove template plasmid DNA template and other potential 
contaminations. Since primers used for the PCR were not phosphorylated at their 5' ends resulting PCR 
products were treated with T4 Polynucleotide Kinase (NEB) (T4 PNK) which catalyzes the transfer of 
a phosphate from ATP to the 5´-hydroxyl terminus of a polynucleotide, thus adding a 5' phosphoryl 
group. The phosphorylation reaction (Table 12) was set up with T4 DNA Ligase Buffer (NEB) which 
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contains 1 mM ATP and provides suitable reaction conditions for T4 PNK activity. Following 30 min 
of incubation at 37°C, T4 PNK was heat-inactivated by incubation for 20 min at 65°C. 
Re-ligation of 5'-phosphorylated PCR products was therefore done by addition of 1 µl of T4 DNA 
Ligase (NEB) directly to the 5'-phosphorylation reaction and incubation overnight at 16°C. Finally, 
reactions were incubated for 10 min at 65° C in order to heat-inactivate the T4 DNA Ligase. Circular 
pGEM plasmids harboring desired mutants of Pro and IN were verified by sequencing (see below) 
before subsequent cloning steps. 
 
Table 12: Reaction for 5'-phosphorylation of linear plasmids generated by PCR-mediated site-directed 
mutagenesis 
2 µl 10x T4 DNA Ligase Buffer 
~150 ng PCR product 
1 µl T4 PNK (10000 units/ml) 
H2Odd to a final volume of 20 µl 
 
3.2.1.10 Generation of plasmids for HML-2 Pro and HML-2 IN expression 
This section describes plasmids employed and cloning strategies used for generation of plasmids for 
prokaryotic and eukaryotic expression of HML-2 Pro and for eukaryotic expression of HML-2 IN. 
PCR conditions used for amplification of DNA constructs with Taq DNA Polymerase are reported in 
chapter 3.2.1.1. Sequences of primers mentioned in this section are listed in Table 1. 
 
3.2.1.10.1 Plasmid backbones 
pET-11d 
The pET-11d vector (Agilent) was used for expression of HML-2 Pro in E. coli. A description of the 
plasmid and a plasmid map can be found in chapter 3.2.2.3. 
 
phCMV-G 
The phCMV-G vector [95] expresses the G glycoprotein of vesicular stomatitis virus (VSV-G) under 
control of the CMV early promoter (Figure 6 A). We employed this plasmid as eukaryotic expression 
vector, replacing (via BamHI digestion) the VSV-G sequence with the insert of interest, consisting of 
a Kozak consensus sequence followed by HML-2 Pro coding sequence. The Kozak sequence plays an 
important role in initiation of translation, ensuring translation from the correct initiation codon and 
increasing translation efficiency in eukaryotic cells [110]. A b-globin intron (enhancing expression of 
coding sequence of interest because more efficient export of spliced mRNA from the nucleus) [95] and 
a polyadenylation signal are located upstream and downstream of the insert, respectively. An 





The pEGFP-C1 vector (Clontech Laboratories, GenBank Accession: U55763) encodes a variant of 
wild-type GFP optimized for brighter fluorescence, therefore called enhanced GFP (EGFP). The 
sequence flanking EGFP contains a Kozak consensus sequence that enhances translation efficiency in 
eukaryotic cells. The multiple cloning site in pEGFPC1 is located between the EGFP coding sequences 
and the SV40 poly A (Figure 6 B). The pEGFP-C1 provides a pUC origin of replication for high copy 
number propagation in E. coli. A bacterial promoter upstream of a neomycin resistance cassette (Neor) 
expresses kanamycin resistance in E. coli. The sequence of interest is cloned into the MCS, in-frame 
with EGFP, so that it can be expressed in mammalian cells as a protein fused to the C-terminus of 
EGFP. Fusions to the C terminus of EGFP retain the fluorescent properties of the native protein. We 




The pcDNA3 vector (Invitrogen/Fisher Scientific) is designed for expression of proteins in mammalian 
cells. pcDNA3 harbors a CMV immediate-early promoter for high-level expression, a multiple cloning 
site flanked by the T7 and SP6 promoters, a pUC origin of replication for high copy number replication 
in E. coli, and an ampicillin-resistance gene (Figure 6 C). For proper and efficient translation, it is 
required that the insert contains a Kozak consensus sequence with an ATG initiation codon. We 
employed pcDNA3 for expression of candidate proteins in cell culture. In each construct, the ATG of 
the Kozak sequence was the starting codon of the cloned candidate-protein encoding sequence. 
 
pSG5 
The pSG5 vector (Agilent Technologies, Santa Clara, USA) is a high-copy plasmid that can be used 
for expression of proteins in vitro and in vivo (Figure 6 D). After transient transfection of cell lines, 
expression is driven from the SV40 promoter and terminated by a polyadenylation signal downstream 
of the MCS. In vitro transcription can be driven from the T7 promoter. The desired expression sequence 
can be cloned via restriction enzyme sites (EcoRI, BamHI and BglII). An ampicillin resistance gene 
serves for antibiotic selection in transformed bacteria. We employed pSG5 for expression of HML-2 
IN in cell culture. 
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Figure 6: Plasmid maps of vectors employed for protein expression in mammalian cells. A) Plasmid map of 
phCMV-G. Only restriction sites used in our cloning strategies are depicted. The plasmid map was generated by 
us using the software Geneious (Biomatters). B) Plasmid map of pEGFP-C1 (retrieved from BD Biosciences 
Clontech Catalog 6084-1, Version PT3028-5). C) Plasmid map of pcDNA3 (retrieved from Invitrogen catalog 
A-150228). D) Plasmid map of pSG5 (retrieved from Agilent Technologies pSG5 Vector Instruction manual 
(Rev. C.0)). 
 
3.2.1.10.2 Novel plasmid constructs generated 
pET11d-Pro 
For prokaryotic expression of HML-2 Pro, nt 3276–3768 from cloned proviral locus HERV-K(HML-
2.HOM) (GenBank acc. no. AF074086.2 [134]), cloned in pBluescript II vector and available in-house, 
were amplified by PCR using the particular plasmid DNA as template. The forward primer 
(HOMProFOR) added an NheI site and the reverse primer (HOMProREV) added a stop codon and a 
downstream BamHI site to the PCR product. The PCR product was cloned into pGEM-T Easy vector 
giving rise to plasmid pGEM HOM Pro (for pET11d). pGEM HOM Pro (for pET11d) was used as 
DNA template for generation of protease mutants by PCR site-directed mutagenesis (see 3.2.1.9). To 
clone the actual expression plasmid, the insert was released from pGEM HOM Pro (for pET11d) and 
respective mutated variants (pGEM Pro mut DTG (for pET11d), pGEM Pro-mutCGA (for pET11d)) 
by an NheI/BamHI digest and cloned into NheI/BamHI-digested pET-11d vector giving rise to 
plasmids pET11d Pro, pET11d Pro-mut DTG and pET11d Pro-mutCGA. For screening of clones, 
presence and orientation of the insert was checked by digestion with MscI and subsequent visualization 
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of expected DNA fragments by agarose gel electrophoresis. A schematic representation of HML-2 Pro 
construct cloned into plasmid for Pro expression in E. coli is shown in Figure 7. 
 
Figure 7: Schematic representation of HML-2 Pro cloned into pET11d vector for Pro expression in E. coli. 
In the upper part, the Pro ORF is depicted in the context of the HML-2 proviral genome. The region 
corresponding to the Pro core domain is colored in blue. A known Pro self-cleavage site in the N-terminus is 
indicated by a vertical violet bar. The precise location of a Pro self-cleavage site in the C-terminus is not known, 
thus a violet horizontal bar indicates the region where such a cleavage might occur. The Pro ORF subregion 
cloned into into pET-11d (see also Figure 9) is indicated with a bracket. Nucleotide numbering is as reported for 
the HERV-K(HML-2.HOM) provirus in GenBank acc. no. AF074086.2 [134]. The engineered stop codon 
(orange) and the restriction enzyme sites used for cloning are indicated. The Pro precursor expressed in E. coli 
and the products of Pro self-processing are depicted. 
 
phCMV-Pro 
For eukaryotic expression of HML-2 Pro, nt 3415-3946 from cloned proviral locus HERV-K(HML-
2.HOM) (GenBank acc. no. AF074086.2 [134]), cloned in pBluescript II vector and available in-house, 
were amplified by PCR using the particular plasmid DNA as template. The forward primer (Pro3415F) 
added a BamHI site, a spacer and a Kozak consensus sequence. The reverse primer (Pro3946R) added 
a BamHI site. The PCR product was cloned into pGEM-T Easy vector giving rise to plasmid pGEM 
Pro (for phCMV). pGEM Pro (for phCMV) was used as DNA template for generation of protease 
mutants by PCR site-directed mutagenesis (see 3.2.1.9). The insert was released from pGEM Pro (for 
phCMV) and the respective mutated variant (pGEM Pro-mut DTG (for phCMV)) by a BamHI 
digestion and cloned into BamHI-digested phCMV-G vector, giving rise to plasmids phCMV-Pro and 
phCMV-Pro mut. For screening of clones, presence and orientation of the insert was checked by 
digestion with MscI and subsequent visualization of expected DNA fragments by agarose gel 
electrophoresis. An HML-2 Pro construct cloned into plasmids for expression of HML-2 Pro in 
mammalian cells is depicted in Figure 8. 
 
pEGFP-Pro 
For eukaryotic expression of an EGFP-Pro fusion protein, Pro and Pro-mut coding sequences were 
amplified by PCR using pGEM Pro (for phCMV) and pGEM Pro-mut DTG (for phCMV) as DNA 
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templates. Forward primer (phCMV-GFPproFOR) and reverse primer (phCMV-GFPproREV) added 
a BamHI site at the 5' and 3' end, respectively, of PCR products. PCR products were digested with 
BamHI and cloned into BamHI-digested pEGFP-C1 vector, in-frame with the EGFP ORF, giving rise 
to plasmids pEGFP-Pro and pEGFP-Pro-mut. For screening of clones, presence and orientation of the 
insert was checked by double-digestion with EcoRI-HF and MscI (in NEB CutSmart® Buffer) and 
subsequent visualization of expected DNA fragments by agarose gel electrophoresis. An HML-2 Pro 
construct cloned into plasmids for expression of EGFP-fused Pro is depicted in Figure 8. 
 
 
Figure 8: Schematic representation of HML-2 Pro construct cloned into different plasmids for expression 
of EGFP-fused Pro and Pro alone in mammalian cells. In the upper part, the Pro ORF is depicted in the context 
of the HML-2 proviral genome. The region corresponding to the Pro core domain is indicated in blue. A known 
Pro self-cleavage site in the N-terminus is indicated by a vertical violet bar. The precise location of the Pro self-
cleavage site in the C-terminus is not known, a violet horizontal bar indicates the region where such a cleavage 
site might occur. A Pro ORF subregion (nt 3415-3946, indicated by a dotted bracket; see also Figure 9) from 
HERV-K(HML-2.HOM) provirus (GenBank acc. no. AF074086.2 [134]) was cloned into pEGFP and phCMV. 
The Kozak sequence (introduced by during PCR) and restriction enzyme sites used for cloning are indicated. The 
Pro precursors expressed in mammalian cells and the products of self-processed Pro are depicted. 
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Figure 9: Pro ORF sequence used for generation of constructs for expression of HML-2 Pro. The DNA 
sequence, including nucleotide numbering, are based on the HERV-K(HML-2.HOM) provirus as reported in 
GenBank acc. no. AF074086.2 [134]. The corresponding aa sequence is given with numbering based on the Pro 
ORF. Forward and reverse primers used for generation of Pro constructs for Pro purification are indicated by 
solid line arrows. Primers for generation of Pro constructs for Pro expression in mammalian cells are indicated 
by dotted line arrows. Furthermore, Pro core domain (blue), a known self-processing site (violet), conserved 
catalytic motifs (green), dUTPase catalytic motifs 3-4 (grey), nucleotides mutated for generation of Pro mutants 
(red), and the frameshift region for translation of Pol ORF (dotted line) are indicated. 
 
pcDNA3 plasmids for eukaryotic expression of HA-tagged candidate proteins 
Full-length coding sequences for human proteins HSP90AA1, CIAPIN1, C15orf57, MAP2K2 and 
TUBA1A were present in plasmids purchased from GE Healthcare/Dharmacon. Clone identifiers of 
cloned coding sequences of candidate proteins are reported in Table 12. We employed those plasmids 
as DNA templates for PCR reactions amplifying full-length coding sequences of respective proteins. 
PCR primers were the same as those used for generation of DNA templates for in vitro translations of 
candidate proteins (see chapter 3.2.2.2). The forward primer added a Kozak consensus sequence. The 
reverse PCR primer added a human influenza hemagglutinin (HA) tag in-frame to the 3' end of the 
coding sequence, followed by a stop codon. The PCR product was cloned into pGEM-T Easy vector, 
released by a NotI digest and cloned into NotI-digested pcDNA3 vector, giving rise to plasmids 
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pcDNA3 HSP90AA1, pcDNA3 CIAPIN1, pcDNA3 C15orf57, pcDNA3 MAP2K2, and pcDNA3 
TUBA1A. Presence and orientation of the insert was checked for each plasmid by digestion with 
restriction enzymes and subsequent visualization of expected DNA fragments by agarose gel 
electrophoresis. Plasmid pcDNA3 HSP90AA1 was double-digested with BglII and XhoI in NEBuffer 
3.1; pcDNA3 CIAPIN1 was digested with HindIII; pcDNA3 C15orf57 was digested with BglII; 
pcDNA3 MAP2K2 was digested with PstI; pcDNA3 TUBA1A was digested with EcoRI-HF. 
 
 
Figure 10: Schematic representation of the cloning strategy for generation of pcDNA3 plasmids for 
expression of HA-tagged candidate proteins in mammalian cells. Plasmids purchased from GE 
Healthcare/Dharmacon contained coding sequences of candidate proteins that were cloned into pcDNA3 
including a Kozak sequence, an HA-tag and a stop codon. Primers used for the amplification of the coding 
sequence of candidate proteins are depicted. A NotI restriction site used for cloning into pcDNA3 is indicated. 
Corresponding protein expressed in mammalian cells after transfection of pcDNA3-candidate plasmids is 
depicted at the bottom. 
 
pSG5-IN 
For eukaryotic expression of HML-2 IN, nt 5592-6483 of cloned proviral locus HERV-K(HML-
2.HOM) (GenBank acc. no. AF074086.2 [134]) were amplified by PCR. The forward primer (HOM-
HA-IN-FOR) added a BamHI site, a Kozak consensus sequence, a spacer and an HA-tag. The reverse 
primer (HOM-HA-IN-REV) added a stop codon and a downstream BamHI site to the PCR product. 
The PCR product was cloned into pGEM-T Easy vector, giving rise to plasmid pGEM HOM-IN pSG5. 
pGEM HOM-IN pSG5 was used as DNA template for generation of a mutant integrase by PCR site-
directed mutagenesis (see chapter 3.2.1.9). The insert was released from pGEM HOM-IN pSG5, as 
well as the respective mutated version (pGEM HOM-IN pSG5 Δ3aa), by a BamHI digest and cloned 
into BamHI-digested pSG5 vector, giving rise to plasmids pSG5 HOM-IN and pSG5 HOM-IN Δ3aa. 
For screening of clones, presence and orientation of the insert was checked by digestion with EcoRI-
HF and subsequent visualization of expected DNA fragments by agarose gel electrophoresis.  
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Figure 11: Schematic representation of HML-2 IN construct cloned into pSG5 vector for HML-2 IN 
expression in mammalian cells. In the upper part, the Pol ORF is depicted in the context of the HML-2 proviral 
genome. Based on previous studies concerning HERV-K10 IN [105], a subregion (nt 5592-6483, in blue) 
corresponding to the IN-encoding region of the HERV-K(HML-2.HOM) Pol ORF (GenBank acc. no. 
AF074086.2 [134]) was cloned into pSG5 expression vector. Kozak sequence (introduced by us) and restriction 
sites used for cloning are indicated. The HA-tagged IN protein expressed in mammalian cells after transfection 
of pSG5 HOM-IN is depicted at the bottom. 
 
3.2.1.11 Verification of plasmid sequences  
For each DNA construct generated in this study, the plasmid portion that included the protein-coding 
sequence of interest was verified by Sanger sequencing [178]. Sequencing was performed by Seq-IT 
GmbH (Kaiserslautern) utilizing an ABI 3730 DNA sequencer. One or two sequence reads per plasmid 
construct were usually generated and sufficient for sequence verification. Vector-specific sequencing 
primers were used, thus primers that bound vector sequence flanking the cloned portion. Sequence 
reads of sufficient quality were usually around 700 bp in length. For the purpose of sequence 
comparisons, sequence reads were aligned to reference sequences using Geneious software 
(Biomatters). Combinations of primers (for primer sequences see Table3) employed for sequencing of 
plasmid constructs were as follows: 
 
Plasmid Primers 
pGEM-T Easy constructs T7 + SP6 
pET11d Pro T7 
pSG5 HOM-IN T7 
pEGFP-Pro EGFP-C F + pEGFP-C.rev 




3.2.2 Protein techniques 
3.2.2.1 Protein concentration measurement 
There are many techniques for measuring protein concentration. When the extinction coefficient is 
known for a protein of interest, a protein´s UV absorbance at 280 nm can be used to calculate the 
concentration of that protein. We have used that method to determine the concentration of purified 
HML-2 Pro, utilizing the extinction coefficient of HML-2 Pro as predicted by Geneious software 
(Biomatters). This method is rapid and does not require special reagents. Alternative assays are 
necessary to determine protein concentrations when there are interfering substances with absorbance 
at 280 nm and diverse proteins present in a protein solution. To determine protein concentration of cell 
lysates, we employed the Bio-Rad DCTM Protein Assay Kit, a colorimetric assay based on the reaction 
of proteins with an alkaline copper tartrate solution and Folin reagent. The assay is similar to the well-
documented Lowry protein assay [124] and furthermore compatible with various commonly used 
detergents used for cell lysis. As reported in the manual of the Bio-Rad DCTM Protein Assay Kit, there 
are two steps which lead to color development. Proteins react with copper ions (Cu2+) in an alkaline 
medium. Subsequently, copper-treated proteins reduce a Folin–Ciocalteu reagent by loss of 1, 2, or 3 
oxygen atoms, thereby producing one or more of several possible reduced species which have a 
characteristic blue color with maximum absorbance at 750 nm and minimum absorbance at 405 nm. 
The assay was performed in 96-well microplates or 1.5 ml Eppendorf tubes. For each measurement 
assay, a protein standard with BSA was prepared in the same buffer as samples, as recommended by 
the manufacturer. Absorbance at 750 nm was measured using a SparkÒ 10M microplate reader (Tecan) 
or a NanoDropTM 2000 Spectrophotometer (Thermo Fisher Scientific). 
 
3.2.2.2 Translation of proteins in vitro using the TNT T7 system  
The TNT® T7 Quick for PCR DNA Kit (Promega), also referred to as TNT T7 system, is a coupled 
transcription/translation system that we used for in vitro production of HML-2 Gag protein, used as 
known substrate of HML-2 Pro, as well as for production of selected candidate proteins investigated 
for processing by HML-2 Pro. The TNT T7 system is able to produce proteins ranging in size from 
10–150 kDa, starting from a DNA template generated by PCR. 
The design of primers was as follows. The PCR primer portion complementary to the 5' end of the 
protein coding sequence was designed to have a melting temperature of approximately 58°C. 
Additional sequence elements were present in the PCR primers. In the forward primer, a T7 phage 
RNA polymerase promoter, flanked by a short spacer sequence on each side (the spacer in the 
5´ terminus being a BamHI restriction site), and a Kozak consensus sequence enabling efficient 
translation initiation, were present upstream of the protein coding-specific portion. The reverse primer 
added a sequence portion encoding an HA-tag and a stop codon downstream of the protein coding 
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sequence, effectively replacing the own stop codon of the protein coding sequence. Sequence elements 
included in PCR primers are shown in Figure 12. 
 
Figure 12: Sequence elements included in PCR primers for generation of DNA templates for translation 
of proteins in vitro by TNT T7 system. See the text for details. 
 
PCR reactions were performed with Taq DNA polymerase employing conditions as reported in chapter 
3.2.1.1. In those PCR reactions, the coding region of full-length protein was amplified from purified 
plasmid template DNA. The coding region of HML-2 Gag was cloned in pBluescript II vector and 
available in-house. Plasmids containing the coding region of candidate proteins were purchased from 
GE Healthcare/Dharmacon. Clone identifiers of cloned coding sequences of candidate proteins are 
reported in Table 13. 
 
Table 13: Clone identifiers of cloned coding sequences of proteins investigated for processing by HML-2 
Pro 
Gene/protein name Clone ID  Gene/protein name Clone ID 
C15orf57 2823236  MAP2K2 2961198 
CALR 4299303  PDIA3 4712175 
CIAPIN1 30389410  PSMC4 4046205 
DDX3X 3617040  RANBP1 3935906 
ENO1 4799584  RNASEH2B 5195426 
HSP90AA1 40118488  S100A4 4247807 
HSP90AB1 3621040  TUBA1A 6050536 
 
Resulting PCR products were analyzed by agarose gel electrophoresis to verify amplification of desired 
PCR products and no byproducts present at considerable amounts. Desired PCR products were directly 
used as DNA templates for the coupled transcription/translation reaction. Reactions were set up as 
reported in Table 14, then incubated for 90 min at 30°C and frozen at -20°C immediately afterwards. 
Translation-grade L-35S-methionine (370 MBq, 10 mCi/ml; Hartmann Analytic, Braunschweig, 
Germany) was employed in the reaction for generation of radiolabeled proteins, whereas "cold" 
L-methionine was included for generation of non-radiolabeled proteins. 
 
Table 14: Reaction for generation of proteins in vitro by using a TNT T7 system 
2.5 µl PCR generated DNA template 
22 µl  TNT® T7 PCR Quick Master Mix 
0.5 µl L-35S-methionine (370 MBq, 10 mCi/ml) or L-methionine (1mM) 
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3.2.2.3 Prokaryotic expression and purification of HML-2 Pro 
pET expression system and BL21 (DE3) competent cells 
The pET expression system (Agilent) was used for prokaryotic expression of HML-2 Pro from the 
provirus HERV-K(HML-2.HOM). pET-11d (Figure 13) is a 5.7 kb plasmid, having as main features 
a T7 promoter with a lac operator (lac O), a ribosome binding site (RBS), a β-lactamase ORF for 
ampicillin resistance, a pBR322 origin of replication (which result in low copy number), and a lacI 
repressor ORF. The protein coding sequence of interest is cloned downstream of, and in-frame with, 
the RBS. pET-11d plasmid constructs were propagated in BL21 (DE3) Competent E. coli cells (NEB). 
BL21 (DE3) is an engineered strain of E. coli that carries a gene coding for the lac repressor (LacI) 
and a gene coding for the T7 RNA polymerase under control of a lacUV5 promoter. When pET-11d is 
transformed into BL21 (DE3), transcription of the gene of interest cloned in pET-11d is prevented via 
two mechanisms. First, LacI interacts with the lacUV5 promoter, repressing expression of T7 RNA 
polymerase (the gene of interest is transcribed from a T7 promoter, thus in absence of T7 RNA 
polymerase its transcription cannot take place). Second, LacI interacts with the lac operator located 
upstream of the gene of interest in the pET-11d vector. Binding of LacI prevents transcription of the 
gene of interest by formation of DNA structures that occlude passage of T7 RNA polymerase. 
Isopropyl-1-thio-β-D-galactopyranoside (IPTG) is a structural mimic of lactose that is able to bind 
LacI causing conformational changes that reduce its affinity for DNA [43]. Thus, IPTG is well suited 
for inducing T7 promoter-mediated target gene expression by unlocking the two repression 
mechanisms mentioned above. Moreover, IPTG is not degraded or otherwise utilized by E. coli cells, 
ensuring a stable IPTG level over hours during which the target protein will be produced, eventually 
comprising the majority of cellular proteins. 
 
 




HML-2 Pro expression in BL21 (DE3) E. coli 
50 µl of BL21 (DE3) E. coli cells (transformation efficiency 1–5 x 107 cfu/µg pUC19 DNA) were 
carefully mixed with 100 ng of pET11d Pro plasmid (see chapter 3.2.1.10.2) and incubated on ice for 
30 min. The mixture was then subjected to a heat shock at 42°C for 90 sec and subsequently placed on 
ice for 5 min. Transformed cells were directly spread onto an agar-plate with ampicillin at standard 
concentration and incubated overnight at 37°C. Then, a single colony of E. coli cells was inoculated 
into 100 ml of LBamp and incubated overnight at 37°C. 20 ml of the overnight culture was then 
inoculated into 1 L LBAmp and incubated at 37°C until the absorbance at 600 nm had reached 0.6. 
Expression of HML-2 Pro was then induced by addition of IPTG at a final concentration of 0.4 mM. 
After 3 h at 37°C, bacterial cells were pelleted by centrifugation at 6800 g for 30 min at 4°C and the 
bacterial pellet was stored at -80°C. 
 
Lysis of bacteria and protein recovery from inclusion bodies 
High level expression of recombinant protein in E. coli often results in accumulation of expressed 
protein molecules in aggregates called inclusion bodies [191]. To recover the protein of interest, it was 
thus necessary to extract, isolate and solubilize inclusion bodies before the actual process of Pro 
purification by chromatography. Compositions of buffers employed for protein recovery from 
inclusion bodies are reported in chapter 3.1.2. The bacterial pellet derived from 1 L of cell culture, 
stored at -80°C until further processing, was resuspended in 50 ml of pre-cooled 5x TE Buffer and 
passed 3-4 times through a glass Dounce homogenizer kept constantly on ice. The lysate mixture was 
then subjected to sonication on ice, using a Branson Ultrasonics™ Sonifier S-250A (program: 10 x 10 
sec, duty cycle 40%, output control 5). The cell lysate was centrifuged for 30 min at 3600 g and 4°C. 
During centrifugation, inclusion bodies mostly precipitated as part of the insoluble fraction of cell 
lysate. Thus, following centrifugation the pellet was subjected to subsequent processing steps, whereas 
the supernatant was discarded. For the solubilization step, the pellet containing inclusion bodies was 
washed twice with 20 ml of 5x TE Buffer each and then dissolved in 100 ml of Solving Buffer. During 
this process, high concentration of chaotropes, such as urea, results in disruption of protein structure 
making necessary a refolding process by removal of the solubilization agent. Removal of urea with 
accompanying refolding of proteins was achieved by dialysis. Dialysis is the separation of molecules 
in solution, based on their differential diffusion through a semipermeable membrane. For this purpose, 
we employed SnakeSkin™ Dialysis Tubing (10K MWCO, 22 mm) (Thermo Fisher Scientific) 
composed of regenerated cellulose. A piece of membrane of a suited size was rehydrated in H2Odd and 
filled with the protein mixture solubilized in Solving Buffer. The dialysis tubing was sealed at both 
ends with tubing clips and floated in Dialysis Buffer using an appropriately sized container. Dialysis 
Buffer was kept in constant slow agitation using a magnetic stirrer. The protein mixture was dialyzed 
against 4 L of Dialysis Buffer at 4°C for 3 h and then against 4 L of fresh Dialysis Buffer at 4°C 
overnight. 
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HML-2 Pro purification by affinity chromatography 
Chromatography is a technique for separation of specific components of a homogeneous mixture. In 
molecular biology, a protein mixture can be fractionated using various chromatography methods, based 
on physical and chemical properties of biomolecules. Affinity chromatography is based on specific 
interactions that can occur on protein surfaces. In general, a solution of proteins (mobile phase) is 
mixed with a porous solid matrix (stationary phase) covalently coupled with a ligand, for instance a 
substrate, an inhibitor or an antibody. The two phases are packed in a chromatography column and 
subjected to wash steps. Proteins specifically interacting with the ligand are retained in the matrix, all 
other proteins and molecules are washed out. The protein-ligand interactions are then disrupted through 
an elution step that induces the release of proteins bound. In this way, desired proteins can be isolated 
in a pure and concentrated form. Being a sensitive method, affinity chromatography requires 
considerable accuracy; only fine-tuned conditions guarantee a high yield and high purity of the desired 
protein.  
We employed affinity chromatography for purification of HML-2 Pro from the HERV-K(HML-
2.HOM) provirus. In our experiment, the mobile phase was a mixture of proteins recovered from 
inclusion bodies and derived from a lysate of bacteria overexpressing HML-2 protease (see above). 
The stationary phase consisted of agarose beads coupled to ligand pepstatin A, a specific and reversible 
aspartyl protease inhibitor. Our procedure followed a previously described protocol with minor 
modifications [112]. Composition of buffers employed for HML-2 Pro purification are reported in 
chapter 3.1.2. 
The dialyzed solution prepared through the procedure for protein recovery from inclusion bodies (see 
previous paragraph) was centrifuged for 30 min at 6800 g and 4°C to remove precipitated proteins and 
then mixed at equal volumes with Buffer A. High salt concentration and low pH of Buffer A were two 
important parameters required for the next step, specifically interaction between pepstatin A and the 
mature HML-2 Pro during affinity chromatography. 5 ml of pepstatin A-agarose (Sigma) suspension 
(referred to as matrix in the following) were washed with 50 ml H2Odd and then 50 ml Buffer A, and 
subsequently added to the dialyzed protein solution previously mixed with Buffer A. The resulting 
matrix-protein solution was incubated overnight at 4 °C with slow agitation. The protein-matrix 
solution was then centrifuged for 15 min at 980 g and 4°C. The supernatant (representing the flow-
through), containing most of the unbound proteins, was removed. The matrix was resuspended in 45 ml 
of Buffer A (Wash 1) and packed onto a chromatography column that was pre-conditioned with 
Buffer A. After Wash 1, another 30 ml of Buffer A were loaded onto the column in order to wash the 
matrix a second time (Wash 2). Proteins remaining in the column up to this point, i.e. proteins bound 
to pepstatin A-agarose, were eluted from the matrix with Buffer B, which has a higher pH and lower 
ionic strength than Buffer A (see section 3.1.2, compare pH and NaCl concentration of the two buffers). 
In fact, as binding of pepstatin A to HIV-1 Pro is pH-dependent and occurs at low pHs but is reduced 
above pH 7 [162], one can assume the same for HML-2 Pro. Six elution fractions of 5 ml each were 
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collected by gravity-flow. Aliquots were collected during the various purification steps in order to 
monitor collected aliquots by SDS-PAGE and subsequent protein visualization by Coomassie-staining 
of PAA-gels. Protease-containing elution fractions were pooled and concentrated using an 
Amicon® Ultra-15 Centrifugal Filter Unit (3000 MWCO). Protein concentration was achieved by 
centrifugation for 40 min at 4000 g and 4°C, to reach a final volume of approximately 2 ml. Protease 
concentration was determined utilizing DCTM Protein assay (Bio-rad) and UV spectrophotometry using 
a molar absorption coefficient of 29115 M-1 cm-1 s (see also chapter 3.2.2.1). The concentrated protein 
solution was aliquoted and stored at -80°C. 
 
3.2.2.4 In vitro enzymatic fluorescence assays for optimization of HML-2 Pro activity 
Fluorophores are substances that absorb energy and re-emit part of that energy as radiation. When an 
exited fluorophore (donor) is in very close proximity (closer than approximately 10 nm) to a molecule 
(acceptor) whose absorption spectrum overlaps with the emission spectrum of the donor, a transfer of 
energy between the two molecules can occur, thus quenching emission from the fluorophore. 
Fluorescence Resonance Energy Transfer (FRET) is a technique based on this phenomenon that can 
be used to determine whether two molecules are within a certain distance to each other [127]. In fact, 
FRET is useful in assays measuring activity of a protease. In such assays, protease activity can be 
monitored using substrates in which a fluorophore is separated from a quencher by a short peptide 
sequence containing a protease-specific cleavage site. The assay that we established for monitoring 
and optimization of HML-2 Pro activity took advantage of the FRET technology. The molecule that 
we used as substrate of HML-2 Pro is 2-aminobenzoyl-Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2 
(BACHEM, also referred to as Anthranilyl-substrate). The Anthranilyl-substrate harbors a fluorescent 
2-aminobenzoic acid (or anthranilic acid) in place of the acetyl group as donor and a p-NO2-Phe at the 
P1' position as acceptor (Figure 14). Cleavage of the peptide by Pro releases the fluorescent N-terminal 
tripeptide from its close apposition to the quenching nitrobenzyl group, resulting in enhanced 
fluorescence (Figure 14). 
Anthranilyl-substrate was incubated with HML-2 Pro under various reaction conditions as described 
in the Results section. Reactions were set up in 96-well microplates (Greiner Bio-One 655087) with a 
50 µl final volume each. Fluorescence measurements were taken using a Tecan Infinite® M200 
spectrophotometer, with excitation at 280 nm and emission measured at 420 nm. Reactions were 
monitored at 37°C by detecting the fluorescent emission at 420 nm for each reaction condition every 
4 min and a total of up to 180 min. When plotting Pro activity, values of fluorescence emission at 420 
nm were corrected by subtracting background fluorescence emission at 420 measured in parallel from 




Figure 14: Molecular structure of the Anthranilyl substrate. The molecular structure of the Anthranilyl-
substrate (2-aminobenzoyl-Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2) is shown before (top) and after (bottom) 
cleavage by Pro. The 2-aminobenzoic acid (donor), depicted in red, is quenched by the nitrobenzyl group 
(acceptor) depicted in blue. For the N-terminal tripeptide produced after cleavage by Pro, the 2-aminobenzoic 
acid depicted in yellow is not quenched. 
 
3.2.2.5 Separation of proteins by SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method for protein 
separation under denaturing conditions. Prior to loading protein samples into a polyacrylamide gel 
(PAA-gel), protein samples are mixed with a sample buffer that contains reducing agents and sodium 
dodecyl sulfate (SDS). Protein samples are then exposed to high temperature (usually 70°C for 10 min 
or 90°C for 5 min) in order to denature proteins. Reducing agents, such as dithiothreitol (DTT), unfold 
polypeptides by reducing disulfide bonds between cysteine residues. SDS is an anionic detergent that 
binds unfolded proteins at a ratio of approximately 1 SDS molecule per two amino acids, thus further 
contributing to protein denaturation. SDS introduces negative charges that mask the intrinsic protein 
charge. The resulting SDS-protein complexes are linearized and negatively charged, thus during 
electrophoresis they migrate towards the anode upon application of an electrical field. The PAA-gels 
are usually composed of a layer with large sized pores (stacking gel) and a layer with smaller sized 
pores (running gel). The stacking gel allows the concentration of proteins at the interface with the 
running gel, where the actual separation start. During the protein migration through the running gel, 
larger proteins migrate more slowly through the gel pores than shorter ones. As a consequence, the 
PAA-gel behaves like a molecular sieve separating proteins by molecular weight. The sample buffer 
usually includes a dye, such as bromophenol blue, that helps tracking the migration of the protein 
sample through the gel. Moreover, a protein marker with proteins of known molecular weight is loaded 
in at least one gel lane as a reference for protein sizes. 
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For our experiments we employed an XCell SureLock™ Mini-Cell Electrophoresis System (Thermo 
Fisher/Novex). PAA-gels were prepared as shown in Table 15. Gels were manually cast into empty 
gel cassettes (Thermo Fisher/Novex). The desired gel porosity was achieved by varying the percentage 
of acrylamid/bis-acrylamid (Bio-Rad). The discontinuous NuPAGE Bis-Tris buffer system was 
employed in two variants, depending on the desired protein resolution. NuPAGE® MOPS SDS 
Running Buffer was used to resolve proteins of medium molecular weight. NuPAGE® MES SDS 
Running Buffer was used to resolve proteins of relatively low molecular weight. Samples were 
prepared by adding 4x NuPAGE® LDS Sample Buffer and DTT at 50 mM final concentration to 
protein mixtures. Before loading, samples were heated at 70°C for 10 min (as recommended by the 
manufacturer) and then briefly centrifuged to collect condensate. Samples containing proteins 
generated by the TNT T7 system were heated at 65°C for 15 min to reduce the amount of extra protein 
bands at higher molecular weight, as suggested by the TNT T7 system manual. 
For monitoring HML-2 Pro during expression in E. coli, 1 ml aliquots of bacterial cell culture were 
pelleted by centrifugation for 5 min at 6800 g. Cell pellets were resuspended in 50 µl 5x TE Buffer. 
12 µl of cell suspension were mixed with 4 µl of 4x NuPAGE® LDS Sample Buffer and incubated for 
5 min at 95°C. After centrifugation, supernatants were loaded onto a PAA-gel and separated by SDS-
PAGE. Precision Plus Protein Dual Color Standard (Bio-rad) was used as molecular weight standard 
for proteins (see chapter 3.1.6). Electrophoresis was performed at 180 V constant. To maintain proteins 
in a reduced state during electrophoresis, a NuPAGE® Antioxidant (Thermo Fisher Scientific) was 
added to the running buffer of the cathode electrophoresis chamber. 
 
Table 15: Pipetting scheme for preparation of stacking and running gel used for SDS-PAGE * 
Components Stacking gel Running gel 
 4% 10% 12% 15% 
3.5x Bis-Tris buffer pH 6.8 0.5 1.42 1.42 1.42 
30% Acrylamid/Bis solution (37.5:1) 0.25 1.67 2 2.5 
H2Odd 1.02 1.91 1.58 1.08 
10% [w/v] APS 0.02 0.025 0.025 0.025 
TEMED 0.01 0.007 0.007 0.007 
*3.5x Bis-Tris Buffer composition is: 52.32g Bis(2-hydroxyethyl) amino-tris(hydroxymethyl) methan (Bis-Tris) 
in 200 ml H2Odd, pH 6.5-6.8 (pH is adjusted with HCl). Acrylamide and methylenebisacrylamide are crosslinked 
through a radical polimerization that involves ammonium peroxodisulfate (APS) as radical initiator, and 
tetramethylethylenediamine (TEMED) as catalyst. Volumes are given in ml. 
 
3.2.2.6 Western blot 
Following separation by SDS-PAGE, proteins can be transferred, that is, blotted, from the PAA-gel to 
a solid support membrane. This opens up a spectrum of possibilities in terms of protein detection and 
analysis not feasible using a rather fragile gel matrix. 
The transfer relies on the same electrophoretic principles that drive migration of proteins during 
separation in SDS-PAGE but is done using an electric field oriented perpendicular to the surface of the 
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gel. The membrane, placed between the gel surface and the positive electrode, can vary in porosity and 
is usually made of nitrocellulose or polyvinylidene difluoride (PVDF). PVDF has a high protein 
affinity but needs to be activated with methanol in order to create a positively charged membrane 
surface thus allowing for interaction with SDS-complexed, thus negatively charged proteins. During 
blotting, proteins are immobilized on the membrane, mirroring their original position in the gel. After 
transfer, desired proteins can be detected on the blot membrane using, for instance, specific antibodies. 
Before antibody probing, a blocking step is required to reduce non-specific binding of the antibody to 
protein-free areas of the membrane. 5% [w/v] BSA or 5% [w/v] non-fat dry milk, both diluted in Tris-
buffered saline (TBS) or phosphate-buffered saline (PBS), are common blocking solutions. Probing by 
indirect immunodetection involves an unlabeled primary antibody which is specific for the target 
protein, followed by binding of a labeled secondary antibody directed against the primary antibody. 
Antibodies can be diluted in blocking solution, with their concentration potentially requiring 
optimization to achieve best results. Moreover, incubations with immunochemical reagents are 
followed by wash steps, fundamental to remove unbound antibodies that could otherwise cause high 
background signal. Detergents, such as Tween-20, are commonly included in standard washing 
solutions. In a final step, depending on the label present in the secondary antibody, a variety of systems 
can be employed for detection of the target protein. For instance, enzyme-based chemiluminescence 
has been extensively developed and in particular antibodies conjugated with horseradish peroxidase 
(HRP) are a convenient method of choice. For this method, hydrogen peroxide induces HRP to catalyze 
oxidation of luminol that results in blue emission at 450 nm as a reaction product. The light emission 
on the blot membrane corresponds to the position of the target protein and can be detected on X-ray 
film or through digital imaging. The light signal can be intensified using detection reagents that 
include, for instance, modified phenols that increase HRP activity. So-called enhanced 
chemiluminescence (ECL) is crucial for detecting proteins present at relatively low-levels and, more 
generally, when high sensitivity and accurate quantification are important. 
 
In our Western blot procedure, following SDS-PAGE, proteins were transferred onto Hybond 0.2 µm 
PVDF membrane (Amersham/GE Healthcare) using an XCell II™ Blot module and 1x NuPAGE® 
Transfer Buffer with 0.1% [v/v] NuPAGE antioxidant and methanol added to a final concentration of 
10% [v/v] when transferring one gel, or 20% [v/v] methanol when transferring two gels in one blot 
module. The PVDF membrane was activated by incubation in methanol for 30 sec, 30 sec wash in 
H2Odd and then equilibrated in 1x NuPAGE Transfer Buffer (including methanol) for 20 min. The blot 
elements were assembled in the gel membrane sandwich as shown in Figure 15. Transfer of proteins 
was performed at 30 V constant for 1 h. 
 62 
 
Figure 15: Assembly of blot elements in the XCell II™ Blot module. Blots were performed by transferring 
one (left) or two (right) gels in a blot module. Blotting pads and filter papers were soaked in transfer buffer before 
assembling the blot module. The gel surface was wetted with transfer buffer before positioning the pre-soaked 
transfer membrane on it. Figure taken from the NuPAGE® Technical Guide (Rev. date: 29 October 2010 Manual 
part no. IM-1001). 
 
After transfer, the blot module was disassembled and the membrane was allowed to dry for 1 h at room 
temperature. The dried membrane was usually labelled in the upper right extremity using a soft graphite 
pencil to mark the side of the membrane containing proteins. When it was necessary to probe different 
parts of the membrane with different antibodies the membrane was cut accordingly using a surgical 
blade. Dry membrane was re-activated by incubation for 30 sec in methanol and 30 sec in H2Odd. The 
following steps, specifically blocking, probing and washing, were performed by putting the blot 
membrane in a 50 ml Falcon tube placed on a lab roller set to constant rotation. Blot membranes were 
blocked for 1 h in Blocking Buffer (see chapter 3.1.2 for buffer composition) and incubated overnight 
at 4°C with primary antibody, diluted in Blocking Buffer. Secondary antibody incubation was done 
using peroxidase-coupled antibodies diluted in Blocking Buffer, for 2 h at room temperature. 
Following primary and secondary antibody incubations, the membrane was washed three times for 10 
min in 50 ml TBS-T (1x TBS, 0.05% [v/v] Tween-20) each. Signal detection was done using 
SignalFireTM Elite ECL Reagent (Cell Signaling Technology). 1x ECL reagent was prepared by 
combining equal parts of 2x Reagent A and 2x Reagent B, usually 250 µl of each, mixing, and then 
spreading of the solution on the membrane in a dropwise manner. The membrane was then sealed in a 
polypropylene envelope to facilitate equal distribution of the ECL reagent on the membrane surface. 
After 1 min incubation, excess ECL reagent was removed. ECL signal on membrane, still in the 
polypropylene envelope to prevent drying-out, was documented using a ChemidocTM Imaging System 
(Bio-Rad). Subsequent image analysis utilized ImageLab 5.2.1 software (Bio-Rad). 
 
3.2.2.7 Protein staining  
For detection of proteins in PAA-gels following electrophoresis, PAA gels were briefly rinsed in H2Odd 
and incubated for 1 h with Coomassie Staining Solution (see chapter 3.1.2 for buffer composition) at 
gentle agitation. Subsequently, gels were washed thoroughly in Coomassie Destaining Solution (see 
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chapter 3.1.2 for buffer composition) at gentle agitation until complete removal of excess stain. 
Coomassie staining was also used for visualization of proteins on PVDF membranes. Since Coomassie 
staining is permanent, it was employed only after protein detection by ECL in the course of the Western 
Blot procedure. To do so, after ECL imaging, membranes were incubated for 2 min in Coomassie 
Staining Solution and subsequently washed for 2 min in Coomassie Destaining Solution. Membranes 
were left at room temperature for complete drying. Coomassie-staining of proteins on PVDF 
membranes was employed in some experiments to evaluate the transfer efficiency and as a loading 
control. Ponceau S is an alternative protein stain that is used to visualize proteins blotted onto a 
membrane. It is less sensitive than Coomassie-staining but with the advantage of being quick and 
reversible. Thus, following protein transfer, we used in certain contexts Ponceau S Solution (see 
chapter 3.1.2 for buffer composition) to visualize proteins in PVDF membranes in order to evaluate 
transfer efficiency and, when necessary, cut parts of interest of membranes for subsequent 
immunodetection. 
 
3.2.2.8 Immunofluorescence microscopy 
The combination of immunostaining and fluorescence microscopy provides a powerful methodology 
for studying the localization and distribution of specific proteins inside the cell. We employed the 
immunofluorescence (IF) technology to investigate potential effects of HML-2 integrase on DNA 
stability and in experiments addressing HML-2 protease-induced cell death. In the following, IF 
procedures employed in the presented work will be described in general. To perform IF, cells were 
seeded onto a proper surface that allowed for efficient cell adhesion and no subsequent interference 
with the microscopic light source. In our experiments, we seeded approximately 2 x 104 cells/well into 
8-well cell culture slides with a removable chamber frame (Sarstedt). Following treatments, cells were 
rinsed briefly with 1x DPBS (Gibco/Life Technologies) and incubated for 15 min in 300 µl/well fixing 
solution (2% [v/v] formaldehyde in 1x DPBS, pH 7.4). After three wash steps with 500 µl/well 1x 
DPBS each, cells were permeabilized by incubation for 5 min in 300 µl/well permeabilizing solution 
(0.2% [v/v] Triton X-100 in 1x DPBS). During permeabilization, 8-well slides were placed on ice. 
Three washes in 500 µl/well 1x DPBS preceded the blocking step, done by incubation for 60 min in 
blocking solution (1% [w/v] BSA in 1x DPBS). Similar to the Western blot procedure, the blocking 
step minimized unspecific binding of antibodies. Subsequently, cells were incubated overnight at 4°C 
with primary antibody diluted in blocking solution. During this incubation, the 8-well slide was placed 
in a humidified chamber to reduce evaporation. Excess unbound antibody was removed by three 
washes in 500 µl/well 1x DPBS, 10 min each. Secondary antibodies were diluted in blocking solution, 
added to the cells and incubated for 1 h at room temperature in the humified chamber. During 
incubations with antibodies the 8-well slide was kept in the dark. Furthermore, handling was done in 
a darkened environment when antibodies were conjugated with fluorescent dyes. After removal of 
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secondary antibody solution and three 10 min washes in 1x DPBS, the 8-chamber frame was carefully 
detached from the slide and slides were mounted with VectashieldÒ Mounting Medium (Vector 
Laboratories), containing 4´,6-diamidino-2-phenylindole (DAPI) which fluoresces with an emission 
maximum at 461 nm (blue) when bound to double-stranded DNA.  
Cells were analyzed with an Olympus AX70 fluorescence microscopy system, equipped with a filter 
set for visualization of DAPI, FITC, Texas-Red and infrared. Images were captured with a camera and 
analyzed using CellSens Imaging Software (Olympus, Tokyo, Japan). When expressing EGFP or 
recombinant proteins tagged with EGFP, the EGFP signal was, in certain experimental contexts, 
observed in living cells (without immunostaining) using an Axiovert 25 CFL inverted microscope (Carl 
Zeiss GmbH) equipped with reflected light fluorescence illumination. 
 
3.2.2.9 Terminal amine isotopic labeling of substrates (TAILS) 
Terminal amine isotopic labeling of substrates (TAILS) [68] is a quantitative proteomics method for 
labeling and isolation of N-terminal peptides. Proteolysis of proteins generates shorter peptides 
displaying new N-terminal ends (N-termini). Therefore, TAILS can be employed as a strategy to 
identify substrates of a protease of interest through the comparison between N-termini isolated from a 
protease-treated sample and N-termini isolated from an untreated control sample [114]. N-termini are 
labeled and blocked. Several processing steps result in purification and concentration of blocked N-
terminal peptides. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) enables the 
analysis and quantification of N-terminal peptides and neo-N-terminal peptides, providing their 
relative quantities in the treated and untreated samples. Following MS/MS, various bioinformatic tools 
are employed to identify actual human proteins having generated particular peptide fragments, actual 
cleavage positions within proteins, protein length, protein features, etc., in order to compile relevant 
information on substrate proteins. 
In our work, TAILS was employed as a search strategy for the identification of potential substrates of 
HML-2 Pro. Parts of the TAILS procedure were performed in our laboratory. A protein mixture derived 
from lysis of HeLa cells was incubated in presence of purified HML-2 Pro at experimental conditions 
as described in the Results section. Incubations in the presence of 200 µM pepstatin A, effectively 
blocking HML-2 Pro activity, were performed as control reactions without HML-2 Pro activity. 
Treated samples and respective controls were sent to the laboratory of Prof. Dr. Oliver Schilling 
(University of Freiburg), where subsequent parts of the TAILS analysis were performed using well-
established protocols [106]. Data generated by the TAILS procedure were analyzed in our laboratory 
using Microsoft Excel (Office 2016) and other analysis tools as described in the Results section. 
Datasets resulting from TAILS analyses were provided to us in tabular format. Various data filtering 
and data overlap functions were used for analysis of data and extrapolation of results. Lists of protein 
IDs were used for Gene Ontology (GO) analysis employing the PANTHER (Protein Analysis Through 
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Evolutionary Relationships) classification system [140]. Protein IDs were also used for retrieving 
respective gene names from UniProt [40]. Lists of gene names were used for intersections with the 
Catalogue Of Somatic Mutations In Cancer (COSMIC) [60] and the Online Mendelian Inheritance in 
Man (OMIM) database [2]. 
 
Preparation of cellular proteins from HeLa cells 
For preparation of cellular proteins for incubation with HML-2 Pro, a total of 1.4 x 108 HeLa cells 
grown to near confluence in eight 160 cm2 tissue culture flasks were washed with 1x DPBS and 
detached by trypsinization (see also chapter 3.2.3.1). Cells were collected in 20 ml 1x DPBS per flask, 
pelleted for 5 min at 250 g, resuspended in 0.5 ml of 5 mM MES pH 6.0 supplemented with protease 
inhibitors (cOmplete, Mini, EDTA-free, Roche) at the recommended concentration and subjected to 
cell lysis by three freeze-thaw cycles. Each freeze-thaw cycle was performed as follows: 15 min 
incubation at -80°C, 10 min at room temperature and incubation on ice until complete thawing. During 
the first incubation on ice, glass beads were added to the samples. During each incubation on ice, 
samples were mixed by vortexing for 5 sec every 5 min. Protein lysates were centrifuged at 4°C for 
30 min at 16.100 g. Supernatants were pooled in a fresh tube and protein concentration was measured. 
HeLa protein lysate was stored in aliquots at -80°C. 
 
Preparation of TAILS reactions 
For preparation of TAILS reactions, 2 mg of HeLa total proteins were incubated with 200 nM HML-2 
Pro in a 2 ml reaction volume. Reaction buffer contained 1 M NaCl, 2% [v/v] DMSO, 100 mM PIPES 
at pH 5.5 or pH 7. Untreated controls included 200 µM pepstatin A. To promote Pro inhibition by 
pepstatin A, samples were pre-incubated for 10 min at room temperature before addition of HeLa total 
protein lysate as the last reaction component. All reaction mixtures were incubated at 37°C for 75 min. 
Reactions were then frozen at -80°C. Samples were shipped on dry-ice to the laboratory of 
Prof. Schilling for subsequent processing steps and tandem mass-spectrometry towards the 
identification of cellular proteins cleaved by HML-2 Pro. 
 
3.2.3 Manipulation of human cells 
3.2.3.1 Culturing of human cell lines 
We employed various adherent human cell lines in our studies (see chapter 3.1.7). All cell lines were 
cultured at 37°C and 5% [v/v] CO2 in a medium supplemented with 10% [v/v] heat-inactivated fetal 
calf serum (FCS), 50 µg/ml penicillin and 50 µg/ml streptomycin. For HeLa and HEK293T cells, 
Dulbecco’s Modified Eagle's Medium (DMEM) was used. For Tera-1, SK-MEL-28, and MeWo cells, 
RPMI 1640 medium was used. For primary cell cultures, cells were cultured in 75 cm2 flasks and split 
between one to two times per week depending on the growth rate of each cell line. Cells were split 
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when their confluence had reached approximately 80% of the total growth area. The procedure for 
splitting cell cultures was as follows: removal of the growth medium from the flask, washing of the 
cell monolayer with sterile 1x DPBS, addition of 2 ml of 0.05% Trypsin-EDTA (Gibco/Life 
Technologies) and incubation for 5-10 min at 37°C, until cells detached from the bottom of the flask. 
Cells were then collected by addition of 8 ml of fresh medium and completely detached by careful 
pipetting. An aliquot of the detached cells was transferred to a new flask containing fresh culture 
medium. Usual dilutions used to split various cell lines are given in chapter 3.1.7. Cells were double-
checked under the microscope before further culturing them. 
 
3.2.3.2 Determination of number of cells  
To estimate the number of human cells in a cell suspension, after cell detachment by Trypsin-EDTA 
(see above), an aliquot of cell suspension was mixed at an equal ratio with 0.4% [w/v] Trypan Blue 
Solution (Sigma). Trypan blue is a negatively charged dye that is not absorbed by vital cells, the 
functional cell membrane of which selectively excludes trypan blue. In contrast, trypan blue can pass 
through the damaged membrane of dead cells. Trypan blue can therefore be employed as a marker of 
cell vitality. Detached cells were subjected to cell counting employing a LunaTM Automated Cell 
Counter (Logos Biosystem) that was compatible with trypan blue staining, thus numbers of live as well 
as dead cells in the cell suspension could be determined. Determination of numbers of cells was used 
as a reference to seed desired numbers of live cells into plates. 
 
3.2.3.3 Transient transfection of cells 
For transient expression of proteins of interest in mammalian cells, we transiently transfected cells 
utilizing FuGENE® HD Transfection Reagent (Promega; in the following indicated as FuGENE 
reagent), a nonliposomal preparation consisting of a mixture of lipids and other components that is 
suitable for transfection of DNA into a wide variety of cell lines, that furthermore comes with relatively 
little cell toxicity. We employed standard transfection conditions as suggested by the manufacturer. 
Specifically, cells were seeded on the day before transfection. Cells were plated at cell numbers so that 
they were approximately 80% confluent on the day of transfection. Plasmid DNA and FuGENE reagent 
were added to Opti-MEMÔ Reduced Serum Medium (Gibco). Total volume, amount of DNA per well 
and amount of FuGENE reagent per well are given in Table 16. The ratio of FuGENE reagent (µl) and 
DNA (µg) was 3:1. Transfection mixes consisting of plasmid DNA, FuGENE reagent, and Opti-MEM 
medium were incubated for 15 min at room temperature to allow for formation of FuGENE 
reagent:DNA complexes. Transfection mixtures were added to wells in a drop-wise manner or pipetted 
into cell culture medium in case of smaller volumes. Transfected cells were incubated at 37°C, 5% 
[v/v] CO2 and further processed depending on the experimental context. 
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Table 16: Conditions established for preparation of transfection mixes 
Plate Total transfection 
volume (per well) 
Amount of DNA 
(per well) 
Amount of FuGENE 
reagent (per well) 
6-well plate 100 µl 2.5 µg 7.5 µl 
12-well plate 50 µl 1 µg 3 µl 
8-well cell culture slide 10 µl 0.2 µg 0.6 µl 
 
3.2.3.4 Harvesting of cells  
To harvest cells (from flasks or wells), we used the following procedure. Growth medium was removed 
by aspiration, the cell monolayer was washed with sterile 1x DPBS; 0.05% [v/v] Trypsin-EDTA were 
added (100 µl/well for 12-well plate, 500 µl/well for 6-well plate, 5 ml for T-160 flask) and incubated 
for 5-10 min at 37°C until detachment of cells from the culture surface. Cells were then collected by 
addition of fresh growth medium and careful pipetting for complete cell detachment. Cell suspension 
was then transferred into a tube and centrifuged for 5 min at 300 g. Supernatant was removed, cell 
pellet was washed with 1x DPBS and centrifuged again. Cell pellets were stored at -80°C or directly 
used for subsequent procedures. 
 
3.2.3.5 Fluorescence-activated cell sorting (FACS)  
Fluorescence-activated cell sorting (FACS) is used to profile cells in a heterogeneous cell suspension. 
A flow cytometer is used to perform FACS. In a flow cytometer, employing a laser-based technology 
[22], individual cells can be analyzed and grouped in distinct sub-populations on the basis of physical 
and chemical characteristics. For such analysis, it is important that samples are prepared in a way that 
cells are properly separated from each other. In a flow cytometer, cells flow one by one across a laser 
beam that, in association with detectors, measures optical properties correlated with cellular 
characteristics. For instance, detecting light scattered at different angles gives indications about cell 
morphology, e.g., forward scatter (FSC) correlates with cell size and side scatter (SSC) is proportional 
to cell granularity. Fluorescence emission can be measured for gating cells that contain proteins labeled 
with a fluorophore. Cell count, cell cycle evaluation, apoptosis measurements, and many other 
applications can be achieved with this powerful methodology. 
In our work, FACS was employed for evaluating cell death induced in a population of cells expressing 
HML-2 Pro fused with EGFP. For sample preparation, HEK293T cells were seeded and transfected in 
12-well plates. After transfection, cells were collected at different time points. At each time point, cells 
were harvested by trypsinization and counted (see above). Each sample consisted of cells derived from 
two wells treated in the same way. 2 x 105 cells/sample were transferred into a fresh Eppendorf tube 
and washed twice with 500 µl 2% [v/v] FCS in 1x DPBS and centrifugation for 5 min at 300 g. Cell 
pellets were reconstituted in 150 µl 2% [w/v] paraformaldehyde in 1x DPBS, transferred to FACS 
tubes and stored at 4°C in the dark until measurement with a flow cytometer. We utilized in our studies 
a BD FACSCanto™ II flow cytometer with FACS Diva software version 6.1.3. FACS and data 
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analyses were performed with the help of Dr. Tina Schmidt and Dr. David Schub (Institute of Virology, 
University of Saarland). 
 
3.2.3.6 Lysis of human cells 
Lysis of HeLa cells under non-denaturing conditions for preparation of protein mixture for TAILS 
reaction, is described in 3.2.2.9. Lysis of human cells for whole protein extraction under denaturing 
conditions was performed as follows. After harvesting of cells from culture plates, cell pellets were 
frozen at -80°C and resuspended in RIPA Buffer (buffer composition in chapter 3.1.2) enriched with 
protease inhibitors (cOmplete, Mini, EDTA-free, Roche) at the recommended concentration, and 
pepstatin A at 1µg/µl. Pellets combined from two 12-well replicates were resuspended in 100 µl RIPA 
Buffer. Pellets from combination of two 6-well replicates were resuspended in 300 µl RIPA Buffer. 
Resuspended cells were incubated for 20 min on ice and mixed by vortexing for 5 sec every 10 min. 
Insoluble cell debris was pelleted by centrifugation at 13,000 g for 15 min at 4°C. Supernatant was 
transferred to a fresh Eppendorf tube and protein concentration was measured. Cell lysates were stored 
at -20°C. 
 
3.2.3.7 Storage of human cells in liquid nitrogen and thawing 
For long-term storage, eukaryotic cells were stored in a Biosafe®-MDβ (Cryotherm) liquid nitrogen 
tank. The freezing medium was composed of growth medium supplemented with 20% (v/v) FCS and 
10% (v/v) dimethyl sulfoxide (DMSO). DMSO acts as a cryo-protective agent that prevents formation 
of ice crystals in the cell lumen thus avoiding damage of the cellular membranes. To prepare cell 
aliquots for cryo-storage, following cell detachment with Trypsin-EDTA (see above), cells were 
pelleted by centrifugation for 5 min at 300 g. The supernatant was removed and the cell pellet was 
resuspended very gently in freezing medium. Cells were aliquoted in 1 ml cryo-vials and frozen down 
using a CoolCell™ at -80°C that allowed for a constant cooling rate of approximately 1°C per minute. 
Frozen cells were then transferred to a Biosafe®-MDβ liquid nitrogen storage tank. Cell stocks stored 
in liquid nitrogen were used for starting a new cell culture of a particular cell line. To thaw cells after 
storage in liquid nitrogen, cell-containing cryo-vials were incubated in a water bath at 37°C until the 
freezing medium was completely molten, then transferred into a 75 cm2 flask with growth medium 
pre-warmed to 37°C and incubated overnight at 37°C, 5% [v/v] CO2. The following day, growth 





The present study focused on the biological impact of two viral proteins, protease (Pro) and integrase 
(IN), derived from the HERV-K(HML-2.HOM) provirus. HERV-K(HML-2.HOM) has been described 
for the first time in a study conducted in our laboratory and in the Department of Virology (University 
of Saarland, Homburg, Germany) [134]. The HERV-K(HML-2.HOM) provirus is located in 
chromosome 7 and represents one of the most intact HERVs identified. HERV-K(HML-2.HOM) 
harbors complete ORFs for all retroviral genes. The Pro and IN ORFs retained conserved amino acids 
within catalytic motifs. The encoded Pro was confirmed to be functional, being able to self-process 
and process the HERV-K(HML-2) Gag protein [134]. The IN ORF of HERV-K(HML-2.HOM) was 
found to be almost identical in sequence to the HERV-K10 IN, the latter known to be functional [105]. 
Also, the HERV-K(HML-2.HOM) provirus contains LTRs with intact sequence motifs for initiation 
and termination of transcription [134]. HERV-K(HML-2.HOM) transcripts were detected in malignant 
cell lines [183] as well as in normal human tissues [184], thus suggesting that proteins encoded by 
HERV-K(HML-2.HOM) might be expressed in various human cells. 
 
In our work, the two viral proteins of interest, specifically HML-2 Pro and IN, were investigated 
employing different approaches. Most of our efforts were dedicated to the study of HML-2 Pro and the 
identification of its potential cellular substrates. The experimental approach was based on purification 
and further characterization of HML-2 Pro, the latter to further assess its behavior under defined 
reaction conditions. We then set up in vitro reactions with purified HML-2 Pro to perform state of the 
art proteomics analyses for identification of cellular substrates of HML-2 Pro. We used online 
protein/gene databases to identify biological properties and potential disease involvement of HML-2 
Pro substrates. We verified in vitro and in vivo the processing of several selected human proteins by 
HML-2 Pro. Moreover, several observations prompted experiments in order to investigate an 
association between HML-2 Pro expression and cell death. Finally, we collected preliminary evidence 
of endogenous HML-2 Pro activity in selected tumor cell lines. 
As for the experimental approach to investigate HML-2 IN, we set up an immunofluorescence assay 
for monitoring DSBs through the detection of 53BP1, a DSB marker. Following transient expression 
of HA-tagged wild-type and mutant HML-2 IN in cell culture, we evaluated, through the established 
immunofluorescence assay, whether HML-2 IN activity induces formation of DSBs in the cell genome. 
During the assay, visualization of transiently expressed HML-2 IN allowed us to obtain information 
about its cellular localization.  
 
In the following, results will be reported in two main chapters. Chapter 4.1 is related to HML-2 Pro 
and chapter 4.2 is related to HML-2 IN. 
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4.1 HML-2 protease 
4.1.1 Expression of HML-2 Pro in E. coli and protein purification 
For studies on HML-2 Pro, we first aimed at purifying HML-2 Pro under defined conditions that 
preserved enzyme integrity and guaranteed a relatively high protein yield. A DNA construct harboring 
a subregion of the wild-type HML-2 Pro ORF was cloned into prokaryotic expression plasmid pET-
11d. The cloned construct (see Materials and Methods, Figure 7) included: 1) the HML-2 Pro core 
domain, analogous to the HERV-K10 core domain previously described [205]; 2) an N-terminal 
flanking region comprised of 171 bp upstream of the Pro core domain; 3) an engineered stop codon at 
the aa position that was previously reported as the C-terminal end of the Pro core domain [205]. The 
resulting protein, referred also as HML-2 Pro precursor, was expressed in E. coli BL21 (DE3) cells 
following induction by IPTG. Since a known Pro self-processing site was present in the HML-2 Pro 
precursor, a portion of 59 aa residues at the N-terminal end of HML-2 Pro precursor was expected to 
be cleaved off in an autocatalytic manner. 
HML-2 Pro protein expression was confirmed by Western blot, employing α-HML-2 Pro polyclonal 
antibody 9367 [185]. Aliquots of E. coli BL21 (DE3) cells before and after addition of IPTG were 
examined. HML-2 Pro precursor appeared as a protein of approximately 18 kDa that already self-
processed to the 12 kDa mature form during prokaryotic expression (Figure 16). 
 
Figure 16: Successful expression of HML-2 Pro in BL21 (DE3) cells. Aliquots from cell culture of BL21 
(DE3) cells harboring an expression plasmid encoding HML-2 Pro were collected before and 2 h after induction 
by IPTG. Cells were pelleted and resuspended in 50 µl 5x TE Buffer. 12 µl of cell suspension were mixed with 
4 µl of 4x NuPAGE LDS Sample Buffer and incubated for 5 min at 95°C. After centrifugation, supernatants 
were loaded onto a 15% PAA-gel and separated by SDS-PAGE. HML-2 Pro was detected by Western blot using 
α-HML-2 Pro polyclonal antibody no. 9367 [185]. 18 kDa HML-2 Pro precursor and 12 kDa self-processed Pro 
are indicated. 
 
HML-2 Pro was purified from inclusion bodies following a previously published protocol [112] with 
minor modifications. In our protocol, the cell lysis procedure included an additional homogenization 
step before sonication to improve cell lysis, and the chromatography procedure was performed by 
gravity, without use of a fast protein liquid chromatography system (see chapter 3.2.2.3). The 
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purification procedure employed pepstatin A, a specific, non-covalent inhibitor of retroviral aspartyl 
proteases, coupled to agarose beads as stationary phase for affinity chromatography. Monitoring of 
proteins during the purification steps (Figure 17) confirmed that contaminant proteins bound to the 
pepstatin A-agarose matrix were largely removed during the first wash step. Only one co-purifying 
protein of ~45 kDa was still detectable in the first elution step. That contaminant protein greatly 
reduced and eventually disappeared in the following elution steps. HML-2 Pro became eluted starting 
with the second elution step as a protein of ~12 kDa. The 18 kDa Pro precursor observed after induction 
in E. coli was not visible in eluates (Figure 17). This suggested that HML-2 Pro completely self-
processed during the purification/renaturation procedure. 
 
Figure 17: Purification of HML-2 Pro. To assess purification of prokaryotically expressed HML-2 Pro, 
samples were taken at various steps of the procedure and separated by SDS-PAGE. Proteins were visualized by 
Coomassie-staining of PAA-gels. Coomassie-stained gels are shown. Documented steps of the procedure are as 
follows: cell lysate after sonification; two washes of inclusion bodies in TE Buffer (TE buff. wash 1/2); 
resuspension (res.) of inclusion bodies in a urea-containing buffer; supernatant (supern.) after centrifugation of 
resuspended inclusion bodies; protein mixture after dialysis; supernatant and pellet after dialysis and 
centrifugation; flow through after incubation of dialyzed protein mixture with pepstatin A-agarose; two washes 
after binding; five elution fractions. Molecular masses of marker proteins are reported on the left each. Purified, 
self-processed HML-2 Pro migrated at ~12 kDa (see the label). 
 
Based on Coomassie-stained proteins, eluates 3, 4, and 5 of purified HML-2 Pro showed almost 
complete absence of contaminant proteins (Figure 17). Thus, those eluates, with a total volume of 5 ml 
per eluate, were pooled together and further concentrated from a starting volume of 15 ml to a final 
volume of 2 ml using an Amicon® Ultra-15 Centrifugal Filter Unit. Aliquots of pooled eluates before 
and after concentration were subjected to SDS-PAGE for monitoring the concentration process and 
ensure lack of protein degradation (Figure 18). Molar absorption coefficient of self-processed HML-2 
Pro, as predicted by Geneious software, was used to determine a Pro final concentration of 270 µg/ml, 
corresponding to a molar concentration of 23 µM. Aliquots of concentrated Pro were stored at -80°C. 
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Figure 18: Concentration of purified HML-2 Pro. 15 µl of pooled eluate before concentration and 5 µl, 10 µl, 
and 15 µl of pooled eluate after concentration were separated by SDS-PAGE. Proteins were visualized by means 
of Coomassie-staining. Note that the ~12 kDa protein band corresponding to HML-Pro is enriched when 
compared to before concentration, and that no degradation products were visible. 
 
Experiments to be performed with active wild-type HML-2 Pro required various controls including an 
inactive HML-2 Pro. For this purpose, two enzymatically inactive mutants of wild-type HML-2 Pro 
were generated by site-directed mutagenesis. As for the first mutant (named Pro-mutDTG), a single 
nucleotide mutation G→A was introduced causing an aa substitution D→N within the catalytic DTG-
motif [180] (Figure 19). As for the second mutant (named Pro-mutGRDL), Wondrak et al. (1991) [221] 
had reported successful purification, employing pepstatin-A affinity chromatography, of an inactive 
HIV-1 protease mutated in the GRNLL region, specifically through an aa substitution R→K [221]. 
The HML-2 Pro ORF harbors an analogous GRDLL region, in which, similarly, we substituted R→K 
by mutating the corresponding triplet sequence CGA →AAA (Figure 19). 
 
 
Figure 19: Amino acid sequence comparison between conserved regions of HIV-1 Pro and HERV-
K(HML-2.HOM) Pro. The aa sequence of DTG and GRDLL regions of HIV-1 pro are compared with the 
corresponding regions of HERV-K(HML-2.HOM) pro [134]. Nucleotide exchanges and resulting aa 
substitutions thus generated in Pro mutants (see text) are indicated in red. 
 
Pro-mutDTG and Pro-mutGRDLL proteins were then expressed in E. coli BL21 (DE3) cells, as 
described for wild-type HML-2 Pro. Just as for purification of wild-type HML-2 Pro, various steps of 
the purification of the two HML-2 Pro mutants were monitored by SDS-PAGE and Coomassie-staining 
(Figure 20). The two HML-2 Pro mutants could be expressed efficiently in E. coli BL21 (DE3) cells, 
with visible accumulation of the 18 kDa Pro precursor. However, neither Pro-mutDTG nor Pro-
mutGRDLL could be purified when employing the protocol established for wild-type HML-2 Pro. This 
was most likely due to inefficient binding of the mutant proteins to pepstatin A-agarose. Strong 
accumulation of the 18 kDa Pro precursors but no visible processed form of 12 kDa clearly indicated 
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that both Pro mutants were unable to self-process. After incubation with pepstatin A-agarose, both 
mutants were present at considerable amounts in the flow-through and in the following wash steps, 
that is, they were eluted together with other unbound proteins. Apart from a ~45 kDa protein also 
observed during purification of wild-type HML-2 Pro (see above), no proteins were detected in eluate 
fractions, thus further confirming unsuccessful purification of the two HML-2 Pro mutants. 
 
Figure 20: Ineffective purification of two HML-2 Pro mutants. As for wild-type HML-2 Pro (see Figure 17), 
various steps during the purification procedure of Pro-mutDTG (A) and Pro-mutGRDL (B) were monitored by 
SDS-PAGE and subsequent Coomassie-staining of proteins. Documented steps of the procedure are as follows: 
pre- and post-induction of protein expression by IPTG; supernatant (supern.) after centrifugation following 
sonification; two washes of inclusion bodies in TE Buffer; resuspension (res.) of inclusion bodies in urea-
containing buffer; supernatant and pellet (Pro-mutDTG only) after centrifugation of resuspended inclusion 
bodies; protein mixture after dialysis; supernatant after centrifugation following dialysis; flow-through after 
incubation of bacterial lysate with pepstatin A-agarose; washes after binding and three elution fractions. Note 
that mutant HML-2 Pro precursors (prec.) of 18 kDa are expressed and that no such proteins, as well as no 
expected (exp.) self-processed HML-2 Pro of 12 kDa are detectable in the elution fractions. 
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4.1.2 Verification of HML-2 Pro activity after purification 
During expression and purification of HML-2 Pro, we documented Pro self-processing from the 18 
kDa precursor to the 12 kDa form, providing preliminary evidence of Pro enzymatic activity (see 
above). However, we did not have confirmation of HML-2 Pro activity after concentration and storage 
at -80°, that could also have affected HML-2 Pro functionality. Moreover, the results so far could not 
discriminate between proteolytic Pro activity in cis and in trans. We therefore aimed at confirmation 
of enzymatic activity of our HML-2 Pro aliquots stored at -80°, with an accompanying confirmation 
of proteolytic activity in trans. To do so, purified HML-2 Pro was combined in a reaction with in vitro 
translated HML-2 Gag, a known substrate of HML-2 Pro [185] that was expected to be efficiently and 
specifically cleaved by proteolytically active Pro. The reaction buffer that we employed was based on 
conditions reported for a previous study on HML-2 Pro [112]. The buffer was composed of 20 mM 
PIPES, 100 mM NaCl, 1 mM DTT, 10% [v/v] glycerol, pH 6.5. Of note, the final composition of the 
reaction buffer was probably slightly different due to poorly definable additional components added 
from the in vitro transcription/translation reaction producing HML-2 Gag protein. Control reactions 
without Pro as well as without buffer were also performed. Reactions were incubated for 1 h at 37°C, 
then subjected to SDS-PAGE and Western blot. HML-2 Gag was detected using α-Gag polyclonal 
antibody no. 2548 [143]. Proteolytic activity of purified HML-2 Pro in trans was evident by a reduced 
amount of full-length Gag protein and appearance of a protein band of ~37 kDa corresponding to Gag 
matrix p15 domain (MA-p15) [66] released from Gag full-length protein by HML-2 Pro activity 
(Figure 21). Intensity of the MA-p15 band further increased when HML-2 Pro was present in the 
reaction at a higher concentration. The MA-p15 domain was not produced in absence of buffer or in a 
control reaction without Pro (Figure 21). We therefore could confirm proteolytic activity in trans for 
purified HML-2 Pro. 
 
Figure 21: Confirmation of proteolytic activity in trans of purified wild-type HML-2 Pro. HML-2 Gag of 
~78 kDa was produced employing a coupled in vitro transcription/translation system (also referred to as TNT T7 
system, see 3.2.2.2). 1 µl of the HML-2 Gag containing TNT T7 reaction was mixed with HML-2 Pro, with the 
latter at final concentrations of 3 µM (+) and 9 µM (++), in a final volume of 10 µl each. Control reactions were 
run without Gag (-), Pro, or buffer (buff.). Reactions were incubated for 1 h at 37°C. Gag was detected by Western 
blot using polyclonal α-Gag antibody no. 2548 [143]. Full-length Gag and MA-p15, that is a major processing 
product formed by HML-2 Pro activity (see text), are indicated. 
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4.1.3 Characterization of HML-2 Pro activity and optimization of reaction conditions 
using an in vitro fluorescence assay 
Following confirmation of purified HML-2 Pro proteolytic activity, we further characterized HML-2 
Pro activity through a series of in vitro assays with varying reaction conditions. The primary purpose 
was the optimization of reaction conditions for downstream analysis, specifically identification of 
human proteins cleaved by HML-2 Pro in vitro (see chapter 4.1.4). At the same time, we wanted to 
validate and potentially expand previously published biochemical properties of HML-2 Pro [205]. To 
do so, we set up a fluorescence assay where purified HML-2 Pro was incubated with 2-aminobenzoyl-
Thr-Ile-Nle-p-nitro-Phe-Gln-Arg-NH2 (hereafter referred to as Anthranilyl-substrate), a substrate 
derived from a known cleavage site of HIV-1 Pro in HIV-1 Gag. The Anthranilyl-substrate was 
previously employed for HIV-1 Pro studies [45] and was expected to be suitable for HML-2 Pro 
activity assays because of similar specificity profiles of the two proteases [17]. The substrate, that 
makes use of fluorescence resonance energy transfer (FRET) (see chapter 3.2.2.4), was engineered in 
a way that cleavage by protease releases a fluorescent molecule from the substrate's N-terminus that is 
then no longer quenched by a molecule at the substrate's C-terminus, resulting in enhanced 
fluorescence emission when subjected to excitation at 280 nm (see Figure 14). 
Reactions were set up in 96-well microplates placed on ice. Numbers of reactions per experiment were 
variable, depending on the number of conditions tested. For each condition, a control reaction without 
Pro was included. Each reaction was prepared in duplicate with a final volume of 50 µl. The 
Anthranilyl-substrate was usually added as the last reaction component. Microplates were then placed 
in a Tecan Infinite® m200 spectrophotometer set at 37°C during the entire measurement. Fluorescence 
measurements were done with excitation at 280 nm and emission at 420 nm, as indicated by the 
manufacturer (Bachem) of the Anthranilyl-substrate. Fluorescent signal intensity was monitored in 
each well every 4 min for a maximum of 180 min. Change in intensity of fluorescence emission at 420 
nm was indicative of the amount of cleaved product, thus of HML-2 Pro activity. Fluorescence 
emission was plotted after subtracting background fluorescence measured for reactions without Pro. 
 
The following description of results is divided into three sections: 1) Selection of a buffer composition 
suited for HML-2 Pro reactions; 2) Examination of HML-2 Pro activity at variable pH for definition 
of the pH optimum for proteolytic activity; 3) Establishing the concentration of pepstatin-A required 
for complete inhibition of HML-2 Pro. 
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4.1.3.1 Selection of a buffer composition suited for HML-2 Pro reactions  
In order to identify a buffer that allowed for high HML-2 Pro activity and to characterize reaction 
parameters that we had to consider for our subsequent experiments, HML-2 Pro activity was assayed 
in four different buffer systems previously reported in studies on HIV-1 Pro or HML-2 Pro. Buffer 
compositions examined varied with regard to the type of buffering agent (PIPES, MES, or MES-TRIS), 
salt concentration, pH, concentration of glycerol, presence of reducing agent (DTT), and presence of 
EDTA. 
 
Buffer compositions were as follows: 
Buffer 1: 20 mM PIPES, 100 mM NaCl, 1 mM DTT, 10% [v/v] glycerol, pH 6.5 
Buffer 2: 50 mM MES, 1 M NaCl, 20% [v/v] glycerol, 1 mM EDTA, pH 5.0  
Buffer 3: 50 mM MES, 1 M NaCl, 1 mM EDTA, pH 5.0 
Buffer 4: 100 mM MES-TRIS, 1.25 M NaCl, pH 6.0 
 
Buffers 1 and 2 were previously reported in Kuhelj et al. (2001) [112] to study HERV-K Pro. Buffer 3 
derived from Buffer 2, having the same composition except for lack of glycerol. Buffer 4 was 
previously employed [156] for characterization of HIV-1 Pro. As Anthranilyl-substrate and pepstatin 
A (see later) were resolved in DMSO, for which a negative effect on HIV protease was previously 
reported [92], we also set up reactions to evaluate the influence of DMSO on HML-2 Pro activity. 
Those reactions were set up in Buffer 4, that was already found to be suitable for HML-2 Pro activity 
in preliminary experiments (not shown). Since Anthranilyl-substrate was resolved in DMSO we could 
not set up meaningful reactions without DMSO. In fact, each reaction contained a minimum amount 
of DMSO corresponding to 2% [v/v] of the total reaction volume. Reactions with 4% [v/v] and 8% 
[v/v] DMSO were performed to observe effects of higher DMSO concentrations on HML-2 Pro 
activity. For each condition, Anthranilyl-substrate was present in reactions at a final concentration of 
20 µM, and HML-2 Pro at 460 nM. Fluorescent emission at 420 nm was measured every 4 min during 
the course of an 80 min incubation. 
 
Based on fluorescence emission, HML-2 Pro was found to be most active in Buffers 3 and 4 (Figure 
22 A), that were both characterized by relatively high NaCl concentrations, no glycerol, and a pH 
below 6.5. In Buffer 2, HML-2 Pro displayed less activity than in Buffer 3. Buffers 2 and 3 differed 
by the presence of glycerol, thus indicating a negative effect of glycerol on HML-2 Pro activity. No 
change in fluorescence emission, that is, no Pro activity was observed for Buffer 1. Buffer 1 presented 
the lowest ionic strength, highest pH, and it contained DTT as opposed to all other buffers. Also, 
glycerol was included in that buffer. Thus, probably because of a combination of factors affecting Pro 
activity negatively, Buffer 1 was completely unsuitable for processing of the Anthranilyl-substrate by 
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HML-2 Pro. From this experiment we could not evaluate the potential influence of PIPES or DTT on 
Pro activity. However, we could observe that MES was clearly suitable and DTT not indispensable for 
Pro activity. Thus, based on the above described results, a buffer composed of 100 mM MES and 1 M 
NaCl was selected for subsequent optimization reactions. 
DMSO at concentrations of 4% [v/v] and 8% [v/v] reduced Pro activity by approximately 20% and 
50%, respectively, when compared with reactions containing 2% [v/v] DMSO (Figure 22 B). Thus, we 
confirmed a negative effect of DMSO on HML-2 Pro activity. We also considered important for further 
experiments to keep DMSO concentration as low as possible to reduce Pro inhibition. In subsequent 
experiments, DMSO concentration never exceeded 4% [v/v]. 
 
 
Figure 22: Monitoring HML-2 Pro activity in four different buffer systems and with increasing DMSO 
concentrations. 460 µM purified HML-2 Pro was incubated with 20 µM Anthranilyl-substrate at different 
reaction conditions. Fluorescent emission at 420 nm with background correction (Y-axis) was measured for the 
indicated time periods (X-axis). Although reactions were run in a single experiment, for the sake of clarity, 
monitoring of reactions in Buffer 4 at various DMSO concentrations are depicted separately in B. A) HML-2 Pro 
activity was monitored in four different buffer systems (see text for buffer compositions). All reactions in A 
contained 2% DMSO. B) Effect of DMSO on HML-2 Pro activity was evaluated monitoring HML-2 Pro activity 
in Buffer 4 with increasing DMSO concentrations. Final DMSO concentrations are indicated. 
 
4.1.3.2 Examination of HML-2 Pro activity at variable pH and definition of pH optimum 
for proteolytic activity 
Enzymes can be variably sensitive to pH changes. Generally, they tend to have an optimal pH at which 
they are catalytically most active. Therefore, pH is a fundamental parameter that should be adjusted 
when setting up enzymatic reactions. Based on results presented in the previous section, we confirmed 
that a relatively low pH was favorable for HML-2 Pro reactions, as also deduced from previously 
published findings [205]. In order to further optimize reaction conditions and to learn how much HML-
2 Pro tolerates pH variations, we designed experimental assays where processing of the Anthranilyl-
substrate by HML-2 Pro was monitored at pH ranging from pH 4.5 to pH 8. As concluded in the 
previous section, the reaction buffer selected was composed of 100 mM MES and 1 M NaCl. In a first 
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assay, processing of the Anthranilyl-substrate by HML-2 Pro at pH ranging from pH 4.5 to pH 6.5 was 
monitored for 130 min (Figure 23 A). HML-2 Pro was found to be active at all pH tested, with highest 
activity at pH 5.5. At pH 4.5, pH 5.0, pH 6.0, and pH 6.5, HML-2 Pro activity was, respectively, 
approximately 25%, 10%, 45%, and 70% lower compared to pH 5.5 (Figure 23 A, B). 
 
Figure 23: Determination of pH optimum for HML-2 Pro activity. A) HML-2 Pro activity was assayed in a 
buffer composed of 100 mM MES, 1 M NaCl, 2% [v/v] DMSO, adjusted to pH between 4.5 and 6.5 as indicated. 
Fluorescence emission at 420 nm with background correction is depicted on the Y-axis. Fluorescence emission 
was measured for the time periods indicated on the X-axis. B) Bar chart depicting slope of reaction curves shown 
in A during the first 40 min of the experiment. The bar chart allows for more accurate evaluation of Pro activity 
at various pHs and determination of the Pro pH optimum. 
 
Considering that HML-2 Pro displayed proteolytic activity also at the higher pH (pH 6.5) tested in the 
first assay, we performed another assay with pH ranging from 5.5 to 8 to further evaluate Pro activity 
at neutral and basic pH. Moreover, the experiment was monitored for a longer time, specifically 180 
min, to compensate for lower HML-2 Pro activity. Although HML-2 Pro activity was gradually 
reduced when gradually increasing pH from 5.5 to pH 8, HML-2 Pro was still active at pH 6.9, with 
10% of the activity measured at pH 5.5. A retained low activity at pH 7.5, with 2% of the activity 
measured at pH 5.5, as well as pH 8.0, with 1% of the activity measured at pH 5.5, was also detectable 
(Figure 24 A). 
Approximately 120 minutes into the experiment, fluorescence emission did not further increase for 
reactions at pH 5.5 and pH 6. For reactions at pH 6.5 and higher, fluorescence emission further 
increased until the end of the experiment. Very likely, in the course of the experiment the Anthranilyl-
substrate became depleted at pH 5.5 and pH 6 due to higher activity of HML-2 Pro compared to pH 
≥6.5.  
We wondered if the lower activity of Pro at pH > 6.5 was due to the lesser suitability of the MES buffer 
at these pH values. To evaluate the influence of the buffering agent in the HML-2 Pro activity, another 
assay was performed at identical conditions except with MES (buffering pH range of 5.5-6.7 [57]) in 
the reaction replaced by PIPES (buffering pH range of 6.1-7.5 [57]). Monitoring HML-2 Pro activity, 
PIPES buffer was more suitable than MES buffer at all pHs tested. At pH 5.5 and 6.0, Pro was 
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approximately 25% less active in MES buffer when compared with PIPES. At pH > 6.0 the reduction 
in Pro activity between MES and PIPES was gradually more pronunced, approximately 55%, 70%, 
80%, 90% lower at pH 6.5, 6.9, 7.5, 8.0, respectively (Figure 24 A, B, C). Our results, suggested that 
PIPES buffer could be more suitable than MES buffer in our system, in particular when monitoring 
Pro activity at pH > 6.0. 
 
Figure 24: Monitoring HML-2 Pro activity at acidic and basic pH. HML-2 Pro activity was monitored in 
reaction buffers containing MES (A) or PIPES (B) at pH ranging from 5.5 to 8.0 during a longer incubation time. 
Time points above 150 min were considered not relevant for the comparison, thus for the sake of convenience 
they were not depicted in B. Fluorescence emission at 420 nm with background correction is depicted on the Y-
axis. Fluorescence emission was measured for the time periods indicated on the X-axis. C) Bar chart depicting 
slope of reaction curves shown in A and B during the first 60 min of the experiments. 
 
4.1.3.3 Monitoring HML-2 Pro saturation by Anthranilyl-substrate and inhibition by 
pepstatin A 
As will be described in more detail in chapter 4.1.4, the experimental set-up for identification of cellular 
proteins that are potential HML-2 Pro substrates is essentially based on the comparison between two 
in vitro reactions. Both reactions include total cellular protein lysate plus enzymatically active HML-
2 Pro in one reaction, and inactive HML-2 Pro in the other. It was originally planned to include in the 
reaction with inactive Pro a mutated, enzymatically inactive variant of HML-2 Pro. Since mutant 
HML-2 Pro could not be purified successfully by means of pepstatin A-agarose (see chapter 4.1.1) it 
was decided to repress HML-2 Pro activity by a specific inhibitor of aspartyl proteases. For this 
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purpose, we selected pepstatin A and established the concentration of pepstatin A, relative to that of 
HML-2 Pro, required to effectively inhibit HML-2 Pro activity in the reaction. 
 
Concentration of Anthranilyl-substrate necessary to saturate HML-2 Pro activity 
Before assaying pepstatin A inhibition, we considered it relevant to know the relative concentration of 
Anthranilyl-substrate necessary to saturate HML-2 Pro activity. For pepstatin A being a competitive 
inhibitor, the inhibitory effect was influenced by the concentration of HML-2 Pro substrate, that 
competes for interaction with HML-2 Pro. This aspect was relevant for subsequent incubations of 
HML-2 Pro with total cell lysate for which it was difficult to predict the amount of interactions of 
HML-2 Pro with cellular substrate proteins. Therefore, assaying pepstatin A inhibition at a saturating 
concentration of Anthranilyl-substrate indicated the concentration of pepstatin A required in the 
negative control, in order to effectively inhibit HML-2 Pro activity also under saturating interactions 
between Pro and cellular substrates.  
We thus defined the Anthranilyl-substrate concentration at which HML-2 Pro in solution was saturated. 
To do so, various reactions were performed with fixed HML-2 Pro concentration (460 nM) and 
different Anthranilyl-substrate concentrations ranging from 5 µM to 60 µM (Figure 25). Resulting 
fluorescence emission-curves reached in some cases a plateau, indicating depletion of Anthranilyl-
substrate. Specifically, fluorescence emission-curves of reactions with 5, 10, and 20 µM Anthranilyl-
substrate reached a plateau after approximately 40, 80, and 130 min, respectively. During the course 
of the 140-min experiment, change in fluorescence emission did not reach a plateau in reactions with 
Anthranilyl-substrate at concentrations of 40 and 60 µM. Slopes of reaction curves based on the first 
40 min of incubation were calculated as indicators of the reaction rate. When plotting slopes of curves 
relative to substrate concentrations we observed that increasing substrate concentrations up to 20 µM 
increased reaction rates proportionally. Reaction rates did not further increase when further increasing 
substrate concentrations from 40 µM to 60 µM. Thus, we concluded that in our experimental system 
activity of HML-2 Pro present at 460 nM became saturated by a substrate concentration of 




Figure 25: HML-2 Pro activity at various substrate concentrations. A fixed HML-2 Pro concentration of 460 
nM was assayed in combination with Anthranilyl-substrate concentrations ranging from 5 µM to 60 µM. A) 
Fluorescence emission at 420 nm with background correction is depicted on the Y-axis. Fluorescence emission 
was measured for the time periods as indicated on the X-axis. B) Slopes of five reaction curves, based on the first 
40 min of incubation, were calculated and are depicted (Y-axis) relative to substrate concentration (X-axis). The 
slope of the reaction curves reached a plateau at a concentration of Anthranilyl-substrate of approximately 40 
µM, indicating that HML-2 Pro became saturated at that substrate concentration. 
 
Establishing the concentration of pepstatin A required for efficient inhibition of HML-2 Pro 
Inhibition of HML-2 Pro by pepstatin A was monitored at 5 different concentrations of inhibitor 
ranging from 1 µM to 200 µM (Figure 26). Of note, when setting up reactions, HML-2 Pro and 
pepstatin A were pre-incubated for 10 min at room temperature before addition of the Anthranilyl-
substrate as the last reaction component. The pre-incubation had the purpose of allowing for interaction 
between HML-2 Pro and pepstatin A before addition of Anthranilyl-substrate, thus optimizing 
inhibition. 
A reaction without pepstatin A was included as a reference indicating 100% HML-2 Pro activity. Other 
reactions with pepstatin A present were compared with the reference reaction to evaluate the reduction 
of Pro activity. Results showed that 1 µM, 10 µM 100 µM, and 200 µM pepstatin A reduced Pro 
activity to approximately 60%, 18%, 12%, and 0%, respectively (Figure 26). Without pre-incubation, 
inhibition in presence of 200 µM pepstatin A was considerable but not complete (still 2% Pro activity). 
Thus, we concluded that 200 µM pepstatin A effectively inhibited HML-2 Pro present at 460 nM when 
the reaction was pre-incubated for 10 min before addition of Anthranilyl-substrate. 
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Figure 26: Effects of pepstatin A concentration on HML-2 Pro activity. A) The inhibitory effect of pepstatin 
A on HML-2 Pro activity was assayed at various concentrations of pepstatin A ranging from 1 µM to 200 µM as 
indicated. Reactions contained 460 µM purified HML-2 Pro and 40 µM Anthranilyl-substrate. When setting up 
reactions, HML-2 Pro was pre-incubated with pepstatin A for 10 min before addition of Anthranyl-substrate. A 
reaction with 200 µM pepstatin without preincubation before addition of substrate was included ("no pre"). 
Fluorescence emission at 420 nm with background correction is depicted on the Y-axis. Fluorescence emission 
was measured for the time periods indicated on the X-axis. B) Slopes of reaction curves, based on the first 40 
min of incubation, were calculated and the HML-2 Pro activity was depicted in the bar chart as percentage of 
activity relative to a reaction with DMSO only, the latter defined as 100% activity. 
 
4.1.4 Identification of human cellular proteins cleaved by HML-2 Pro 
Retroviral aspartyl proteases can process not only retrovirus-encoded proteins but also cellular proteins 
(see Introduction, chapter 2.4.2), as shown, for instance, in a recent study [82] related to cellular 
substrates of HIV-1. In that study, a proteome-wide analysis was employed to identify more than 120 
cellular proteins that were processed by HIV-1 in vitro. Cellular protein substrates identified in that 
study located to different cellular compartments and many of the proteins had physiologically 
important roles. Thus, that study as well as other previous studies (see Introduction, chapter 2.4.2) 
suggest that the proteolytic activity of a retroviral protease could potentially impact the cell. Up to date, 
no such particular proteomic analyses were conducted with regard to substrates of endogenous 
retroviruses-encoded aspartyl proteases. 
 
In the following, we employed a sophisticated experimental approach that could tell whether HML-2 
Pro is able to process human cellular proteins, specifically identifying proteins eventually processed 
and providing more detailed information on cleavage events. 
Our experimental system involved in vitro reactions combining a native protein mixture derived from 
HeLa cells with purified, active HML-2 Pro. The reaction buffer was optimized with regard to 
buffering agent, salt concentration, and pepstatin A concentration (see chapter 4.1.3). Concerning pH, 
since HML-2 Pro was enzymatically active within an acidic to basic pH range (see chapter 4.1.3.2) we 
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examined HML-2 Pro activity at two different pH conditions. One experiment was performed at pH 
5.5, defined by us as optimal pH for HML-2 Pro activity (in our system). The other experiment was 
performed at pH 7.0, at which HML-2 Pro showed reduced but still significant activity. Given that 
HML-2 Pro localization inside a cell was not investigated so far and HML-2 Pro could potentially 
locate and be active in various cellular compartments, reactions a two different pHs was expected to 
inform about the ability of HML-2 Pro to cleave substrates at pH conditions similar to those of acidic 
compartments, like endosomes, or to those of neutral compartments, like cytosol. 
In collaboration with Prof. Dr. Oliver Schilling (University of Freiburg), we utilized a sensitive 
proteome-wide methodology for identification of protease substrates, called Terminal Amine Isotopic 
Labeling of Substrates (TAILS). The data generated by TAILS were further examined in our 
laboratory. 
 
4.1.4.1 Preparation of a protein mixture from HeLa cells 
A cellular protein mixture for incubation with HML-2 Pro was extracted through lysis of HeLa cells 
by freeze/thaw cycles in a buffer composed of 100 mM MES, 1 M NaCl, pH 6.0 (see chapter 3.2.2.9). 
Cell lysis conditions avoided use of detergents that are usually employed for efficient membrane 
disruption during cell lysis. Such detergents may have altered protein structure and interfered with 
downstream TAILS procedures. Preparation of HeLa proteome involved centrifugation of the cell 
lysate for removal of cell membranes and cellular debris. The supernatant was stored and used for 
reactions with purified HML-2 Pro. Detection of histone H3 in supernatants derived from HeLa lysates 
confirmed disruption of nuclear compartments and release of nuclear proteins (Figure 27 A). 
 
4.1.4.2 Small-scale experiment to confirm reaction conditions for TAILS 
Before setting up actual reactions for TAILS, reaction conditions were verified in a small-scale 
experiment that, besides established reaction components, included in vitro-translated HML-2 Gag 
protein for monitoring HML-2 Pro activity via processing of a known substrate. For this experiment, 
200 µM HML-2 Pro was incubated for 1 h with 1 µl of in vitro-translated HML-2 Gag in presence of 
20 µg of proteins of HeLa total cell lysate, at pH 5.5 and pH 7 and with pepstatin A at two different 
concentrations, in a final reaction volume of 20 µl. Processing of HML-2 Gag was then examined by 
Western blot using α-HML-2 Gag rabbit polyclonal antibody 2548 [143] (Figure 27 B). HML-2 Pro 
processed HML-2 Gag efficiently at pH 5.5, reducing the amount of full-length Gag and generating 
two distinct Gag cleavage products, one of ~37 kDa likely representing the MA-p15 domain, and the 
second, slightly smaller one likely representing the CA-NC domain [66]. As expected, HML-2 Pro 
exhibited lower activity at pH 7. Only the MA-p15 Gag cleavage product could be detected with 
certainty and at a lower amount in comparison with the reaction at pH 5.5. When comparing reactions 
with and without HeLa total cell lysate (Figure 27 B, lanes 3 and 4) presence of HeLa cellular proteins 
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seemed to influence HML-2 Gag processing, slightly reducing the degree of full-length Gag 
processing. In presence of pepstatin A at concentrations of 200 µM and 100 µM (Figure 27 B, lanes 5 
and 6), the amount of full-length Gag was not significantly different from that in the control (Figure 
27 B, lane 2). Also, Gag cleavage products were drastically lower than respective reactions without 




Figure 27: Verification of experimental conditions for a full-scale TAILS experiment. A) For confirmation 
of efficient disruption of nuclei during lysis, 15 µg total cellular proteins from a HeLa cell lysate prepared by a 
freeze/thaw lysis procedure (see 3.2.2.9) were subjected to SDS-PAGE and Western blot. Histone H3, that locates 
to the nucleus, was detected using a monoclonal α-histone H3 antibody. In the upper part, the PAA-gel was 
stained with Coomassie after electrophoresis for documenting presence of manifold other cellular proteins. B) 
Various reactions were set up as indicated. Reaction components were included (+) as follows: 1 µl of in vitro 
translated HML-2 Gag reaction produced in a TNT T7 system; 100 mM PIPES pH 5.5 or pH 7.0; 20 µg protein 
from HeLa total cell lysate; 200 nM (+) and 460 nM (++) HML-2 Pro; 100 µM (+) and 200 µM (++) final 
concentration of pepstatin A. Final reaction volume was 20 µl each. Full-length Gag and two processing products 
(MA-p15 and CA-NC domain) produced by HML-2 Pro activity (see text) are indicated. 
 
4.1.4.3 Set up of larger-scale reactions for TAILS 
The small-scale experiment confirmed that at the established conditions for TAILS reactions HML-2 
Pro was enzymatically active in trans, specifically HML-2 Pro efficiently processed HML-2 Gag, a 
known Pro substrate [185]. Thus, the next step was to prepare larger-scale reactions for the actual 
TAILS experiment in order to examine processing of cellular proteins. The final volume of reactions 
for TAILS was 100-fold larger than for the small-scale experiment as the TAILS procedure required a 
larger amount of total protein in a larger volume. We wanted to ensure a sufficiently large reaction 
volume if repeated TAILS analysis would be required. 
For larger-scale TAILS reactions, 2 mg of HeLa total protein were incubated with HML-2 Pro at a 
final concentration of 200 nM in a final reaction volume of 2 ml. Buffer conditions were as follows: 1 
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M NaCl, 2% [v/v] DMSO, 100 mM PIPES at pH 5.5 or pH 7. Control reactions in presence of 200 µM 
pepstatin A, effectively blocking HML-2 Pro activity, were also included. Control reactions with 
pepstatin A were pre-incubated for 10 min at room temperature before addition of HeLa total protein 
as the last reaction component. All reaction mixtures were thoroughly mixed and incubated at 37°C 
for 75 min. Two replicate reactions were prepared for each pH condition. As will be described later, 
because of technical issues with specific devices for TAILS in the laboratory of Prof. Schilling, two 
more replicates were subsequently prepared in order to repeat reactions at pH 7. Reactions were frozen 
at -80°C, packed and shipped, on dry ice, to the laboratory of Prof. Oliver Schilling at University of 
Freiburg. Reactions were then subjected to further steps of the TAILS procedure in that laboratory, 
specifically actual identification of cellular proteins cleaved in presence of HML-2 Pro. 
 
4.1.4.4 TAILS procedure 
The TAILS methodology employed in our study is based on an N-terminomics approach capable of 
distinguishing in amino acid chains between "regular" N-termini and N-termini being protease 
cleavage products [106]. Since TAILS was not performed in our laboratory, the basic procedure 
[106,108] will be described only briefly below. 
After incubation of HeLa-derived protein mixture with active HML-2 Pro (designated Pro-treated 
sample) or inhibited HML-2 Pro (designated untreated sample), samples are denatured and reduced. 
Lysine amines and free (α)-amino groups of N-termini of proteins and their protease cleavage products 
are simultaneously blocked and labelled with stable isotopes applying a reductive dimethylation. 
Methyl groups containing 13C (heavy) or 12C (light) are introduced in Pro-treated samples and untreated 
samples, respectively. The labelling with stable isotopes allows the distinction between peptides 
originated in the Pro-treated sample and untreated sample. Pro-treated samples and respective controls 
are pooled together to ensure identical treatment in the following steps. The combined protein mixtures 
are then subjected to trypsinization generating novel internal tryptic peptides with free N-termini, 
whereas labeled N-termini of the original proteins remain blocked. Blocked N-terminal peptides are 
selectively isolated and concentrated by negative selection. To do so, hyperbranched polymers 
specifically reacting with free N-termini of newly generated tryptic peptides are added to samples. 
Dimethylated lysines, isotopically labeled N-terminal peptides and the neo-N-terminal peptides of their 
cleavage products remain unbound, thus they are recovered by ultrafiltration. Relative abundances of 
peptides and actual peptide sequences in Pro-treated and control samples are then determined by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) and LC-MS/MS data analysis. A 
combination of MS/MS measurements and stringent bioinformatic analysis assign peptides to 
respective human protein sequences, and also provide precise information on positions of cleavage 
sites within those human proteins. 
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Raw data output from TAILS analyses was provided to us in tabular format. Tables reported non-prime 
and prime peptide fragments identified, thus cleavage sites in human proteins, and various additional 
information. A representative dataset with TAILS results for two cleaved human proteins is 
exemplified in Table 17. 
 
Table 17: Example of data output from a TAILS experiment 
Protein ID 1 P07900 P36507 
Protein ID 2 Q58FF7  
Protein ID 3 P08238  
Experiment pH5.5 Rep2 pH5.5 Rep2 
Non prime RKKLSELLRY EQQKKRLEAF 
Prime YTSASGDEMVSLKDYCTR LTQKAKVGELKDDDFER 
P1  Y F 
P1´ R L 
Name Heat shock protein HSP 90-alpha Dual specificity mitogen-activated protein kinase kinase 2 
Alternative 
Name 
Heat shock 86 kDa; Lipopolysaccharide-associated 
protein 2; Renal carcinoma antigen NY-REN-38 








Protein length 732 400 
Modifications N-ter +37.08 Da, K +37.08 Da, C +57.02 Da N-ter +37.08 Da, K +37.08 Da 
Hyperscore 26 39,4 
Ppm -2,0398 -0,3741 
Charge 3 3 
Mass 2154.05 2135.33 
GO 
compartment 
cytoplasm; cytosol; endocytic vesicle lumen; 
extracellular exosome; extracellular region; ficolin-1-rich 
granule lumen; lysosomal lumen; melanosome; 
membrane; myelin sheath; nucleoplasm; nucleus; plasma 
membrane; ruffle membrane; secretory granule lumen;  
cell-cell junction; cytoplasmic side of plasma membrane; 
cytosol; early endosome; endoplasmic reticulum; extracellular 
region; focal adhesion; Golgi apparatus; late endosome; 
microtubule; mitochondrion; nucleus; perinuclear region of 
cytoplasm; peroxisomal membrane; plasma membrane 
GO process chaperone-mediated autophagy; chaperone-mediated 
protein complex assembly; ciliary basal body docking; 
ERBB2 signaling pathway; Fc-gamma receptor signaling 
pathway involved in phagocytosis; G2/M transition of 
mitotic cell cycle; mitochondrial transport; neutrophil 
degranulation; positive regulation of nitric oxide 
biosynthetic process; positive regulation of telomerase 
activity; protein import into mitochondrial outer 
membrane; protein refolding; protein stabilization; 
protein unfolding; receptor-mediated endocytosis; 
regulation of cellular response to heat; regulation of 
nitric-oxide synthase activity; regulation of protein 
complex assembly; regulation of protein ubiquitination; 
response to antibiotic; response to cold; response to heat; 
response to unfolded protein; signal transduction; 
telomerase holoenzyme complex assembly; telomere 
maintenance via telomerase; vascular endothelial growth 
factor receptor signaling pathway;  
activation of MAPK activity; ERK1 and ERK2 cascade; MAPK 
cascade; negative regulation of gene expression; peptidyl-serine 
autophosphorylation; positive regulation of ERK1 and ERK2 
cascade; positive regulation of production of miRNAs involved 
in gene silencing by miRNA; positive regulation of protein 
serine/threonine kinase activity; positive regulation of 
transcription, DNA-templated; proteolysis in other organism; 
regulation of early endosome to late endosome transport; 
regulation of Golgi inheritance; regulation of stress-activated 
MAPK cascade 
GO function ATP binding; ATPase activity; disordered domain 
specific binding; DNA polymerase binding; GTPase 
binding; histone deacetylase binding; identical protein 
binding; MHC class II protein complex binding; nitric-
oxide synthase regulator activity; nucleotide binding; 
protein homodimerization activity; protein tyrosine 
kinase activity; protein tyrosine kinase binding; RNA 
binding; TPR domain binding; unfolded protein binding;  
ATP binding; MAP kinase kinase activity; metal ion binding; 
PDZ domain binding; protein serine/threonine kinase activator 
activity; protein serine/threonine kinase activity; protein 
serine/threonine/tyrosine kinase activity; protein tyrosine kinase 
activity; scaffold protein binding; signal transducer, downstream 
of receptor, with serine/threonine kinase activity 
SP localization Cytoplasm ECO 0000250  
UniProtKB P07901  
Cytoplasm ECO 0000269  
PubMed 10409742  
 
The sequence of each identified peptide fragment was automatically associated with a human protein 
and a respective protein ID, that is, an accession number identifying proteins unambiguously in protein 
sequence databases. For proteins with known isoforms, IDs of isoforms were also reported (see Table 
17, Protein ID 2 and Protein ID 3). For the sake of convenience, we considered in our analysis only 
the first protein ID. The protein ID and the cleavage position, as defined by sequences of non-prime 
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and prime peptide fragments, were two fundamental pieces of information that we used for extraction 
of numbers of the proteolytically generated N-termini. The fold-change, derived from comparison of 
abundances of respective peptide fragments between protease-treated sample and untreated sample, 
was given as the binary logarithm (log2 n) indicating enrichment of respective peptide fragments. For 
each identified peptide, aa residues flanking the cleavage site and several peptide properties were also 
reported, such as Gene Ontology (GO) terms [8] for cellular process, function and compartment of 
human proteins identified by TAILS as cleaved by HML-2 Pro. 
 
4.1.4.5 Analysis of raw data output from TAILS 
TAILS results were subjected to filtering and data overlap employing various tools implemented in 
Microsoft Excel (Office 2016) in order to select high-confidence biologically relevant candidate 
substrates from all possible candidates identified from neo-N-terminal peptides. We focused mainly 
on protein IDs, cleavage position and fold-change. To simplify the terminology employed in the 
following, processing of a particular protein at a specific aa position will be designated as “cleavage 
event”. 
 
As for the TAILS experiment at pH 5.5, TAILS identified for the two replicates greater than 9800 and 
8500 cleavage events (Figure 28). Thus, as an initial rule to collect proteolytically generated N-termini, 
we filtered cleavage events that were enriched at least 2-fold upon HML-2 Pro incubation. Applying 
such a filter, 4370 cleavage events were identified in replicate 1 and 2633 cleavage events in replicate 
2 (Figure 28). Of those, 931 cleavage events were common to both replicates (Figure 29), 
corresponding to 548 human proteins cleaved in the same position. The number of replicated cleavage 
events exceeded the effective number of cleaved proteins indicating that many proteins were cleaved 
in more than one position. In fact, although the majority of proteins was cleaved in a single position, 
several proteins were cleaved at more than one position (Figure 30). In some cases, multiple cleavage 
events per protein were surprisingly numerous (Figure 30). Proteins with a higher number of different 
cleavages within the particular protein are reported in Table 18. For example, heat shock protein 90 
alpha family class B member 1 (HSP90AB1) was cleaved in 30 and 50 positions in replicate 1 and 
replicate 2, respectively. For myosin heavy chain 9 (MYH9), 25 and 60 cleavage events were observed, 
for actin beta (ACTB) 38 and 32, for eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) 21 
and 25. In total, we identified 322 proteins common to both replicates for which there was evidence 
for 2-fold enriched multiple cleavages (Figure 29). 
 
When focusing our attention on positions of cleavage events, we noticed that among cleavage events 
that did not occurr exactly in the same position in both replicates, many had nevertheless occured 
within a relatively narrow region of a particular protein in both replicates. In approximately 50% of 
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cases, at least one cleavage had occurred in the same 50 aa-region within a particular protein. In 25% 
of cases, at least one cleavage had occurred within a 5 aa-region within a particular protein. We 
hypothesized that HML-2 Pro is able to specifically interact with some protein regions and then process 
the protein within that region but not necessarily at a specific cleavage site. More specific 
investigations would be necessary to understand if structural or chemical characteristics of some 
proteins could eventually influence such a phenomenon. Such investigations were out of the aim of the 
study though. However, in view of this observation, when we next aimed at identifying actual proteins 
cleaved in both replicates (with at least 2-fold enrichment) we did not consider only those proteins 
necessarily cleaved in the same position within a protein. Using such a criterium, we identified 2024 
and 1170 proteins in replicate 1 and 2, respectively. Those corresponded to 809 human proteins cleaved 
in both experiments, thus with replicated evidence of cleavage by HML-2 Pro. 
 
As for the TAILS experiment at pH 7, two replicates were initially performed. One replicate at pH 7 
could not be processed and completed properly due to technical issues with devices in the laboratory 
of Prof. Schilling. Two more replicates were performed later on for the sake of a more complete 
analysis. Thus, we will refer in the following to three replicates at pH 7. Like for the TAILS at pH 5.5, 
raw data from three TAILS replicates at pH 7 were subjected to a filtering procedure. Greater than 
3100 cleavage events were identified for replicates 1, greater than 3500 for replicate 2 and greater than 
7000 for replicate 3 (Figure 28). Raw numbers already indicated fewer cleavage events than for the 
TAILS experiment at pH 5.5, possibly due to lower enzymatic activity of HML-2 Pro at pH 7. For an 
initial estimate of cleavage events replicated in all three assays, a less stringent (1.5-fold instead of 2-
fold) enrichment cut-off was applied for the first filtering step; 1074 (replicate 1), 514 (replicate 2) and 
2314 (replicate 3) cleavage events were enriched greater than 1.5-fold (Figure 28). Overlapping 
cleavage events with 1.5-fold enrichment among the three replicates identified 11 cleavage events 
common to all three replicates, 58 cleavage events common to replicate 1 and 2, 182 cleavage events 
common to replicate 1 and 3, and 41 cleavage events common to replicate 2 and 3 (Figure 29). Thus, 
some degree of variability of common cleavage events among replicates was observed. Replicate 1 
and 3, which showed a higher number of enriched cleavage events and the greatest overlap (182) of 
1.5-fold enriched cleavage events, were used for a more stringent filtering to identify replicated 
cleavage events enriched greater than 2-fold. At a cut-off value of 2-fold change, 694 (replicate 1) and 
1985 (replicate 3) cleavage events were generated by HML-2 Pro, with a total of 129 cleavage events 
common to both replicates (Figure 29).  
Similar to the TAILS experiment at pH 5.5, we observed at pH 7 multiple cleavage events within 
several of the human proteins (Figure 30). For instance, we identified 74 proteins common to replicate 
1 and 3 for which there was reported evidence of 2-fold enriched multiple cleavages. Among those 
proteins were 15 and 10 cleavage events in replicates 1 and 3, respectively, for HSP90AB1, 32 and 6 
events for MYH6, 15 and 12 for VCP, and 23 and 11 events for HSPA8 (Table 18). Overlapping the 
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two replicates at pH 5.5 with replicate 1 and 3 at pH 7 revealed 52 common proteins with 2-fold 
enrichment cleaved in more than one position. 
As for the two replicates at pH 5.5, we also identified in replicates 1 and 3 at pH 7 proteins cleaved 
with at least 2-fold enrichment, yet not necessarily cleaved in the same position within a protein. At a 
cut-off value of 2-fold change, 342 (replicate 1) and 1134 (replicate 3) different human proteins were 
cleaved by HML-2 Pro. Combining replicates 1 and 3, a total of 217 human proteins showed replicated 
evidence of cleavage by HML-2 Pro at pH 7 (Figure 29). 
 
Lastly, we evaluated the overlap in cleaved proteins among the two TAILS replicates at pH 5.5 
(pH5.5_Rep1, pH5.5_Rep2) and two TAILS replicates at pH 7 (pH7_Rep1, pH7_Rep3) (Figure 29, 
four-color Venn diagrams). That analysis identified 154 different human proteins cleaved by HML-2 
Pro that were detected in the four TAILS experiments when applying 2-fold enrichment (Figure 29). 
187 cleaved proteins were common to the four experiments when applying 1.5-fold enrichment for the 
two replicates at pH 7 and 2-fold enrichment for replicates at pH 5.5 (not shown). 
 
Altogether, we considered the above findings to bear evidence of potential processing of human 
proteins by HML-2 Pro. HML-2 Pro was able to cleave many cellular proteins at acidic as well as 
neutral pH. The 809 human proteins common to the two pH 5.5 experiments plus the 217 proteins 
common to the two pH 7 experiments (see above), resulted in a total of 872 unique proteins (154 
proteins were common to the two lists, thus 809 + 63), all of them with at least 2-fold enrichment, thus 
with strong evidence of processing by HML-2 Pro in vitro. The 872 proteins (see Appendix, Table 21) 
can be considered as cellular substrates of HML-2 Pro that could be potentially processed by HML-2 





Figure 28: Filtering of cleavage events identified by TAILS. Results of filtering of raw data from experimental 
replicates at pH 5.5 (pH5.5_Rep) and pH 7 (pH7_Rep) are depicted. Filters were applied for 1.5-fold or 2-fold 
enrichment of cleavage events. Numbers of cleavage events after applying the various filters are depicted by bars 




Figure 29: Venn diagrams depicting overlap of cleavage events and protein IDs among replicate 
experiments performed at pH 5.5 and pH 7. Overlap of cleavage events with 1.5-fold enrichment is shown on 
the top (middle) for three replicates at pH 7. Of those, replicate 1 and 3 (highlighted in grey) showed higher 
numbers of 1.5-fold enriched cleavage events and the greatest overlap. They were therefore considered for 
identification of replicated cleavage events at pH 7 with 2-fold enrichment. The other Venn diagrams considered 
cleavage events or protein IDs with 2-fold enrichment. The overlap among protein IDs detected in two pH 7 
replicates and the two pH 5 replicates is depicted in the four-color Venn diagram at the top. The four-color Venn 




Figure 30: Numbers of cleavage events for proteins identified as substrates of HML-2 Pro. Results are 
depicted for the two TAILS experiments at pH 5.5 and for two TAILS experiments at pH 7. Only cleavage 
events with greater than 2-fold enrichment were considered. The majority of proteins was cleaved in a single 
position, fewer proteins were cleaved at more than one position, and a relatively small number of proteins 
were cleaved at many different positions within the particular protein. 
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Table 18: Examples of human proteins cleaved by HML-2 Pro in multiple positions * 
pH5.5; Fc>2 
Protein ID gene symbol protein name Rep1 Rep2 
P60709 ACTB Actin beta 38 32 
P08238 HSP90AB1 Heat shock protein 90 alpha family class B member 1 30 50 
P22314 UBA1 Ubiquitin like modifier activating enzyme 1 29 21 
P35579 MYH9 Myosin heavy chain 9 25 60 
P68104 EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 21 25 
P07900 HSP90AA1 Heat shock protein 90 alpha family class A member 1 17 26 
Q00839 HNRNPU Heterogeneous nuclear ribonucleoprotein U 17 20 
Q92598 HSPH1 Heat shock protein family H (Hsp110) member 1 17 15 
P62937 PPIA Peptidylprolyl isomerase A 16 16 
P43487 RANBP1 RAN binding protein 1 15 13 
P04406 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 14 11 
P00558 PGK1 Phosphoglycerate kinase 1 13 18 
P62917 RPL8 Ribosomal protein L8 13 14 
P06744 GPI Glucose-6-phosphate isomerase 12 10 
P11142 HSPA8 Heat shock protein family A (Hsp70) member 8 11 36 
Q13263 TRIM28 Tripartite motif containing 28 11 15 
P63261 ACTG1 Actin gamma 1 11 14 
Q04637 EIF4G1 Eukaryotic translation initiation factor 4 gamma 1 11 12 
Q71U36 TUBA1A Tubulin alpha 1a 11 11 
P62753 RPS6 Ribosomal protein s6 10 12 
     
pH7; Fc>2     
Protein ID gene symbol protein name Rep1 Rep3 
P35579 MYH9 Myosin heavy chain 9 32 6 
P11142 HSPA8 Heat shock protein family A (Hsp70) member 8 23 11 
P55072 VCP Transitional endoplasmic reticulum ATPase 15 12 
P08238 HSP90AB1 Heat shock protein 90 alpha family class B member 1 15 10 
P26038 MSN Moesin 14 5 
P14618 PKM Pyruvate kinase M1/2 13 8 
P06733 ENO1 Alpha-enolase 10 6 
P60709 ACTB Actin beta 9 14 
P18206 VCL Vinculin 9 8 
O43707 ACTN4 Actinin alpha 4 8 6 
P07437 TUBB Tubulin beta class I 7 9 
P07900 HSP90AA1 Heat shock protein 90 alpha family class A member 1 7 8 
P0DMV9 HSPA1B Heat shock protein family A (Hsp70) member 1B 7 6 
P00558 PGK1 Phosphoglycerate kinase 1 7 5 
P22314 UBA1 Ubiquitin like modifier activating enzyme 1 5 11 
P78371 CCT2 T-complex protein 1 subunit beta 5 7 
Q9Y490 TLN1 Talin-1 5 7 
P29401 TKT Transketolase 5 6 
P63261 ACTG1 Actin gamma 1 4 6 
* For the TAILS experiments at pH 5.5, proteins with 2-fold enrichment and 10 or more identified cleavage 
events in different positions in either replicate (Rep1, Rep2) are listed. For the TAILS experiments at pH 7, 
proteins with at least 4 observed cleavage events (Rep1, Rep3) and 2-fold enrichment for the two selected 
replicates are shown. Protein IDs, gene symbols and protein names are depicted. 
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4.1.5 Cellular substrates of HML-2 Pro: cellular localization, biological processes and 
association with diseases 
In order to gain some insights into potential biological impact of an enzymatically active HML-2 Pro 
expressed in human cells, we determined cellular localization and biological function of human 
proteins that, on the basis of TAILS results, are substrates of HML-2 Pro. The 872 identified proteins 
(see the previous chapter) were subjected to Gene Ontology (GO) analysis. GO is a bioinformatic 
initiative that annotates and classifies genes and gene products using a set of predefined bins called 
terms [39]. The terms incorporate information related to cellular localization, molecular activity and 
biological processes in which a specific gene/protein is likely or factually involved. Each gene can be 
annotated through various terms organized hierarchically. Data provided by the GO system are 
associated with online tools that can apply different methods to profile sets of genes/proteins on the 
basis of various GO terms. For our profilings we used the PANTHER (Protein Analysis Through 
Evolutionary Relationships) classification database [140], a public website where our set of 872 protein 
IDs was loaded in order to retrieve for each protein in our list GO terms regarding cellular 
compartments and biological processes. Our analysis was primarily interested in the range of GO 
categories associated with our 872-protein list and numbers of proteins for each category of interest. It 
needs to be considered here that human proteins are dynamic and multifunctional elements inside a 
cell that are not necessarily associated with a single compartment or process. Thus, a protein can be 
related to multiple GO terms. The GO analysis also included an overrepresentation test that used a 
binomial statistics tool to compare the input set with a reference list (composed of all human genes 
included in the PANTHER database) and statistically determine over- or under- representation of 
PANTHER classification categories. However, that particular test was not relevant for our purpose.  
We ran two GO term analyses through PANTHER. Selected annotation datasets were "GO cellular 
component complete" and "GO biological processes complete". 
 
The PANTHER analysis related to cellular components revealed that potential substrates of HML-2 
Pro locate to diverse cellular compartments (Figure 31). The majority of proteins were associated with 
cytoplasm and nucleus, with ~580 and ~550 proteins, respectively. Many proteins were associated with 
plasma membrane (~150), membrane part (~130), extracellular space (~300), and cell projection 
(~125). Subcellular organelles enclosed by membrane were also associated with a number of proteins: 
~70 proteins with secretory granules, ~20 with primary lysosome, and ~300 with exosome. Also, ~90 
and ~50 proteins were associated with mitocondrion and ribosome, respectively.  
The PANTHER analysis related to biological processes revealed that proteins cleaved by HML-2 Pro 
are involved in several processes. Relevant biological processes associated with HML-2 Pro cellular 
substrates included response to stress (~230 proteins), immune system process (~160 proteins), cell 
death (~120 proteins), cell differentiation (~100 proteins), cytoskeleton organization (~100 proteins), 
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regulation of cell cycle (90 proteins), DNA repair (~40 proteins), DNA replication (~20 proteins), 
mRNA processing (~60 proteins), translation (~100 proteins), protein folding (~60 proteins), 
mitochondrion organization (~20 proteins), and nervous system process (~10 proteins). The complete 
list of GO terms for biological processes considered by us, with respective number of HML-2 Pro 
substrates, is depicted in Figure 31. That list provides a picture of biological processes associated with 
HML-2 Pro substrates, thus indicating cellular processes that could be potentially influenced by HML-
2 Pro activity. 
 
 
Figure 31: Summary of Gene Ontology term analysis of human proteins identified as substrates of HML-
2 Pro by TAILS. Selected cellular compartments and biological processes are depicted. Numbers of proteins 
associated with the depicted Gene Ontology (GO) terms were obtained using the PANTHER (Protein ANalysis 
THrough Evolutionary Relationships) database as provided at http://www.pantherdb.org. 
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Furthermore, we aimed at evaluating the involvement of the identified HML-2 Pro substrates in human 
cancer, a condition in which HML-2 is implicated [171]. HML-2 upregulation has been previously 
associated with several tumor types [58,64]. Also, HML-2-encoded proteins have been detected in 
some of those tumor tissues [171]. 
For our analysis, the human genes corresponding to the selected 872 human proteins were intersected 
with genes included in the Catalogue Of Somatic Mutations In Cancer (COSMIC) database 
(https://cancer.sanger.ac.uk). COSMIC is a detailed and comprehensive resource collecting 
information on human genes/proteins and somatic mutations associated with cancer [201]. Our analysis 
identified 64 genes/proteins (in the following referred to as proteins) with an established relevance in 
oncology. Fifty-six of those proteins were associated with somatic mutations in cancer (see Table 19), 
4 proteins (BUB1B, ERCC5, FH and SMARCE1) were associated with germline mutations that 
predispose to cancer, and 4 proteins (CDC73, MSH6, POLD1, MSH6) were associated with both. A 
total of 59 tumor types were associated with the 64 proteins. There were proteins associated with only 
one tumor type and proteins associated with various tumor types. Some tumors were more represented 
than others, with cases of more than 10 different proteins associated with a certain tumor, for instance, 
leukemia and lymphoma. Several proteins were associated with tumors of interest in the context of 
HML-2. Such proteins are reported in the following. B2M, ERCC5 and MAP2K2 were associated with 
melanoma, a type of cancer where HML-2 is found upregulated [29,183]. DAXX and IDH1 were 
associated with glioblastoma. FUBP1 was associated with oligodendroglioma. Glioblastoma and 
oligodendroglioma are brain tumors. A previous expression analysis of various brain tumor types, 
including glioblastoma, indicated that quite a number of HML-2 proviruses are transcriptionally active 
in those tissues [58]. MSH6 and PPP2R1A were associated with ovarian tumor, DDX5 and 
HNRNPA2B1 with prostate tumor, CTCF and ZMYM3 with breast cancer, three tumor types with 
reported altered HML-2 transcription [58,214]. Twelve proteins were associated with lymphoma, 
which could be of interest considering that HML-2 RNA was found at high levels in the plasma of 
patients with lymphoma [42]. 
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Table 19: Involvement of potential HML-2 Pro cellular substrates in human cancers * 
Gene symbol Protein name Tumour types (somatic) Tumour types (germline) 
ARAF A-Raf proto-oncogene, serine/threonine kinase cholangiocarcinoma, 
adenocarcinoma, Langerhans cell 
histiocytosis 
 




B2M beta-2-microglobulin DLBCL, melanoma, colorectal 
adenocarcinoma 
 
BCL3 B-cell CLL/lymphoma 3 CLL 
 
BCL9L B-cell CLL/lymphoma 9-like colorectal cancer, endometrial 
carcinoma, gastric cancer 
 




CALR calreticulin MPN, MDS 
 
CDC73 cell division cycle 73 parathyroid adenoma parathyroid adenoma, multiple 
ossifying jaw fibroma 
CLIP1 CAP-GLY domain containing linker protein 1 Spitzoid tumour 
 
CNBP CCHC-type zinc finger, nucleic acid binding protein aneurysmal bone cyst 
 
CTCF CCCTC-binding factor endometrial, breast, head and neck 
cancer 
 
CTNND1 catenin delta 1 large intestine carcinoma 
 
DAXX death-domain associated protein pancreatic neuroendocrine tumour, 
paediatric glioblastoma 
 
DDX3X DEAD-box helicase 3, X-linked CLL, medulloblastoma 
 
DDX5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 prostate 
 
EIF3E eukaryotic translation initiation factor 3, subunit E colorectal 
 
ERCC5 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 (xeroderma pigmentosum, 
complementation group G (Cockayne syndrome)) 
 
skin basal cell, skin squamous 
cell, melanoma 
EZR ezrin NSCLC 
 
FH fumarate hydratase 
 
leiomyomatosis, renal 
FLNA filamin A phyllodes tumour of the breast 
 
FUBP1 far upstream element (FUSE) binding protein 1 oligodendroglioma 
 
GMPS guanine monphosphate synthetase AML 
 
HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 prostate 
 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 NHL 
 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 NHL 
 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble glioblastoma 
 
KIF5B kinesin family member 5B NSCLC, Spitzoid tumour 
 
LASP1 LIM and SH3 protein 1 AML 
 
MAP2K2 mitogen-activated protein kinase kinase 2 NSCLC, melanoma 
 
MSH6 mutS homolog 6 (E. coli) colorectal colorectal, endometrial, ovarian 
MSN moesin ALCL 
 
MYH9 myosin, heavy polypeptide 9, non-muscle ALCL 
 
NACA nascent-polypeptide-associated complex alpha polypeptide NHL 
 
NONO non-POU domain containing, octamer-binding papillary renal 
 
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) NHL, APL, AML 
 
NT5C2 5'-nucleotidase, cytosolic II relapse ALL 
 
NUMA1 nuclear mitotic apparatus protein 1 APL 
 
NUP214 nucleoporin 214kDa (CAN) AML, T-ALL 
 
NUP98 nucleoporin 98kDa AML 
 
PABPC1 poly(A) binding protein cytoplasmic 1 HNSCC, biliary tract carcinoma 
 
PCBP1 poly(rC) binding protein 1 CRC  
PCM1 pericentriolar material 1  (PTC4) papillary thyroid, CML, MPN 
 
PHF6 PHD finger protein 6 ETP ALL 
 
PML promyelocytic leukemia APL, ALL 
 
POLD1 DNA polymerase delta 1, catalytic subunit CRC CRC 
PPP2R1A protein phosphatase 2, regulatory subunit A, alpha clear cell ovarian carcinoma 
 
RANBP2 RAN binding protein 2 inflammatory myofibroblastic 
tumour 
 
RPL22 ribosomal protein L22 (EAP) AML, CML 
 
RPL5 ribososomal protein L5 T-ALL 
 
SET SET translocation T-ALL 
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SF3B1 splicing factor 3b, subunit 1, 155kDa MDS 
 
SFPQ splicing factor proline/glutamine rich(polypyrimidine tract 
binding protein associated) 
papillary renal 
 
SMARCE1 SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily e, member 1 
 
meningioma 
SND1 staphylococcal nuclease and tudor domain containing 1 pancreas acinar carcinoma 
 
STAT3 signal transducer and activator of transcription 3 (acute-phase 
response factor) 
T-cell large granular lymphocytic 
leukaemia 
paediatric large granular 
lymphocytic leukaemia 




THRAP3 thyroid hormone receptor associated protein 3 (TRAP150) aneurysmal bone cyst 
 
TPM3 tropomyosin 3 papillary thyroid, ALCL, NSCLC, 
Spitzoid tumour 
 
TPM4 tropomyosin 4 ALCL 
 
TPR translocated promoter region papillary thyroid, NSCLC 
 
TRIM33 tripartite motif-containing 33 (PTC7,TIF1G) papillary thyroid 
 
UBR5 ubiquitin protein ligase E3 component n-recognin 5 mantle cell lymphoma, gastric, 
colorectal 
 
YWHAE tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide (14-3-3 epsilon) 
endometrial stromal sarcoma 
 
ZMYM3 zinc finger MYM-type containing 3 CRC, breast cancer 
 
* Human genes corresponding to proteins identified by TAILS as substrates of HML-2 Pro were intersected with 
cancer-relevant genes as compiled in COSMIC (Catalogue Of Somatic Mutations In Cancer; 
https://cancer.sanger.ac.uk/cosmic) [60]. The resulting genes list is reported, specifying associated tumor types. 
Tumor types in somatic cells and/or germ cells are indicated. ALCL: anaplastic large-cell lymphoma; ALL: acute 
lymphocytic leukaemia; AML: acute myeloid leukaemia; APL: acute promyelocytic leukaemia; CLL: chronic 
lymphocytic leukaemia; CML: chronic myeloid leukemia; CRC: colorectal cancer; DLBCL: diffuse large B-cell 
lymphoma; ETP-ALL: early T-cell precursor acute lymphoblastic leukemia; HNSCC: head and neck squamous 
cell carcinoma; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; NHL: non-Hodgkin 
lymphoma; NSCLC: non small cell lung cancer; T-ALL: T-cell acute lymphoblastic leukaemia. 
 
For an additional evaluation of an involvement of the identified HML-2 Pro substrates in diseases, our 
dataset of 872 proteins was also intersected with genetic disorders included in the Online Mendelian 
Inheritance in Man (OMIM) database [2], an online catalog of human genes and genetic phenotypes. 
OMIM focuses on gene-phenotype relationships, thus it provides information to understand how 
alteration of certain genes (and respective proteins) could lead to specific diseases. Our analysis 
identified 289 different disorder phenotypes of which approximately 250 were described as inherited. 
Detailed results from OMIM analyses are provided along with the electronic version of this 
dissertation. The identified phenotypes included various tumors, for example, neuroblastoma, 
colorectal cancer, prostate cancer, endometrial cancer, leukemia, and meningioma. Some of those 
tumor types were also identified by COSMIC analysis (see above). Among many other phenotypes, 
several neurological disorders were identified. For example, ALS, mental retardation, peripheral 
neuropathy, neurodegeneration with brain iron accumulation, Parkinson disease, and Huntington 
disease. Neurological disorders as well as different tumor types are of particular interest as previously 
pointed out in the context of HML-2 [35]. 
Taken together, our analyses indicated that among cellular substrates of HML-2 Pro there are many 
proteins for which their impairment has been associated with human diseases. 
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4.1.6 Further validation of potential substrates of HML-2 Pro 
The TAILS analysis provided initial evidence of specific cleavage of many human proteins by HML-
2 Pro. To provide further support to this, we considered verification of HML-2 Pro activity by 
additional, more specific experiments that could demonstrate processing of human proteins in vitro 
and in vivo. Eventually confirmed cleavages of cellular substrates could thus lend further support to a 
potential impact of HML-2 Pro in cellular processes in which cleaved proteins participate. 
 
4.1.6.1 Verification experiments in vitro 
Our in vitro experimental approach involved 1) selection of candidate proteins for verification 
experiments, 2) in vitro generation of selected candidate proteins tagged with an HA tag or a 
radioactive label, 3) incubation of candidate proteins with purified HML-2 Pro and analysis of cleavage 
of candidate proteins by means of either Western blot, or SDS-PAGE and phosphorimaging.  
 
4.1.6.1.1 Selection of candidate proteins for verifications in vitro 
The 2-fold enriched cleavage events identified in the two TAILS experiments at pH 5.5 were used as 
a starting point for selection of HML-2 Pro substrates to be tested. To reduce the initially long list of 
proteins to a reasonable number of candidates, we applied a series of criteria for filtering. Our criteria 
considered the amino acid specificities of HML-2 Pro cleavage sites (Figure 32 A), as recently reported 
[17]. The specificity profile of HML-2 Pro revealed P1 and P1', which refer to the two amino acids 
comprising the processed peptide bond, as major determinants of specificity of HML-2 Pro proteolysis. 
In particular, a preference for phenylalanine (F), tryptophan (W), tyrosine (Y) and glycine (G), thus 
primarily aromatic aa residues, was observed for P1. Whereas, phenylalanine (F), isoleucine (I), 
leucine (L), valine (V) and tryptophan (W), thus aromatic and aliphatic aa residues, were observed for 
P1'. Based on those published findings, we filtered the initial list of cleavage events by considering 
only proteins with F, G, Y, or W in P1, and F, I, L, V, or W in P1' (Figure 32 B). After applying filters 
for P1 and P1', 4370 (replicate 1) and 2633 (replicate 2) cleavage events were reduced to 355 and 260, 
respectively. Those cleavage events corresponded to 305 and 219 different human proteins, with 145 
human proteins common to both datasets. Those 145 proteins were subjected to further filtering (Figure 
32 C). Molecular mass of proteins had to be compatible with an in vitro coupled 
transcription/translation system. In general, proteins of larger molecular mass tend to require a longer 
time to be transcribed/translated or are produced relatively inefficiently by that system. That might 
have resulted in a (too) low yield of protein for our experiments. To ensure relatively high yield, we 
therefore considered only proteins with a length of less than 800 aa, or approximately 90 kDa, resulting 
in 107 different human proteins. Furthermore, we selected proteins that, based on associated GO terms, 
located to various cellular compartments, e.g., cytoplasm, cytosol, nucleus, endoplasmic reticulum, 
mitochondrion, and were furthermore known to be involved in relevant cellular processes, e.g., 
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transcriptional regulation, growth control, protein folding, regulation of cell cycle. We also included 
one protein (C15orf57) for which cellular location and function were unknown. Eventually, we 
selected 14 different human proteins (Table 20) for subsequent experiments. 
 
 
Figure 32: Criteria for filtering of candidate proteins for in vitro verification experiments. A) Specificity 
profile of HML-2 Pro as published recently [17]. The heatmap, retrieved from Biniossek et al. (2016) [17], sums 
up for observed cleavage sites the aa occurrences for each position, also taking into account frequencies of the 
various aa in human proteins. Aa specificities in positions P1 and P1´ were used as criteria for selection of 
candidate proteins for subsequent experiments in vitro. B) 2-fold enriched cleavage events identified in the two 
TAILS experiments at pH 5.5 were filtered by considering only cleavage events with F, G, Y, or W in P1, and 
F, I, L, V, or W in P1'. Bars depict numbers of cleavage events before and after filtering. Precise numbers of 




Table 20: Candidate proteins selected for verification of processing by HML-2 Pro in vitro * 
Protein ID  
Gene/protein  
(protein full name) 




acrosomal vesicle; cell surface; cytoplasm; 
cytosol; endocytic vesicle lumen; endoplasmic 
reticulum; endoplasmic reticulum lumen; 
endoplasmic reticulum-Golgi intermediate 
compartment membrane; external side of 
plasma membrane; extracellular exosome; 
extracellular region; extracellular space; focal 
adhesion; Golgi apparatus; integral 
component of lumenal side of endoplasmic 
reticulum membrane; intracellular; 
membrane; MHC class I peptide loading 
complex; nucleus; perinuclear region of 
cytoplasm; phagocytic vesicle membrane; 
polysome; proteinaceous extracellular matrix; 
sarcoplasmic reticulum lumen; smooth 
endoplasmic reticulum. 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I, TAP-dependent; antigen processing and presentation of peptide antigen 
via MHC class I; ATF6-mediated unfolded protein response; cardiac muscle cell 
differentiation; cellular calcium ion homeostasis; cellular response to lithium 
ion; cellular senescence; chaperone-mediated protein folding; cortical actin 
cytoskeleton organization; glucocorticoid receptor signaling pathway; negative 
regulation of cell cycle arrest; negative regulation of intracellular steroid 
hormone receptor signaling pathway; negative regulation of neuron 
differentiation; negative regulation of retinoic acid receptor signaling pathway; 
negative regulation of transcription from RNA polymerase II promoter; negative 
regulation of transcription, DNA-templated; negative regulation of translation; 
negative regulation of trophoblast cell migration; peptide antigen assembly with 
MHC class I protein complex; positive regulation of cell cycle; positive 
regulation of cell proliferation; positive regulation of dendritic cell chemotaxis; 
positive regulation of DNA replication; positive regulation of endothelial cell 
migration; positive regulation of gene expression; positive regulation of 
NIK/NF-kappaB signaling; positive regulation of phagocytosis; positive 
regulation of substrate adhesion-dependent cell spreading; protein export from 
nucleus; protein folding; protein folding in endoplasmic reticulum; protein 
localization to nucleus; protein maturation by protein folding; protein 
stabilization; receptor-mediated endocytosis; regulation of apoptotic process; 
regulation of meiotic nuclear division; regulation of transcription, DNA-
templated; response to drug; response to estradiol; response to testosterone; 
sequestering of calcium ion; spermatogenesis; vesicle fusion with endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC) membrane. 
O00571 
DDX3X  
(DEAD-Box helicase 3, X-
linked) 
cytoplasm; cytoplasmic stress granule; 
cytosol; extracellular exosome; extracellular 
region; ficolin-1-rich granule lumen; 
mitochondrial outer membrane; nuclear speck; 
nucleus; secretory granule lumen. 
cellular response to arsenic-containing substance; cellular response to osmotic 
stress; chromosome segregation; extrinsic apoptotic signaling pathway via 
death domain receptors; innate immune response; intracellular signal 
transduction; intrinsic apoptotic signaling pathway; mature ribosome 
assembly; negative regulation of apoptotic process; negative regulation of cell 
growth; negative regulation of cysteine-type endopeptidase activity involved 
in apoptotic process; negative regulation of intrinsic apoptotic signaling 
pathway; negative regulation of protein complex assembly; negative regulation 
of translation; neutrophil degranulation; positive regulation of apoptotic 
process; positive regulation of cell growth; positive regulation of chemokine 
(C-C motif) ligand 5 production; positive regulation of cysteine-type 
endopeptidase activity involved in apoptotic process; positive regulation of 
G1/S transition of mitotic cell cycle; positive regulation of gene expression; 
positive regulation of interferon-beta production; positive regulation of 
transcription from RNA polymerase II promoter; positive regulation of 
translation; positive regulation of translational initiation; positive regulation of 
viral genome replication; protein localization to cytoplasmic stress granule; 
response to virus; RNA secondary structure unwinding; stress granule 




cell cortex region; cell surface; cytoplasm; 
cytosol; extracellular exosome; extracellular 
space; M band; membrane; nucleus; 
phosphopyruvate hydratase complex; plasma 
membrane. 
canonical glycolysis; gluconeogenesis; negative regulation of cell growth; 
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway; 
negative regulation of transcription from RNA polymerase II promoter; negative 
regulation of transcription, DNA-templated; positive regulation of ATP 
biosynthetic process; positive regulation of muscle contraction; positive 




(heat shock protein 90 
alpha family class B 
member 1) 
apical plasma membrane; aryl hydrocarbon 
receptor complex; basolateral plasma 
membrane; brush border membrane; cell 
surface; cytoplasm; cytosol; extracellular 
exosome; extracellular region; ficolin-1-rich 
granule lumen; inclusion body; lysosomal 
membrane; melanosome; membrane; 
mitochondrion; nucleoplasm; nucleus; 
ooplasm; protein complex; secretory granule 
lumen; sperm head plasma membrane. 
cellular response to drug; cellular response to interleukin-4; cellular response to 
organic cyclic compound; chaperone-mediated protein complex assembly; Fc-
gamma receptor signaling pathway involved in phagocytosis; negative 
regulation of cell cycle arrest; negative regulation of complement-dependent 
cytotoxicity; negative regulation of neuron apoptotic process; negative 
regulation of proteasomal ubiquitin-dependent protein catabolic process; 
negative regulation of transforming growth factor beta activation; neutrophil 
degranulation; placenta development; positive regulation of cell differentiation; 
positive regulation of cell size; positive regulation of nitric oxide biosynthetic 
process; positive regulation of phosphoprotein phosphatase activity; positive 
regulation of protein binding; positive regulation of protein import into nucleus, 
translocation; positive regulation of protein localization to cell surface; positive 
regulation of protein serine/threonine kinase activity; positive regulation of 
telomerase activity; positive regulation of transforming growth factor beta 
receptor signaling pathway; protein folding; protein stabilization; regulation of 
cellular response to heat; regulation of interferon-gamma-mediated signaling 
pathway; regulation of protein ubiquitination; regulation of type I interferon-
mediated signaling pathway; response to cocaine; response to salt stress; 
response to unfolded protein; supramolecular fiber organization; telomerase 
holoenzyme complex assembly; telomere maintenance via telomerase; virion 
attachment to host cell; xenobiotic metabolic process. 
P30101 
PDIA3  
(protein disulfide isomerase 
family A member 3) 
cell surface; endoplasmic reticulum; 
endoplasmic reticulum lumen; extracellular 
exosome; extracellular space; focal adhesion; 
melanosome; myelin sheath; nucleus; 
phagocytic vesicle; recycling endosome 
membrane. 
antigen processing and presentation of exogenous peptide antigen via MHC 
class I, TAP-dependent; antigen processing and presentation of peptide antigen 
via MHC class I; cell redox homeostasis; positive regulation of extrinsic 
apoptotic signaling pathway; protein folding; protein folding in endoplasmic 
reticulum; protein import into nucleus; protein retention in ER lumen; response 




(proteasome 26S subunit, 
ATPase 4) 
cytosol; cytosolic proteasome complex; 
inclusion body; membrane; nuclear 
proteasome complex; nucleoplasm; nucleus; 
proteasome accessory complex; proteasome 
complex; proteasome regulatory particle, base 
subcomplex; synapse. 
anaphase-promoting complex-dependent catabolic process; antigen processing 
and presentation of exogenous peptide antigen via MHC class I, TAP-
dependent; blastocyst development; Fc-epsilon receptor signaling pathway; 
MAPK cascade; negative regulation of canonical Wnt signaling pathway; 
negative regulation of G2/M transition of mitotic cell cycle; negative regulation 
of ubiquitin-protein ligase activity involved in mitotic cell cycle; NIK/NF-
kappaB signaling; positive regulation of canonical Wnt signaling pathway; 
positive regulation of RNA polymerase II transcriptional preinitiation complex 
assembly; positive regulation of ubiquitin-protein ligase activity involved in 
regulation of mitotic cell cycle transition; proteasome-mediated ubiquitin-
dependent protein catabolic process; protein deubiquitination; protein 
polyubiquitination; proteolysis; regulation of cellular amino acid metabolic 
process; regulation of mRNA stability; regulation of transcription from RNA 
polymerase II promoter in response to hypoxia; SCF-dependent proteasomal 
ubiquitin-dependent protein catabolic process; stimulatory C-type lectin 
receptor signaling pathway; T cell receptor signaling pathway; transmembrane 
transport; tumor necrosis factor-mediated signaling pathway; ubiquitin-




(RAN binding protein 1) 
centrosome; cytoplasm; cytosol; nuclear 
envelope; nucleus. 
G1/S transition of mitotic cell cycle; positive regulation of mitotic centrosome 
separation; protein import into nucleus; RNA export from nucleus; signal 
transduction; spindle organization; ubiquitin-dependent protein catabolic 
process; viral process. 
Q5TBB1 
RNASEH2B 
(ribonuclease H2 subunit 
B) 
nucleus; ribonuclease H2 complex. in utero embryonic development; negative regulation of gene expression; 
positive regulation of fibroblast proliferation; regulation of DNA damage 
checkpoint; regulation of G2/M transition of mitotic cell cycle; ribonucleotide 
metabolic process; RNA catabolic process. 
P26447 
S100A4  
(S100 calcium binding 
protein A4) 
extracellular exosome; extracellular space; 
neuron projection; nucleus; perinuclear region 
of cytoplasm.  









(cytokine induced apoptosis 
inhibitor 1) 
cytoplasm; mitochondrial intermembrane 
space; mitochondrion; nucleolus; 
nucleoplasm. 
apoptotic process; hemopoiesis; iron-sulfur cluster assembly; negative 
regulation of apoptotic process. 
P07900 
HSP90AA1  
(heat shock protein 90 
alpha family class A 
member 1) 
cytoplasm; cytosol; endocytic vesicle lumen; 
extracellular exosome; extracellular region; 
ficolin-1-rich granule lumen; lysosomal 
lumen; melanosome; membrane; myelin 
sheath; nucleoplasm; nucleus; plasma 
membrane; ruffle membrane; secretory 
granule lumen. 
chaperone-mediated autophagy; chaperone-mediated protein complex 
assembly; ciliary basal body docking; ERBB2 signaling pathway; Fc-gamma 
receptor signaling pathway involved in phagocytosis; G2/M transition of mitotic 
cell cycle; mitochondrial transport; neutrophil degranulation; positive regulation 
of nitric oxide biosynthetic process; positive regulation of telomerase activity; 
protein import into mitochondrial outer membrane; protein refolding; protein 
stabilization; protein unfolding; receptor-mediated endocytosis; regulation of 
cellular response to heat; regulation of nitric-oxide synthase activity; regulation 
of protein complex assembly; regulation of protein ubiquitination; response to 
antibiotic; response to cold; response to heat; response to unfolded protein; 
signal transduction; telomerase holoenzyme complex assembly; telomere 
maintenance via telomerase; vascular endothelial growth factor receptor 




kinase kinase 2) 
cell-cell junction; cytoplasmic side of plasma 
membrane; cytosol; early endosome; 
endoplasmic reticulum; extracellular region; 
focal adhesion; Golgi apparatus; late 
endosome; microtubule; mitochondrion; 
nucleus; perinuclear region of cytoplasm; 
peroxisomal membrane; plasma membrane. 
activation of MAPK activity; ERK1 and ERK2 cascade; MAPK cascade; 
negative regulation of gene expression; peptidyl-serine autophosphorylation; 
positive regulation of ERK1 and ERK2 cascade; positive regulation of 
production of miRNAs involved in gene silencing by miRNA; positive 
regulation of protein serine/threonine kinase activity; positive regulation of 
transcription, DNA-templated; proteolysis in other organism; regulation of early 
endosome to late endosome transport; regulation of Golgi inheritance; 
regulation of stress-activated MAPK cascade. 
Q71U36 
TUBA1A  
(tubulin alpha 1a) 
cytoplasmic microtubule; cytoplasmic 
ribonucleoprotein granule; cytosol; 
extracellular exosome; membrane raft; 
microtubule; microtubule cytoskeleton; 
myelin sheath; nucleus; recycling endosome. 
cell division; ciliary basal body docking; cytoskeleton-dependent intracellular 
transport; G2/M transition of mitotic cell cycle; microtubule-based process. 
* A representative protein ID, approved gene/protein symbols and full names are given each. GO compartments 
and GO processes for respective genes/proteins were compiled from UniProt [40]. 
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4.1.6.1.2 Generation of candidate proteins in an in vitro transcription/translation system 
Candidate proteins were produced in vitro employing TNT® T7 Quick for PCR DNA, referred to as 
TNT T7 system in the following. The TNT T7 system consisted of a rabbit reticulocyte cell-free extract 
(hereafter designated as TNT T7 Master Mix), containing a T7 RNA polymerase and the essential 
molecular machinery for protein translation. For each selected candidate protein, a DNA template 
encompassing the protein coding region, as present in a respective coding sequence-harboring 
commercially available plasmid, was amplified by PCR. The PCR added to the DNA template, by 
means of specifically designed PCR primers, a T7 promoter, a spacer and a Kozak sequence upstream 
of the protein start codon. To the 3' end of the protein coding sequence were added an HA-tag and a 
stop codon (see Materials and Methods, Figure 12). PCR-generated DNA templates were added to the 
TNT T7 Master Mix in presence of either L-35S-methionine or L-methionine to produce radiolabeled 
or “cold”, respectively, proteins. Several parameters can influence the yield of protein produced by the 
utilized in vitro coupled transcription/translation system, for instance, DNA template characteristics, 
like the aa sequence encompassing the ATG translation initiation codon, amount of DNA template, 
and template purity. Time and temperature of incubation of reactions are also relevant. Thus, before 
setting up reactions for generation of candidate proteins, we confirmed that our experimental 
conditions (see also chapter 3.2.2.2) ensured an adequate yield of candidate protein. To do so, we 
produced an HA-tagged EGFP protein by using the TNT T7 system and we verified, by Western blot, 
that the protein was produced at a readily detectable amount (Figure 33 A). Indeed, EGFP was detected 
at reasonable amount with both an α-GFP and an α-HA antibody. The approximately 30 kDa band 
observed with both antibodies was of the expected size. No considerable amount of bands of side 
products was detected. As the HA-tag was present at the C-terminus, detection via the α-HA antibody 
furthermore confirmed that the protein was transcribed/translated in full-length. Subsequently, 
radiolabeled and “cold” candidate proteins were generated with established TNT T7 system conditions. 
Production of desired proteins was verified by SDS-PAGE followed by phosphorimaging or Western 
blot depending on 35S or HA-only protein labels, respectively (Figure 33 B, C). The produced full-
length candidate proteins matched the expected sizes. HML-2 Gag was also generated in vitro to be 




Figure 33: Generation of candidate proteins using an in vitro transcription/translation system. Proteins 
were produced via a TNT T7 system (see text) and detected by Western blot and phosphorimaging. A) HA-
tagged EGFP produced in the TNT T7 system was detected by α-HA and α-GFP antibodies. Controls with TNT 
T7 mixtures without DNA templates are included. In the bottom part, blot membranes were stained with 
Coomassie after the detection procedure. B) Representative Western blot result with different candidate proteins 
produced in vitro and detected via HA-tag. C) Representative result of a dried SDS-PAGE gel with different 35S-
labeled candidate proteins produced in vitro and detected by phosphorimaging. HML-2 Gag was also included 
(rightmost lane). Note that in some cases, besides bands corresponding to full-length proteins, slower migrating, 
lower intensity bands were detected. We attributed those extra bands to incomplete denaturation of proteins 
before SDS-PAGE. 
 
4.1.6.1.3 Incubation of candidate proteins with HML-2 Pro and verification of protein 
cleavage 
In vitro transcribed/translated, radioactively or HA-labeled candidate proteins were incubated with 
purified HML-2 Pro to confirm processing by HML-2 Pro in vitro. For each candidate protein, 1 µl of 
the TNT T7 in vitro reaction was incubated with 400 nM purified HML-2 Pro. Two control reactions 
were included for each candidate protein tested: a reaction without HML-2 Pro and a reaction with 
HML-2 Pro enzymatic activity inhibited by presence of 400 µM pepstatin A. The buffer composition 
was the same as for the TAILS reactions, specifically 1 M NaCl and 0.1 M PIPES, pH 5.5. Reactions 
were incubated for 180 min at 37°C in a final volume of 16 µl, then the entire reaction volume was 
each loaded onto a PAA-gel (10% or 12% polyacrylamide) and subjected to SDS-PAGE. Protein 
detection was by phosphorimaging of dried gels for radiolabeled target proteins or Western blot for 
“cold” target proteins. 
 
For our verification experiments, evidence of processing of candidate proteins by HML-2 Pro included 
(1) a more or less reduced amount of full-length candidate protein compared to amounts of full-length 
protein in control reactions without HML-2 Pro and with HML-2 Pro plus pepstatin A; (2) one or 
several additional protein bands of size(s) smaller than full-length protein in the reaction with HML-2 
Pro compared to control reactions without HML-2 Pro or inhibited HML-2 Pro activity; (3) such 
additional protein bands also being present in the reaction with HML-2 Pro plus pepstatin A, yet at 
(much) lower amounts compared to the reaction with HML-2 Pro. Various combinations of those 
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criteria were observed in our verification experiments. For 8 candidate proteins, specifically C15orf57, 
CIAPIN1, HSP90AA1, HSP90AB1, MAP2K2, RANBP1, RNASEH2 and TUBA1A, we observed 
processing of candidate proteins along with generation of one or more cleavage products not visible in 
control reactions (Figure 34). For those candidate proteins we also observed a more or less pronounced 
reduction of full-length protein in presence of HML-2 Pro. In some cases (for instance HSP90AA1 and 
C15orf57), cleavage products were detectable also in the control reaction with HML-2 Pro plus 
pepstatin A, yet at much lower amounts compared to the reaction with HML-2 Pro. The same 
phenomenon was visible in reactions with HML-2 Gag, a specific substrate of HML-2 Pro. Such a 
phenomenon could result from higher specificity of HML-2 Pro for those substrates, thus it would be 
impossible to completely avoid such cleavages with the amount of pepstatin A included in controls. 
For PDIA3, evidence of cleavage was supported only by reduction of the full-length protein without 
appearance of detectable cleavage products. For DDX3X, the in vitro verification produced 
inconclusive results as no reduction of the amount of full-length protein was seen via the 35S-label, 
although a lower molecular weight protein band of approximately 60 kDa increased in intensity in 
presence of HML-2 Pro. In contrast, when detecting the HA-tag, a slight reduction of full-length 
DDX3X protein was visible, yet without appearance of cleavage products. No evidence of processing 
by HML-2 Pro was obtained for CALR, ENO1, PSMC4 and S100A, for which no reduction of full-
length protein or appearance of additional bands was observed. 
 
Analysis of cleavage products generated by HML-2 Pro in combination with in silico analysis could 
provide indications about cleavage positions within the candidate protein of interest. The software 
Geneious provided functions necessary for this purpose. The precise amino acid sequence of a specific 
protein could be analyzed and the expected size in kDa for each desired portion of the protein could be 
predicted. Thus, using Geneious, we evaluated in which position of a candidate protein a cleavage 
might have generated fragments with a size also observed in in vitro verifications. For cleavage 
products detected via HA-tag, the C-terminus of the fragment was evident (visualized by detection of 
the HA-tag), thus the size of those products could provide unambiguous information concerning 
cleavage positions. On the contrary, for fragments detected via the 35S-label the fragment termini were 
not known, thus the size of fragments provided rather ambiguous information for predicting cleavage 
positions. In order to reduce ambiguities, considering that TAILS experiments had provided 
information on actual cleavage site positions in candidate proteins, we evaluated similarities between 
data from the TAILS experiments at pH 5.5 and results from in vitro verifications (Figure 34 B). 
As for C15orf57, the three cleavage sites identified by TAILS could effectively match with the 
products observed via the 35S-label (Figure 34 B). A cleavage product of ~20 kDa detected via the 35S-
label was confirmed by HA-tag detection. It should be noted that, as indicated by TAILS results, for 
several candidate proteins cleavages occured in the proximity of the C-terminus, thus close to the HA-
tag. Cleavages in those positions eventually produced 1) C-terminal HA-fragments of small size that, 
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for technical limitations, could not be detected; 2) N-terminal fragments that could be detected only 
via the 35S-label. Two cases that likely represent such a situation are CIAPIN1 and RANBP1, whose 
N-terminal fragments after cleavage were visible via 35S-label detection, while no cleavage product 
was visible by HA-tag detection. However, for both candidates, observed cleavage products matched 
with the cleavage sites identified by TAILS. As for MAP2K2, the cleavage product of ~40 kDa 
observed via 35S-label and HA-tag, matched clearly with the unique cleavage site identified by TAILS. 
For TUBA1A the only cleavage product of ~50 kDa observed by HA-tag could correspond to one of 
the two cleavage sites identified by TAILS in the N-terminal part of the protein and replicated in pH 
5.5 TAILS experiments. For RNASEH2B a cleavage product of ~28 kDa was observed by 35S-label. 
Such cleavage product did not perfectly match with the cleavage product identified in both pH 5.5 
TAILS experiments and predicted as a ~22 kDa peptide. The ~6 kDa discrepancy between expected 
and observed could be due to specific (structural or chemical) properties of that specific peptide, likely 
affecting migration during electrophoresis. In two cases, HSP90AA1 and HSP90AB1, processing 
products observed via the 35S-label were difficult to assign due to too many cleavage sites reported by 
TAILS, although the only cleavage product observed via HA-tag matched with cleavage sites identified 
by TAILS.  
 
Taken together, our in vitro verification experiments confirmed processing by HML-2 Pro for 9 out of 
14 candidate proteins. Moreover, analysis of cleavage products generated by HML-2 Pro provided 
insight into cleavage site positions. For 6 of the candidate proteins, molecular weights of additional 
protein bands detected in vitro appeared to match sizes of processing products predicted by cleavage 





Figure 34: Verification of cleavage of candidate proteins by HML-2 Pro in vitro. A) Selected Western blot 
and phoshporimaging results from incubation of candidate proteins with HML-2 Pro. Each candidate protein was 
incubated for 180 min and with three different reactions: one without protease (“C”), one with protease (“+”), 
and one with protease plus pepstatin A (“+/P”). Reactions were subjected to SDS-PAGE in 10% or 12% 
polyacrylamide gels and further processed for subsequent phosphorimager analysis or HA-tag-specific Western 
blots depending on the protein label ("35S" or "HA"). Full-length candidate proteins are indicated by an arrow, 
while arrowheads indicate additional protein bands ascribed to HML-2 Pro activity. Processing of Gag by HML-
2 Pro was included as a control (blue frame). Results for candidate proteins with evidence of specific cleavage 
by HML-2 Pro are in a green frame. Results for candidate proteins with no evidence of specific cleavage by 
HML-2 Pro are in a red frame. Experiments with uncertain evidence of cleavage by HML-2 Pro (see text) are in 
an orange frame. For PDIA3 no lower-sized processing products could be observed, although specific cleavage 
by HML-2 Pro was supported by reduction of the amount of full-length protein. Note that C15orf57 migrated 
slower in gel electrophoresis than predicted by molecular mass. B) Depiction of candidate proteins that were 
confirmed to be processed by HML-2 Pro. Each protein is depicted as a line with number of amino acids and 
molecular mass indicated by scales on the top. Indicated for each protein are positions of methionines (“M”) and 
cleavage sites (grey and black arrowheads), the latter as identified by TAILS experiments at pH 5.5. Dashed lines 
indicate processing products observed experimentally for candidate proteins either labeled by 35S-methionine 
("35S") or HA-tag ("HA"). Note that the latter protein label will only detect C-terminal processing products. For 
the two HSP90 proteins, cleavage products observed via 35S-label were difficult to assign because of too many 
cleavage sites identified by TAILS.  
 
4.1.6.2 Verification experiments in vivo 
The in vitro verification experiments had confirmed the ability of HML-2 Pro to cleave several of the 
human proteins tested. We next were interested in whether such a proteolytic activity of HML-2 Pro 
could also be observed in vivo. To do so, five different HA-tagged human candidate proteins that we 
had confirmed to be substrates of HML-2 Pro in vitro were co-expressed together with HML-2 Pro in 
HEK293T cells. Processing of candidate proteins was then monitored by Western blot through 
detection of the HA-tag. 
The five selected HA-tagged candidate proteins were as follows: four candidate proteins (C15orf57-
HA, HSP90AA1-HA, MAP2K2-HA, TUBA1A-HA) that had produced processing products detectable 
via the HA-tag in in vitro experiments; one candidate protein (CIAPIN1A-HA) that had produced a 
processing product that was detectable only via the 35S-label in in vitro experiments (see above). 
 
Of note, the HML-2 Pro precursor expressed in mammalian cells was slightly different from the HML-
2 Pro precursor expressed in bacteria for Pro purification (compare Figure 7 and Figure 8). In 
particular, the Pro ORF subregion cloned into constructs for expression in mammalian cells included 
1) 33 bp upstream of the Pro core domain, thus a shorter N-terminal region in comparison with Pro 
constructs for Pro purification; 2) the region downstream of the Pro core domain up to the end of the 
Pro ORF, with that region not included in Pro constructs for Pro purification. The known Pro self-
cleavage site in the N-terminus was still present. Since the complete C-terminal portion of the Pro ORF 
was included, the Pro self-cleavage site in the C-terminus was also present, although its position was 
not precisely known, since it has not been mapped so far. 
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For verifications in vivo, HEK293T cells were seeded at a density of 2 x 105 cells per well in 12-well 
plates. Cells were transfected the following day. We employed two transfection set-ups. In a first set-
up, cells were co-transfected with pcDNA3 plasmid producing an HA-tagged candidate protein and a 
phCMV plasmid producing either wild type (Pro-wt) or mutant (Pro-mut) HML-2 Pro. As a control, 
cells were co-transfected with plasmid producing the candidate protein and an empty phCMV vector. 
In a second set-up, cells were co-transfected with pcDNA3 plasmid producing an HA-tagged candidate 
protein and a pEGFP-Pro plasmid producing either wild type (EGFP-Pro) or mutant (EGFP-Pro-mut) 
HML-2 Pro, each fused in frame to an EGFP ORF at the N-terminus. As a control, cells were co-
transfected with plasmid encoding a candidate protein and a pEGFP plasmid, producing sole EGFP. 
Transfection set-ups for verifications of processing of candidate proteins by HML-2 Pro in vivo were 
as follows: 
 
Set-up 1  
Pro-wt + candidate: 0.5 µg phCMV-Pro + 0.5 µg pcDNA3-candidate protein 
Pro-mut + candidate: 0.5 µg phCMV-Pro mut + 0.5 µg pcDNA3-candidate protein 
Control: 0.5 µg phCMV + 0.5 µg pcDNA3-candidate protein 
Set-up 2  
EGFP-Pro + candidate protein: 0.5 µg pEGFP-Pro + 0.5 µg pcDNA3-candidate protein 
EGFP-Pro-mut + candidate protein: 0.5 µg pEGFP-Pro-mut + 0.5 µg pcDNA3-candidate protein 
Control: 0.5 µg pEGFP + 0.5 µg pcDNA3-candidate protein 
 
Cells were harvested 24 hpt and lysed in RIPA Buffer enriched with a protease inhibitor cocktail. Since 
the cocktail of protease inhibitors employed did not include aspartyl protease inhibitors, pepstatin A 
was supplemented to the lysis buffer at a final concentration of 1 µg/µl. Cell lysates were subjected to 
reducing SDS-PAGE. 15 µg total protein per gel lane were loaded onto PAA-gels (10% or 12% 
polyacrylamide). Proteins of interest were detected by Western blot. HA-tagged candidate protein was 
detected using an a-HA antibody. Expression of HML-2 Pro and EGFP-Pro was monitored using either 
a polyclonal a-HML-2 Pro antibody 9367 [185] or an a-GFP antibody.  
 
Criteria that we applied for verification of candidates were as for the verification experiments in vitro 
(see above). For all blots, staining of proteins by Coomassie was used as a loading control, confirming 
no significant difference of total protein loaded among samples. 
Results of verification experiments in vivo can be summarized as follows. When expressing Pro and 
Pro-mut, HML-2 Pro could be detected as ~18 kDa and ~19 kDa protein bands representing self-
processed Pro and unprocessed Pro, respectively (Figure 35 Aa, bottom blot). When HML-2 Pro was 
expressed as EGFP-Pro or EGFP-Pro-mut fusion protein, proteins of ~30 kDa and ~47 kDa, 
representing processed and unprocessed EGFP(-Pro), respectively, could be detected with an α-GFP 
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antibody (Figure 35 Ab, middle blot). The 30 kDa processed EGFP included a short N-terminal 
flanking region of Pro (see Figure 8). Self-processed Pro and unprocessed EGFP-Pro(-mut) of ~18 kDa 
and ~50 kDa, respectively, could be detected when using an α-HML-2 Pro antibody (Figure 35 Ab, 
bottom blot; Ac). 
The verification experiments provided evidence of processing of candidate proteins by HML-2 Pro in 
vivo. For HSP90AA1, a slight reduction of full-length protein and the appearance of an additional 
fragment of approximately 65 kDa was observed only when co-expressing wild-type HML-2 Pro. 
Interestingly, the size of the processing product generated in vivo corresponded with the one observed 
in vitro (Figure 35 A, compare proteins labeled with arrowheads in panel Aa and Ab with that in Ad). 
For C15orf57-HA, the amount of full-length protein was reduced to below detection limits in presence 
of active HML-2 Pro and a cleavage product of ~20 kDa was generated, that furthermore coincided in 
size with the one observed in vitro. For MAP2K2-HA, there was a discernible reduction of full-length 
protein in presence of active HML-2 Pro and appearance of a ~40 kDa processing product. A 
processing product of the same size was also observed in the in vitro verification experiment. For 
CIAPIN1-HA, there was evidence of processing by HML-2 Pro in vivo from a considerable reduction 
of full-length protein, as already observed in vitro through HA-tag detection. Also, for TUBA1A-HA, 
reduction of full-length protein was considerable but the cleavage product observed in vitro could not 
be deteced in vivo, possibly due to reduced stability of that product in vivo (compare Figure 35 A and 
B). 
Taken together, we obtained experimental evidence of self-processing of active HML-2 Pro and 
processing of candidate proteins by HML-2 Pro in vivo. Evidence for the latter came from more or less 
pronounced reduction of the amount of full-length candidate proteins and, for three candidate proteins, 
also from processing products of lower molecular weight. Observed processing products were 
furthermore similar in size to processing products detected in vitro.  
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Figure 35: Experimental verification of cleavage of candidate proteins by HML-2 Pro in vivo. Five different 
candidate proteins were co-expressed together with HML-2 Pro in HEK293T cells and subsequently detected by 
Western blot in order to monitor their processing in vivo. For each blot, the left-most lane was a control co-
transfected with plasmid encoding candidate protein and either a GFP-encoding plasmid or empty phCMV. 
Loaded onto middle and right-most lanes were candidate proteins co-expressed with wild-type Pro (Pro) or 
mutant Pro (Pro-mut), respectively. Pro was expressed as either sole Pro or EGFP-fused Pro. Full-length 
candidate proteins are indicated by arrows. Arrowheads indicate clearly discernible cleavage products. Blots 
were probed with α-HA, α-GFP, or α-Pro as indicated. A) Representative results from experiments co-expressing 
HSP90AA1 with either HML-2 Pro (Aa) or EGFP-Pro (Ab and Ac). Relevant blot regions are shown. Note the 
slight reduction of amounts of full-length HSP90AA1 and formation of a processing product corresponding to 
the product observed in vitro. For the sake of convenience, a blot from in vitro verification (already depicted in 
Figure 34 A) is shown (Ad). B) Selected Western blot results from co-expression of candidate proteins and HML-
2 Pro. Note the reduction of amounts of full-length candidate protein, and sometimes processing products, in 
lanes with co-expressed HML-2 Pro. For experiments shown in both A and B, blotted membranes were stained 
with Coomassie after the ECL step to document same amounts of protein loaded onto gel lanes. 
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4.1.6.3 Additional cellular proteins verified as substrates of HML-2 Pro 
During our project, we established a collaboration with Dr. John Goodier (McKusick-Nathans Institute 
of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA). An 
additional set of potential substrates of HML-2 Pro was subjected to verification experiments in vivo 
in the laboratory of Dr. Goodier. Additional tested proteins were of functional interest and readily 
available in that laboratory as cloned cDNAs. Of note, tested proteins were labelled with tags other 
than HA-tag. In particular, proteins tagged with FLAG, Myc, T7 or HA tag were included. 
The additional tested proteins had been identified in our TAILS analysis with replicated evidence of 
processing by HML-2 Pro and at least 2-fold enrichment. Although, most of those proteins were not 
included in the list of 145 proteins filtered on the basis of favorable amino acids (for cleavage by HML-
2 Pro) in P1 and P1´ (see chapter 4.1.6.1.1). This indicated that those additional verification 
experiments could also provide crucial information on cleavage of candidate proteins in vivo with no 
favorable amino acids in P1 and P1´ positions of cleavage sites as identified by TAILS.  
As in our set-up for verification experiments, each protein was co-expressed with HML-2 Pro (or the 
respective mutant) in HEK293T cells. Different from our set-up, during expression of recombinant 
proteins, cells were treated approximately 18 hpt with proteasome inhibitor MG132 (Millipore-Sigma), 
then incubated for another 4–5 h before cell lysis. MG132 was included with the intent of reducing 
instability of potential cleavage products, thus facilitating validation of additional HML-2 Pro 
substrates by detecting cleavage products. Processing of proteins was monitored by SDS-PAGE and 
Western blot. Proteins were detected via the specific tag present in each protein. 
Results produced in the laboratory of Dr. Goodier provided evidence of processing of 16 additional 
cellular proteins by HML-2 Pro in vivo (see Table 22 and [164]). Fourteen of those proteins had no 
favorable amino acids in P1 and P1´ positions of cleavage sites as identified by TAILS. Selected 
examples of relevant proteins are reported in the following. Among the 16 validated substrates were 
ribonuclease H2 (RNASEH2) subunit A and subunit B (RNASEH2A and RNASEH2B) that are two 
out of the three subunits that comprise the functional RNASEH2 protein. Notably, the processing of 
RNASEH2B by HML-2 Pro had been verified already by us in vitro. The list further included: 
endoplasmic reticulum chaperone BiP (HSPA5) and heat shock protein beta-1 (HSPB1), members of 
the family of the heat shock proteins [40], which also includes HSP90AB1 and HSP90AA1, the latter 
verified by us in vitro and in vivo; STIP1 homology and U-Box containing protein 1 (STUB1), that 
targets misfolded chaperone substrates towards proteasomal degradation; eukaryotic translation 
initiation factors 4 gamma 1 (EIF4GI) and 4B (EIF4B), two members of the eIF4 translation initiation 
factor family; transcription intermediary factor 1-beta (TRIM28), that mediates transcriptional control. 
 
For all 16 validated candidates, a significant reduction of full-length protein was observed in presence 
of active HML-2 Pro. In some cases, cleavage products could also be visualized.  
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A supplementary experiment was performed in the laboratory of Dr. Goodier in order to document 
processing of constitutively expressed HSP90 protein by HML-2 Pro. Specifically, HSP90 was 
monitored via specific α-HSP90 antibody in cells expressing recombinant HML-2 Pro. Cleavage of 
endogenous HSP90 by HML-2 Pro was confirmed by generation of two cleavage products, one of 
which showed a size similar to that of a cleavage product detected in our experiments testing 
HSP90AA1 and HSP90AB1. 
 
Overall, results of experiments performed in the laboratory of Dr. Goodier significantly expanded the 
number of cellular substrates of HML-2 Pro verified in the cellular context. The analysis also provided 
evidence of processing by HML-2 Pro of candidate proteins having no favorable amino acids in P1 
and P1´ positions of cleavage sites as identified by TAILS. The additional findings corroborated our 
TAILS results and provided further support to our in vivo verifications. Small variations between our 
experimental set up and the one of Dr. Goodier, for instance, monitoring of protein cleavage using 
various protein tags, further corroborated reliability of our observations in vivo. 
 
4.1.7 Initial investigation into the potential involvement of HML-2 Pro in cell death  
When expressing active HML-2 Pro cells in cell culture, we noticed that approximately 24 hpt an 
unusually high number of detached rounded cells were floating in the medium. Controls without HML-
2 Pro or with inactive HML-2 Pro did not produce such a phenotype. This suggested a cytotoxic effect 
of HML-2 Pro, as already observed for other retroviral proteases, e.g., HIV-1 Pro [18]. To further 
address this phenomenon, we performed a number of experiments to gain further insight into a potential 
involvement of HML-2 Pro in cell death. 
 
4.1.7.1 Analysis of cell morphology during transient expression of HML-2 
In one preliminary experiment investigating HML-2 Pro cytotoxicity, we used fluorescence 
microscopy for direct observation of Pro-expressing cells identified by staining with an α-HML-2 Pro 
antibody 9367 [185]. HeLa cells were used in this experiment because they were found more suitable 
than HEK293 because of much stronger adhesion to the cell culture chamber employed for this 
procedure. HeLa cells were seeded in an 8-well cell culture chamber suited for immunofluorescence 
staining. After 24 h, cells were transfected with phCMV-Pro and phCMV-Pro mut plasmids for 
expression of wild-type or mutant HML-2 Pro, respectively. Cells were fixed 24 hpt and 
immunostained with an α-HML-2 Pro polyclonal antibody 9367 [185]. Cells were mounted in presence 
of DAPI, which stains cell nuclei, followed by fluorescence microscopy (Figure 36). 
Among cells transfected with expression plasmid encoding wild-type Pro, some cells displayed an 
altered rounded morphology with a condensed nucleus, implying cell death potentially due to 
apoptosis. Immunostaining confirmed that cells with altered morphology harbored HML-2 Pro (Figure 
 113 
36), although not all Pro-expressing cells displayed the particular morphology. Cell morphology and 
viability appeared normal when expressing mutant HML-2 Pro, thus further suggesting that cell death 
was associated with HML-2 Pro activity. 
 
Figure 36: Altered cell morphology following expression of HML-2 Pro in HeLa cells. HeLa cells were 
transfected with plasmids expressing either enzymatically active (Pro-wt) or inactive (Pro-mut) HML-2 Pro. 
Cells were fixed 24 hpt and immunostained with an α-HML-2 Pro polyclonal antibody n. 9367 [185]. Cells were 
mounted in presence of DAPI. Cell nuclei (blue) and HML-2 Pro (red) were visualized by fluorescence 
microscopy. 
 
4.1.7.2 Analysis of apoptosis markers during transient expression of HML-2 Pro 
We further investigated whether cell death caused by HML-2 Pro involved apoptosis, a type of 
programmed cell death that can be triggered by different stimuli. In rather different ways, apoptosis 
initiating events lead up to activation of so-called caspases (cysteine aspartases), members of a family 
of proteases that carry out the process of cell death in a controlled manner through an irreversible 
cascade of proteolytic cleavages. In order to be activated, caspases need to be released through 
proteolytic cleavage of inactive precursors called procaspases. Some procaspases are designated as 
initiator procaspases because they are activated at the beginning of the proteolytic cascade. So-called 
executioner procaspases are activated in an advanced stage of the apoptotic process. Once activated, 
all caspases target several hundred proteins for proteolysis [202]. Poly [ADP-ribose] polymerase 1 
(PARP), a DNA single strand repair enzyme, is a known substrate of caspases [23]. PARP cleavage, 
as well as the cleavage of procaspases to produce active caspases, provide evidence of apoptosis 
activation. Therefore, PARP and (pro)caspases are commonly used as apoptosis markers (for instance 
see [125]). 
In our experiments, HeLa cells were transfected with phCMV-Pro plasmid to express wild-type HML-
2 Pro. As negative controls, transfections with empty phCMV plasmid and plasmid expressing mutant, 
enzymatically inactive HML-2 Pro were performed. Moreover, as a positive control for apoptosis 
activation, HeLa cells were treated for 6 h with staurosporine, a strong inducer of apoptosis [12]. A 
sample with untreated cells was also included. Apoptosis biomarkers (pro)caspase 3 and PARP were 
monitored by Western blot at 6 and 24 h post transfection to evaluate apoptosis activation. Procaspase 
3 is one of the executioner procaspases that during apoptosis is proteolytically cleaved releasing active 
caspase 3. Both procaspase 3 and caspase 3 were detected using a caspase 3 monoclonal antibody. 
PARP was monitored using a monoclonal antibody for specific detection of the 89 kDa PARP fragment 
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(referred as cleaved PARP) that is generated from the full-length PARP by active caspases [202]. 
Antibodies were provided as a cocktail that included also an α-muscle actin rabbit antibody as a loading 
control for normalization purposes. 
As for Western blot results, induction of apoptosis could be inferred from increase of cleaved PARP, 
decrease of procaspase 3 and increase of caspase 3, the three events being clearly visible in samples 
treated with staurosporine (Figure 37) that strongly activated apoptosis of the entire cell population. 
No apoptosis was induced in untreated cells. Concerning cells expressing HML-2 Pro, levels of cleaved 
PARP, procaspase 3, and caspase 3 were not significantly different at 6 hpt when comparing cells 
expressing wild-type HML-2 Pro with negative controls, thus indicating that during the 6 h following 
transfection, apoptosis was not specifically induced by active HML-2 Pro, probably due to low level 
of HML-2 Pro at that time point. However, at 24 hpt, the level of cleaved PARP and caspase 3 in cells 
expressing wild-type HML-2 Pro was ~2-fold higher than that of negative controls, thus providing 
evidence of activation of apoptosis due to HML-2 Pro activity. As expected, in the presence of active 
HML-2 Pro, the increase in caspase 3 was also accompanied by a decrease in procaspase 3. Taken 
together, apoptosis marker proteins indicated that HML-2 Pro activity could activate apoptotic 
processes. 
 
Figure 37: Activation of apoptosis marker proteins in HeLa cells expressing HML-2 Pro. HeLa cells were 
transfected with plasmid encoding either HML-2 Pro (Pro-wt) or an enzymatically inactive mutant HML-2 Pro 
(Pro-mut), or empty plasmid (phCMV). Cells were harvested and lysed 6 and 24 hpt. As a positive control for 
apoptosis, cells were treated for 6 h with 1 µM or 5 µM staurosporine. A) Cleaved PARP, procaspase 3, cleaved 
caspase 3, and actin, were detected by Western blot using specific monoclonal antibodies in an antibody cocktail. 
B) Bar chart depicting, for all samples, normalized intensities of proteins bands corresponding to cleaved PARP 
at 6 and 24 hpt. C) Bar chart comparing normalized intensities of protein bands corresponding to cleaved PARP, 
procaspase 3 and cleaved caspase 3 for samples at 24 hpt. Note that the amount of cleaved PARP and caspase 3 
increases while the amount of procaspase 3 decreases when expressing wild-type HML-2 Pro. For relative 
quantification, band intensities of proteins of interest were normalized by actin signal intensities. 
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4.1.7.3 Monitoring of timing and intensity of HML-2 Pro cytotoxic effect using FACS 
To further characterize a cytotoxic effect of transiently expressed HML-2 Pro, we evaluated in more 
detail timing and intensity of such an effect using Fluorescence-Activated Cell Sorting (FACS). For 
this analysis, we employed plasmids expressing EGFP-fused Pro (EGFP-Pro) and the respective 
mutant (EGFP-Pro-mut). The same plasmid constructs were employed for verifications of cleavage of 
candidate proteins in vivo (see chapter 4.1.6.2), where it was shown that enzymatically active HML-2 
Pro, fused in-frame with EGFP, could self-process with similar efficiency as "sole" Pro. Self-
processing of EGFP-Pro released self-processed HML-2 Pro and EGFP (see Figure 35 Ab), the latter 
including a short C-terminal protein portion of the Pro ORF upstream of the N-terminal self-processing 
site (see Figure 8). As a consequence, and important for interpretation of experiments, EGFP-positive 
cells also contained free, enzymatically active HML-2 Pro. 
We firsty evaluated by fluorescence microscopy the impact of EGFP-Pro expression on cell viability. 
To do so, HEK293T cells were seeded in a 12-well plate and transfected with plasmid constructs for 
expression of EGFP-Pro, with or without 1 µM indinavir, a known strong inhibitor of HIV-1 Pro. As 
a control, cells were transfected with EGFP-Pro-mut. EGFP-positive cells were examined under the 
fluorescence microscope 30 hpt (Figure 38). Cell viability was altered when EGFP-Pro was expressed 
in cells. Seemingly dead cells of a rounded morphology, in part detached and floating in the medium 
were observed. The majority of those cells appeared EGFP-positive, although not all green, thus Pro-
expressing cells appeared to have undergone cell death until 30 hpt. Cell death appared considerably 
reduced when EGFP-Pro was expressed in presence of 1 µM indinavir, that hampered Pro activity. 
Cell viability appeared unaffected when expressing EGFP-Pro-mut, that is proteolytically inactive. 
Overall, the experiment provided evidence of a cytotoxic effect induced by active HML-2 Pro. Even 
with a set-up involving EGFP-Pro, the effect of HML-2 Pro on cell viability and cell phenotype was 




Figure 38: Microscopy images documenting cytotoxic effects following expression of EGFP-Pro in 
HEK293T cells. HEK293T cells were transfected with plasmid constructs for expression of EGFP-fused HML-
2 Pro (EGFP-Pro) or respective inactive mutant (EGFP-Pro-mut). EGFP-Pro was also expressed in presence of 
1 µM indinavir, a known inhibitor of HIV-1 Pro. EGFP-positive cells were examined under the fluorescence 
microscope 30 hpt. Note the less dense cell layer when expressing EGFP-Pro. 
 
We next monitored at different time points, using FACS, the percentage of dead cells in a population 
of cells transiently expressing HML-2 Pro. We transfected HEK293T cells with plasmids expressing 
either EGFP, EGFP-Pro, or EGFP-Pro-mut. Cells were harvested 5, 10, 24, 30, and 48 hpt, fixed at 
each time point and subsequently analyzed by FACS. A control with transfection reagent only, but no 
plasmid DNA, was also included. 
Employing forward and side scatter density plots (FSC-A/SSC-A), we gated the main population of 
cells, within size and granularity ranges for live HEK293T cells (Figure 39 A). Cells with FSC-A 
and/or SSC-A values above the range of values of the main population probably represented single 
events consisting of 2 or more independent cells (likely not properly detached). Such events were 
excluded from the analysis. The population of cells with FSC-A values below the range of values of 
the main population represented dead cells. That cell population was gated and quantified relative to 
the total number of cells counted. The percentage of EGFP-positive cells in the population of live and 
dead cells was also determined (Figure 39 B). 
 
FACS results showed that at 24, 30, and 48 hpt, dead cells (P1 population) gradually accumulated in 
EGFP-Pro samples, representing approximately 6%, 12% and 15%, respectively, of the total cell count 
(Figure 40 A). At 5 h and 10 h, no significant difference in numbers of dead cells was observed when 
comparing samples. This indicated that in samples transfected with EGFP-Pro, but not in samples with 
EGFP-Pro mut or EGFP-only, cells began to die between 10 and 24 h following transfection. The 
majority of dead cells were EGFP-positive (Figure 40 B), further corroborating the association between 
HML-2 Pro and cell death. 
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During the course of the experiment many cells expressing active HML-2 Pro remained alive, as 
evidenced by the relative numbers of green live cells (Figure 40 C). The percentage of EGFP-positive 
(thus Pro-positive) living cells reached a plateau around 24 hpt. Those cells represented approximately 
50% of the main cell population. Probably as a consequence of cell death affecting a portion of the cell 
population, the percentage of HML-2 Pro-positive living cells started to decline around 48 hpt, contrary 
to cells expressing EGFP-Pro-mut, for which number of EGFP-positive cells was still increasing until 
the last time point (Figure 40 C). 
 
Figure 39: Representative FACS results of cells expressing EGFP-Pro. HEK293T cells were transfected with 
plasmids expressing either EGFP, EGFP-Pro, or EGFP-Pro-mut. A control sample treated with transfection 
reagent in absence of plasmid DNA (Mock) was included. Cells were fixed 30 hpt and subjected to FACS 
analysis. A) Forward scatter area (FSC-A) vs side scatter area (SSC-A) plots gating mock-transfected cells as a 
reference for live HEK293T cells. The population of smaller sized dead cells (P1) was gated to examine the effect 
of HML-2 Pro on cell viability. B) EGFP fluorescence vs side scatter plots gating EGFP-positive cells (P2) for 
the P1 population. The fluorescence of cells in a mock sample was used as reference for gating EGFP-negative 
cells, indicated by blue dots. EGFP-positive cells, indicated by green dots, present variable levels of EGFP. The 
number of EGFP-positive cells detected in the P1 population from EGFP-Pro sample is much higher than the 
number of EGFP-positive cells detected in the P1 population from EGFP and EGFP-Pro-mut samples, thus 




Figure 40: Monitoring cell viability during expression of HML-2 Pro. HEK293T cells were transiently 
transfected with plasmids expressing EGFP, EGFP-Pro-wt, or EGFP-Pro-mut. A mock transfection with 
transfection reagent only was also included. Cells were fixed after the indicated time periods and analyzed by 
FACS. Means and standard deviations from two experiments are given. Between 9000 and 150,000 cells were 
gated. A) Quantification of dead cells (P1 population, see also Figure 37 A) expressed as percentage of the total 
number of cells analyzed in each sample. B) Percentage of EGFP-positive, thus HML-2 Pro expressing cells, in 
the P1 population. Note that percentages can be misleading, e.g., white bars in EGFP-Pro-mut, when not taking 
into account relatively small cell numbers in respective P1 populations. C) Quantification of EGFP-positive live 
cells expressed as percentage of the total number of cells analyzed in each sample. On the right, an alternative 
depiction of cell numbers of EGFP-positive cells for cells expressing EGFP-Pro or EGFP-Pro-mut is shown for 
the sake of a better comparison of cell viabilities. 
 
4.1.8 Processing of candidate proteins tested in vivo was not due to caspase activity 
As demonstrated above, expression of HML-2 Pro can trigger cell death going along with activation 
of apoptotic processes. Therefore, we wondered whether the cleavage of candidate proteins by HML-
2 Pro in vivo was due to activation of caspases following apoptosis induction, that would then process 
respective candidate proteins. To address this issue, processing of candidate proteins was monitored in 
cells driven into apoptosis and compared with processing in presence of HML-2 Pro. Since detection 
of specific cleavage products would be helpful for discerning HML-2 Pro activity from apoptotic 
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activities, we tested candidate proteins that had generated stable cleavage products during verification 
experiments in vivo, specifically HSPA90AA1, MAP2K2, and C15orf57 (see chapter 4.1.6.2). 
 
The particular candidate proteins were expressed in HEK293T cells under six different conditions: 1) 
co-expression with EGFP; 2) co-expression with EGFP and addition of 2 µM staurosporine at 20 hpt; 
3) co-expression with EGFP, addition of pan-caspase inhibitor Q-VD at 18 hpt and addition of 2 µM 
staurosporine at 20 hpt; 4) co-expression with EGFP-Pro; 5) co-expression with EGFP-Pro and 
addition of pan-caspase inhibitor Q-VD  at 18 hpt; 6) co-expression with EGFP-Pro-mut. Staurosporine 
induced strong activation of apoptosis, thus activation of caspases. Q-VD was included at a 
concentration of 25 µM to block caspase activity. Cells were harvested 25 hpt and lysed. Cell lysates 
(15 µg total protein per lane) were subjected to reducing SDS-PAGE followed by Western blot and 
detection of HA-tagged candidate proteins. 
 
When examining Western blot results, no significant reduction of full-length protein as well as no 
cleavage products could be observed for the three candidate proteins in presence of 2 µM staurosporine 
(with or without caspase inhibitor) (Figure 41). On the contrary, a reduction of full-length candidate 
proteins as well as appearance of cleavage products, could be observed in presence of active HML-2 
Pro. Cleavage products in presence of HML-2 Pro were of sizes as expected from previous experiments 
in vitro and in vivo (see chapters 4.1.6.1 and 4.1.6.2). Also, the amount of cleavage products was not 
reduced in the presence of Q-VD. 
Taken together, our observations confirmed that processing of candidate proteins was not due to 
caspase activity since no significant reduction of full-length proteins or detection of stable cleavage 
products were documented after activation of caspases. Also, processing products observed when co-
expressing HML-2 Pro likely were not due to caspase but due to HML-2 Pro activity, as indicated by 
the specific size of cleavage products and by the fact that broadly inhibiting activity of caspases with 




Figure 41: Rebuttal of processed protein products due to caspase activity. HEK293T cells were seeded in 
12-well plates and transfected with plasmids encoding candidate protein HSP90AA1-HA, MAP2K2-HA, or 
C15orf57-HA. Cells were co-transfected with plasmids encoding EGFP, EGFP-fused Pro (EGFP-Pro) or EGFP-
fused Pro inactive mutant (EGFP-Pro-mut). 18 hpt, selected wells were supplemented with pan-caspase inhibitor 
Q-VD (final concentration 25 µM) and/or staurosporine (final concentration 2 µM), the latter added 2 h after Q-
VD addition. Cells were harvested and lysed 25 hpt, thus 5 h after addition of staurosporine. Samples were 
subjected to SDS-PAGE and Western blot detecting the HA-tag. Note that cleavage products of candidate 
proteins were observed only in samples with active HML-2 Pro (see text). Blot membranes subsequently stained 
with Coomassie are shown at the bottom. 
 
4.1.9 Preliminary data providing evidence of endogenous HML-2 Pro activity in tumor-
derived cell lines 
In the experiments performed in cell culture, expression of HML-2 Pro in cells was driven from specific 
plasmid constructs. We wanted to gain initial evidence of endogenous proteolytic activity from 
endogenous HML-2 Pro. To do so, we investigated presence of endogenous HML-2 Pro activity in cell 
lines derived from germ cell tumors (GCTs) and melanoma, two tumor tissues for which expression of 
HERV-K(HML-2) was documented previously [28,171,179]. We employed the following cell lines: 
Tera-1 and NCCIT, two cell lines derived from human teratocarcinoma [59,203]; SK-MEL-28 and 
MeWo, two cell lines derived from human melanoma [28,144]. 
 
We first examined presence of endogenous HML-2 Pro in those tumor cell lines. HEK293T cells 
transiently expressing wild-type HML-2 Pro (HEK pro-wt) were used as a positive control for presence 
of self-processed HML-2 Pro. Untransfected HEK293T and HeLa cells were included as negative 
controls. The choice of those negative controls considered results from previous investigations (not 
shown) that did not detect HML-2 Pro or Pro precursor in those cells. For our investigation, 
approximately 20 µg of total protein lysates of each cell line were subjected to SDS-PAGE and Western 
blot followed by detection of HML-2 Pro using a polyclonal α-HML-2 Pro antibody 9367 [185]. 
 
Results of Western blots were as follows. An ~18 kDa protein band detected in HEK pro-wt 
represented self-processed HML-2 Pro, as already observed in previous experiments (for instance, see 
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Figure 35). Proteins of sizes of ~14 and ~12 kDa were also detected in HEK pro-wt. The origin of 
those protein bands could not be explained with certainty although their relatively strong intensity in 
HEK pro-wt and their absence in untransfected HEK cells suggested that they might also represent 
HML-2 Pro portions (Figure 42). The Pro bands visualized in HEK pro-wt served as reference for 
evaluating expression of endogenous self-processed HML-2 Pro in the other cell lines. None of the 
abovementioned protein bands was visible in untransfected HEK293T cells. Instead, protein bands of 
~18 kDa were detected in Tera-1, MEWO and NCCIT cell lines, thus providing evidence of HML-2 
Pro expression in those cell lines. In SK-MEL-28 cells, the ~18 kDa protein band was rather faint, 
although a protein band of ~14 kDa was more pronounced (Figure 42, arrowhead). Such an ~14 kDa 
band could represent one of the smaller proteins detected in HEK pro-wt. In this case, the ~14 kDa 
band could also support expression of HML-2 Pro in SK-MEL-28 cells. In HeLa cells, a faint protein 
band of ~18 kDa was detected. This might indicate low-level expression of HML-2 Pro also in this cell 
line.  
 
Figure 42: Detection of endogenous HML-2 Pro in cell lines known to overexpress HERV-K(HML-2). Total 
protein lysates from cell lines Tera-1, SK-MEL-28, MeWo and NCCIT were subjected to SDS-PAGE and 
Western blotting followed by detection of HML-2 Pro using a polyclonal a-HML-2 Pro antibody 9367 [185]. 
Total protein lysates from cell lines HEK293T and HeLa served as negative controls. Wild-type HML-2 Pro 
transiently expressed in HEK293T cells was included as a positive control (HEK pro-wt). The ~18 kDa protein 
detected in HEK pro-wt was used as main reference (arrow) for presence of self-processed HML-2 Pro in the 
other cell lines. HML-2 Pro bands of sizes of ~14 and ~12 kDa, thus smaller than expected, were also present in 
HEK pro-wt. The origin of those protein bands could not be explained with certainty. The ~14 kDa protein 
(arrowhead) was detected also in SK-MEL-28. On the right, the same blot was subjected to a longer exposure 
time. The blot membrane was stained with Coomassie after development to document equal amounts of protein 
loaded. 
 
We next aimed at establishing a relatively straightforward assay for specific detection of proteolytic 
activity from endogenous HML-2 Pro. Our strategy involved transfection of cell lines Tera-1, SK-
MEL-28, and MeWo with a plasmid expressing EGFP-Pro-mut, a fusion protein consisting of EGFP 
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and mutant Pro. EGFP-Pro-mut harbors sites for HML-2 Pro self-processing, but it is unable to self-
process (see chapter 4.1.6.2). In contrast, EGFP-Pro-mut can be cleaved in trans by an active HML-2 
Pro. Thus, EGFP-Pro-mut represented in this context a specific HML-2 Pro substrate, the cleavage of 
which was expected only in presence of proteolytic activity of endogenous HML-2 Pro. We also 
expressed EGFP-Pro-mut in presence of retroviral protease inhibitor indinavir in order to see if 
inhibition of endogenous HML-2 Pro activity effectively reduced EGFP-Pro-mut processing. 
 
In a control experiment, wild-type HML-2 Pro (sole, not fused to EGFP) was co-expressed in 
HEK293T cells together with EGFP-Pro-mut to show processing of EGFP-Pro-mut in trans. Co-
expression in HEK293T cells was also performed in presence of indinavir at concentrations of 1 µM, 
10 µM, and 50 µM. In cell lines Tera-1, SK-MEL-28 and MeWo, EGFP-Pro-mut was expressed with 
or without 50 µM indinavir. Cells were harvested and lysed 24 hpt. Approximately 15 µg of total 
protein lysates were subjected to SDS-PAGE and Western blot followed by detection of EGFP. 
Transfection efficiency in NCCIT cells was too low for proper evaluation of results, thus results for 
NCCIT are not shown. 
 
The control experiment in HEK293T cells showed that EGFP-Pro-mut was processed in trans when 
wild-type, active HML-2 Pro was co-expressed. Processing became evident by appearance of "free" 
EGFP of ~30 kDa (Figure 43 A). The amount of "free" EGFP appeared reduced in presence of 
increasing concentrations of indinavir, although indinavir did not completely block HML-2 Pro activity 
at the highest concentration tested (Figure 43 A). Importantly, transiently expressed EGFP-Pro-mut 
was likewise processed in Tera-1, SK-MEL-28 and MeWo, likewise releasing the ~30 kDa EGFP 
portion (Figure 43 B). Moreover, for SK-MEL-28 cells the amount of such processing was visibly 
reduced in presence of indinavir. For Tera-1 and MeWo cells, reduction of processing in presence of 
indinavir was not as pronounced as in SK-MEL-28 cells. In view of these results, it is reasonable to 
conclude that endogenous HML-2 Pro activity is present in cell lines Tera-1, SK-MEL-28, and MeWo. 
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Figure 43: Evidence for presence of enzymatically active HML-2 Pro in cell lines known to overexpress 
HERV-K(HML-2). A) Control experiment showing the processing of EGFP-Pro-mut by HML-2 Pro and the 
inhibition of such activity by increasing concentrations of indinavir. HEK293T cells were co-transfected with 
pEGFP-Pro-mut, encoding an EGFP-fused mutant Pro (EGFP-Pro-mut) and either empty phCMV or phCMV-
Pro, the latter encoding wild-type HML-2 Pro. EGFP-Pro-mut is unable to self-process, thus its cleavage, with 
release of the expected 30 kDa “free” EGFP, was used as a reporter of HML-2 Pro proteolytic activity. Co-
transfection of EGFP-Pro-mut with phCMV-Pro was performed also in presence of three different concentrations 
(1 µM, 10 µM, 50 µM) of retroviral protease inhibitor indinavir. Processing of EGFP-Pro-mut was monitored by 
Western blot. B) Cell lines known to overexpress HERV-K(HML-2) were transiently transfected with pEGFP-
Pro-mut, with or without indinavir at 50 µM. Untransfected cells were included as a control. For experiments 
shown in both A and B, cells were harvested 24 hpt and lysed. Total protein lysates were subjected to SDS-PAGE 
and Western blot followed by detection of EGFP by an α-GFP antibody. Processing of full-length EGFP-Pro-
mut (arrow) generated the expected smaller-sized, "free" EGFP (arrowhead), indicating presence of proteolytic 
activity from endogenous HML-2 Pro. Blot membranes were stained with Coomassie after ECL to document 
equal amounts of protein loaded. 
 
4.2 HML-2 integrase as potential inducer of DNA damage 
The integrase (IN) of HERV-K(HML-2) is the second enzymatic protein that we considered for 
potential biological implications. Retroviral INs are multifunctional enzymes that catalyze the 
retroviral integration, a molecular process that disrupts the integrity of the host genome [120]. A non-
sequence specific endonuclease activity (nonspecific alcoholysis) has been demonstrated for HIV-1 IN 
and other retroviral INs, capable of generating DNA strand-breaks independent from the process of 
retroviral integration [151,193]. For sites of DNA damage induced by IN activity, DNA double-strand 
breaks (DSBs) could be caused [176]. DSBs contribute to genome instability which is associated with, 
for instance, tumorigenesis [210]. If not properly repaired by the cellular machinery, DSBs can also 
induce activation of programmed cell death [25]. Thus, IN activity could potentially cause detrimental 
effects in the cell. In this context, HML-2 IN has particular relevance since HML-2 expression is 
occasionally upregulated in human cells. Several HML-2 loci that potentially encode an intact IN exist 
in the human genome [25] and some of these HML-2 loci are already known to be expressed in various 
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tumor tissues [58,183]. Previous experiments in vitro confirmed that HML-2 IN is functional [105], 
thus supporting the notion that, if expressed, this enzyme could affect genome integrity through its 
enzymatic activities. 
 
We aimed at a preliminary evaluation of the impact of HML-2 IN on the genome of cultured human 
cells. The HML-2 IN employed in this investigation is derived from the HERV-K(HML-2.HOM) 
provirus [134], from which HML-2 Pro (see above) was derived as well. Experiments involving HML-
2 IN employed a specific method for quantification of DSBs by fluorescence microscopy [198]. DSB 
formation was indirectly monitored through immunostaining of the 53 Binding Protein 1 (53BP1), one 
of the key proteins recruited as scaffold protein by the cellular DSB repair system and widely used as 
a marker of DNA damage [150]. 53BP1 molecules can be visualized by fluorescence microscopy as 
discrete foci formed in the cell nucleus in co-localization with DSBs where the cellular DNA repair 
machinery is assembled temporarily. As reported in the literature, 53BP1 foci formation and the 
associated kinetics aspects were described mainly in response to ionizing radiation (IR) [132,186]. IR 
is well-known to induce formation of DSBs in genomic DNA. Therefore, control assays establishing 
experimental conditions monitored 53BP1 foci formation in HeLa cells after exposure to 1 Gy of IR 
(Figure 44). Following irradiation, cells were incubated for 30 min at 37° C in order to allow for 
recovery, and then fixed with formaldehyde. Based on previous reports involving different cell lines 
(including HeLa) the average number of 53BP1 foci per cell reaches a peak after 30 min [132,186]. 
Cells were immunostained using a primary α-53BP1 polyclonal antibody produced in rabbit and a 
secondary antibody α-rabbit IgG coupled with Alexa Fluor 488. 53BP1 foci were analyzed under a 
fluorescence microscope after mounting cells in presence of DAPI that stained the DNA in cell nuclei. 
Numbers of 53BP1 foci within cells were evaluated by eye, counting foci directly under the microscope 
or in images captured with a camera. 
Fluorescence microscopy revealed that irradiated cells presented 53BP1 protein different from that in 
unirradiated control cells. In irradiated cells, there were approximately 25 53BP1 foci per cell, whereas 
the majority of unirradiated cells showed between 3 foci and none at all, with some unirradiated cells 
sporadically presenting higher numbers of foci. In both irradiated and unirradiated samples, 53BP1 
foci were of variable size and morphology, ranging from very small dots to larger rounded granules. 
Control assays thus suggested that experimental conditions established for detection of DSBs were 
adequate for the documentation of such DNA damage induced in nuclear DNA by a genotoxic agent 
other than IR. 
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Figure 44: Control assay for monitoring DSBs via detection of 53BP1 foci. 53BP1 foci were visualized by 
immunostaining and fluorescence microscopy in HeLa cells exposed to 1 Gy of ionizing radiation. After 
irradiation, cells were incubated for 30 min at 37°C, fixed for 15 min with 4% [v/v] formaldehyde. Cells were 
permeabilized by a 5-min incubation with 0.2% [v/v] TritonX-100 on ice. Cells were blocked for 30 min with 
1% [w/v] BSA and incubated overnight at 4°C with an α-53BP1 polyclonal antibody produced in rabbit. 
Following wash steps, cells were incubated for 1 h with a secondary α-rabbit IgG antibody conjugated with Alexa 
Fluor 488, washed again and mounted in presence of DAPI. Cell nuclei (in blue) and 53BP1 foci (in green) were 
visualized by fluorescence microscopy. 
 
We then performed experiments utilizing HML-2 IN as an agent potentially causing DSBs. We aimed 
in those experiments at evaluating if presence of HML-2 IN in human cells could affect the number of 
53BP1 foci, thus the number of DSBs. To do so, HeLa cells were transfected with plasmids encoding 
either pSG5 IN or pSG5 IN-mut to induce expression of wild-type HML-2 IN and an enzymatically 
inactive mutant (mutated in the catalytic domain), respectively, with both IN proteins labeled with an 
HA-tag at the N-terminus. Experiments also included untransfected cells as controls. Cells were fixed 
24 hpt and stained with antibodies for subsequent immunofluorescence analysis. We established 
experimental conditions for a multiple immunostaining procedure that permitted examination of 
different proteins simultaneously. We detected the HA-tag in order to visualize cells specifically 
expressing IN, thus directly focusing our attention on cells in the cell culture that were transfected and 
harbored HML-2 IN. Detection of 53BP1, thus visualization of 53BP1 foci present in cell nuclei, 
allowed us to evaluate numbers of DSBs. 53BP1 signaling may be antagonized by cellular factors at 
different stages of the cell cycle [56]. Thus, we also took into account that 53BP1 foci might have 
presented variable levels of activation depending on the cell cycle phase. To minimize potential biases 
due to variable cell cycle phases, we considered cells that had been fixed in the same phase of the cell 
cycle. We therefore stained the protein Ki-67, a nuclear protein that is variably expressed during 
different phases of the cell cycle [195] (Figure 45 B). Ki-67 is typically used as proliferation marker 
since it is undetectable specifically in non-dividing cells [141]. More specifically, Ki-67 is degraded 
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continuously in G0 and G1 and accumulates during S to M phases [141]. It appears that in actively 
proliferating cells the Ki-67 level is at a minimum at the end of the G1 phase [141]. We therefore 
considered for the analysis of 53BP1 foci only cells with Ki-67 levels below the detection limit (Ki-67 
negative cells), as those cells likely represented cells in G1 or G0 phase (leftmost in Figure 45 B). We 
thus reduced the number of cells considered in our analysis to potentially improve accuracy of results. 
As for the immunostaining procedure, primary antibodies raised in different species and directed 
against different target proteins of interest were added to fixed cells in parallel. The mixture of primary 
antibodies included: 1) a monoclonal α-HA antibody produced in rat; 2) an α-53BP1 antibody produced 
in rabbit and conjugated with fluorescent dye Alexa Fluor 488 (green), the latter allowing direct 
detection without the need for a secondary antibody; 3) a monoclonal α-Ki67 antibody produced in 
mouse. Secondary antibodies were: α-rat IgG and α-mouse IgG antibodies, both produced in goat and 
labelled with fluorescent dyes Alexa Fluor 594 (red) and Alexa Fluor 647 (infrared), respectively. 
Secondary antibodies were likewise incubated in parallel. Cell nuclei were stained with DAPI during 
mounting. Multi-color detection of the various probed proteins was performed using a fluorescence 
microscope equipped with a filter set for visualization of DAPI (blue), FITC (green), Texas-Red (red) 
and infrared. 53BP1 foci were analyzed and counted by eye in acquired images. Examination of 53BP1 
foci was performed for a total of 210 Ki-67-negative cells. Those 210 cells analyzed included 70 cells 
expressing HA-tagged wild-type IN (IN-wt), 70 cells expressing HA-tagged IN mutant (IN-mut) and 
70 untransfected cells. 
When analyzing acquired images, we observed that IN localized in the nucleus and the cytoplasm of 
transfected cells, although in most of the cells IN appeared to be more enriched in the cytoplasm than 
in the nucleus. IN appeared to be distributed homogeneously both in the cell nucleus and cytoplasm of 
transfected cells. Although, IN also appeared to be enriched at discrete loci in the cytoplasm of some 
cells. Those higher-density spots may represent intracellular precipitates of IN as observed in 
experiments involving transiently expressed HIV-1 IN [155]. We did not notice differences in cellular 
localization and distribution when comparing IN-wt and IN-mut. Since IN localized in the cell nucleus, 
there was evidence to believe that IN could have interacted with the host DNA. However, analysis of 
53BP1 foci did not reveal significant differences in numbers of 53BP1 foci when comparing IN-wt, 
IN-mut and untransfected cells (Figure 45 C, D). In each group of cells, there were approximately 3 
foci per cell. Also, no differences in sizes of foci were noticed when comparing cells in the different 
groups. In all groups, 53BP1 foci were of variable dimensions, with a majority of small-sized foci and 
occasionally foci of larger size (Figure 45 A). Thus, a particular effect regarding the number, size, and 
morphology of 53BP1 foci in presence of HML-2 IN activity could not be documented in our initial 
experiments. Therefore, the employed experimental conditions did not produce evidence to conclude 
that HML-2 IN can damage DNA in a way that causes formation of DSBs. 
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Figure 45: Evaluating the ability of HML-2 IN to induce formation of DSBs. A) Representative sizes and 
morphologies of 53BP1 foci detected by immunofluorescence. Foci with variable dimensions, ranging from 
small-sized foci to large-sized foci were counted. B) Representative examples of cell nuclei stained with Ki-67 
(yellow). Ki-67 was distributed in the cell nucleus (blue) in variable patterns corresponding to different phases 
of the cell cycle. Ki-67-negative cells (leftmost image), possibly cells in G1 or G0 phase, were considered for 
analysis of 53BP1 foci. C) Representative cells (indicated with a star) fulfilling selection criteria for inclusion in 
the analysis of 53BP1 foci. Cells expressing HA-tagged IN or IN-mut (red) were detected with a monoclonal α-
HA antibody produced in rat. Ki-67 (yellow) was detected with a monoclonal α-Ki-67 antibody produced in 
mouse. For the detection of 53BP1 (green), a polyclonal α-53BP1 antibody produced in rabbit and conjugated 
with Alexa fluor 488 was employed. Cell nuclei (blue) were stained with DAPI. D) Averages of 53BP1 foci 
number per cell based on analysis of 70 HA-IN-expressing cells, 70 HA-IN mutant expressing cells and 70 
untransfected cells, with all of them fixed in the same cell cycle phase. Standard deviations are indicated.  
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5. Discussion 
In the context of a retroviral infection, inside the cell, viral proteins interact with the cellular machinery 
to coordinate a process that results in viral spreading through production of viral particles. In the course 
of this process, the cellular integrity is not necessarily preserved. On the contrary, viral proteins 
perform multiple functions with several consequences in the cellular environment. Side effects, not 
necessarily relevant to the viral strategy, are also induced. Altogether, activities of viral proteins alter 
cellular functionalities resulting in detrimental, if not lethal, effects. 
In view of this, HERV-K(HML-2) (hereafter HML-2), a group of HERVs that include proviruses 
retaining particularly intact genomes, represents a source of retroviral proteins that, whenever 
expressed, could exhibit enzymatic activities with a negative impact on cell biology. All human cells 
have the potential to produce such retroviral proteins. Currently, HML-2 transcription is known to be 
upregulated in various disease tissues and expression of HML-2 proteins was observed in tumor cells. 
In those pathological contexts, HML-2 proteins could represent initiators or promoters of cellular 
impairment and cell transformation, although the underlying mechanisms are still unexplored. 
 
This work focused on HML-2 protease (Pro) and HML-2 integrase (IN), two HML-2 encoded proteins 
little investigated so far, whose enzymatic activities could potentially interfere with cellular processes. 
In the following, findings will be discussed in two sections: the first (5.1) related to HML-2 Pro and 
the second (5.2) to HML-2 IN. 
 
5.1 HML-2 protease 
The proteolytic activity of HML-2 Pro was demonstrated in previous studies, in which self-processing 
of HML-2 Pro and processing of HML-2 Gag proteins were directly observed through expression in 
E. coli [134] and through in vitro cleavage assays [185]. The presence of a functional HML-2 Pro has 
been inferred in germ cell tumors (GCTs), where properly processed HML-2 Gag proteins were 
detected [112,179]. Previous studies have observed the budding of HML-2 viral particles with mature 
morphology in GCT cells. Mature morphology is attributed to the presence of active HML-2 Pro [20]. 
Despite the evidence of a functional HML-2 Pro in some human cells, the proteolytic activity of this 
enzyme was only demonstrated against retroviral substrates. Whereas, we considered crucial to 
investigate the proteolytic activity of HML-2 Pro as a potentially harmful factor to which cellular 
proteins could be exposed. Some studies already demonstrated processing of cellular proteins by 
retroviral proteases, although those studies involved exogenous retroviruses (for instance, see 
[194,212]). Thus, in our study we aimed to know whether HML-2 Pro could be able to process cellular 
proteins and, by doing so, induce detrimental effects in the cell. Confirming such activity for an enzyme 
that is inducible in all human cells has potentially important implications. It was our specific intent to 
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identify potential cellular substrates of HML-2 Pro, assess their roles in the cell and eventually confirm 
their cleavage by HML-2 Pro under physiological conditions. 
 
5.1.1 Expression of HML-2 Pro in bacteria and protein purification 
Most of our investigation on HML-2 Pro was based on an in vitro setup, which allowed the study of 
HML-2 Pro activity at well-defined conditions. Prerequisite for our experimental approach was the 
generation of purified, functional HML-2 Pro, that could be included at proper concentrations to 
reactions. HML-2 Pro was successfully purified following a protocol for isolation of HML-2 Pro from 
inclusion bodies as previously published [112]. That protocol is based on a method described by 
Wondrak et al. (1991) [221] for HIV-1 Pro purification. Of note, Kuhelj et al. (2001) [112] reported 
purification of two forms of HML-2 Pro: 1) a truncated form, including the complete functional Pro 
core domain, but lacking 50 aa in the C-terminus that were demonstrated as not necessary for catalytic 
activity; 2) a full-length his-tagged Pro. Kuhelj et al. (2001) [112] observed identical specificities for 
the two Pro variants, although the truncated HML-2 Pro displayed a catalytic efficiency twice as high 
as that of full-length Pro. An important aspect of our study was to test HML-2 Pro activity against 
cellular substrates whose specificity for processing by HML-2 Pro was unknown. Since processing of 
candidates could have been hardly detectable if occurring at low level, we considered favorable for our 
experiments in vitro to employ the HML-2 Pro form that could display higher proteolytic activity. 
Thus, we purified a C-terminally truncated form of HML-2 Pro. Although truncated in the C-terminus, 
HML-2 Pro was expressed in bacteria as a precursor that included the complete HML-2 Pro core 
domain and an N-terminal region flanking the N-terminal autocatalytic cleavage site, the latter 
important for monitoring HML-2 Pro activity through its self-processing. 
 
There were two noteworthy modifications with regard to the protocol of Kuhelj et al. (2001) [112]. 
First, for lysis of E. coli cells expressing HML-2 Pro, before sonication we homogenized bacteria by 
using a dounce homogenizer for improved lysis of bacteria in an inexpensive and practical way. Of 
note, this step was quick, did not require addition of reagents and could be performed in the cold. Thus, 
it can be assumed that that modification did not affect HML-2 Pro integrity. Second, chromatography 
for HML-2 isolation was performed by gravity flow instead of using a fast protein liquid 
chromatography (FPLC) system. Our method worked well, thus it represents an alternative for HML-
2 Pro purification laboratories that do not have access to an FPLC system. 
 
HML-2 Pro was purified at a sufficient level of purity. Only a contaminant protein of ~45 kDa appeared 
co-isolated during the elution steps. The HML-2 Pro eluates in which the contaminant protein was 
barely detectable (eluates 3 and 4), or not at all detectable (eluate 5) (see Figure 17), were pooled into 
an HML-2 Pro stock for further experiments. We assumed that the ~45 kDa contaminant protein, as 
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well as other contaminant proteins below detection limits, would have been further diluted during set 
up of further assays, thus becoming even less relevant. 
The yield of purified HML-2 Pro could be considered reasonable. Inducing HML-2 Pro expression in 
1 L of bacterial culture (absorbance at 600 nm was 0.6) and incubating the culture for 3 h after induction 
yielded a total of 540 µg of HML-2 Pro at the end of the purification procedure, that was aliquoted and 
stocked at -80°C. Approximately 90% of those 540 µg of purified HML-2 Pro were consumed in the 
course of the various experiments. Some modifications might have further improved purity of HML-2 
Pro and consequently the amount of (pure) HML-2 Pro to be used for further experiments. For example, 
during purification the eluate containing the higher amount of HML-2 Pro could not be used because 
of higher amounts of the ~45 kDa contaminant protein (see Figure 17, eluate 2). Pro of higher purity 
may be obtained by additional washing steps to remove the contaminant 45 kDa protein before elution 
of HML-2 Pro. Considering that modification of ionic strength (1M NaCl in the binding buffer, no 
NaCl in the elution buffer) and pH (pH 6.5 in the binding buffer, pH 8.0 in the elution buffer) are key 
factors for elution of retroviral proteins specifically bound to pepstatin A [221], additional washing 
steps could employ buffers with intermediate concentrations of NaCl and pH, optimized towards 
elution of the 45 kDa contaminant protein without dramatically destabilizing the binding of HML-2 
Pro to pepstatin A. Washing buffers with different concentrations of NaCl between 0 and 1 M and/or 
pH between 6.5 and 8 should be tested empirically. 
Alternatively, considering that the molecular weight of the 45 kDa contaminant protein is significantly 
higher than the molecular weight of self-processed HML-2 Pro (~12 kDa), a filtering step after elution, 
for instance by size-exclusion chromatography, could also represent a good strategy for removal of the 
contaminant protein and thus purer HML-2 Pro. 
 
We have shown that the HML-2 Pro from the provirus HERV-K(HML-2.HOM) is enzymatically 
active, corroborating a previous report about this specific protease [134]. HML-2 Pro exhibited 
enzymatic activity during expression in bacteria, as already observed in other studies in which bacterial 
expression of HML-2 Gag-Pro polyprotein led to specific cleavage into individual Gag domains 
[134,143]. In our experiments, two hours after protein induction, self-processing of HML-2 Pro 
precursor (~18 kDa) with release of the mature HML-2 Pro (~12 kDa) could be observed readily (see 
Figure 16). It can be assumed that, at the time when bacteria were pelleted for subsequent lysis, 
expression of HML-2 Pro was still ongoing, thus a certain amount of the 18 kDa Pro precursor was 
subjected to purification. Kuhelj et al. (2001) [112] reported that during purification of HML-2 Pro, 
the complete processing of the precursor took place during dialysis, when Pro renaturated. In our case, 
through monitoring of Coomassie-stained proteins following SDS-PAGE (see Figure 17) we could not 
discriminate during which step(s) of the purification procedure HML-2 Pro precursor eventually self-
processed. In any case, only the 12 kDa HML-2 Pro was detected in eluates, thus confirming complete 
processing of the 18 kDa Pro precursor during the purification/renaturation procedure. 
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The procedure for HML-2 Pro purification and subsequent concentration, aliquoting and storage 
at -80°C preserved the enzymatic functionality. This was confirmed through a reaction in which 
purified, frozen and thawed HML-2 Pro processed in vitro-translated HML-2 Gag efficiently. Of note, 
this verification experiment also confirmed that our purified HML-2 Pro could process a substrate in 
trans. Such Pro activity could not be specifically discriminated during expression in bacteria, when 
monitoring just the cleavage of the 18 kDa HML-2 Pro precursor. Because of the efficient cleavage 
observed in those experiments, HML-2 Gag was employed as a positive control for processing by 
HML-2 Pro in several of our subsequent experiments. 
 
5.1.2 No Purification of HML-2 Pro mutants  
We could not purify enzymatically inactive HML-2 Pro mutants because of inefficient binding of 
mutant HML-2 Pro with pepstatin A. In particular, we tried to purify two Pro mutants that could have 
been employed as negative controls in in vitro assays for studying HML-2 Pro activity. One Pro mutant 
harbored an amino acid substitution D→N within the catalytically important DTG-motif. The D→N 
mutation is known to be critical for the active site geometry of retroviral proteases [180]. Thus, it was 
not entirely unexpected that such a mutant would not interact with pepstatin as well as  wild-type HML-
2 Pro. The second mutant was motivated by a study that reported successful purification, by pepstatin-
A affinity chromatography, of an inactive HIV-1 protease with an R→K substitution in the GRNLL 
region [221], that is highly conserved and relevant for enzyme activity and structure [85]. We 
introduced an analogous substitution in the GRDLL region of HML-2 Pro (see chapter 4.1.1), but that 
mutation, in our case, did not permit efficient binding of the mutant HML-2 Pro to pepstatin A. The 
discrepant outcome between Wondrak et al. (1991) [221] and our study is currently not clear but may 
be due to variations in the purification procedure or different behavior of the two proteases involved. 
For instance, in Wondrak et al. (1991) [221] the buffer used for resuspension and binding of Pro with 
pepstatin-A-agarose has a relatively high concentration of ammonium sulfate, whereas ammonium 
sulfate was not present in the buffer employed in our purifications. That component could thus be 
considered relevant for optimized purification of HML-2 Pro mutants. 
The substituted R residue within the GRNLL region is highly conserved among retroviral proteases 
and it is known to contribute to the protein structure and activity of HIV-1 Pro [85]. Since the R→K 
substitution introduces a relatively minor change in the GRNLL region, maintaining a positive charge 
on the side chain, one could speculate that, with regard to binding ability, the micro-environment of 
the cleavage site of HML-2 Pro could be less tolerant towards changes than that of HIV-1 Pro. Specific 
investigations would be required to produce further evidence. In any case, alternative HML-2 Pro 
mutants could be tested with regard to their suitability for purification. For example, substitution of the 
G residue in the GRDLL region could be tested. Mutations in other conserved regions of HML-2 Pro, 
for example, in the “flap” motif, could also be tested. 
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Use of a purified mutant of HML-2 Pro may represent an optimal control for in vitro assays. However, 
as we observed, purification of such mutants may require optimizations, with no success guaranteed. 
Our experimental strategy did not necessarily depend on such purified Pro mutants. Instead, as an 
alternative strategy for our assays, we considered it sufficient to inhibit HML-2 Pro activity by means 
of a specific inhibitor. For that purpose, we employed pepstatin A, a well-known inhibitor of aspartyl 
proteases that we confirmed to also efficiently inhibit purified HML-2 Pro. In particular, we found that 
in our experimental system, 200 µM pepstatin A could efficiently inhibit HML-2 Pro present at 460 
nM, reducing its activity by 98% compared to controls without inhibitor. We also showed that in 
presence of 200 µM pepstatin A, complete inhibition (100%) of HML-2 Pro activity could be achieved 
when pre-incubating pepstatin A with HML-2 Pro for 10 min before addition of the protease substrate. 
We suppose that the pre-incubation step favored a more stable interaction of pepstatin A with HML-2 
Pro before setting off interaction with substrate. This could be an important aspect to be considered 
when setting up negative controls for assays testing HML-2 Pro activity against substrates that are 
processed with high efficiency. 
 
5.1.3 Characterization of HML-2 Pro and optimization of reaction condition 
Enzymatic activity of HML-2 Pro was assessed and partially characterized in previous studies that 
monitored processing of synthetic, fluorescent substrates by means of fluorescence assays in vitro 
[112,205]. In our study, we used a similar approach to characterize enzymatic activity of purified 
HML-2 Pro, corroborating previous findings concerned with biochemical aspects of that enzyme. At 
the same time, we aimed at establishing reaction conditions suited for subsequent TAILS experiments, 
which required samples prepared in a buffer that, ideally, consisted of relatively few buffer 
components. 
It is known that, besides HML-2 Gag, HML-2 Pro can also process HIV-1 Gag polyprotein [205]. In 
fact, in previous studies, the fluorogenic peptide substrates Lys-Ala-Arg-Val-Tyr-/-Phe-(NO2)-Glu-
Ala-Nle-NH2 [205] and 2-aminobenzoyl-Ala-Thr-His-Gln-Val-Tyr-/-Phe-(NO2)-Val-Arg-Lyr-Ala, 
derived from HIV-1 Gag and originally designed as substrates for HIV-1 Pro, have been shown to be 
efficiently cleaved by HML-2 Pro. When we established the strategy for our fluorescence assay, both 
peptides were not available commercially at reasonable prices. We therefore chose another HIV-1 Gag 
derived peptide, the hexapeptide FRET substrate 2-aminobenzoyl-Thr-Ile-Nle-/-Phe-(NO2)-Gln-Arg-
NH2 (hereafter Anthranilyl-substrate), that was commercially available from Bachem AG. The 
Anthranilyl-substrate was likely also processed by HML-2 Pro, since it includes in its sequence aa 
residues favored for P1 and P1'. Specifically, Nle (Norleucine, an isomer of Leu) is present at the 
putative P1 site. Nle/Leu is hydrophobic and unbranched at the β-carbon as is the majority of aa 
residues found in P1 of cleavage sites of HML-2 Pro within HML-2 Gag [66]. Furthermore, Phe and 
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Ile are present in the putative P1' and P2 sites, respectively, which are aa residues favored for those 
positions, as per recently published specificity profile of HML-2 Pro cleavage sites [17]. 
 
Monitoring the processing of the Anthranilyl-substrate by HML-2 Pro at different buffer conditions 
corroborated that buffers with low pH and high ionic strength are particularly favorable for HML-2 
Pro activity, as also shown in previous studies [112,205]. 
Different buffer systems have been used in previous studies on HML-2 Pro or other retroviral proteases 
(see [112,156,205]). Since our protocol for HML-2 Pro purification was based on the protocol 
published by Kuhelj et al. (2001) [112], we considered that study as main reference for buffer 
conditions for our in vitro fluorescence assays. We also tested a buffer used by Porter et al. (2002) 
[156] for assaying HIV-1 Pro activity against Anthranilyl-substrate. 
One buffer retrieved from Kuhelj et al. (2001) [112] and composed of 50 mM MES, 1 M NaCl, 20% 
[v/v] glycerol, 1 mM EDTA, pH 5.0, turned out to be suitable for cleavage of Anthranilyl-substrate by 
HML-2 Pro. In the same buffer, but without glycerol, HML-2 Pro activity was ∼30% higher. This 
indicated that lack of glycerol increased HML-2 Pro activity in our experimental system. The buffer 
reported by Porter et al. (2002) [156] had a simpler composition, specifically 100 mM MES-TRIS, 
1.25 M NaCl, pH 6.0, and also appeared as suitable for cleavage of Anthranilyl-substrate by HML-2 
Pro. This indicated that, apart from glycerol, other components commonly included in reaction buffers, 
like EDTA and DTT, were dispensable for assaying HML-2 Pro activity. We also demonstrated a 
negative effect of DMSO on Pro activity. DMSO is a solvent agent that is often used to resuspend 
inhibitors or other chemicals, reducing or avoiding such a component in assays of HML-2 Pro will thus 
increase proteolytic activity. Moreover, we evaluated in a specific experiment that use of PIPES instead 
of MES could favor HML-2 Pro activity (see also later). Altogether, our experiments provided relevant 
information for setting up in vitro assays for HML-2 Pro in vitro. A buffer composed of 100 mM PIPES 
and 1 M NaCl was eventually favored for assaying enzymatic activity of purified HML-2 Pro towards 
Anthranilyl-substrate and for subsequent TAILS experiments. 
 
Another buffer reported by Kuhelj et al. (2001) [112], composed of 20 mM PIPES, 100 mM NaCl, 
1 mM DTT, 10% [v/v] glycerol, pH 6.5, appeared as unsuited for cleavage of Anthranilyl-substrate by 
HML-2 Pro. HML-2 Pro was completely inactive in that buffer. Of note, the Kuhelj et al. (2001) study 
[112] used that buffer specifically for cleavage of in vitro translated HML-2 Gag. In line with the 
Kuhelj et al. (2001) study [112], the same buffer was suitable for cleavage of in vitro translated HML-2 
Gag also in our study (see Figure 21). One can hypothesize that because of a combination of buffer 
features negatively affecting the enzyme activity (presence of glycerol, low ionic strength, high pH), 
HML-2 Pro could not efficiently process the Anthranilyl-substrate in that buffer. However, a complete 
absence of proteolytic activity was unexpected. Unsuitability of that buffer for our fluorescence assays 
may be due to the specific substrate involved. Additional investigations would be necessary to identify 
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the cause of that inactivity. Since we had other suited buffer compositions for HML-2 Pro activity at 
hand such investigations were not required though. We therefore did not further consider that unsuited 
buffer in our subsequent experiments. 
 
5.1.4 Activity of HML-2 Pro at different pHs 
We defined more precisely the pH required for optimal HML-2 Pro activity by monitoring the 
processing of the Anthranilyl-substrate in a set of reactions with acidic pH ranging from 4.5 to 6.5. A 
previous study [205] that assayed HML-2 Pro activity at variable pHs reported that the pH profile of 
HML-2 Pro activity was bell-shaped with a peak activity at approximately pH 4.5. In our experiments, 
the pH profile of HML-2 Pro activity was likewise bell-shaped, but with a peak at pH ∼5.5. Our result 
is partially in disaccord with the previous report, although the slight difference in the observed HML-
2 Pro pH optimum could be due to differences in buffer composition and/or fluorogenic substrate 
employed. The factual reason for the different pH optimum would have to be investigated in specific 
experiments; it appeared less relevant for our subsequent studies. 
 
In a second set of experiments, HML-2 Pro activity was assayed along an extended pH range, 
specifically from pH 5.5 to 8.0, in order to further evaluate HML-2 Pro activity at higher pH. HML-2 
Pro activity around neutral pH was of particular relevance since that pH range is found in major cellular 
compartments, namely nucleus and cytoplasm [31]. Knowledge of HML-2 Pro activity at different pHs 
becomes relevant concerning susceptibility of proteins from different cellular compartments for 
cleavage by HML-2 Pro. Remarkable stability of HML-2 Pro activity over a wider pH range was 
pointed out by Towler et al. (1998) [205]. For instance, it was shown that more than 60% of HML-2 
Pro activity could be recovered after prolonged incubation at room temperature over a pH range from 
pH 3 to 9, both in presence and absence of 1 M NaCl [205]. However, in that particular experiment, 
residual HML-2 Pro activity was measured at a fixed pH 6.2. Concerning tolerance of HML-2 Pro 
activity towards pH variations, in that experiment, no HML-2 Pro activity was observed at pH > 6.5, 
both in presence or absence of 1 M NaCl. In our experiments (in presence of 1 M NaCl), we found that 
HML-2 Pro activity was not restricted to acidic pH. In fact, HML-2 Pro was still active at neutral pH, 
with approximately 10% of the activity observed at the optimal pH, and furthermore at basic pH (up 
to pH 8.0), with approximately 1% of the activity observed at the optimal pH. 
 
Towler et al. (1998) [205] reported HML-2 Pro activity up to pH 8.5 when tested in a buffer with 1.25 
M ammonium sulfate [205]. The authors of that study attributed higher HML-2 Pro activity to the 
nature of the salt, assuming that ammonium sulfate is more favorable than NaCl for stabilization of 
hydrophobically driven interactions between the substrate and Pro, thus increasing dimer stability and 
consequently the enzyme's efficiency even at basic pH. In our study, we found that the nature of the 
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buffering agent could also influence HML-2 Pro activity. In particular, we observed that at pHs ranging 
from 5.5 to 8.0 HML-2 Pro was more active in PIPES buffer than MES buffer. Comparing the two 
buffering agents the difference in Pro activity was gradually more pronounced at pH > 6.0. Pro activity 
was approximately 55%, 70%, 80%, 90% lower in MES buffer than in PIPES buffer when monitored 
at pH 6.5, 6.9, 7.5, 8.0, respectively. Thus, in our system PIPES buffer appeared as more suited than 
MES buffer, especially at pH > 6.0. 
 
Considering that the cellular localization of HML-2 Pro is currently unknown, our own and previous 
findings suggest that HML-2 Pro would be enzymatically highly active when located in cellular 
compartments with acidic pHs, for example, organelles of the secretory and endocytic pathways (pH 
6.7-4.7 [31]). However, there is also evidence that HML-2 Pro could potentially be active in cellular 
compartments with pH close to neutral, for example, nucleus, endoplasmic reticulum, and cytoplasm 
(the three compartments having pH 7.2 [31]), and in cellular compartments with alkaline pH, for 
example, mitochondrial matrix (pH 8.0 [31]). 
 
5.1.5 Preparation of cellular protein mixture for incubation with HML-2 Pro 
Apart from having a purified functional HML-2 Pro available and having knowledge of optimal in 
vitro conditions for its activity, another important aspect for identification of potential HML-2 Pro 
substrates concerned cellular proteins reacting with HML-2 Pro. This concerned in particular 1) a 
proper source for human proteins; 2) preparation of a protein mixture that preserved protein integrity 
and employing buffer components compatible with the subsequent TAILS procedure. 
Human proteins subjected to HML-2 Pro processing derived from cell lysates of HeLa cells. HeLa is 
a well known human cell line that is widely employed in laboratories. That cell line was readily 
available in our laboratory. Considering that HeLa cells divide relatively quickly and can be maintained 
easily, it was considered a suited source for extraction of a higher amount of cellular proteins for use 
in our experiments. Expression of endogenous HML-2 Pro was not reported in the literature for HeLa 
cells. We verified in Western blot experiments (not shown) that endogenous HML-2 Pro was not 
expressed, at least not at a detectable level, in the HeLa cell line employed in our experiments. This 
was relevant in order to ensure that 1) in the in vitro reactions for TAILS experiments, HML-2 Pro 
activity derived from the exogenous HML-2 Pro added to the TAILS reaction; 2) exogenous Pro 
activity could be then inhibited efficiently by established concentrations of pepstatin A. 
In a more recent experiment, using a more sensitive Western blot procedure, we gained preliminary 
evidence (requiring further corroboration) of very low level HML-2 Pro expression in HeLa cells (also 
discussed below). In any case, a low level of catalytically active endogenous HML-2 Pro was not 
considered an issue in our TAILS experiments. Even if present, such endogenous HML-2 Pro activity 
would have been inhibited by pepstatin A in control reactions as well.  
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Our procedure for preparation of a protein mixture from HeLa cells released proteins from their cellular 
compartments under native conditions, thus preserving their native state. That aspect was important in 
the context of subsequent incubations with HML-2 Pro, where we wanted to establish interactions with 
native proteins as they could also occur within the cell. Also, not properly folded proteins probably 
would have presented protein regions that in a native state would not have interacted with HML-2 Pro. 
Thus, incubating HML-2 Pro with denatured proteins would have produced flawed results not 
representative of cleavage events that could occur in a cellular context. 
 
To preserve the native state of proteins, our procedure for lysis of HeLa cells was based on a physical 
disruption method that avoided factors inducing protein denaturation, e.g. denaturing (ionic) detergents 
or higher temperature. The cell lysis was achieved by freeze-thaw cycles in a detergent-free buffer, 
combined with short vortexing in presence of glass beads. Non-ionic detergents, that typically do not 
denature proteins [91], could have been employed to further promote disruption of cellular membranes 
without dramatically affecting protein integrity. Nevertheless, those detergents may have interfered 
with the subsequent TAILS procedure. We therefore omitted non-ionic detergents during cell lysis. 
 
After cell lysis, all proteins in solution were, in principle, susceptible to protein degradation due to 
activity of cellular proteases released from cellular compartments [163]. Our procedure aimed at 
preserving protein integrity by reducing protein degradation due to cellular proteases. This aspect was 
relevant in order to better monitor the specific proteolytic activity exhibited by HML-2 Pro. The buffer 
employed for cell lysis therefore included a cocktail of protease inhibitors that inhibited a broad 
spectrum of cellular proteases. Of note, the cocktail of protease inhibitors employed did not contain 
inhibitors of aspartyl proteases, which was fundamental in order to not block HML-2 Pro activity in 
subsequent reactions. 
 
5.1.6 Set up of reactions for TAILS 
We verified in a small-scale experiment (see Figure 27 B) reaction conditions for TAILS documenting 
the processing of in vitro-translated HML-2 Gag by HML-2 Pro at pH 5.5 and pH 7. As expected, 
HML-2 Pro exhibited higher activity at pH 5.5, although proteolysis of HML-2 Gag could be observed 
also at pH 7.0. We also noticed that processing of HML-2 Gag by HML-2 Pro seemed to be slightly 
reduced in presence of HeLa-derived cellular proteins. We speculate that a lower level of processing 
was due to reduced interaction of HML-2 Pro with HML-2 Gag caused by competition of HML-2 Gag 
with other cellular substrates of HML-2 Pro. 
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Reaction conditions verified in small-scale experiments were employed for lager-scale reactions for 
TAILS. In TAILS reactions, 2 mg of HeLa-derived cellular proteins were incubated with 200 nM 
purified HML-2 Pro for 75 min at 37° C. One set of reactions was performed at pH 5.5, another set at 
pH 7. TAILS reactions at pH 5.5 could be expected to identify an as high as possible number of cellular 
proteins processed by HML-2 Pro because of high HML-2 Pro activity. Reactions at pH 7 could be 
expected to provide evidence of processing of cellular proteins by HML-2 Pro also at a pH typical for 
the cytoplasmic compartment, where HML-2 Pro locates most likely. Controls included pepstatin A at 
200 µM, a concentration that, based on optimization experiments, was sufficient to block HML-2 Pro 
at 200 nM efficiently. At the end of incubations, we stopped HML-2 Pro activity by freezing reactions 
down on dry-ice and subsequently storing them at -80°C. This ensured that no additional reaction 
components for inactivation of HML-2 Pro that may have interfered with the subsequent TAILS 
procedure were added to reactions. Reactions were shipped on dry-ice to the laboratory of Dr. Schilling 
for the TAILS procedure. 
 
5.1.7 TAILS analysis 
Cellular substrates of proteases encoded by ERVs were not investigated so far. In accord, there were 
no known cellular proteins processed by HML-2 Pro. As for proteases encoded by exogenous 
retroviruses, most studies focused on non-viral substrates of HIV-1 Pro (for instance, see [82,87,187]). 
Such studies give an idea of the approaches used to identify cellular targets of HIV-1 Pro. In earlier 
studies, identification of substrates of HIV-1 Pro was based on observations of cellular effects during 
HIV-1 infections or transient expression of HIV-1 Pro in cell culture. For instance, altered cell shape 
during HIV-1 infection prompted researchers to investigate ability of HIV-1 Pro to process 
intermediate filament proteins [187]. Cell damage and lysis during HIV-1 infection prompted studies 
whether HIV-1 Pro could degrade microtubule proteins [213]. Induction of apoptosis during HIV-1 
infection or cytotoxic effects of transiently expressed HIV-1 Pro prompted the investigation of 
cleavage of apoptosis-regulating proteins by HIV-1 Pro [146]. Altogether, results from various such 
studies identified several substrates of HIV-1 Pro, although the number of candidate proteins 
investigated in each study was very limited since selection of (relatively few) candidate proteins was 
just hypothesis-driven. 
More recently, several advanced approaches were developed to screen protease substrates in a more 
systematic fashion [14]. Among such approaches, those based on proteomics technologies are known 
to facilitate high-throughput identification of protease substrates [14]. In the context of substrates of 
HIV-Pro, the great potential of a large-scale proteomics approach was demonstrated by a study by 
Impens et al. (2012) [82], that employed a proteomics technology termed Combined Fractional 
Diagonal Chromatography (COFRADIC) and identified 123 potential host cell substrates of HIV-1 
Pro. That study reported, from a single analysis, a collection of HIV-1 Pro substrates much more 
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comprehensive than those of previous investigations. The reported catalogue of putative HIV-1 Pro 
host cell substrates provides information that allows to speculate on unknown roles of HIV-1 Pro in 
infected cells, and it can be used as an authentic reference for studies that aim at validating cellular 
targets of HIV-1 Pro and involvement of HIV-1 Pro in specific cellular processes. 
 
Use of a large-scale proteomics approach was also recommended for our investigation of HML-2 Pro 
for which processing of cellular proteins was completely unknown so far. Similar to the Impens et al. 
(2012) [82] study, we also employed a large-scale proteomics approach, yet a slightly different, newer 
methodology developed for identification of substrates of proteases. Terminal Amine Isotopic Labeling 
of Substrates (TAILS) is a sophisticated proteomics technique that, like COFRADIC, is a so-called N-
terminomics method, as it is based on labeling and identification of N-termini of proteins processed by 
a protease [106]. We had access to this methodology through a collaboration with Prof. Dr. Oliver 
Schilling (University of Freiburg), whose laboratory has vast expertise in TAILS and established 
protocols suited for our experimental set-up. 
The TAILS technique discovers protease substrates by identification of protein processing fragments, 
specifically N-terminal protein fragments, that are quantified comparing a protease-treated sample with 
control reactions [14]. Substrates of various proteases have been investigated by TAILS [36,73,80], 
including substrates of viral proteases [86]. 
As described above, in our experimental design, samples for TAILS consisted of reactions where 
HML-2 Pro had been incubated with a protein mixture derived from HeLa cells. Control reactions 
differed from protease-treated samples by presence of pepstatin A that blocked HML-2 Pro activity 
[112]. N-terminal protein fragments generated during the reactions were isolated and identified by 
established protocols in the laboratory of Prof. Dr. Schilling. Different abundances of N-terminal 
protein fragments in protease-treated versus control reactions, as determined by TAILS, identified N-
terminal protein fragments enriched in presence of HML-2 Pro, thus identifying actual human proteins 
cleaved by HML-2 Pro. 
 
Our TAILS analysis demonstrated for the first time that HML-2 Pro activity can induce cleavage of 
hundreds of cellular proteins. As a consequence of HML-2 Pro activity, a considerable number of N-
terminal protein fragments were identified as enriched in TAILS reactions. Since N-terminal protein 
fragments are products of unique cleavages, in the following we will refer to “cleavage events”, i.e., 
processing of a specific protein at a specific aa position. When regarding cleavage events with at least 
2-fold enrichment, we identified approximately 4300 and 2600 cleavage events in the two TAILS 
experiments performed at pH 5.5, whereas 690 and 1900 cleavage events were identified in two TAILS 
experiments performed at pH 7.0. The great number of cleavage events enriched at both pHs confirmed 
ability of HML-2 Pro to process cellular proteins under variable pH conditions. The lower number of 
cleavage events at pH 7.0 was probably due to lower activity of HML-2 Pro, which was expected 
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considering that through biochemical characterization of HML-2 Pro we documented approximately 
10-fold lower Pro activity at pH 7.0 compared to pH 5.5. Also, small-scale reactions for TAILS showed 
a lower level of processing of HML-2 Gag at pH 7.0 compared to pH 5.5. Despite lower activity of 
HML-2 Pro at pH 7, the number of enriched cleavage events was still very high at this pH, indicating 
that even under non-optimal pH conditions HML-2 Pro could impact the integrity of many cellular 
proteins. 
 
The multitude of cleavage events documented by TAILS amounted to hundreds of human proteins 
processed by HML-2 Pro. However, when regarding numbers, a discrepancy was observed between 
cleavage events and actual proteins cleaved. For instance, 931 cleavage events common to both TAILS 
pH 5.5 replicates corresponded to only 548 cleaved proteins. Such discrepancies were also noted in 
other studies that used TAILS or similar proteomics approaches [157][82]. Such discrepancies could 
be attributed to multiple cleavages in many of the cellular proteins cleaved in presence of protease. We 
counted approximately 300 proteins common to the two replicates at pH 5.5 and approximately 70 
proteins common to two replicates at pH 7.0 with evidence of at least 2-fold enriched multiple 
cleavages (not necessarily in the same positions among replicates). In several instances, we observed 
a higher number of cleavages within the same protein, with some proteins being processed in more 
than 30 different positions (see Table 18).  
Cleavage of a protein in only one position could be sufficient to knock down or at least alter its 
functionality. If one hypothesizes that interaction of HML-2 Pro with a specific cleavage site in a 
substrate occurs by chance, one could speculate that proteins with multiple cleavage sites have a higher 
chance of being processed when in contact with HML-2 Pro as several cleavage sites would be 
presented during the encounter. Consequently, one could speculate that proteins having many HML-2 
Pro cleavage sites could be more susceptible to impairment due to HML-2 Pro proteolytic activity. 
Those proteins may deserve specific attention in the context of HML-2 Pro cellular targets. The 
relevance of multiple cleavages in particular proteins may be investigated in detail through further 
studies. 
 
Combining results from TAILS at pH 5.5 and pH 7.0, we generated a list of 872 cellular proteins (see 
Table 21) for which TAILS provided evidence of processing by HML-2 Pro in vitro. Such a collection 
of potential targets of HML-2 Pro could be of interest for further investigations. For instance, studies 
validating cellular substrates of HML-2 Pro could employ that list as a reliable starting point for 
selection of candidate proteins. For studies that aim at elucidating biological roles of HML-2 Pro, that 
list could be a source of interesting hints when linking HML-2 Pro to biological pathways associated 
with identified substrates. Studies investigating cellular substrates of other retroviral proteases could 
also benefit from our list for comparative analyses. 
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The above-mentioned study by Impens et al. (2012) [82] that used COFRADIC to identify cellular 
substrates of HIV-1 Pro, reported 120 human proteins processed in vitro. In view of that study, our 
results have shown a higher number of proteins cleaved by HML-2 Pro. Differences could derive from 
the different design of experiments and different methodologies employed. Moreover, our TAILS-
based experimental approach can be expected to be more sensitive and to thus identify more proteins 
than the approach employed by Impens et al. (2012) [82]. Interestingly, 60 proteins identified in our 
study were also identified by Impens et al. (2012) [82] likely because of overall similar specificity 
profiles of HIV-1 and HML-2 Pro [17]. Note that in Impens et al. (2012) [82] the total cellular protein 
for screening experiments derived from Jurkat T cells, while it derived from HeLa cells in our case. 
We assume that an even higher overlap between the identified substrates would have been observed if 
the same cell type had been used in both studies. 
 
5.1.8 Even more human proteins than observed may be substrates of HML-2 Pro 
The number of potential HML-2 Pro substrates identified in our experiments supports the assumption 
that HML-2 Pro activity could impact cell biology if expressed. It suffices to consider that altering the 
amount of a single cellular protein could potentially impact cell homeostasis. Some limitations of the 
experimental system utilized imply that even more human proteins than observed in our experiments 
could be substrates of HML-2 Pro. Three main factors limiting our screening are considered in the 
following. 
First, lysis conditions likely yielded an incomplete cellular proteome. Thus, we assume that not the 
entire HeLa proteome has been subjected to HML-2 Pro activity. As discussed above, our procedure 
for extraction of proteins from HeLa cells was based on a physical cell lysis method that prioritized 
preservation of protein integrity rather than aiming to extract as many proteins as possible. In particular, 
use of detergents was avoided because of suspected incompatibility with TAILS. Detergents break 
lipid-lipid and protein-lipid interactions, promoting disruption of membranes and solubilization of 
membrane proteins [91]. We can assume that due to inadequate membrane disruption proteins 
associated with cellular membranes and proteins contained in subcellular compartments had a lower 
chance than, for instance, cytosolic proteins, to be resolved in the supernatant and not being 
precipitated with cell debris during centrifugation steps for protein mixture clarification. For a more 
complete protein extraction, protocols including mild non-denaturing detergents could be employed. 
In such experiments, detergents should be removed before TAILS by, for instance, dialysis, in order 
to avoid interferences with the TAILS procedure. 
A second aspect is represented by the analysis of human proteins that are expressed at very low level 
in the cell. A comprehensive transcriptomic and proteomic study involving around 13,000 protein 
coding genes reported that approximately 10% of proteins could not be detected likely due to 
abundance below detection limits [216]. We suppose that, although present in the protein extract and 
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exposed to HML-2 Pro activity, proteins present at very low concentration (or their eventual cleavage 
products) went undetected in the TAILS analysis. HML-2 Pro activity against proteins expressed at 
very low level may be of particular interest. Alterations of their amount in the cell could induce stronger 
effects since the total number of respective proteins would be reduced considerably and only few 
remaining copies of respective proteins could compensate the degradation. Such aspects should be 
addressed in the future when further improved experimental strategies will enable analyses of proteins 
expressed at very low level in the cell. 
Third, our analysis certainly missed human proteins that are not expressed in HeLa cells. Although all 
the different cell types of an organism contain the same DNA, they do not necessarily express the same 
proteins. In fact, each type of specialized cell type has its own pattern of gene expression and, 
consequently, it contains a specific set of proteins [216]. Therefore, TAILS experiments using protein 
extracts from human cell lines other than HeLa, or from different human tissues, can be expected to 
identify additional proteins as (candidate) substrates of HML-2 Pro. Novel detections could involve 
hundreds of proteins, as can be inferred from studies comparing protein expression profiles across 
different cell lines. For instance, a recent comparative analysis of expression profiles of cancer cell 
lines derived from nine human tissue types reported that ~5000 proteins could be identified in at least 
one cell line of every single tissue group, while another ~5000 proteins showed a distinct expression 
pattern between tissues [69]. 
 
After all, the three above described limitations were not considered an issue in our experiments because 
we did not intend to identify all the cellular substrates of HML-2 Pro, instead we aimed to provide 
proof of principle of HML-2 Pro processing of cellular proteins and produce a representative list of 
potential substrates of HML-2 Pro that could represent a starting point for future investigations. 
 
5.1.9 Validation of substrates of HML-2 Pro identified by TAILS 
As our own and other studies (for instance, see [82][86]) demonstrated, proteomics-based technologies 
for protease substrate discovery produce meaningful results. However, it needs to be considered that 
such technologies have limitations with regard to reproducibility and sensitivity. Because of this, 
proteomics-based analysis may be regarded as screening strategies requiring biochemical and cell-
based assays for validation of putative substrates of proteases [182]. 
 
In our study, our compilation of data from TAILS experiments provided a list of proteins that we 
defined as “potential” substrates of HML-2 Pro since further experimental evidence will be required 
to validate their processing by HML-2 Pro. Other studies that employed TAILS or similar proteomics 
approaches for protease substrate identification typically reported specific experiments for validation 
of candidate proteins in vitro and, in some cases, in the cellular context (for instance, see [86,106,107]).  
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Since our study provided for the first time a collection of potential substrates of HML-2 Pro, it was 
particularly important to validate results from TAILS experiments. Therefore, we performed a number 
of specific experiments that aimed at verifying processing of candidate proteins both in vitro and in 
vivo. 
 
Independent from the approach employed, verification experiments for hundreds of proteins could not 
be performed for practical reasons. Various criteria can be applied for narrowing down proteins for 
further studies. For instance, some criteria applied by other studies prioritized 1) proteins with family 
members that are known substrates of the protease of interest or of similar proteases [157]; 2) proteins 
with specific aa residues in P1 and P1' of identified cleavage sites [86,107]; 3) proteins involved in 
molecular pathways of particular interest in the specific context of the study [86]; 4) proteins 
considered biologically relevant on the basis of their cellular localization [106]. Sometimes, proteins 
were chosen randomly (for instance, see [86]). 
We aimed at a reasonable number of candidate proteins for verification experiments. TAILS data 
included detailed information related to the proteins identified, for instance, position of the cleavage 
site, specific aa residues present at the cleavage site, molecular mass, GO terms for cellular localization, 
processes, functions. We applied several criteria to that additional information in order to filter a 
starting list of potential candidate proteins. 
 
To initially facilitate selection of proteins efficiently cleaved by HML-2 Pro, we started the filtering 
based on our list of 809 potential substrates identified in TAILS experiments at pH 5.5, for which the 
higher activity of HML-2 Pro favored higher confidence identification of substrates. The selection of 
candidates further involved a filter for certain aa residues in positions P1 and P1' of observed cleavage 
sites. After filtering for favored aa residues in positions P1 and P1' to be required for more efficient 
cleavage by HML-2 Pro, still 145 human proteins had to be considered as potentially processed by 
HML-2 Pro. Further filtering criteria therefore included a specific molecular mass range due to 
technical limitations of the in vitro transcription/translation system used for verification purposes, as 
well as cellular localization and potentially disease-relevant biological functions of candidates. The 
entire filtering procedure resulted in 14 candidate human proteins (see Table 20) to be further tested in 
in vitro and in vivo experiments. 
 
5.1.10 Verification experiments in vitro 
Employing specific cleavage assays in vitro, we investigated whether the 14 selected candidate proteins 
identified by TAILS were bona fide substrates of HML-2 Pro. In vitro cleavage assays are typically 
performed to validate targets of a protease of interest biochemically [86,106,157]. When considering 
other studies reported in the literature, approaches employed for such cleavage assays share a common 
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denominator, specifically they incubate a full-length candidate substrate with active or inactive 
protease of interest and document, taking into account control reactions, a reduced amount of full-
length candidate substrate and appearance of cleavage products, with these two criteria indicating 
processing of the full-length protein. 
 
For our verifications in vitro, selected candidate proteins were transcribed/translated in vitro 
introducing 35S-labelled methionines or, alternatively, an HA-tag in their C-terminus. Candidate 
proteins generated in vitro were incubated with purified HML-2 Pro under buffer conditions 
established for optimal HML-2 Pro activity. Control reactions lacked HML-2 Pro, or HML-2 Pro was 
inhibited by pepstatin A. Processing of HA-tagged or 35S-labelled candidate proteins was visualized 
through SDS-PAGE/Western blot or phosphor imaging, respectively. 
Our experimental approach was convenient regarding several aspects as briefly discussed in the 
following. The convenience of our system prompted us to subject a subset of 14 candidate proteins to 
in vitro validations, a number considerably higher compared to numbers of candidate proteins 
examined in similar studies [106,157,196]. The experimental system (TNT T7 system) used for 
generation of candidate proteins in vitro (see Material and Methods, chapter 3.2.2.2), allowed for 
expression of sufficient amounts of proteins, in a practical way while preserving the proteins' native 
state. As an alternative approach employed in other studies (for instance, see [86,157]), candidate 
proteins were transiently expressed in cells from specific expression plasmids, and cell lysates were 
used for incubations with the protease of interest. Instead, the TNT T7 system was suited for 
transcription/translation in an Eppendorf tube using PCR products as DNA templates. Generation of 
proteins in vitro required only 90 min of incubation and yielding sufficient amounts of proteins for our 
experiments. Thus, that approach did not require cloning steps for generation of specific expression 
plasmid constructs that would have been necessary for protein expression in cells. Moreover, protein 
extractions after transient expression in cells were not required, thus also reducing exposure of proteins 
to cellular factors causing denaturation or degradation of proteins. Altogether, the experimental 
procedure for verifications in vitro was less time consuming and more straightforward than procedures 
involving expression of candidate proteins in cells. 
Our approach allowed us to biochemically validate results from TAILS analysis using two detection 
approaches, HA-tag and a 35S-label. Two detection approaches proved advantageous for better 
visualization of processing products. Because the HA-tag was included at the C-terminus of proteins, 
the HA-tag approach could not detect processing products consisting of internal regions of candidate 
proteins lacking the HA-tag. However, such processing products could be detected via 35S-labeled 
methionine provided that the processing product contained a methionine and the signal was above 
detection limits.  
Sets of candidate proteins marked with the same tag/label were furthermore advantageous for 
experiments because it did not require specific antibodies for detecting candidate proteins in Western 
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blots. Antibodies are relatively expensive and may require optimization experiments. When validating 
14 different candidate proteins the use of different primary antibodies would have been relatively costly 
and more time consuming than the favored approach. 
 
Our verification assays confirmed processing by HML-2 Pro for 9 out of 14 candidate proteins in vitro. 
For 8 candidate proteins we documented formation of cleavage products accompanied by a more or 
less pronounced reduction of full-length protein. In two cases (HSP90AA1 and C15orf57) cleavage 
products were also observed in controls with pepstatin A, although at much lower level. The same was 
observed in positive control reactions monitoring processing of HML-2 Gag, a specific substrate of 
HML-2 Pro. Presence of cleavage products in controls with pepstatin A may suggest high specificity 
of HML-2 Pro for HSP90AA1 and C15orf57, the cleavage of which likely could not be completely 
inhibited by the amount of pepstatin A present in the reaction. For one candidate protein (PDIA3), 
cleavage was evidenced only by reduction of full-length protein. In that case, absence of detectable 
cleavage products could not be explained with certainty, although it could be due to small 
(undetectable) sizes of cleavage products. Verification of one candidate protein (DDX3X) remained 
ambiguous. 
The 9 verified substrates corresponded to 65% of candidate proteins selected. Projecting that 
percentage to the list of 145 proteins filtered for selection of candidates with favored amino acids in 
positions P1 and P1’ of TAILS-identified cleavage sites, one would expect approximately 80 other 
proteins with a high chance of successful verification of cleavage by HML-2 Pro. Moreover, it is 
conceivable that a multitude of potential substrates, initially excluded by filtering for favored aa 
residues in P1 and P1', could also be verified. As also discussed further below, certain experiments in 
vivo verified cleavage of proteins with no favored amino acids in P1 and P1' as per TAILS results. One 
would expect verification of those proteins also in vitro, where reaction conditions are highly favorable. 
In view of that, when projecting in vitro verification results to the unfiltered list of 809 proteins used 
for selection of candidates, one can expect not just 80, but hundreds of proteins with a high chance of 
successful verification of cleavage by HML-2 Pro. 
 
As speculated above, proteins with multiple cleavages could be particularly susceptible to HML-2 Pro 
processing. Out of the 9 validated candidates, 7 proteins showed multiple cleavages based on TAILS 
data, and 2 proteins showed a single cleavage. The majority of validated candidates showing multiple 
cleavages would be in line with our hypothesis at first sight. However, there was another aspect, 
described in the following, that was not in line with our hypothesis. Levels of reduction of full-length 
protein may provide indications of greater susceptibility of candidates with multiple cleavage sites to 
processing by HML-2 Pro. One may have expected greater reduction (in presence of HML-2 Pro) of 
full-length protein for those candidates with a higher number of cleavage sites. However, in our assays, 
reduction (in presence of HML-2 Pro) of full-length proteins showed variable levels among candidates, 
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with no obvious association between the level of reduction and the number of cleavage sites as reported 
by TAILS. This suggested that among the candidates tested susceptibility to cleavage by HML-2 Pro 
was independent of the number of cleavage sites. Certainly, additional specific investigations will be 
required in order to further elucidate this. 
 
As for verified candidate proteins with multiple cleavage sites, most of the time there was at least one 
cleavage product observed in verification experiments that was also predicted by cleavage sites 
predicted by TAILS. Such an overlap of results from different experimental approaches corroborated 
both experimental approaches. However, not all the cleavage products predicted by TAILS were 
observed in verification experiments. This incongruence could be due to higher sensitivity of TAILS 
in comparison with verifications in vitro. It is conceivable that several processing products generated 
in verification assays in vitro were below the detection limit of Western blot and phosphor imaging. 
Also, some processing products could not be detected even if present at high level, specifically 
processing products without the C-terminal HA could not be detected via Western blot, and processing 
products without methionines could not be detected via the 35S-label. Molecular weight of processing 
products must also be considered as a factor influencing detection. In particular, detection of cleavage 
products of low molecular weight was probably difficult in light of a relatively low concentration of 
polyacrylamide (10% or 12%) used in gels for SDS-PAGE. It is likely that that polyacrylamide matrix 
did not effectively separate smaller-sized protein fragments. Moreover, for experiments involving 
Western blot, it is likely that small-size proteins were not immobilized efficiently at the blot membrane 
during transfer. As can be seen in, for instance, Figure 35, Coomassie-stained blotted small-sized 
proteins appear much fainter in comparison with larger-sized proteins. Specific experiments aimed at 
identification of small-sized cleavage products could make use of gels with a higher concentration of 
polyacrylamide or gradient gels. Time of transfer during Western blot could also be optimized to avoid 
loss of small-sized proteins. 
 
5.1.11 Verification experiments in vivo 
So far, experiments demonstrating cleavage of human proteins by HML-2 Pro were based on an in 
vitro set-up. However, experiments in vitro are not necessarily representative of protein processing in 
the cellular, in vivo context. Within a cell, reaction conditions may vary. Proteins are not distributed 
homogeneously but may be enriched in cellular compartments. Conditions can differ considerably 
between cellular compartments. Proteins are subjected to protein turnover, that is, continuous synthesis 
and breakdown. Also, a multitude of cofactors play important roles by influencing molecular 
interactions. Thus, experimental verifications in vivo were fundamental to confirm that proteolytic 
activities observed for HML-2 Pro in vitro also applied to the complex environment of the human cell. 
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For our validations in vivo, we focused on five candidate proteins (CIAPIN1, HSP90AA1, MAP2K2, 
TUBA1A, C15orf57) for which processing by HML-2 Pro had been already verified by experiments 
in vitro. Those candidates included four proteins with well-known crucial functions in the human cell. 
CIAPIN1 is involved in the negative control of cell death [40]. HSP90AA1 is a molecular chaperone 
that promotes maturation, structural maintenance and proper regulation of specific target proteins 
involved, for instance, in cell cycle control and signal transduction [40]. MAP2K2 is a protein kinase 
known to play critical roles in important signal pathways involved in cell cycle regulation and 
proliferation [40]. TUBA1A is the major constituent of microtubules [40]. We also included C15orf57, 
a protein with currently unknown cellular functions [40]. 
 
The experimental approach used for validations in vivo consisted of transient co-expression of selected 
HA-tagged candidate proteins together with HML-2 Pro in HEK293T cells. As controls, candidate 
proteins were expressed without HML-2 Pro, or they were co-expressed with a mutant, enzymatically 
inactive HML-2 Pro. Cells were lysed 24 hpt and processing of candidate proteins was monitored via 
detection of the HA-tag by Western blot. Criteria for validating candidate proteins in vivo were the 
same as in verification experiments in vitro, i.e., document a reduced amount of full-length candidate 
substrate, ideally accompanied by appearance of cleavage products. 
 
Our experiments provided evidence of processing by HML-2 Pro for the five tested candidate proteins, 
providing first documentation of cellular substrate of HML-2 Pro in the cellular context. Moreover, in 
the course of our project, a collaboration with Dr. John Goodier (McKusick-Nathans Institute of 
Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA) allowed us 
to increase the number of cellular proteins confirmed as substrates of HML-2 Pro in vivo. Results from 
this collaboration have been published in Rigogliuso et al. (2019) [164]. In the laboratory of Dr. 
Goodier, a set of proteins of biological and clinical interest that were readily available as cloned cDNAs 
in that laboratory were co-expressed with HML-2 Pro in HEK293T cells. The HML-2 Pro co-expressed 
was identical to the one used in our own in vivo experiments as plasmid constructs for wild-type HML-
2 Pro and respective mutant Pro were provided by us. Tested proteins were each labeled with tags such 
as FLAG, T7, Myc, or HA. 
 
Experiments conducted in the laboratory of Dr. Goodier provided evidence of processing by HML-2 
Pro for 16 additional human proteins (see Table 22), so that a total of 21 different cellular proteins 
could be demonstrated as substrates of HML-2 Pro in vivo. The proteins verified in our own 
experiments and those of Dr. Goodier further validated our TAILS analysis as they were included in 
the list of 872 potential substrates of HML-2 Pro identified by TAILS. Moreover, 14 proteins verified 
in Dr. Goodier's laboratory did not present favored aa residues (for processing by HML-2 Pro) in P1 
and P1' as per TAILS results. Such evidence suggested that, among the 872 proteins identified as 
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potential substrates of HML-2 Pro, even proteins with unfavored aa residues in HML-2 Pro cleavage 
sites as identified by TAILS should be considered of interest for further validations. 
The 21 different human proteins validated in vivo can be considered as primary candidates for further 
studies aiming at elucidating potential roles of HML-2 Pro within the cell. For example, heat shock 
protein HSP 90-alpha (HSP90AA1), heat shock protein family A member 5 (HSPA5) and heat shock 
protein beta-1 (HSPB1) could represent interesting candidates for further studies. As apparent from 
their names, the three proteins are members of the same protein family, heat shock proteins (HSPs), 
and it is conceivable that even more proteins from the same family could be susceptible to processing 
by HML-2 Pro. We already verified processing of HSP90AB1 in vitro, observing similar cleavage 
products generated by the processing of HSP90AA1 both in vitro and in vivo. HSP90AB1 displays 
high aa sequence similarity with HSP90AA1 and HML-2 Pro cleavage site sequences, as identified by 
TAILS, were nearly identical in both proteins. Thus, there is significant information to believe that 
HSP90AB1 could be processed by HML-2 Pro in vivo as well. In any case, there is evidence to assume 
that cellular processes involving HSPs could be vulnerable to HML-2 Pro activity. Many HSPs 
(including the four mentioned above) are chaperones, i.e., factors assisting in protein folding, 
maintenance of proteome integrity, and protein homeostasis (proteostasis) [104]. Chaperones are 
upregulated upon stress conditions but also expressed under normal conditions to maintain proteostasis 
[104]. In view of our results, the network of molecular chaperones could potentially be deregulated in 
the case of HML-2 Pro expression. It is known that disruption of proteostasis is implicated in the 
pathogenesis of numerous diseases, including neurodegenerative diseases like Parkinson’s disease, 
Huntington’s disease and Alzheimer’s disease, but also other aging-related diseases like cancer [104]. 
Deregulation of HML-2 proviruses in several diseases including cancer and neurologic diseases has 
been already pointed out [35,64,171]. Further studies could investigate an association between HML-
2 Pro activity and deregulated proteostasis contributing to degenerative diseases. Such investigations 
could involve, for example, transient expression of HML-2 Pro in cells and monitoring of protein 
misfolding with associated formation of intracellular deposits of aggregated proteins, that is typical for 
several neurodegenerative diseases [104]. Techniques for monitoring protein misfolding and 
aggregation in living cells are available [74]. 
In the context of HSPs as targets of HML-2 Pro, an important piece of information was provided by 
an experiment performed in the laboratory of Dr. Goodier that documented processing of endogenous 
HSP90 protein by transiently expressed HML-2 Pro. HSP90 processing was monitored specifically by 
an α-HSP90 antibody. Documenting experimentally an altered level of constitutively expressed 
endogenous HSP90 protein in presence of HML-2 Pro provided additional support to the notion that 
endogenous counterparts of candidate proteins transiently expressed by us in verification experiments 
are also processed by HML-2 Pro. 
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5.1.12 Instability of processing products generated in vivo 
In our own and the experiments in the laboratory of Dr. Goodier, levels of processing of candidate 
proteins in vivo ranged from slight to complete reduction of full-length candidate protein, sometimes 
accompanied by presumed processing products. Different levels of reduction of full-length proteins 
and respective cleavage products could be due to variable specificity, thus cleavage efficiency, of 
HML-2 Pro against each candidate protein. Protein levels could have also been influenced by cellular 
factors, for instance, different turnover rates of candidate proteins within the cell. 
When considering experiments conducted in our laboratory, no processing products were detected for 
two candidates cleaved by HML-2 Pro in vivo. In the case of CIAPIN1, this was somewhat expected 
since no cleavage products could be detected via an HA-tag in an in vitro assay, likely due to cleavage 
in proximity of the HA-tag. For candidates with processing products detected in vivo, those products 
were of low amounts based on Western blot intensities, especially when compared with stronger 
signals observed in assays in vitro. Absence or low level of processing products could be a consequence 
of an instability of such processing products in the cellular environment. Improved experimental set-
ups could decrease a suspected instability of processing products, for instance, treatment of cells with 
proteasome inhibitors, thus inhibiting degradation of processing products. 
Assays performed in the laboratory of Dr. Goodier included proteasome inhibitor MG132, a peptide 
aldehyde commonly used for inhibiting multiple peptidase activities of the proteasome [90]. Several 
of the verification experiments done by Dr. Goodier documented reduction of full-length proteins 
without generation of detectable cleavage products, which may argue for instability of processing 
products even in presence of MG132. Other cellular factors could influence detection of cleavage 
products, for instance, processing of proteins in proximity of the tag with generation of small tagged 
peptides undetectable by Western blot due to inefficient separation during electrophoresis and binding 
to the Western blot membrane. Other studies employing MG132 in HEK293T cells applied different 
MG132 concentrations and different time points of cell exposure to MG132 [90]. In experiments by 
Dr. Goodier, HEK293T cells were treated with MG132 for 4-5 h at a final concentration of 10 µM. 
Alternative conditions for treatment of cells with MG132 could be tested to verify whether more 
optimal parameters may promote stability of cleavage products. In such experiments, inclusion of 
controls monitoring the proteasome activity under different conditions may be of benefit. A GFP-based 
proteasome functionality reporter detectable via Western blot might be employed in this context [122]. 
 
5.1.13 Processing products in vitro vs in vivo 
Processing products observed in vivo were similar in size to processing products observed in 
verification experiments in vitro. This overlap corroborated results, firmly indicating that proteolytic 
events verified in vitro were not just due to optimized in vitro conditions, instead such specific 
cleavages occurred in the same way under physiological conditions. 
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Such an overlap could not be verified for processing products identified in experiments in the 
laboratory of Dr. Goodier since respective proteins had not been subjected to specific verification 
experiments in vitro by us. However, we could verify that the size of processing products detected in 
experiments in the laboratory of Dr. Goodier matched well with cleavage products predicted by 
cleavage sites as identified in TAILS experiments. Those findings provide further evidence of the 
overlap between processing products detected in in vitro and in vivo experiments. 
 
5.1.14 Novel protein fragments generated by HML-2 Pro activity could have biological 
implications in cellular processes 
It was shown that HIV-1 Pro directly cleaves procaspase 8 with formation of a novel Casp8p41 
fragment which, in turn, induces apoptosis [147]. In a similar way, processing products generated by 
HML-2 Pro activity could have biological implications in the cellular processes. Concerning 
procaspase 8, the protein was present in our complete, unfiltered TAILS result list. However, the 
position of the cleavage was not located in the protein region necessary for release of the Casp8p41, 
suggesting that processing of procaspase 8 by HML-2 Pro would not have the biological implications 
reported for HIV-1 Pro. In any case, other cellular proteins could potentially produce biologically 
active products due to cleavage by HML-2 Pro. 
For example, caspase 1 was represented in the 872-protein list and is likewise an enzyme translated as 
a physiologically inactive zymogen that requires cleavages in order to become activated. Caspase 1 is 
activated by autoproteolysis which results in the generation of the two characteristic subunits of the 
catalytically active enzyme, as well as the removal of the N-terminal CARD (caspase activation and 
recruitment domain) [27]. As for the region within caspase 1 cleaved by HML-2 Pro, according to 
TAILS results caspase 1 was cleaved in the so-called “propeptide”, a region that represents a modulator 
of functional activity of proteases [47] and also harboring the CARD domain in the case of caspase 1. 
Maintaining enzymes in an inactive state is among the best-known functions of propeptides [47]. 
Caspase 1 is also known as interleukin-1 converting enzyme (ICE) for its ability to activate interleukin-
1 that plays a central role in the inflammatory response. One can hypothesize that, by cleaving the 
propeptide, HML-2 Pro could potentially activate caspase 1/ICE, thus indirectly also activating 
interleukin-1. Interleukin-1 is considered to play an important role in autoinflammatory diseases [94]. 
By indirect activation of interleukin-1, HML-2 Pro might trigger uncontrolled inflammatory response, 
that is a cellular process for which impairment was previously associated with HML-2 upregulation 
[62]. On the other side, HML-2 Pro processed caspase 1 at aa 34, while the CARD domain is usually 
released by cleavage at aa 103 [27]. Only approximately one third of the CARD domain is thus 
removed from caspase 1 by HML-2 Pro. The functional consequences of such a cleavage of caspase 1 
by HML-2 Pro are currently unknown and thus need to be investigated in more detail. Specific 
experiments to verify potential mechanisms of modulation of caspase 1 and interleukin-1 by HML-2 
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Pro would thus be of great interest. Specific analyses of other zymogens potentially activated by HML-
2 Pro substrates would be equally interesting but remain to be done as well. 
 
5.1.15 Use of HEK293T cells in verification experiments 
For verification experiments in vivo, we have used HEK293T cells because they were readily available 
to us and were advantageous regarding three important aspects. 
First, HEK293T cells do not express detectable amounts of endogenous HML-2 Pro, as we initially 
confirmed in preliminary experiments (not shown) detecting endogenous HML-2 Pro in HEK293T 
cells by employing an α-HML-2 Pro polyclonal antibody 9367 [185]. Absence of HML-2 Pro in 
HEK293T cells was also evident in all the verification experiments in vivo (see Figure 35) where HML-
2 Pro could not be detected (via α-HML-2 Pro antibody 9367 [185]) in HEK293T cells transfected 
with control plasmids, whereas it was clearly present in HEK293T transfected with HML-2 Pro-
encoding expression plasmid. Moreover, we attempted in another experiment detection of endogenous 
HML-2 Pro in various tumoral cell lines (see Figure 42). There was no endogenous HML-2 Pro 
detectable in untransfected HEK293T cells, the latter also included in that specific experiment as a 
negative control. 
Second, HEK293T could be readily transfected in order to transiently express proteins of interest, with 
relatively high transfection efficiencies and no detectable cytotoxicity. 
Third, expression of proteins of interest in HEK293T proved very efficient when driven from a CMV 
promoter [158] that was present in plasmid constructs employed. 
 
5.1.16 Experiments in vivo did not involve exactly the same subregion of HML-2 Pro 
ORF used for experiments in vitro. 
HML-2 Pro expressed in in vivo experiments was not identical to HML-2 Pro expressed in in vitro 
experiments. In particular, Pro expressed in in vitro experiments consisted of a subregion of the HML-
2 Pro ORF excluding a C-terminal region that was included in HML-2 Pro expressed in vivo. Since the 
C-terminal region was suggested to exert a regulatory/inhibitory effect in cis against HML-2 Pro 
activity [205] the in vivo experimental design may be closer to physiological conditions in this regard. 
We therefore tested HML-2 Pro activity in vivo in presence of the C-terminal region. In view of the 
potentially relevant experimental differences, a quantitative comparison of proteolytic activity of 
HML-2 Pro between experiments in vitro and in vivo was not attempted. However, we noticed that 
presence of the C-terminal region did not alter HML-2 Pro activity considerably, as the enzyme was 
still capable of efficient self-cleavage and cleavage in trans. Moreover, examples of candidate proteins 
cleaved in the same positions by both HML-2 Pro variants, evidenced by similar-sized cleavage 
products, indicate that identical cleavages could be catalyzed with or without the C-terminal region. 
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5.1.17 HML-2 Pro was expressed at levels sufficient for observing its activity 
In order to document HML-2 Pro activity within cells, we had to avoid undetectable processing of 
candidate proteins because of low-level expression of HML-2 Pro. Two expedients were considered to 
express HML-2 Pro at a level sufficient for observing its activity. 
First, our in vivo experimental set-up relied on plasmid constructs that enabled high expression of 
HML-2 Pro from a human cytomegalovirus (CMV) immediate-early promoter present. A CMV 
promoter is commonly used to drive gene expression in mammalian expression vectors, and although 
its promoter efficiency can be variable from cell to cell, CMV is known to induce strong expression in 
HEK293T cells [158]. 
Second, with regard to HML-2 proviral structure it is known that HML-2 Pro is translated as a Gag-
Pro polyprotein from which HML-2 Pro self-processes [78,185]. Since HML-2 Gag-Pro precursor 
protein is translated via an occasional ribosomal frameshift between Gag and Pro ORFs, lesser amounts 
of Pro are thus likely produced in cells in comparison with Gag. To promote high levels of HML-2 
Pro, HML-2 Pro was not expressed as Gag-Pro precursor in our experiments but as a precursor 
comprised of a subregion of the Pro ORF, from which Pro then self-processed. We assumed that, 
independent of the Pro precursor HML-2 Pro would, once released, exhibit identical proteolytic 
activity. This assumption was supported by equivalent proteolytic activity exhibited by HML-2 Pro 
and EGFP-Pro, the two different HML-2 Pro precursors transiently expressed in our experiments in 
vivo (Figure 35, compare Aa and Ab). 
 
5.1.18 Monitoring of HML-2 Pro activity while expressed in cells 
Our experimental design ensured monitoring of HML-2 Pro activity within cells and not during or after 
isolation of cell lysates. Following protein expression, cell lysis was performed in presence of a cocktail 
of protease inhibitors, that prevent degradation of proteins by cellular proteases during cell lysis. 
Notably, the lysis buffer employed included pepstatin A to ensure that candidate proteins were not 
processed by HML-2 Pro during and after cell lysis. The same precaution applied to experiments 
performed in the laboratory of Dr. Goodier.  
 
5.1.19 HA-tag is not processed by HML-2 Pro  
During our verification experiments, we ruled out the possibility that HML-2 Pro may have cleaved 
the HA-tag added to the C-teminus of candidate proteins, thus misleading interpretation of results. That 
hypothesis arose from considerable reduction of some full-length proteins in presence of HML-2 Pro 
but no apparent cleavage products. We ruled out processing of the HA-tag for the following reasons. 
First, if the HA-tag would have been processed by HML-2 Pro, all candidate proteins incubated with 
active HML-2 Pro should have shown a similar reduction of full-length protein due to processing of 
the HA-tag. This was not the case, specifically levels of full-length protein reduction were very variable 
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among candidates, with candidate proteins not affected by presence of active HML-2 Pro. Second, 
experiments performed by Dr. Goodier showed reduced levels of full-length protein for candidate 
proteins tagged with epitopes other than HA. This supports the conclusion that the observed cleavage 
of candidate proteins was not due to specificity of HML-2 Pro against the HA-tag of candidate proteins. 
 
5.1.20 Processing of candidates or HA-tag is not due to activation of apoptosis 
We were able to document cell death following expression of HML-2 Pro in cells (see later). As for 
verification experiments in vivo, we therefore had to consider activation of caspases. It was previously 
reported that the HA-tag loses immunoreactivity during apoptosis by cleavage by caspase-3 and-7 
[181]. Also, candidate proteins might have been processed by caspases rather than HML-2 Pro. 
We ruled out those concerns. First, verification experiments in vivo involved candidate proteins for 
which processing had been verified in experiments in vitro. Experiments in vitro did not involve 
caspases; thus, processing of candidate proteins could be attributed solely to HML-2 Pro, the specificity 
of which was further demonstrated by reduced processing in the presence of pepstatin A. Moreover, 
processing products observed in vivo were of sizes similar to those of processing products observed in 
vitro, providing additional strong evidence that they were generated specifically by HML-2 Pro activity 
and not by caspase activity. 
Second, FACS data (see Figure 40) showed that 24 hpt, the time point when cell lysates for 
verifications in vivo were collected, only a minor proportion (~6%) of the cell population expressing 
HML-2 Pro was undergoing cell death. Thus, if processing of candidate proteins in verification in vivo 
was due to activation of apoptosis, one would expect only a slight reduction (~6%) of full-length 
protein signal for all proteins tested. This was not the case in our verifications in vivo, in fact, amounts 
of full-length candidate proteins were reduced considerably (greater than 6%) in presence of HML-2 
Pro, with complete disappearance of the full-length protein in one case (C15orf57). 
Third, measuring levels of cleaved PARP and caspase 3, both cellular markers of apoptotic proteolytic 
processes, amounts of those proteins were reduced considerably following treatment of cells with 
apoptosis-inducing staurosporin. However, activation of apoptosis by staurosporin, together with 
activation of caspases did not reduce amounts of full-length candidate proteins and did not induce 
formation of processing products derived from candidate proteins. 
Fourth, verification experiments performed in the laboratory of Dr. Goodier also showed reduced 
levels of full-length protein for candidate proteins carrying epitope-tags other than HA. 
 
5.1.21 Establishing conditions for more physiological expression levels of HML-2 Pro 
As mentioned above, high level expression of HML-2 Pro was important for the purpose of our 
investigation. Further analyses may establish more physiological expression levels of HML-2 Pro in 
cell culture experiments. This could be achieved by, for instance, plasmid constructs carrying 
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promoters inducing lower expression levels of cloned coding sequences compared to CMV. Human 
ubiquitin C promoter (UBC), mouse phosphoglycerate kinase 1 promoter (PGK) and herpes simplex 
virus thymidine kinase (TK) promoter are examples of promoters that have been shown to be much 
weaker than CMV [63,158]. Employing conventional cloning strategies, CMV promoter could be 
replaced in our so far expression plasmids by one of those weaker promoters, or HML-2 Pro coding 
sequences could be cloned into eukaryotic expression vectors harboring respective promoters.  
 
In order to establish more physiological expression systems, knowledge of physiological amounts of 
endogenous HML-2 Pro in cells in the disease-context would be very helpful. In preliminary 
experiments (discussed in more detail further below), we investigated presence of endogenous HML-
2 Pro in cell lines derived from tumor tissues with known upregulated HML-2 transcription. 
Endogenous HML-2 Pro levels in those cell lines were above Western blot detection limits when using 
an α-HML-2 Pro polyclonal antibody 9367 [185]. Levels of endogenous HML-2 Pro was much lower 
in those cell lines than the level of HML-2 Pro in transiently transfected HEK293T cells. However, we 
also established experimentally that endogenous HML-2 Pro present in those cell lines efficiently 
processes a transiently expressed HML-2 Pro precursor (unable to self-process) in trans. This 
suggested that, proteolytic activity of HML-2 Pro at physiological levels was sufficient to detect its 
proteolytic activity in Western blot experiments (this aspect is discussed in more detail further below). 
Levels of endogenous HML-2 Pro present in those cell lines thus may be employed as a reference for 
establishing additional tools to express HML-2 Pro at physiological levels. 
 
5.1.22 Advantages of an EGFP-fused HML-2 Pro 
HML-2 Pro was expressed as a sole HML-2 Pro or as an EGFP-fused HML-2 Pro (EGFP-Pro). Both 
forms consisted of the HML-2 Pro precursor including the HML-2 Pro self-processing sites that 
allowed for monitoring of HML-2 Pro autocatalytic activity. EGFP could be readily detected through 
Western blot, providing a suited system for monitoring the self-processing of EGFP-Pro. The EGFP-
Pro set-up was favorable when monitoring transfected cells under the microscope regarding 
transfection efficiency and cell viability of EGFP-positive cells. In both set-ups HML-2 Pro exhibited 
autocatalytic activity, releasing itself from the precursor protein as expected. Also, the HML-2 Pro 
activity against cellular substrates was not different between the two HML-2 Pro variants. Thus, the 
EGFP-tag did not seem to affect HML-2 Pro activities. In view of the experimental advantages, the 
EGFP-Pro may be preferable for further studies on HML-2 Pro in vivo. 
 
5.1.23 Potential involvement of HML-2 Pro in cell death 
This work comprises an initial investigation of a potential involvement of HML-2 Pro in cell death. 
During cell culture experiments, we noted that expression of HML-2 Pro in HeLa or HEK293T cells 
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caused altered cell morphology accompanied by detachment of cells from the surface of tissue culture 
flasks. Accumulation of cells floating in the culture medium became particularly evident around 24 
hpt, when HML-2 Pro expression was ongoing for several hours. Floating cells were of a rounded 
morphology, suggesting that they were undergoing cell death, potentially apoptosis. Such a phenotype 
appeared considerably reduced when HML-2 Pro was expressed in presence of 1 µM indinavir, a potent 
inhibitor of HIV-1 Pro [209]. Moreover, cells were not affected in a similar way when an HML-2 Pro 
inactive mutant was expressed. This lead us to conclude that the observed cell death was a direct 
consequence of HML-2 Pro activity. 
Analysis of apoptosis markers showed enhanced activation of apoptotic processes likely due to HML-
2 Pro activity. In particular, 24 hpt, levels of cleaved PARP and caspase 3, two commonly used 
apoptosis markers, were significantly higher in cells expressing HML-2 Pro when compared with cells 
expressing inactive HML-2 Pro and untreated cells. This observation suggested that apoptosis may be 
the actual mechanism of cell death that is activated by HML-2 Pro. This would be in line with a 
previous report that HIV-1 Pro induces cell death via the apoptotic pathway [169]. For COS7 cells 
expressing HIV-1 Pro, morphological changes typical of necrosis have been observed [18], suggesting 
that mechanisms of cell death other than apoptosis could also be triggered by HIV-1 Pro. As for HML-
2 Pro, one cannot rule out involvement of different mechanisms of cell death based on the currently 
very limited state of knowledge.  
 
Using fluorescence microscopy, we focused on the Pro-positive cell population present in in vivo 
expression experiments. In one experiment, after HML-2 Pro expression in HeLa cells, Pro-positive 
cells were immunostained with α-HML-2 Pro polyclonal antibody 9367 [185]. In another experiment, 
we expressed EGFP-Pro, that self-processes releasing EGFP and Pro, in HEK293T cells and visualized 
EGFP-positive (thus Pro-positive) cells. In both experiments, we visualized by fluorescence 
microscopy the Pro-positive cell population. Many cells expressing HML-2 Pro were of a normal 
morphology, even 24 hpt. This suggested that only a small proportion of the Pro-expressing cell 
population was driven into cell death during the course of the expression experiment. We quantified 
by FACS analysis the relative amount of cell death following HML-2 EGFP-Pro expression in 
HEK293T cells. We found that 24, 30 and 48 hpt, the proportion of HML-2 Pro-expressing dying or 
dead cells represented approximately 6%, 12% and 15%, respectively, of the entire cell population. 
However, these numbers indicate that many Pro-positive cells were still alive up to 48 hpt. Those cells 
represented approximately 50% of gated live cells. Based on those findings, HML-2 Pro does not seem 
to exert a cytotoxic effect that induces cell death inevitably. The reasons for why not all cells respond 
in the same way to HML-2 Pro expression remain to be clarified. Experiments monitoring Pro-
expressing cells later than 48 hpt should be addressed specifically in order to elucidate whether cells 
can survive even after overexpressing HML-2 Pro for longer time periods. 
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Among potential cellular substrates of HML-2 Pro, approximately 100 proteins were involved in cell 
death (discussed also below). Those proteins included negative and positive regulators of apoptosis. 
One can speculate that HML-2 Pro activity might impair levels of apoptosis regulators, thus promoting 
or suppressing induction of cell death. Involvement of HML-2 Pro in cell death may have pathological 
implications. Alteration of apoptotic processes is related to cancer, neurological disorders, 
cardiovascular disorders and autoimmune diseases [55]. Among diseases that have been associated 
with HML-2 [64], there are several cell-death related diseases including various types of cancer and 
amyotrophic lateral sclerosis. By influencing apoptotic processes, HML-2 Pro may have crucial roles 
in development of diseases associated with cell death. 
More specific investigations will be required to elucidate in more detail the mechanism(s) by which 
HML-2 Pro causes cell death.  
 
5.1.24 Preliminary experiments showing presence of endogenous HML-2 Pro in human 
cells 
We demonstrated presence of enzymatically active endogenous HML-2 Pro in cell lysates from two 
cell lines derived from teratocarcinoma, namely Tera-1 and NCCIT, and two cell lines derived from 
human melanoma, namely SK-MEL-28 and MeWo. We focused on those cell lines because they are 
derived from tumor types with upregulated HML-2 expression [28,171,179]. Our findings 
corroborated in particular findings for Tera-1 and NCCIT cell lines, for which presence of endogenous 
HML-2 Pro had been reported before [112,179]. In Sauter et al. (1995) [179] expression of endogenous 
HML-2 Pro in Tera-1 cells was demonstrated indirectly by detection of processed HML-2 Gag-derived 
proteins. Similarly, Kuhelj et al. (2001) [112] observed processing of endogenous HML-2 Gag in 
NCCIT cells, moreover demonstrating that Gag processing could be blocked by synthetic Pro 
inhibitors, further supporting the HML-2 Pro involvement. In our experiments, HML-2 Pro was 
detected by Western blot using α-HML-2 Pro polyclonal antibody 9367 [185], that we also employed 
for detection of HML-2 Pro transiently expressed in bacteria and human cells. Our experiments 
provided direct evidence for self-processed, mature HML-2 Pro, corroborating previous reports on 
presence of enzymatically active HML-2 Pro in teratocarcinoma cells. Presence of enzymatically 
active HML-2 Pro in melanoma cell lines was not reported so far, thus such an enzyme activity was 
demonstrated in this study for the first time. Based on our results, HeLa cells may also express 
endogenous HML-2 Pro since a protein with a size of self-processed HML-2 Pro (~18 kDa), was 
detected at very low level also in this cell line. Such an observation was not in line with a previous 
Western blot experiment (not shown) that we performed to identify a cell line suitable (likely not 
expressing HML-2 Pro at high level) for preparation of total protein lysates for TAILS reactions 
(discussed above). This discrepancy probably was due to enhanced chemiluminescence (ECL) reagents 
employed in the two experiments. SignalFireTM ECL Reagent was employed in the first experiment 
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and SignalFireTM Elite ECL Reagent (both from Cell Signaling Technology) was employed in 
subsequent experiments. The Elite reagent is particularly suited for detection of very low abundance 
proteins. 
 
We did not attempt absolute quantification of endogenous HML-2 Pro detected in investigated tumor 
cell lines. However, we noticed that HML-2 Pro levels were much lower than levels of recombinant 
HML-2 Pro overexpressed in HEK293T cells. This was not surprising as HML-2 Pro expression from 
plasmid constructs was driven by a strong CMV promoter, very likely not comparable with 
physiological protein expression. 
 
Our experimental findings indicate that endogenous HML-2 Pro is active and capable of proteolytic 
activity. In fact, transient expression of EGFP-Pro-mut (the precursor that harbors sites for HML-2 Pro 
self-processing but that is unable to self-process) in Tera-1, MeWo and SK-Mel cells lines resulted in 
processing of EGFP-Pro-mut, with release of Pro and EGFP subregions, as expected in presence of 
endogenous HML-2 Pro activity. The amount of such processing was reduced in the presence of HIV 
Pro inhibitor indinavir. It thus can be concluded that active HML-2 Pro present in those cells processed 
EGFP-Pro-mut through proteolytic activity in trans. Speculations about involvement of HML-2 Pro in 
tumor diseases benefit from our results showing presence of mature and functional HML-2 Pro in 
various tumor cell lines. For further studies, it would be interesting to investigate endogenous HML-2 
Pro in a greater number of cell lines with known or suspected HML-2 expression. Various healthy and 
disease-derived tissues show transcription of HML-2 [113]. For a screening experiment examining 
presence of HML-2 Pro, involvement of cell lysates from normal and disease-derived human tissues 
could be also of interest. For an investigation of cell/tissue types potentially expressing HML-2 Pro, 
development of an α-HML-2 Pro monoclonal antibody could be of great benefit. The α-HML-2 Pro 
polyclonal antibody 9367 [185] employed in this study is currently the only one available to us for 
probing HML-2 Pro. Use of a monoclonal antibody would likely increase sensitivity and specificity of 
HML-2 Pro detection, reducing the risk of ambiguities that arise from polyclonal antibodies cross-
reacting with unspecific proteins. An α-HML-2 Pro monoclonal antibody could also be valuable to 
investigate with higher specificity cellular localization of HML-2 Pro via immunofluorescence 
microscopy. 
 
5.1.25 Proteins processed by HML-2 Pro locate to various cellular compartments and 
participate in diverse cellular processes 
The list of human proteins that we identified by TAILS as potential HML-2 Pro substrates represents 
an important reference for further investigations regarding the impact of HML-2 Pro in cell biology. 
We employed that protein list to evaluate cellular compartments in which potential Pro substrates 
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localize and biological processes in which they participate. For such analysis we used Gene Ontology 
(GO), a system that is used to classify proteins in protein databases. GO classifies proteins via specific 
hierarchically-organized terms and thus annotates information associated with proteins. We subjected 
the 872 proteins in our list to GO term analysis via PANTHER (Protein Analysis Through Evolutionary 
Relationships) classification database [140]. Information on cellular localization and biological 
processes of potential HML-2 Pro substrates was retrieved. 
Cellular proteins potentially susceptible to HML-2 Pro activity are localized in major cellular 
compartments including cytosol, nucleus and plasma membrane. A number of proteins also localized 
to exosome, secretory granules and primary lysosome. Of note, those organelles are characterized by 
acidic pH, thus one could suppose that if HML-2 Pro locates to such compartments, particular 
organelle-associated proteins could be cleaved relatively efficiently. Also, several proteins are 
associated with the mitochondrion, which could be relevant in view of the fact that HIV-1 Pro has been 
reported to localize to and cause biological effects in the mitochondrion [169]. Considering that our 
experimental approach for substrate identification involved a protein mixture derived from a total cell 
lysate, it was not surprising that proteins cleaved by HML-2 Pro derive from different cellular 
compartments. Since there is no published information regarding HML-2 Pro cellular localization yet, 
it is unknown whether HML-2 Pro could locate in the various above-mentioned compartments. In case 
of HML-2 Pro expression, proteins identified by us and associated with those cellular compartments 
could be likely subjected to HML-2 Pro proteolysis if HML-2 Pro locates in those compartments. 
Although, proteins located in cellular compartments where HML-2 Pro is not specifically located could 
be processed anyway during trafficking to those compartments. As a consequence, HML-2 Pro could 
potentially have a direct or indirect impact in those cellular compartments. 
 
Besides the observation that potential HML-2 Pro substrates located to different cellular compartments, 
it was not unexpected that those proteins were also involved in a multitude of biological processes 
including response to stress, immune response, cell death, cell cycle regulation, DNA repair, DNA 
replication, translation, mRNA modification, protein folding. Thus, various processes that are crucial 
for cellular functions could be potentially affected by enzymatically active HML-2 Pro. Some 
biological processes that could be influenced by HML-2 Pro activity appear as particularly relevant. 
Approximately 200 different human proteins were associated with response to stress. Stress conditions 
trigger a global reprogramming of gene transcription [216], that could potentially also increase 
transcription of HML-2 proviruses, thus expression of HML-2 Pro. Results from our experiments allow 
to speculate that HML-2 Pro expression in stressed cells could affect the stress response by altering 
levels of stress response proteins. In the light of a list of 200 potential protein substrates it is currently 
difficult to evaluate if such a modulation would be negative or positive for the cell. Specific 
experiments investigating such aspects would be of great value in order to understand the impact of 
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HML-2 Pro on the stress response. As mentioned above, HML-2 Pro likely processes various heat 
shock proteins in vivo, that have crucial roles in the stress response.  
 
Approximately 100 human proteins being potential substrates of HML-2 Pro in vitro were associated 
with organization of the cytoskeleton. This observation is in line with findings from previous studies 
that identified cellular substrates of other retroviral proteases. For instance, there is evidence that HIV-
1 Pro cleaves cytoskeletal proteins actin, myosin, tropomyosin [189], tubulin [82], and microtubule 
associated proteins [213], all of which were also identified in our screening as potential substrates of 
HML-2 Pro. Of note, we verified processing of tubulin alpha-1A chain (TUBA1A) in vivo, providing 
further evidence that HML-2 Pro could potentially influence the cytoskeleton. Since the cytoskeleton 
is associated with a multitude of cellular functions including mechanical resistance, intracellular 
transport, cellular signaling, chromosome segregation, one can speculate that, through processing of 
proteins involved in the organization of the cytoskeleton, HML-2 Pro activity could influence many 
cellular processes. 
 
Approximately 100 potential substrates of HML-2 Pro were associated with regulation of cell death. 
This finding is also in line with previous reports on HIV-1 Pro. For instance, there is documented 
cleavage of mitochondrial proteins by HIV-1 Pro followed by induction of molecular events leading 
to apoptosis [169]. Several proteins in our list were associated with apoptosis and/or mitochondrial 
organization, with the latter being involved in the activation of the intrinsic apoptosis pathway. Among 
cell death mechanisms, apoptosis could be effectively influenced by HML-2 Pro, as our specific 
investigation in that regard has demonstrated (see above). Among the apoptosis factors identified, 
cytokine induced apoptosis inhibitor 1 (CIAPIN1) was verified by us in experiments in vivo. CIAPIN1 
is involved in negative control of cell death via an anti-apoptotic effect. One can speculate that 
processing of this anti-apoptotic factor by HML-2 Pro may reduce its cellular levels, thus potentially 
promoting activation of apoptosis. It is known that both reduced and increased apoptosis can have 
pathological relevance [55]. Various types of cancer, neurological disorders, infectious diseases, 
autoimmune diseases are among the diseases influenced by altered apoptotic mechanisms. Impairment 
of the apoptotic pathway due to HML-2 Pro activity may have a role in those diseases. 
 
5.1.26 Overlap of potential substrates of HML-2 Pro with cancer-relevant genes/proteins  
HML-2 has been implicated in tumor development in previous studies, and its upregulation has been 
associated with several tumor types [6,15,76,171]. HML-2 proteins Env, Rec and Np9 have been 
investigated regarding their tumorigenic properties [19,33,119]. The potential role of HML-2 Pro in 
cancer remains unexplored, although endogenous HML-2 Pro activity has been observed in various 
tumor tissues and derived cell lines [112,179]. We therefore performed more specific analyses to 
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evaluate the involvement of HML-2 Pro substrate proteins in tumor diseases. The genes corresponding 
to the 872 human proteins identified as potential substrates of HML-2 Pro were intersected with genes 
included in the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, an online database 
that contains up-to-date information on known cancer genes and associated tumor types. Our analysis 
identified 64 human genes/proteins (in the following referred to as proteins for the sake of simplicity) 
with a known relevance in oncology. One can speculate that altered amount or altered functionality of 
those proteins, due to processing by HML-2 Pro, could represent a mechanism contributing to tumor 
development. Based on information retrieved from the COSMIC database, the 64 identified proteins 
were associated with a total of 59 tumor types. Many proteins were associated with more than just one 
tumor type (see Table 19), thus having stronger evidence of an involvement in tumor diseases. Those 
proteins could deserve particular attention in the context of HML-2 Pro as a potential promoter of 
tumor development. Several of the tumor types identified in our analysis were associated with HML-
2 previously, i.e, melanoma [29,183], ovarian cancer [215], prostate tumor [113], breast cancer [214], 
brain cancer [58], and lymphoma [42]. Endometrial carcinoma, also included in our results, was not 
directly associated with HML-2 before, although HERV-encoded proteins derived from other HERV 
groups were found in such tumor type [171]. The HML-2 Pro substrates overlapping with the COSMIC 
collection could represent a key to elucidate molecular mechanisms behind the association of HML-2 
upregulation and development of abovementioned tumor types. For instance, one can speculate that 
expression of HML-2 Pro in melanocytes could impair B2M, ERCC5 and MAP2K2 proteins, three 
potential substrates of HML-2 Pro that are associated with melanoma, thus potentially triggering 
molecular mechanisms leading to melanoma. More specific investigations will be necessary and of 
great interest in order to reveal such unknown aspects behind tumor diseases. 
 
Our analysis revealed many tumor types that, to our knowledge, have not been associated with HML-
2 so far, like colorectal cancer, papillary thyroid cancer, glioblastoma, epithelial lung cancer. In view 
of the notion that HML-2 Pro could potentially negatively affect proteins involved in those diseases, 
those tumor types could be investigated for presence of HML-2 transcripts and HML-2 Pro. Such 
investigations could eventually reveal unknown associations between HML-2 and specific tumor types. 
 
5.1.27 Overlap of potential substrates of HML-2 Pro with OMIM database 
We also intersected the list of 872 potential substrates of HML-2 Pro with genes and phenotypes 
compiled in the Online Mendelian Inheritance in Man (OMIM) database. A total of 289 diseases was 
identified in which HML-2 Pro could potentially have a role. Diseases of particular interest in the 
context of HML-2 included, apart from several types of tumors, various neurological diseases. Notably, 
five proteins (SOD1, VCP, HNRNPA1, TUBA4A, SQSTM1) have been associated with ALS, a 
disease that has been associated with HML-2 before [121]. Though, the role of HML-2 in the 
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pathophysiology of ALS is not clear at the moment, HML-2 Pro and ALS may be pathologically 
connected by an activity of HML-2 Pro against human proteins having a potential or factual role in 
ALS. 
Overall, above described disease associations currently remain speculative, but provide rationale for 
further investigations concerning the role of HML-2 Pro in cancer and other diseases. 
 
5.1.28 Conclusions for HML-2 Pro 
The approach used in our investigation successfully combined TAILS with profiling of potential 
substrates of HML-2 Pro and experimental verification of candidate proteins in vitro and in vivo. As 
our results have shown, such an experimental approach represents a valuable strategy to get insight 
into potential substrates of under-investigated proteases. Our study revealed that hundreds of human 
proteins are potential substrates of HML-2 Pro. The vast list of HML-2 Pro substrates that we obtained 
is a precious source of information for further research in the context of retrovirus-encoded proteases. 
We provided experimental evidence to believe that, if expressed, HML-2 Pro could potentially affect 
levels of proteins involved in important cellular processes and disease-relevance. We obtained 
preliminary evidence for expression of functional HML-2 Pro in various tumoral cell lines, although 
the physiological consequences of an active HML-2 Pro within cells need to be elucidated. We initially 
characterized cell death following transient expression of HML-2 Pro and observed that apoptotic 
processes may be activated in the presence of HML-2 Pro activity. Our observations call for further 
studies that could elucidate the impact of HML-2 Pro expression on cell biology. Experiments 




5.2 HML-2 integrase 
5.2.1 Investigations of HML-2 IN as a potential genotoxic agent  
The second part of our studies on biological relevance of enzymatically active HML-2 proteins focused 
on HML-2 IN. Kitamura et al. (1996) [105] demonstrated that IN of HERV-K10 (an HML-2 provirus) 
is active and capable of typical catalytic activities of retroviral INs (see Introduction). That finding 
raises the question of cellular consequences of an active retroviral IN potentially expressed in human 
cells. As an enzyme that specifically interacts and cleaves DNA molecules, HML-2 IN could contribute 
to genome instability. Bray et al. (2016) [25] remarked that several HML-2 loci are able to encode an 
intact IN. Transcripts derived from various HML-2 loci having an intact IN ORF were demonstrated 
in tumor tissues and derived cell lines [58,183]. Such evidence lets one hypothesize that an active 
HML-2 IN could be present in human cells and cause DNA damage, thus contribute to human disease. 
 
Retroviral INs are known to induce DNA lesions during the process of provirus formation, during 
which a double-strand break (DSB) is created in the host cell DNA, leaving single-strand DNA 
(ssDNA) gaps that flank the site of viral genome integration [172]. DNA damage could be induced 
also via the so-called nonspecific c [100], an activity that has been shown for retroviral INs from 
different genera [151,193]. Nonspecific alcoholysis by a retroviral IN can potentially nick a DNA 
sequence in any position, independently of the presence of viral LTRs. That activity of transiently 
expressed HIV-1 IN may cause mutagenic effects leading to a lethal phenotype in yeast cells [151]. 
Besides typical retroviral activities, HML-2 IN may exert nonspecific alcoholysis as well, although 
this has not been investigated so far. 
As a consequence of genotoxic stress potentially induced by HML-2 IN, DNA double-strand breaks 
(DSBs) might occur in the cellular genome [192]. In particular, at the level of DNA single strand 
damage, nuclease activity or spontaneous hydrolysis could induce generation of DSBs [193]. DSBs 
are particularly severe DNA lesions because DSB repair by the host machinery is intrinsically more 
complex than that of other types of DNA damage [103]. Induction of DSBs by HML-2 IN could have 
an impact on the cell biology considering that DSBs stimulate inflammatory immune response, trigger 
programmed cell death and cause deleterious mutations increasing the risk of tumorigenesis [103,210]. 
Until now, there are no published studies having investigated the ability of HML-2 IN, or any other 
ERV-derived IN, to induce DNA lesions in the host genome. In this study, we attempted an experiment 
to initially investigate genotoxicity of HML-2 IN in vivo. The strategy that we adopted counted DSBs 
induced in cells transiently expressing wild-type HML-2 IN (IN-wt) and compared numbers with those 
in cells expressing an inactive HML-2 IN (IN-mut) due to a mutated catalytic site. Untransfected cells 
were also examined as another control. All the cells included in the analysis were in the same phase of 
the cell cycle (see below). DSBs were examined by probing tumor suppressor p53-binding protein 1 
(53BP1) and by immunofluorescence microscopy. 53BP1 is a key player in the DSB repair pathway 
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[150] that is assembled at sites of DNA damage as a scaffold for recruitment of other DSB-responsive 
proteins [150]. 53BP1 is a commonly used marker for DNA damage that, when probed with specific 
antibodies, can be visualized under the fluorescence microscope as discrete foci that co-localize with 
DSBs in the host genome [132]. An abnormal number of 53BP1 foci in presence of a genotoxic agent 
is indicative of induction of DSBs by that particular agent. DNA damage induced by different types of 
genotoxic stress, for instance, ionizing and UV radiation, camptothecin, etoposide and alkylating agent 
methylmethanesulfonate, have been shown to trigger recruitment of 53BP1 to discrete nuclear 
foci [159]. 
In this work, we examined HML-2 IN activity as a potential genotoxic agent. The number of 53BP1 
foci counted in IN-wt were not significantly different from numbers of 53BP1 foci in control cells (IN-
mut and untransfected). We observed a relatively large standard deviation for foci per cell (see Figure 
45 D), with approximately 3 foci per cell for each group (70 cells per group). A previous study [132] 
investigating the dose-response of 53BP1 foci to IR reported that control unirradiated HeLa cells 
contained one or two 53BP1 foci when analyzed 24 h post-irradiation. In view of that report, presence 
of some 53BP1 foci in untreated HeLa cells could be expected in our experiments. With regard to 
53BP1 foci number, we observed a seemingly slightly higher standard deviation for IN-wt than 
controls. It remains to be seen whether an effect of HML-2 IN activity on DSBs formation could be 
potentially revealed by analysis of a larger number of cells than in our initial experiments. Rappold et 
al. (2001) [159] documented a variation in size of 53BP1 foci depending on the genotoxic agent 
applied. We also examined sizes of 53BP1 foci in treated cells, as sizes of foci may have been affected 
by HML-2 IN activity. We did not notice significant differences in size of 53BP1 foci when comparing 
IN-wt with controls. Most of the 53BP1 foci showed a very small size in all the cells examined, 
although sporadically larger foci were observed. Taken together, our experiments did not provide 
evidence to conclude that HML-2 IN can damage DNA in a way causing formation of DSBs. 
 
5.2.2 Caveats and pitfalls of our initial experiments assaying HML-2 IN 
Results from our initial experiments assaying HML-2 IN should be interpreted with caution. Several 
factors might have influenced the outcome of our analysis. Some aspects limiting our analysis and 
possible improvements for further studies shall be discussed in the following. 
 
In cells treated with IR, the dose of IR and the time until fixation of cells represent important factors 
affecting numbers of 53BP1 foci [132]. When considering a transiently expressed enzyme as a 
potential genotoxic agent, one could suppose that 1) the amount of HML-2 IN expressed and 2) the 
time of exposure to HML-2 IN, thus the interval between cell transfection (with a plasmid expressing 
IN) and cell fixation may represent relevant factors in the 53BP1 assay. We fixed cells 24 hpt, a time 
point when transiently expressed HML-2 IN was present at considerably high level in the cytoplasm 
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and nucleus of cells. We cannot exclude that DSBs induced by the HML-2 IN during the transient 
expression period may have been largely repaired by 24 h post transfection. Thus, DSBs may have 
been detectable more readily at earlier time points. On the other side, we cannot exclude that longer 
exposure to IN activity, for instance, fixing cells only at 48 hpt, could have revealed higher numbers 
of DSBs due to accumulation of DNA damage induced by HML-2 IN. Monitoring numbers of 53BP1 
foci at different time periods of transient expression of HML- IN may be recommended. Use of an 
inducible expression system, for instance, a system based on a tetracycline-controlled operator [93], 
could be of great benefit to synchronize expression of HML-2 IN in cells. 
 
Molecular processes behind 53BP1 signaling involve factors that may behave differently at different 
stages of the cell cycle [56]. As a consequence, 53BP1 focus formation might be influenced by the 
phase of the cell cycle. In view of this, we aimed in our 53BP1 foci analysis at reducing biases from 
cell cycle variations. To do so, we counted solely those cells that, based on Ki-67 staining, appeared 
to be in the same phase of the cell cycle when fixed. Ki-67 is a widely used marker of cell proliferation, 
with the expression level within the cell correlating with the cell-cycle phase. Ki-67 is known to be 
degraded continuously in G0 and G1 phase [195]. For our analysis we considered only cells with a Ki-
67 level below the detection limit (Ki-67 negative cells), likely representing cells in G0 or G1 phase. 
Among cells with noticeable Ki-67 staining (Ki-67 positive cells), the level and distribution of Ki-67 
was rather variable and not easily interpretable with regard to the actual cell cycle phase. 
An analysis focused on cells in other phases of the cell cycle when fixed might be worthwhile. 
Considering that DNA single-strand breaks (SSBs) can collapse into DSBs if met by a replication fork 
during DNA replication [172] one might expect during the S-phase of the cell cycle more IN-induced 
SSBs eventually converted into DSBs. Thus, further investigations evaluating DSBs in presence of 
HML-2 IN activity could be meaningful when focusing attention on cells fixed during the S-phase. On 
the basis of our observations (see above), Ki-67 is not well suited for unambiguous discrimination of 
such cells. As an alternative, the proliferating cell nuclear antigen (PCNA) could be employed since 
cells not in S-phase (G0 included) stain only weakly with α-PCNA antibodies [32]. 
 
Our experiments employed asynchronous cell populations. This was not favorable with regard to 
selection of certain cell cycle phases. In fact, a large number of images of cells had to be taken and 
analyzed when evaluating 53BP1 foci. A relatively low number of HML-2 IN (or its mutant) positive 
cells were also Ki-67 negative. Identification of cells meeting our selection criteria (HML-2 IN positive 
and Ki-67 negative) was laborious and time consuming. Therefore, the total number of cells analyzed 
was limited to a total of approximately 200. For further experiments, use of a system to synchronize 
cells or arrest them in a certain phase of the cell cycle could be of great benefit to increase the number 
of positive cells examined, thus increase consistency of the analysis. For instance, synchronization of 
cells could be achieved by chemical blockade. Various inhibitors exist that block cells in specific 
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phases of the cell cycle [9]. Before transfection, cells could be arrested in a certain cell cycle phase 
with one or more (through parallel experiments) drugs [155]. Synchronized cells could be fixed at 
different time points after transfection and subjected to immunostaining for DNA damage analysis. 
 
Our investigation required acquisition and analysis of hundreds of images. For those images, counting 
of 53BP1 foci was done by eye. Although certainly accurate, evaluation by eye is time consuming and 
may bias results. Software for analyzing foci have been reported (for instance, see [132]). Use of 
computerized in silico systems for foci analysis could save time and allow analysis of much larger 
numbers of cells. The latter is expected to produce more accurate mean values, thus (better) results that 
could potentially change our overall conclusions on DNA damage induced by HML-2 IN. In future 
studies, a combination of the established immunostaining approach and computerized foci counting 
systems could be of great benefit. 
 
Repair kinetics of DSBs, thus of 53BP1 formation, may cause differences depending on the cell line 
utilized [98]. In our experiments, we utilized HeLa cells because they adhered firmly to the surface of 
tissue culture plates used for immunofluorescence assays. However, it is currently unknown whether 
other cell lines may be more suited for monitoring DNA damage induced by HML-2 IN activity. Use 
of alternative cell lines should thus be considered for further investigations of DNA damage induced 
by HML-2 IN. 
 
Apart from 53BP1, other proteins involved in the repair of DSBs, that are part of foci observable by 
immunofluorescence, could be used as DSB markers [217], e.g., histone H2A variant (H2AX), which 
is specifically phosphorylated in response to DSB induction [217]. Phosphorylated H2AX, also known 
as gamma (γ)-H2AX, has been initially considered as DSB marker for our experiments since it showed 
to be highly sensitive and well characterized in previous studies [217], and it was already shown to 
locate at sites of retroviral integration during viral infection [150]. Moreover, this γ-H2AX has been 
used in a preliminary investigation conducted in our lab in the course of a bachelor thesis (Brill 2011), 
with some experiments having indicated a higher number of γ-H2AX foci in cells expressing 
transiently expressed HML-2 IN compared to cells expressing controls or mock-transfected cells. 
However, in that preliminary work, no quantification by counting of γ-H2AX foci was attempted. In 
our experiments, when establishing conditions for γ-H2AX assays, γ-H2AX foci could not be 
quantified reliably due to presence of too small (uncountable) foci and high background staining (not 
shown). Those issues might have been due to cross-reacting antibodies. Therefore, we focused on 
quantification of 53BP1 foci, because 53BP1 is known to co-localize with γ-H2AX at DSB sites [217] 
and also because 53BP1 foci could be visualized well in our experiments. 
Since the phosphorylation of H2AX (at residue 139) is a highly specific event that takes place (and is 
amplified involving many H2AX molecules) in response to DNA damage [166] the levels of γ-H2AX 
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within the cell provide information about the amount of DSBs [166]. Although microscopy-based foci 
quantitation is among the most sensitive assays to measure DSB levels [89], other less laborious 
immunological methods could be attempted to study the genotoxicity of HML-2 IN via γ-H2AX. In 
particular, following transient expression of wild-type and mutant HML-2 IN in cell culture, a 
comparative analysis of γ-H2AX levels between two cell samples could be done by flow cytometry, 
which is a rapid and technically relatively simple method for an automated high throughput analysis 
[24]. Alternatively, γ-H2AX levels could be measured in cell lysates by Western blot or enzyme-linked 
immunosorbent assay (ELISA) [89]. Other proteins participating in DSB repair that are phosphorylated 
in response to DSBs, e.g., serine/threonine kinases ATM and Chk2, as well as 53BP1 [217], could be 
included in a comprehensive study monitoring those phosphorylated proteins during HML-2 IN 
expression employing above-mentioned immunological technologies. 
 
Considering that DNA damage induced by retroviral IN consists of SSBs that, if not repaired, can 
transform into DSBs only secondarily [192], one might envisage evaluation of formation of SSBs as 
an alternative approach when investigating an ability of HML-2 IN to induce DNA damage. We 
focused in our investigations on the evaluation of DSBs since their detection by immunofluorescence 
assays using markers such as 53BP1 has been successfully applied and is well characterized [217]. 
Moreover, preliminary work by Brill (2011) mentioned above had provided indications in favor of 
HML-2 IN causing DSBs. In any case, evaluation of SSBs should be considered when further 
investigating genotoxicity of HML-2 IN. For such an investigation, X-ray repair cross complementing 
1 protein (XRCC1) could represent a good candidate marker for monitoring SSBs. XRCC1 is required 
for DNA SSB repair in human cells [26] and has already been employed for detection of unrepaired 
SSBs via immunofluorescence assays [145]. 
 
HML-2 IN activity has been previously confirmed in vitro, using oligonucleotides that simulate the 
LTRs of the viral dsDNA genome [105]. However, experiments assaying HML-2 IN activity (or 
activity of IN from other ERVs) in a cellular context have not been attempted so far, to the best of our 
knowledge. Our in vivo experimental conditions did not investigate actual enzymatic activity of HML-
2 IN transiently expressed in cell culture. Therefore, whether HML-2 IN is enzymatically active in vivo 
remains an unresolved question that requires further investigations employing specific experimental 
strategies that were not the focus of our initial studies. 
 
Another aspect of our experimental set-up raised another question related to HML-2 IN activity. HML-
2 IN was expressed in our experiments with an HA-tag in its N-terminus. One might wonder whether 
presence of an HA-tag may have hindered enzymatic activity. In support of the HA tag not impacting 
IN activity, it was reported before [153] that infectivity of HIV-1 harboring an IN fused to a C-terminal 
HA-tag was not affected, suggesting that a C-terminal HA-tag does not inhibit normal activities of 
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HIV-1 IN. We had employed an HA-tag because we had a well-functioning α-HA monoclonal antibody 
available in our laboratory and we also had well-established conditions for HA detection by 
immunofluorescence. Although activity of HA-tagged HML-2 IN was not assayed by us, it was 
previously demonstrated that a His-tag in the N-terminus of HML-2 IN does not hinder its activity 
[105]. One can thus assume that the 9 aa HA-tag, like a 6xHis tag, does not dramatically affect IN 
activity. Certainly, that assumption requires confirmation by specific experiments that, for example, 
could employ established assays in vitro [105], assaying HML-2 IN with at least an N-terminal HA-
tag. 
 
On the basis of HML-2 proviral organization, HML-2 IN is expected to be expressed as part of a Gag-
Pro-Pol polyprotein and then released by HML-2 Pro activity. Retroviral proteases are often activated 
after virion budding [200]. One may wonder whether HML-2 IN can be released from its precursor 
protein within the cell, outside or inside retroviral particles. We have demonstrated for HML-2 Pro that 
HML-2 Pro can be activated independent from assembly of viral particles (see above). HML-2 Pro was 
thereby able to process its own viral and other cellular substrates in the cytoplasm. Therefore, there is 
evidence to believe that in case of HML-2 expression, HML-2 IN could be released from its precursor 
by active HML-2 Pro. Such a release could take place in the cytoplasm of cells, from which HML-2 
IN could then translocate into the cell nucleus. A simple experiment to document the proper release of 
HML-2 IN from its precursor could involve transient expression of an HML-2 Pro-Pol protein with an 
engineered tag (for instance, HA) at the 3' end of the Pol. Detection of HA by Western blot would then 
show a band of a size expected for the HML-2 IN domain that was generated by HML-2 Pro activity. 
 
In our analysis we observed HML-2 IN localizing in the cytoplasm and in the nucleus of cells, that was 
not reported before. HML-2 IN localizing in the cell nucleus indicated that this enzyme could have 
karyophilic properties already known for HIV-1 IN [155]. Such an observation allows for speculations 
about interaction of HML-2 IN with the host genomic DNA. Therefore, it can be considered a piece of 
evidence that supports (independent from our results obtained through 53BP1 foci analysis) the 
hypothesis that HML-2 IN could potentially influence host genome stability. 
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5.2.3 Conclusions for HML-2 IN 
Our investigation of HML-2 IN addressed the potential ability of the enzyme to induce DNA damage 
in the cellular genome. Experiments performed can be considered pioneering as the biological impact 
of HML-2 IN in cells has not been investigated experimentally so far according to the published 
literature. Our analysis involved stringent criteria for evaluation of DSBs induced in presence of HML-
2 IN. However, several factors not considered in this first investigation may have limited our analysis. 
Although we did not obtain evidence that allowed us to conclude that HML-2 IN activity could 
contribute to induction of DSBs in the host genome we have collected initial information that will be 
useful for further studies exploring biological roles of HML-2 IN. This first investigation provided an 
example of an experimental approach that can be further improved in future analysis to elucidate 
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Table 21: Gene/protein names of potential cellular substrates of HML-2 Pro identified by TAILS analysis 
AARS1 BOLA2 CPS1 EIF3G GPN3 IPO5 NCL PFN2 PSMD2 RPS15A SRM UBA1 
ACAT1 BORCS5 CRCP EIF3I GPS1 IPO7 NCOA7 PGAM1 PSMD3 RPS16 SRP19 UBA2 
ACAT2 BTF3 CSDE1 EIF3J GPT2 IQGAP1 NDRG3 PGAM4 PSMD4 RPS18 SRP9 UBA3 
ACBD6 BUB1B CSNK1E EIF3L GRIPAP1 IVNS1ABP NDUFA5 PGD PSMD7 RPS19 SSB UBA5 
ACIN1 C11orf98 CSRP1 EIF3M GRSF1 JPT1 NDUFS6 PGK1 PSME2 RPS2 SSBP3 UBAC1 
ACLY C12orf29 CSTB EIF4A1 GSK3A JPT2 NEDD8 PGM1 PSMG1 RPS20 SSNA1 UBAP2L 
ACO1 C12orf57 CSTF2 EIF4B GSK3B KCTD16 NELFE PHACTR4 PTBP1 RPS21 ST13 UBE2L3 
ACTA1 C15orf57 CTCF EIF4G1 GSPT1 KDM3B NHP2 PHF5A PTGES3 RPS23 STAT3 UBE2O 
ACTA2 C1orf198 CTDP1 EIF4G2 GSPT2 KHSRP NME1 PHF6 PTMS RPS24 STIM1 UBE2Q1 
ACTB C1orf52 CTNND1 EIF5 GSR KIF5B NME2P1 PHGDH PUF60 RPS25 STIP1 UBE2S 
ACTBL2 C2orf49 CTPS1 EIF5A GSTM3 KLC1 NMT1 PHPT1 PUS7 RPS27 STMN1 UBE3A 
ACTC1 C8orf33 CTR9 ELAC2 GTF2E1 KLC2 NOLC1 PIN1 PWP1 RPS27A STUB1 UBQLN1 
ACTG1 C9orf40 CTTN ELF1 GTF2I KLF13 NONO PITPNM1 PYM1 RPS28 SUB1 UBQLN4 
ACTG2 CACYBP CWF19L1 ELOA GTF3C5 KLHDC4 NOSIP PKM QARS1 RPS3A SUGT1 UBR4 
ACTL6B CALD1 CYRIB ELOB H2AZ1 KPNA2 NPM1 PLCB3 RAD23A RPS4X SURF6 UBR5 
ACTN1 CALM1 DAB2 ELOC H2BC9 KPNA6 NSFL1C PLEKHG2 RAD23B RPS5 SWAP70 UBR7 
ACTN4 CALR DARS1 ENAH H3C15 KPNB1 NSUN2 PLIN3 RAI14 RPS6 TACC2 UBXN1 
ACTR1A CALU DAXX ENO1 HARS1 KRT18 NT5C2 PLS3 RAN RPS6KA3 TACC3 UBXN4 
ACTR3 CAMK1D DBN1 ENO3 HDGF KRT8 NT5DC1 PML RANBP1 RPS7 TAGLN2 UCHL3 
ADAMTS7 CAPNS1 DBNL ENSA HDGFL2 KTI12 NUB1 PMM2 RANBP2 RPS8 TARS1 UCHL5 
ADH5 CAPZB DCAF1 EPRS1 HECTD1 LAMTOR5 NUBP1 POLD1 RANBP3 RPS9 TBCB UGDH 
ADRM1 CARHSP1 DCAF6 EPS15L1 HERC1 LARP1 NUCKS1 POLE3 RANGAP1 RPSA TCERG1 UHRF1 
AHCYL1 CASP1 DCTN2 ERCC5 HEXIM1 LARP4 NUDC POTEE RARS1 RRBP1 TCOF1 UPF1 
AHSA1 CAST DDB1 ERCC6L HGH1 LARS1 NUFIP2 POTEI RBBP5 RRM1 TCP1 USF1 
AIMP2 CAVIN1 DDI2 ERH HHATL LASP1 NUMA1 POTEKP RBBP7 RRM2 TDP2 USP14 
AJUBA CBR1 DDTL ERP44 HINT1 LENEP NUP153 PPA1 RCN1 RRP15 TECPR2 USP15 
AK1 CBX3 DDX1 ESD HINT2 LIMA1 NUP214 PPIA RCN3 RSL1D1 TFG USP5 
AKAP12 CCAR2 DDX17 EXOSC1 HMGB1 LIMCH1 NUP98 PPID REPS1 RTCB TGM2 UTP3 
AKAP13 CCDC124 DDX21 EZR HMGB3 LRRFIP1 OBSL1 PPIE REXO4 RTN4 THG1L VARS1 
AKAP2 CCDC43 DDX3X FABP5 HMGN5 LSM2 OGA PPIF RFC4 RUVBL2 THOP1 VASP 
AKR7A2 CCDC50 DDX46 FAM114A1 HNRNPA0 LTV1 OGFR PPIL1 RGCC S100A10 THRAP3 VCL 
AKT1S1 CCT2 DDX5 FAM120A HNRNPA1 LZIC OLA1 PPIP5K2 RIOK1 S100A11 TKFC VCP 
ALDH9A1 CCT3 DFFA FAM136A HNRNPA1L2 MACROD1 ORC2 PPM1B RIPOR1 S100A4 TKT VTA1 
ALDOA CCT4 DHX15 FAM172A HNRNPA2B1 MAGED2 OSBPL10 PPM1G RNASEH2A S100A6 TLN1 WAPL 
ALDOC CCT5 DHX9 FASN HNRNPAB MAP2K2 OTUB1 PPP1R14B RNASEH2B SAE1 TMOD3 WASHC2A 
ANAPC16 CCT6A DLGAP5 FDPS HNRNPD MAP4 OTULIN PPP1R2B RNF146 SAMD4B TMSB10 WBP4 
ANKZF1 CCT7 DMD FH HNRNPH1 MAP7 OXSR1 PPP2CB RNF25 SARS1 TNKS1BP1 WDHD1 
ANP32A CCT8 DNAJA1 FHL1 HNRNPK MAP7D1 P4HB PPP2R1A RNH1 SDF2L1 TNPO1 WDR1 
ANP32E CD2BP2 DNAJA2 FKBP1A HNRNPR MAPRE1 PA2G4 PPP2R1B RPAP1 SEC16A TNRC6B WIPI2 
ANXA1 CDC37 DNAJC21 FKBP2 HNRNPU MAT2A PABPC1 PPP3R1 RPAP3 SERPINH1 TOE1 WNK1 
ANXA2 CDC42 DNAJC7 FKBP4 HNRNPUL1 MBD3 PABPC4 PPP4R2 RPL10 SET TP53BP1 XPNPEP1 
ANXA3 CDC73 DNAJC8 FLNA HP1BP3 MCM2 PABPN1 PPP6R3 RPL10A SF1 TPD52 XRCC1 
ANXA5 CDK11B DNM1L FLNB HSD17B10 MCM4 PAICS PPT1 RPL10L SF3B1 TPD52L2 XRCC4 
AP1B1 CDV3 DNMT1 FLYWCH2 HSD48 MCM6 PAIP2 PRAG1 RPL11 SF3B2 TPI1 XRCC5 
APPL1 CEP170 DOHH FOXK1 HSP90AA1 MDC1 PALM2 PRDX1 RPL13 SF3B5 TPM2 XRCC6 
APRT CEP170B DPP7 FPGT HSP90AB1 MDH2 PANK2 PRDX2 RPL17 SFN TPM3 XRN2 
ARAF CFL1 DPYSL2 FSCN1 HSP90B1 MFAP1 PAPOLA PRDX5 RPL19 SFPQ TPM4 YAP1 
ARAP1 CHAC2 DSTN FUBP1 HSPA1B MICAL3 PAPSS1 PRDX6 RPL22 SGTA TPR YARS1 
ARCN1 CHAMP1 DUT G3BP1 HSPA2 MIF PARD3 PRKCSH RPL23 SHTN1 TRAFD1 YBX1 
ARHGAP40 CHML DYNC1I2 G3BP2 HSPA4 MKI67 PARK7 PRKDC RPL24 SKP1 TRAP1 YBX3 
ARHGDIA CHMP4B DYNC1LI1 GANAB HSPA4L MOB4 PASK PRMT5 RPL26L1 SLC4A1AP TRIM28 YJU2 
ARHGEF1 CHMP5 DYNC1LI2 GAPDH HSPA5 MPG PAWR PROSER2 RPL27 SLK TRIM33 YOD1 
ARIH1 CHORDC1 EARS2 GAPVD1 HSPA6 MSH6 PC PRPF4 RPL27A SMAP TRMT112 YWHAB 
ARPC4 CIAPIN1 EBNA1BP2 GARS1 HSPA8 MSN PCBP1 PRPS1 RPL29 SMARCA2 TRMT2A YWHAE 
ARPIN CKAP5 ECPAS GART HSPA9 MTA2 PCBP2 PRPS2 RPL3 SMARCE1 TRMT5 YWHAG 
ASS1 CKB EDC3 GBF1 HSPB1 MTHFD1 PCLAF PRPSAP1 RPL30 SMC2 TRMT6 YWHAQ 
ATIC CKS1B EDF1 GCLM HSPB8 MTRR PCM1 PRRC2A RPL32 SMC4 TRUB1 YWHAZ 
ATP5F1B CKS2 EEF1A1 GDI1 HSPD1 MYBBP1A PCNP PRRC2B RPL34 SNAP29 TSNAX YY1 
ATP6V1G1 CLIC1 EEF1A2 GDI2 HSPE1 MYH10 PDAP1 PRRC2C RPL35 SNCG TTC1 ZC3H14 
ATP6V1H CLIC4 EEF1B2 GEMIN5 HSPH1 MYH9 PDCD10 PSAT1 RPL36 SND1 TTC9C ZC3H8 
ATXN2L CLIP1 EEF1D GFER HTT MYL12A PDCD4 PSMA1 RPL36AL SNRPB TTLL12 ZFYVE16 
ATXN7L3B CLNS1A EEF1G GFM1 HUWE1 MYL6 PDCD6IP PSMA3 RPL39P5 SNRPC TUBA1A ZFYVE19 
B2M CMPK1 EEF2 GID8 HYOU1 MYL9 PDCL PSMA5 RPL4 SNUPN TUBA1C ZGPAT 
BAG2 CNBP EFHC2 GIGYF2 ICAM1 MYPN PDE12 PSMA7 RPL5 SNX1 TUBA4A ZMYM3 
BAG3 CNDP2 EFHD2 GKAP1 IDE NAA10 PDE3A PSMB1 RPL7 SOD1 TUBB ZNF428 
BAG6 CNN2 EIF2D GLCCI1 IDH1 NACA PDIA3 PSMB4 RPL8 SORD TUBB4B ZNF622 
BAIAP2L1 CNPY2 EIF2S2 GLRX3 IGBP1 NADK PDLIM1 PSMC2 RPLP0P6 SP1 TUBB6 ZPR1 
BANF1 COBL EIF3A GMPS IGF2BP1 NANS PEX19 PSMC3 RPP25 SP2 TUFM ZWINT 
BCL3 COPB2 EIF3B GOLGA2P5 ILRUN NAP1L1 PFAS PSMC4 RPRD2 SPAG9 TWF2 ZYX 
BCL9L COPG1 EIF3CL GOLGA3 IMPDH2 NAP1L4 PFDN2 PSMC5 RPS10 SPINDOC TXNDC5 
 
BIN1 COPZ1 EIF3D GOLGA4 INF2 NAPRT PFDN6 PSMC6 RPS12 SPTBN1 TXNDC9 
 
BLVRB CORO1B EIF3E GPI INPPL1 NASP PFKP PSMD11 RPS13 SQSTM1 TXNRD1 
 
BOD1L1 CPNE1 EIF3F GPKOW INTS3 NAXE PFN1 PSMD12 RPS14 SREK1 TYMS 
 
* Gene/protein names were retrieved from UniProt [40] providing, as identifiers, protein IDs of potential 
cellular substrates identified by TAILS analysis. 
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aggresome; cell; chaperone 
complex; cytoplasm; 
cytosol; neuron projection; 
nucleus; plasma membrane; 
stress fiber; Z disc 
aggresome assembly; autophagosome assembly; brain development; cellular response to heat; cellular 
response to mechanical stimulus; cellular response to unfolded protein; chaperone-mediated autophagy; 
chaperone-mediated protein transport; extrinsic apoptotic signaling pathway in absence of ligand; 
extrinsic apoptotic signaling pathway via death domain receptors; muscle cell cellular homeostasis; 
negative regulation of apoptotic process; negative regulation of protein targeting to mitochondrion; 
negative regulation of striated muscle cell apoptotic process; negative regulation of transcription from 
RNA polymerase II promoter in response to stress; positive regulation of aggrephagy; positive regulation 
of protein export from nucleus; positive regulation of protein import into nucleus; protein folding; protein 









defense response to virus; innate immune response; osteoblast differentiation; positive regulation of gene 
expression, epigenetic; positive regulation of I-kappaB kinase/NF-kappaB signaling; positive regulation 
of myeloid dendritic cell cytokine production; response to exogenous dsRNA; rRNA processing; 







translation initiation factor 
4F complex; polysome 






factor 4 gamma 1) 
cytoplasm; cytosol; 
eukaryotic translation 
initiation factor 4F 
complex; membrane; 
nucleus; polysome 
behavioral fear response; cap-dependent translational initiation; cellular macromolecule biosynthetic 
process; cellular response to nutrient levels; developmental process; energy homeostasis; negative 
regulation of autophagy; negative regulation of neuron death; negative regulation of peptidyl-threonine 
phosphorylation; nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; positive 
regulation of cell death; positive regulation of cell growth; positive regulation of cellular protein 
metabolic process; positive regulation of eukaryotic translation initiation factor 4F complex assembly; 
positive regulation of G1/S transition of mitotic cell cycle; positive regulation of miRNA mediated 
inhibition of translation; positive regulation of mRNA cap binding; positive regulation of neuron 
differentiation; positive regulation of peptidyl-serine phosphorylation; positive regulation of translation 
in response to endoplasmic reticulum stress; regulation of cellular response to stress; regulation of gene 
silencing by miRNA; regulation of mRNA stability; regulation of polysome binding; regulation of 






binding protein 1) 
cytoplasm; cytoplasmic 
stress granule; cytosol; 
focal adhesion; nucleus; 
perikaryon; 
ribonucleoprotein complex 
defense response to virus; innate immune response; negative regulation of canonical Wnt signaling 
pathway; positive regulation of stress granule assembly; Ras protein signal transduction; stress granule 
















extracellular exosome; focal 
adhesion; integral 










ATF6-mediated unfolded protein response; cellular response to antibiotic; cellular response to calcium 
ion; cellular response to cAMP; cellular response to drug; cellular response to gamma radiation; cellular 
response to glucose starvation; cellular response to interleukin-4; cellular response to manganese ion; 
cellular response to nerve growth factor stimulus; cellular response to unfolded protein; cerebellar 
Purkinje cell layer development; cerebellum structural organization; chaperone cofactor-dependent 
protein refolding; endoplasmic reticulum unfolded protein response; ER overload response; IRE1-
mediated unfolded protein response; luteolysis; maintenance of protein localization in endoplasmic 
reticulum; negative regulation of apoptotic process; negative regulation of IRE1-mediated unfolded 
protein response; negative regulation of protein-containing complex assembly; negative regulation of 
transforming growth factor beta receptor signaling pathway; neuron apoptotic process; neuron 
differentiation; PERK-mediated unfolded protein response; positive regulation of cell migration; positive 
regulation of neuron projection development; positive regulation of protein ubiquitination; positive 
regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; 
posttranslational protein targeting to membrane, translocation; protein folding in endoplasmic reticulum; 
protein refolding; regulation of ATF6-mediated unfolded protein response; regulation of IRE1-mediated 
unfolded protein response; regulation of PERK-mediated unfolded protein response; regulation of protein 
folding in endoplasmic reticulum; response to cocaine; response to methamphetamine hydrochloride; 
response to unfolded protein; stress response to metal ion; substantia nigra development; toxin transport; 
ubiquitin-dependent ERAD pathway 
P04792 
HSPB1 
(heat shock protein 
beta-1) 
axon cytoplasm; cytoplasm; 
cytoskeleton; cytosol; 
extracellular exosome; 
extracellular space; focal 
adhesion; nucleus; plasma 
membrane; proteasome 
complex; spindle; Z disc 
anterograde axonal protein transport; cellular response to vascular endothelial growth factor stimulus; 
chaperone-mediated protein folding; intracellular signal transduction; negative regulation of apoptotic 
process; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; negative 
regulation of protein kinase activity; platelet aggregation; positive regulation of angiogenesis; positive 
regulation of blood vessel endothelial cell migration; positive regulation of endothelial cell chemotaxis; 
positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor 
receptor signaling pathway; positive regulation of interleukin-1 beta production; positive regulation of 
tumor necrosis factor biosynthetic process; regulation of autophagy; regulation of I-kappaB kinase/NF-
kappaB signaling; regulation of mRNA stability; regulation of protein phosphorylation; regulation of 











cell aging; cellular response to UV; CENP-A containing nucleosome assembly; centrosome cycle; 
chromatin remodeling; DNA repair; intracellular protein transport; negative regulation of apoptotic 
process; negative regulation of cell population proliferation; negative regulation of centrosome 
duplication; negative regulation of protein kinase activity by regulation of protein phosphorylation; 
nucleocytoplasmic transport; nucleosome assembly; positive regulation of cell cycle G2/M phase 
transition; positive regulation of cell population proliferation; positive regulation of NF-kappaB 
transcription factor activity; positive regulation of transcription, DNA-templated; positive regulation of 
transcription by RNA polymerase II; positive regulation of translation; protein localization; regulation of 
 177 
complex; spindle pole 
centrosome 
centriole replication; regulation of centrosome duplication; regulation of eIF2 alpha phosphorylation by 
dsRNA; regulation of endodeoxyribonuclease activity; regulation of endoribonuclease activity; regulation 
of mRNA stability involved in cellular response to UV; regulation of transcription by RNA polymerase 
II; ribosomal large subunit biogenesis; ribosomal large subunit export from nucleus; ribosomal small 
subunit biogenesis; ribosomal small subunit export from nucleus; ribosome assembly; rRNA export from 




binding protein 1) 
catalytic step 2 




cytoplasmic stress granule; 
cytosol; extracellular 
exosome; focal adhesion; 
membrane; nucleus; 
ribonucleoprotein complex 
gene silencing by RNA; mRNA polyadenylation; mRNA splicing, via spliceosome; mRNA stabilization; 
negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay; nuclear-
transcribed mRNA catabolic process, nonsense-mediated decay; positive regulation of nuclear-
transcribed mRNA catabolic process, deadenylation-dependent decay; positive regulation of nuclear-
transcribed mRNA poly(A) tail shortening; positive regulation of viral genome replication; regulation of 










brain development; glutaminyl-tRNA aminoacylation; negative regulation of apoptotic signaling 
pathway; negative regulation of protein kinase activity; negative regulation of stress-activated MAPK 







ribonuclease H2 complex 






ribonuclease H2 complex 
in utero embryonic development; negative regulation of gene expression; positive regulation of fibroblast 
proliferation; regulation of DNA damage checkpoint; regulation of G2/M transition of mitotic cell cycle; 






exosome; Ino80 complex; 
intracellular; membrane; 





nucleus; R2TP complex; 
ribonucleoprotein complex; 
Swr1 complex 
box C/D snoRNP assembly; cellular response to estradiol stimulus; cellular response to UV; chromatin 
remodeling; DNA recombination; DNA repair; establishment of protein localization to chromatin; histone 
acetylation; histone H2A acetylation; histone H4 acetylation; negative regulation of canonical Wnt 
signaling pathway; negative regulation of estrogen receptor binding; positive regulation of histone 
acetylation; positive regulation of telomerase RNA localization to Cajal body; positive regulation of 
transcription by RNA polymerase II; protein folding; regulation of growth; regulation of transcription by 









nuclear inclusion body; 
nucleoplasm; nucleus; 
ubiquitin conjugating 
enzyme complex; ubiquitin 
ligase complex; Z disc 
cellular response to heat; cellular response to hypoxia; cellular response to misfolded protein; chaperone-
mediated autophagy; DNA repair; endoplasmic reticulum unfolded protein response; ERBB2 signaling 
pathway; negative regulation of protein binding; negative regulation of transforming growth factor beta 
receptor signaling pathway; positive regulation of chaperone-mediated protein complex assembly; 
positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of 
protein ubiquitination; positive regulation of ubiquitin-protein transferase activity; proteasome-mediated 
ubiquitin-dependent protein catabolic process; protein autoubiquitination; protein K63-linked 
ubiquitination; protein maturation; protein polyubiquitination; protein quality control for misfolded or 
incompletely synthesized proteins; protein ubiquitination; regulation of glucocorticoid metabolic process; 
regulation of protein stability; response to ischemia; ubiquitin-dependent ERAD pathway; ubiquitin-











complex; RNA polymerase 
II transcription factor 
complex 
chromatin organization; convergent extension involved in axis elongation; DNA methylation involved in 
embryo development; DNA repair; embryo implantation; embryonic placenta morphogenesis; epithelial 
to mesenchymal transition; innate immune response; negative regulation of DNA demethylation; negative 
regulation of single stranded viral RNA replication via double stranded DNA intermediate; negative 
regulation of transcription, DNA-templated; negative regulation of transcription by RNA polymerase II; 
negative regulation of viral release from host cell; positive regulation of DNA binding; positive regulation 
of DNA repair; positive regulation of methylation-dependent chromatin silencing; positive regulation of 
protein import into nucleus; positive regulation of transcription, DNA-templated; protein 
autophosphorylation; protein sumoylation; Ras protein signal transduction; regulation of genetic 








perinuclear region of 
cytoplasm; protein-
containing complex 
cellular response to DNA damage stimulus; DNA repair; negative regulation of double-strand break 
repair; negative regulation of histone H2A K63-linked ubiquitination; positive regulation of canonical 
Wnt signaling pathway; positive regulation of gene expression; positive regulation of protein import into 
nucleus; progesterone receptor signaling pathway; protein K48-linked ubiquitination; protein 
polyubiquitination; regulation of double-strand break repair; viral process 
* Experiments validating additional cellular substrates of HML-2 Pro were conducted by Dr. John Goodier's 
laboratory (McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, 
Baltimore, MD, USA). A representative protein ID, approved gene/protein symbols and full names are given 






°C Degree Celsius 
~ Approximately 
53BP1 53 binding protein 1  
aa Amino acid(s) 
ALS Amyotrophic lateral sclerosis 
bp Base pair 
BSA Bovine serum albumine 
CMV Cytomegalovirus 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DPBS Dulbecco’s phosphate-buffered saline 
DSB DNA double-strand break 
dsDNA Double-stranded DNA 
dUTPase Deoxyuridine triphosphatase 
E. coli Escherichia coli 
e.g. Exempli gratia (for example) 
ECL Enhanced chemiluminescence 
EGFP Enhanced green fluorescent protein 
Env Envelope 
ERV Endogenous retrovirus 
etc Et cetera 
FACS Fluorescence-activated cell sorting 
g Relative centrifugal force 
Gag Group-specific antigen 
GCT Germ cell tumor 
GFP Green fluorescent protein 
GO Gene ontology 
h Hours 
H2Odd Double distilled water 
HERV Human endogenous retrovirus 
HIV-1 Human immunodeficiency virus type 1 
HML Human MMTV-like 
hpt Hours post-transfection 
HSP Heat shock protein 
HTLV Human T-lymphotropic virus 
i.e. id est (that is) 
IgG Immunoglobulin G 
IN Integrase 
IPTG Isopropyl β-D-1-thiogalaktopyranoside 




LTR Long terminal repeat 
m Milli (10-3) 
M Molar (mol/l) 
min Minutes 
MMTV Mouse mammary tumor virus 
mRNA Messenger-RNA 
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n Nano (10-9) 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
nt Nucleotide 
ORF Open reading frame 
PAA-gel  Polyacrylamide gel 
PAGE Polyacrylamide gel electrophoresis 
PARP Poly [ADP-ribose] polymerase 1 
PBS Primer binding site 
PCR Polymerase chain reaction 
Pro Protease 
RNA Ribonucleic acid 
RSV Rous sarcoma virus 
RT Reverse transcriptase 
SA Splice acceptor 
SD Splice donor 
SDS Sodium dodecyl sulfate 
sec Second 
SP Signal peptide 
SSB DNA single-strand break 
ssDNA Single-stranded DNA 
SU Surface 
TAE Tris-acetate-EDTA 




V/V Volume/volume percentage 
W/V Weight/volume percentage 
µ Micro (10-6) 
 
Amino acids   
1-letter code 3-letter code name  1-letter code 3-letter code name 
A Ala Alanine  K Lys Lysine 
R Arg Arginine  M Met Methionine 
N Asn Asparagine   Nle Norleucine 
D Asp Aspartic acid  F Phe Phenylalanine 
C Cys Cysteine  P Pro Proline 
Q Gln Glutamine  S Ser Serine 
E Glu Glutamic acid  T Thr Threonine 
G Gly Glycine  W Trp Tryptophan 
H His Histidine  Y Tyr Tyrosine 
I Ile Isoleucine  V Val Valine 
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